10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

___________________________________

FORM 10-Q

___________________________________

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2023

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________ to ________

Commission File Number: 001-38924

UpHealth, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware		83-3838045
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)
14000 S. Military Trail,	Suite 203	33484
Delray Beach,	Florida
(Address of principal executive offices)		(Zip Code)

(888) 424-3646

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	UPH	New York Stock Exchange
Redeemable Warrants, exercisable for one share of Common Stock at an exercise price of $115.00 per share	UPH.WS	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of August 9, 2023, the registrant had 17,161,024 shares of common stock, $0.0001 par value per share, outstanding.

TABLE OF CONTENTS

	Page
Part I - Financial Information	3
Item 1. Financial Statements	3
Condensed Consolidated Balance Sheets	4
Condensed Consolidated Statements of Operations	5
Condensed Consolidated Statements of Comprehensive Loss	6
Condensed Consolidated Statements of Stockholders’ Equity	7
Condensed Consolidated Statements of Cash Flows	9
Notes to Condensed Consolidated Financial Statements	10
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	29
Item 3. Quantitative and Qualitative Disclosures About Market Risk	44
Item 4. Controls and Procedures	44
Part II - Other Information	45
Item 1. Legal Proceedings	45
Item 1A. Risk Factors	47
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	51
Item 3. Defaults Upon Senior Securities	51
Item 4. Mine Safety Disclosures	51
Item 5. Other Information	51
Item 6. Exhibits	55
Signatures	57

Part 1 - Financial Information

Item 1. Financial Statements

3

UPHEALTH, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, unaudited)

	June 30, 2023		December 31, 2022
ASSETS
Current Assets:
Cash and cash equivalents	$	46,803	$	15,557
Accounts receivable, net	22,369		21,851
Inventories	18		161
Prepaid expenses and other current assets	2,121		3,005
Assets held for sale, current	—		2,748
Total current assets	71,311		43,322
Property and equipment, net	13,997		14,069
Operating lease right-of-use assets	5,728		7,213
Intangible assets, net	29,069		31,362
Goodwill	153,318		159,675
Equity investment	21,200		21,200
Other assets	455		438
Assets held for sale, noncurrent	—		62,525
Total assets	$	295,078	$	339,804
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts payable	$	12,694	$	17,983
Accrued expenses	39,002		39,380
Deferred revenue	2,512		2,738
Related-party debt, current	181		—
Lease liabilities, current	5,141		5,475
Other liabilities, current	453		74
Liabilities held for sale, current	—		3,319
Total current liabilities	59,983		68,969
Related-party debt, noncurrent	—		281
Debt, noncurrent	141,255		145,962
Deferred tax liabilities	1,202		1,200
Lease liabilities, noncurrent	6,947		8,741
Other liabilities, noncurrent	276		727
Liabilities held for sale, noncurrent	—		7,787
Total liabilities	209,663		233,667
Commitments and Contingencies (Note 16)
Stockholders’ Equity:
Common stock	2		2
Additional paid-in capital	694,554		688,355
Treasury stock, at cost	(17,000)		(17,000)
Accumulated deficit	(593,419)		(566,209)
Total UpHealth, Inc., stockholders’ equity	84,137		105,148
Noncontrolling interests	1,278		989
Total stockholders’ equity	85,415		106,137
Total liabilities and stockholders’ equity	$	295,078	$	339,804

The accompanying notes are an integral part of these condensed consolidated financial statements.

4

UPHEALTH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts, unaudited)

	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
Revenues:
Services	$	31,087	$	28,096	$	62,028	$	53,782
Licenses and subscriptions	2,852		6,812		4,788		8,593
Products	3,884		8,760		13,152		17,265
Total revenues	37,823		43,668		79,968		79,640
Costs of revenues:
Services	14,954		16,232		28,698		31,990
License and subscriptions	403		217		722		450
Products	2,490		6,296		7,896		12,286
Total costs of revenues	17,847		22,745		37,316		44,726
Gross profit	19,976		20,923		42,652		34,914
Operating expenses:
Sales and marketing	2,421		3,539		7,040		6,973
Research and development	848		2,011		2,133		3,769
General and administrative	12,765		12,880		23,774		24,347
Depreciation and amortization	1,736		4,700		3,347		9,936
Stock-based compensation	1,058		1,088		2,047		2,462
Impairment of goodwill, intangible assets, and other long-lived assets	8,246		—		8,741		6,249
Acquisition, integration, and transformation costs	3,644		6,749		7,090		9,133
Total operating expenses	30,718		30,967		54,172		62,869
Loss from operations	(10,742)		(10,044)		(11,520)		(27,955)
Other expense:
Interest expense	(7,136)		(6,603)		(13,994)		(13,598)
Other income, net, including interest income	126		1,950		127		6,858
Total other expense	(7,010)		(4,653)		(13,867)		(6,740)
Loss before income tax benefit (expense)	(17,752)		(14,697)		(25,387)		(34,695)
Income tax benefit (expense)	(867)		2,232		(867)		4,525
Net loss	(18,619)		(12,465)		(26,254)		(30,170)
Less: net income (loss) attributable to noncontrolling interests	508		(27)		956		(287)
Net loss attributable to UpHealth, Inc.	$	(19,127)	$	(12,438)	$	(27,210)	$	(29,883)
Net loss per share attributable to UpHealth, Inc.:
Basic and diluted	$	(1.05)	$	(0.86)	$	(1.60)	$	(2.07)
Weighted average shares outstanding:(1)
Basic and diluted	18,220		14,462		16,975		14,458

(1)Amounts as of June 30, 2022 and before that date differ from those published in our prior condensed consolidated financial statements as they were retrospectively adjusted as a result of the Reverse Stock Split (as described below in Note 1, Organization and Business). Specifically, the number of common shares outstanding during periods before the Reverse Stock Split are divided by the exchange ratio of 10:1, such that each ten shares of common stock were combined and reconstituted into one share of common stock effective December 8, 2022.

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

UPHEALTH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(In thousands, unaudited)

	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
Net loss	$	(18,619)	$	(12,465)	$	(26,254)	$	(30,170)
Foreign currency translation adjustments, net of tax	—		(2,480)		—		(3,857)
Comprehensive loss	(18,619)		(14,945)		(26,254)		(34,027)
Comprehensive income (loss) attributable to noncontrolling interests	508		(27)		956		(287)
Comprehensive loss attributable to UpHealth, Inc.	$	(19,127)	$	(14,918)	$	(27,210)	$	(33,740)

The accompanying notes are an integral part of these condensed consolidated financial statements.

6

UPHEALTH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(In thousands, unaudited)

	Common Stock					Treasury Stock
	Shares	Amount		Additional Paid-In Capital		Shares	Amount		Accumulated Deficit		Total UpHealth, Inc. Stockholders’ Equity		Noncontrolling Interests		Total Stockholders’ Equity
Balance as of January 1, 2023	15,054	$	2	$	688,355	170	$	(17,000)	$	(566,209)	$	105,148	$	989	$	106,137
Equity award activity, net of shares withheld for taxes	80	—		(3)		—	—		—		(3)		—		(3)
Issuance of common stock in connection with 2023 private placement, net of issuance costs of $348	1,650	—		4,155		—	—		—		4,155		—		4,155
Stock-based compensation	—	—		989		—	—		—		989		—		989
Distribution to noncontrolling interests	—	—		—		—	—		—		—		(44)		(44)
Net loss	—	—		—		—	—		(8,083)		(8,083)		448		(7,635)
Balance as of March 31, 2023	16,784	2		693,496		170	(17,000)		(574,292)		102,206		1,393		103,599
Equity award activity, net of shares withheld for taxes	277	—		—		—	—		—		—		—		—
Exercise of pre-funded warrants	100	—		—		—	—		—		—		—		—
Stock-based compensation	—	—		1,058		—	—		—		1,058		—		1,058
Distribution to noncontrolling interests	—	—		—		—	—		—		—		(623)		(623)
Net loss	—	—		—		—	—		(19,127)		(19,127)		508		(18,619)
Balance at June 30, 2023	17,161	$	2	$	694,554	170	$	(17,000)	$	(593,419)	$	84,137	$	1,278	$	85,415

7

	Common Stock					Treasury Stock
	Shares	Amount		Additional Paid-In Capital		Shares	Amount		Accumulated Deficit		Accumulated Other Comprehensive Loss		Total UpHealth, Inc. Stockholders’ Equity		Noncontrolling Interests		Total Stockholders’ Equity
Balance as of January 1, 2022(1)	14,428	$	1	$	665,474	—	$	—	$	(343,209)	$	(3,802)	$	318,464	$	15,379	$	333,843
Equity award activity, net of shares withheld for taxes(1)	37	—		(67)		—	—		—		—		(67)		—		(67)
Stock-based compensation	—	—		1,374		—	—		—		—		1,374		—		1,374
Net loss	—	—		—		—	—		(17,445)		—		(17,445)		(260)		(17,705)
Foreign currency translation adjustments	—	—		—		—	—		—		(1,377)		(1,377)		—		(1,377)
Balance as of March 31, 2022(1)	14,465	1		666,781		—	—		(360,654)		(5,179)		300,949		15,119		316,068
Equity award activity, net of shares withheld for taxes(1)	390	1		(1,159)		—	—		—		—		(1,158)		—		(1,158)
Stock-based compensation	—	—		1,088		—	—		—		—		1,088		—		1,088
Common stock repurchased in connection with forward share purchase agreement(1)	(170)	—		17,000		170	(17,000)		—		—		—		—		—
Purchase of noncontrolling interest	—	—		—		—	—		—		—		—		(30)		(30)
Distribution to noncontrolling interests	—	—		—		—	—		—		—		—		(139)		(139)
Net loss	—	—		—		—	—		(12,438)		—		(12,438)		(27)		(12,465)
Foreign currency translation adjustments	—	—		—		—	—		—		(2,480)		(2,480)		—		(2,480)
Balance at June 30, 2022(1)	14,685	$	2	$	683,710	170	$	(17,000)	$	(373,092)	$	(7,659)	$	285,961	$	14,923	$	300,884

(1)Amounts as of June 30, 2022 and before that date differ from those published in our prior condensed consolidated financial statements as they were retrospectively adjusted as a result of the Reverse Stock Split (as described below in Note 1, Organization and Business). Specifically, the number of common shares outstanding during periods before the Reverse Stock Split are divided by the exchange ratio of 10:1, such that each ten shares of common stock were combined and reconstituted into one share of common stock effective December 8, 2022.

The accompanying notes are an integral part of these condensed consolidated financial statements.

8

UPHEALTH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands, unaudited)

	Six Months Ended June 30,
	2023		2022
Operating activities:
Net loss	$	(26,254)	$	(30,170)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	5,461		12,725
Amortization of debt issuance costs and discount on convertible debt	5,566		6,969
Stock-based compensation	2,047		2,462
Impairment of property and equipment, goodwill, intangible assets, and other long-lived assets	8,741		5,459
Provision for credit losses	19		(37)
Loss (gain) on fair value of warrant liabilities	8		(190)
Loss (gain) on fair value of derivative liability	3		(6,670)
Deferred income taxes	—		(4,596)
Amortization of operating lease right-of-use assets	1,116		—
Changes in operating assets and liabilities, net of effects of acquisitions:
Accounts receivable	(432)		(6,151)
Inventories	142		(55)
Prepaid expenses and other current assets	(1,016)		540
Accounts payable and accrued expenses	(5,653)		8,347
Operating lease liabilities	(1,170)		—
Deferred revenue	(225)		3,838
Other liabilities	(406)		(312)
Net cash used in operating activities	(12,053)		(7,841)
Investing activities:
Purchases of property and equipment	(2,918)		(3,783)
Proceeds from sale of business, net of expenses	54,861		—
Net cash provided by (used in) investing activities	51,943		(3,783)
Financing activities:
Proceeds from equity issuance	4,155		—
Repayments of debt	(10,273)		—
Payment of debt issuance costs	—		(3,234)
Repayment of forward share purchase	—		(18,521)
Payments of finance and capital lease obligations	(1,756)		(1,619)
Net tax withholdings from share-based compensation	(3)		(67)
Payments of amounts due to members	(100)		—
Distribution to noncontrolling interest	(667)		(139)
Net cash used in financing activities	(8,644)		(23,580)
Effect of exchange rate changes on cash and cash equivalents	—		(460)
Net increase (decrease) in cash and cash equivalents	31,246		(35,664)
Cash and cash equivalents, beginning of period	15,557		76,801
Cash and cash equivalents, end of period	$	46,803	$	41,137
Supplemental cash flow information:
Cash paid for interest	$	8,496	$	5,269
Cash paid for income taxes	$	457	$	521
Non-cash investing and financing activity:
Property and equipment reclassified from other assets	$	—	$	3,751
Property and equipment acquired through capital lease and vendor financing arrangements	$	179	$	1,628
FIN 48 liability reclassified from deferred tax liabilities	$	—	$	1,750
Reconciliation of cash and cash equivalents and restricted cash:
Cash and cash equivalents	$	46,803	$	40,629
Restricted cash	—		508
Total cash and cash equivalents and restricted cash	$	46,803	$	41,137

The accompanying notes are an integral part of these financial statements.

9

UPHEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in dollars, unaudited) 

1.Organization and Business

UpHealth, Inc. (“UpHealth,” “we,” “us,” “our,” “UpHealth,” or the “Company”) is the parent company of both UpHealth Holdings, Inc. (“UpHealth Holdings”) and Cloudbreak Health, LLC (“Cloudbreak”).

GigCapital2, Inc. (“GigCapital2”), the Company’s predecessor, was incorporated in Delaware on March 6, 2019. GigCapital2 was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company’s business combinations (the “Business Combinations”) were consummated on June 9, 2021, and in connection with the Business Combinations, GigCapital2 changed its corporate name to UpHealth, Inc.

Deconsolidation of Glocal

As a result of events which occurred in the three months ended September 30, 2022, we determined that a reconsideration event occurred in July 2022, which required us to reassess whether Glocal Healthcare Systems Private Limited (“Glocal”), which was included in our Virtual Care Infrastructure segment, was a Variable Interest Entity (“VIE”) and whether we continued to have a controlling financial interest in Glocal. Based on this assessment, we concluded that Glocal was a VIE, and furthermore, that we no longer had the ability to direct any activities of Glocal and no longer have a controlling financial interest. As a result, effective July 2022, we deconsolidated Glocal and recorded a $37.7 million loss on deconsolidation of equity investment in our unaudited condensed consolidated statements of operations, measured as the difference between the probability-weighted fair value of Glocal of $21.2 million and the carrying amount of Glocal’s assets and liabilities as of July 1, 2022. The probability-weighted fair value of Glocal, which is included in equity investment in our unaudited condensed consolidated balance sheets, incorporated scenarios where control of Glocal was gained and Glocal would continue as a going concern, control of Glocal was gained and Glocal would need to be liquidated, and control of Glocal was not gained and the equity investment in Glocal would be worthless. Further, we assessed the prospective accounting for our equity investment in Glocal. Since we no longer had the ability to exercise significant influence over operating and financial policies of Glocal, we concluded the investment should be accounted for utilizing the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification Topic 321, Investments - Equity Securities (“ASC 321”) measurement alternative, whereby the investment was measured at cost and will continue to be evaluated for any indicators of impairment. In addition, we derecognized $14.3 million of noncontrolling interests related to Glocal. In the six months ended June 30, 2023, there has been no change in the status of Glocal, and accordingly, we continue to account for it as an equity investment. If through legal processes we are able to obtain the ability to direct the activities of Glocal, and it is our intent to exercise all legal rights and remedies to achieve such a result, then we will further reassess the appropriate accounting treatment of our investment in Glocal.

The financial results of Glocal in the three and six months ended June 30, 2022 are included in our unaudited condensed consolidated financial statements, and the financial position of Glocal as of June 30, 2023 and December 31, 2022 and the financial results of Glocal in the three and six months ended June 30, 2023 are not included in our unaudited condensed consolidated financial statements. The only transactions between us and Glocal subsequent to July 1, 2022 was the transfer by us in the three months ended September 30, 2022 of $5.1 million to a designated “Share Account” maintained with a leading bank in India in the name of Glocal for which our Chief Financial Officer is the sole authorized signatory.

Reverse Stock Split

On December 5, 2022 our stockholders approved an amendment to our Second Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) to effect a reverse split of the outstanding shares of our common stock, par value $0.0001 per share, at a specific ratio within a range of 4:1 to 10:1, with the specific ratio to be fixed within this range by our board of directors in its sole discretion without further stockholder approval (the “Reverse Stock Split”). Our board of directors fixed the Reverse Stock Split ratio at 10:1, such that each ten shares of common stock were combined and reconstituted into one share of common stock effective December 8, 2022. Except as noted, all share, stock option, restricted stock unit (“RSU”), and per share information throughout this Quarterly Report on Form 10-Q (this “Quarterly Report”) has been retroactively adjusted to reflect this Reverse Stock Split.

Sale of Innovations Group

On February 26, 2023, we agreed to sell 100% of the outstanding capital stock of our wholly owned subsidiary, Innovations Group, Inc. (“Innovations Group”), to Belmar MidCo, Inc., a Delaware corporation and a wholly owned subsidiary of Belmar Holdings, Inc., a Delaware corporation, a portfolio company of Webster Capital IV, L.P., a Delaware limited partnership, pursuant to a stock purchase agreement (the “Stock Purchase Agreement”), dated February 26, 2023. The sale closed on May 11, 2023 for gross proceeds of $56.0 million, subject to working capital, closing debt, and other adjustments. See Note 3, Significant Transactions, for further information.

10

2.Summary of Significant Accounting Policies

Basis of Presentation and Principles of Consolidation

Our accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information and the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Our unaudited condensed consolidated financial statements, including the condensed notes thereto, are unaudited and exclude some of the disclosures required in audited consolidated financial statements. Our unaudited condensed consolidated balance sheet as of December 31, 2022 has been derived from our audited consolidated financial statements as of that date, but do not include all of the information and footnotes required by U.S. GAAP for complete financial statements.

In the opinion of management, our accompanying unaudited condensed consolidated financial statements contain all adjustments and eliminations, consisting only of normal recurring adjustments necessary for a fair presentation in conformity with U.S. GAAP. The results of operations in the three months ended June 30, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023 or any future period. Our accompanying unaudited condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements for the year ended December 31, 2022.

Our unaudited condensed consolidated financial statements include the accounts of UpHealth and its consolidated subsidiaries. As described in Note 1, Organization and Business, our Glocal subsidiary was deconsolidated effective July 2022.

All intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts in the unaudited condensed consolidated financial statements and accompanying notes thereto.

Significant estimates and assumptions made by management include the determination of:

•The identification and reporting of variable interest entities (“VIEs”). We consolidate VIEs when we have variable interests and are the primary beneficiary. We continually evaluate our involvement with VIEs to determine when these criteria are met.

•The valuation of equity investments, including our determination of the carrying value of Glocal;

•The valuation of assets acquired and liabilities assumed for business combinations, including intangible assets and goodwill;

•The estimated economic lives and recoverability of intangible assets;

•The valuations prepared in connection with the review of goodwill, intangible assets, and other long-lived assets for impairment:

•The timing and amount of revenues to be recognized, including standalone selling price (“SSP”) of performance obligations for revenue contracts with multiple performance obligations;

•The identification of and provision for uncollectible accounts receivable;

•The capitalization and useful life of internal-use software development costs;

•The valuation of derivatives and warrants; and

•The recognition, measurement, and valuation of current and deferred income taxes and uncertain tax positions.

Actual results could differ materially from those estimates. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the result of which forms the basis for making judgments about the carrying values of assets and liabilities.

Allowance for Expected Credit Losses

We closely monitor our accounts receivable balances and estimate the allowance for expected credit losses. The estimate is primarily based on historical collection experience and other factors, including those related to current market conditions and events. Credit losses associated with accounts receivable have not been material historically.

Equity Investment

11

As discussed in Deconsolidation of Equity Investment in Note 1, Organization and Business, as of June 30, 2023 and December 31, 2022, we held an interest in the privately-held equity securities of Glocal in which we did not have a controlling interest and were unable to exercise significant influence. Based on the terms of these privately-held securities, we concluded the investment should be accounted for utilizing the Accounting Standards Codification (“ASC”) 321 measurement alternative, whereby the investment was measured at cost and will continue to be evaluated for any indicators of impairment.

Held for Sale

Assets and liabilities to be disposed of by sale (“disposal groups”) are reclassified into assets and liabilities held for sale on our consolidated balance sheets as of December 31, 2022. The reclassification occurs when an agreement to sell exists, or management has committed to a plan to sell the assets within one year. Disposal groups are measured at the lower of carrying value or fair value less costs to sell and are not depreciated or amortized. When the net realizable value of a disposal group increases during a period, a gain can be recognized to the extent that it does not increase the value of the disposal group beyond its original carrying value when the disposal group was reclassified as held for sale. The fair value of a disposal group, less any costs to sell, is assessed each reporting period it remains classified as held for sale and any remeasurement to the lower of carrying value or fair value less costs to sell is reported as an adjustment to the carrying value of the disposal group. and reported in impairment of goodwill, intangible assets, and other long-lived assets in our unaudited condensed consolidated statements of operations.

New Accounting Pronouncements Not Yet Adopted

In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). This ASU simplifies the accounting for convertible instruments by eliminating the conversion option separation model for convertible debt that can be settled in cash and by eliminating the measurement model for beneficial conversion features. Convertible instruments that continue to be subject to separation models are (1) those with conversion options that are required to be accounted for as bifurcated derivatives and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. This ASU also requires entities to use the if-converted method for all convertible instruments in the diluted earnings per share calculation and include the effect of share settlement for instruments that may be settled in cash or shares, except for certain liability-classified share-based payment awards. This ASU will be effective for us on January 1, 2024. Early adoption is permitted, but no earlier than the fiscal year beginning on January 1, 2021, including interim periods within that fiscal year. We are currently evaluating the effect of the adoption of this ASU will have on our unaudited condensed consolidated financial statements.

Recently Adopted Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, and subsequently issued several supplemental/clarifying ASUs (collectively, “ASC 326”). This ASU requires entities to estimate a lifetime expected credit loss for most financial assets, including trade and other receivables, other long-term financings including available for sale and held-to-maturity debt securities, and loans. Subsequently, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments-Credit Losses, which amended the scope of ASC 326 and clarified that receivables arising from operating leases are not within the scope of the standard and should continue to be accounted for in accordance with ASC 842. This ASU was effective for us on January 1, 2023, and the adoption did not have a material effect on our unaudited condensed consolidated financial statements.

Reclassifications

Certain prior period amounts have been reclassified to conform to the current year presentation as shown below:

12

	Three Months Ended June 30, 2022						Six Months Ended June 30, 2022
	As Reported		Reclassifications		As Adjusted		As Reported		Reclassifications		As Adjusted
Revenues:
Services	$	28,096	$	—	$	28,096	$	53,782	$	—	$	53,782
Licenses and subscriptions	6,812		—		6,812		8,593		—		8,593
Products	8,760		—		8,760		17,265		—		17,265
Total revenues	43,668		—		43,668		79,640		—		79,640
Costs of revenues:
Services	14,762		1,470		16,232		29,207		2,783		31,990
License and subscriptions	217		—		217		450		—		450
Products	6,296		—		6,296		12,286		—		12,286
Total costs of revenues	21,275		1,470		22,745		41,943		2,783		44,726
Gross profit	22,393		(1,470)		20,923		37,697		(2,783)		34,914
Operating expenses:
Sales and marketing	3,486		53		3,539		6,212		761		6,973
Research and development	1,782		229		2,011		3,369		400		3,769
General and administrative	14,632		(1,752)		12,880		28,291		(3,944)		24,347
Depreciation and amortization	4,700		—		4,700		9,936		—		9,936
Stock-based compensation	1,088		—		1,088		2,462		—		2,462
Impairment of goodwill, intangible assets, and other long-lived assets	—		—		—		6,174		75		6,249
Acquisition, integration, and transformation costs	6,749		—		6,749		9,208		(75)		9,133
Total operating expenses	32,437		(1,470)		30,967		65,652		(2,783)		62,869
Loss from operations	(10,044)		—		(10,044)		(27,955)		—		(27,955)
Other expense:
Interest expense	(6,603)		—		(6,603)		(13,598)		—		(13,598)
Other income, net, including interest income	1,950		—		1,950		6,858		—		6,858
Total other expense	(4,653)		—		(4,653)		(6,740)		—		(6,740)
Loss before income tax benefit (expense)	(14,697)		—		(14,697)		(34,695)		—		(34,695)
Income tax benefit (expense)	2,232		—		2,232		4,525		—		4,525
Net loss	(12,465)		—		(12,465)		(30,170)		—		(30,170)
Less: net loss attributable to noncontrolling interests	(27)		—		(27)		(287)		—		(287)
Net loss attributable to UpHealth, Inc.	$	(12,438)	$	—	$	(12,438)	$	(29,883)	$	—	$	(29,883)

Certain prior period amounts have been reclassified to conform with our current period presentation.

3. Significant Transactions

Sale of Innovations Group

On February 26, 2023, we agreed to sell 100% of the outstanding capital stock of our wholly owned subsidiary, Innovations Group, to Belmar MidCo, Inc., a Delaware corporation and a wholly owned subsidiary of Belmar Holdings, Inc., a Delaware corporation, a portfolio company of Webster Capital IV, L.P., a Delaware limited partnership, pursuant to the Stock Purchase Agreement dated February 26, 2023. The sale closed on May 11, 2023 for gross proceeds of $56.0 million, subject to working capital, closing debt, and other adjustments. Accordingly, the financial results of Innovations Group for the period from April 1, 2023 through May 10, 2023, the period from January 1, 2023 through May 10, 2023, and the three and six months ended June 30, 2022, and the financial position of Innovations Group as of December 31, 2022 are included in our unaudited condensed consolidated financial statements.

In connection with entering into this agreement, we concluded that the disposal group met the held for sale criteria and classified the assets and liabilities as held for sale as of December 31, 2022. There were no businesses classified as held for sale as of June 30, 2023. Assets and liabilities that were classified as held for sale were $65.3 million and $11.1 million, respectively, as of December 31, 2022.

In connection with the held for sale classification, upon the remeasurement of the disposal group to its fair value, less cost to sell, we recorded a loss of $0.5 million in the three months ended March 31, 2023 and a loss of $1.8 million in the three months ended December 31, 2022, which were recorded in impairment of goodwill, intangible assets, and other long-lived assets in the unaudited condensed consolidated statements of operations. In connection with the sale closing on May 11, 2023, based on net proceeds of $54.9 million, we recorded an additional loss of $1.4 million in the three months ended June 30, 2023, which was recorded in impairment of goodwill, intangible assets, and other long-lived assets in our unaudited condensed consolidated statements of operations.

13

4. Revenues

As discussed in Note 1, Organization and Business, we deconsolidated Glocal in the three months ended September 30, 2022; accordingly, the financial results of Glocal in the three and six months ended June 30, 2022 are included in our unaudited condensed consolidated financial statements, and the financial results of Glocal in the three and six months ended June 30, 2023 are not included in our unaudited condensed consolidated financial statements.

Revenues by geography consisted of the following:

	Three months ended June 30,				Six months ended June 30,
(In thousands)	2023		2022		2023		2022
Americas	$	37,823	$	40,073	$	79,968	$	72,736
Asia	—		3,595		—		6,904
Total revenues	$	37,823	$	43,668	$	79,968	$	79,640

Our revenues are entirely derived from the healthcare industry. Revenues recognized over-time were approximately 86% and 68% of the total revenues in the three months ended June 30, 2023 and 2022, respectively. Revenues recognized over-time were approximately 80% and 71% of the total revenues in the six months ended June 30, 2023 and 2022, respectively.

Contract Assets

There were no impairments of contract assets, consisting of unbilled receivables, in the three and six months ended June 30, 2023 and 2022.

The change in contract assets was as follows:

	Six Months Ended June 30,
(In thousands)	2023		2022
Unbilled receivables, beginning of period	$	694	$	784
Reclassifications to billed receivables	(694)		(232)
Revenues recognized in excess of period billings	711		417
Unbilled receivables, end of period	$	711	$	969

Contract Liabilities

The change in contract liabilities, consisting of deferred revenue, was as follows:

	Six Months Ended June 30,
(In thousands)	2023		2022
Deferred revenue, beginning of period	$	2,737	$	2,649
Revenues recognized from balances held at the beginning of the period	(2,620)		(1,998)
Revenues deferred from period collections on unfulfilled performance obligations	2,395		5,801
Deferred revenue, end of period	$	2,512	$	6,452

Revenues recognized ratably over time are generally billed in advance and includes software-as-a-service (“SaaS”) internet hosting, subscriptions, construction of digital hospitals and dispensaries, and related consulting, implementation, services support, and advisory services.

Revenues recognized as delivered over time include professional services billed on a time and materials basis, and fixed fee professional services and training classes that are primarily billed, delivered, and recognized within the same reporting period.

Approximately 3.1% and 3.3% of revenues recognized in the three and six months ended June 30, 2023, was from the deferred revenue balance existing as of December 31, 2022. Approximately 1% and 2.5% of revenues recognized in the three and six months ended June 30, 2022, was from the deferred revenue balance existing as of December 31, 2021.

Remaining Performance Obligations

Remaining performance obligations consisted of the following as of June 30, 2023:

14

(In thousands)	Remaining 2023		2024		Total
Subscriptions	$	2,882	$	3,739	$	6,621
Program management and professional services	1,143		963		2,106
Total	$	4,025	$	4,702	$	8,727

5. Supplemental Financial Statement Information

As discussed in Note 1, Organization and Business, we deconsolidated Glocal in the three months ended September 30, 2022; accordingly, the financial results of Glocal in the three and six months ended June 30, 2022 are included in our unaudited condensed consolidated financial statements, and the financial position of Glocal as of June 30, 2023 and December 31, 2022 and the financial results of Glocal in the three and six months ended June 30, 2023 are not included in our unaudited condensed consolidated financial statements.

Property and equipment consisted of the following: 

(In thousands)	June 30, 2023		December 31, 2022
Leasehold improvements	$	908	$	868
Electrical and other equipment	21		21
Computer equipment, furniture and fixtures	16,599		16,222
Vehicles	272		302
Capitalized software development costs	7,801		4,404
Capitalized software development costs in progress	1,322		2,590
	26,923		24,407
Accumulated depreciation and amortization	(12,926)		(10,338)
Total property and equipment, net	$	13,997	$	14,069

Depreciation expense was $1.9 million and $1.8 million in the three months ended June 30, 2023 and 2022, respectively, and $3.2 million and $3.2 million in the six months ended June 30, 2023 and 2022, respectively.

Accrued expenses consisted of the following:

(In thousands)	June 30, 2023		December 31, 2022
Accrued professional fees	$	14,885	$	14,245
Accrued products and licenses	17,820		17,820
Accrued interest on debt	673		741
Accrued payroll and bonuses	4,301		5,163
Due to related party	304		229
Income tax payable	796		388
Other accruals	223		794
Total accrued expenses	$	39,002	$	39,380

Other liabilities, noncurrent consisted of the following

(In thousands)	June 30, 2023		December 31, 2022
Derivative liability, noncurrent	$	59	$	56
Warrant liabilities, noncurrent	17		9
Other liabilities, noncurrent	200		662
Total other liabilities, noncurrent	$	276	$	727

Impairment of goodwill, intangible assets, and other long-lived assets consisted of the following:

15

	Three months ended June 30,				Six months ended June 30,
(In thousands)	2023		2022		2023		2022
Impairment of goodwill	$	7,797	$	—	$	8,292	$	5,494
Impairment of long-lived assets	449		—		449		75
Impairment of intangible assets	—		—		—		680
Total impairment of goodwill, intangible assets, and other long-lived assets:	$	8,246	$	—	$	8,741	$	6,249

Other income, net, including interest income consisted of the following:

	Three months ended June 30,				Six months ended June 30,
(In thousands)	2023		2022		2023		2022
Gain (loss) on fair value of derivative liability	$	(29)	$	1,841	$	(3)	$	6,670
Gain (loss) on fair value of warrant liabilities	—		95		(8)		190
Other income, net, including interest income	155		14		138		(2)
Total other income, net, including interest income	$	126	$	1,950	$	127	$	6,858

6. Intangible Assets

As discussed in Note 1, Organization and Business, we deconsolidated Glocal in the three months ended September 30, 2022; accordingly, the financial results of Glocal in the three and six months ended June 30, 2022 are included in our unaudited condensed consolidated financial statements, and the financial position of Glocal as of June 30, 2023 and December 31, 2022 and the financial results of Glocal in the three and six months ended June 30, 2023 are not included in our unaudited condensed consolidated financial statements.

The following table summarizes the gross carrying amount and accumulated amortization for intangible assets as of June 30, 2023:

(In thousands)	Trade Names		Technology and Intellectual Property		Customer Relationships		Total
Gross carrying amount as of June 30, 2023	$	15,242	$	10,634	$	17,613	$	43,489
Accumulated amortization	(4,012)		(5,521)		(4,887)		(14,420)
Intangible assets, net as of June 30, 2023	$	11,230	$	5,113	$	12,726	$	29,069

The following table summarizes the gross carrying amount and accumulated amortization for intangible assets as of December 31, 2022:

(In thousands)	Trade Names		Technology and Intellectual Property		Customer Relationships		Total
Gross carrying amount as of December 31, 2022	$	15,242	$	10,634	$	17,613	$	43,489
Accumulated amortization	(3,295)		(4,762)		(4,070)		(12,127)
Intangible assets, net as of December 31, 2022	$	11,947	$	5,872	$	13,543	$	31,362

No impairment charges were recognized in the three and six months ended June 30, 2023. No impairment charge was recognized in the three months ended June 30, 2022; however, an impairment charge of $0.7 million was recognized in the six months ended June 30, 2022 in our Services segment.

The estimated useful lives of trade names are 3-10 years, the estimated useful lives of technology and intellectual property are 5-7 years, and the estimated useful life of customer relationships is 10 years.

Amortization expense was $1.1 million and $4.2 million in the three months ended June 30, 2023 and 2022, respectively. Amortization expense was $2.3 million and $9.3 million in the six months ended June 30, 2023 and 2022, respectively.

16

The estimated amortization expense related to definite-lived intangible assets for the five succeeding years is as follows:

(In thousands)	Trade Name Amortization		Technology and Intellectual Property Amortization		Customer Relationships Amortization		Total
Remaining 2023	$	709	$	770	$	808	$	2,287
2024	1,417		1,540		1,616		4,573
2025	1,417		1,540		1,616		4,573
2026	1,417		909		1,616		3,942
2027	1,417		354		1,616		3,387
Thereafter	4,853		—		5,454		10,307
	$	11,230	$	5,113	$	12,726	$	29,069

7. Goodwill

In the three months ended June 30, 2023, we recorded an impairment charge of $6.4 million in our Services segment in connection with the wind-down of a company within our Behavioral business and an impairment charge of $1.4 million in our Services segment in connection with the strategic sale of Innovations Group, which was classified as held for sale. No impairment charge was recorded in the three months ended June 30, 2022. In the six months ended June 30, 2023 we recorded a $6.4 million impairment charge in our Services segment in connection with the wind down of a company within our Behavioral business, and a $1.9 million impairment charge in our Services segment in connection with the strategic sale of Innovations Group. See Note 3, Significant Transactions, for further information. In the six months ended June 30, 2022, as a result of measurement period adjustments in our Virtual Care Infrastructure segment, we increased goodwill in the amount of $5.5 million, which was immediately impaired.

The carrying amount of goodwill consisted of the following:

(In thousands)	Goodwill
Balance as of December 31, 2022	$	159,675
Impairments	(6,357)
Balance as of June 30, 2023	$	153,318

8. Debt

As discussed in Note 1, Organization and Business, we deconsolidated Glocal in the three months ended September 30, 2022; accordingly, the financial results of Glocal in the three and six months ended June 30, 2022 are included in our unaudited condensed consolidated financial statements, and the financial position of Glocal as of June 30, 2023 and December 31, 2022 and the financial results of Glocal in the three and six months ended June 30, 2023 are not included in our unaudited condensed consolidated financial statements.

Debt consisted of the following: 

(In thousands)	June 30, 2023		December 31, 2022
2025 Notes	$	57,227	$	67,500
2026 Notes	115,000		115,000
Total debt	172,227		182,500
Less: unamortized original issue and debt discount	(30,972)		(36,538)
Total debt, net of unamortized original issue and debt discount	141,255		145,962
Less: current portion of debt	—		—
Noncurrent portion of debt	$	141,255	$	145,962

2026 Unsecured Convertible Notes and Indenture

On January 20, 2021, GigCapital2 entered into convertible note subscription agreements, each dated January 20, 2021 and amended on June 8, 2021, with certain institutional investors, pursuant to which GigCapital2 agreed to issue and sell unsecured convertible notes in a private placement to close immediately prior to the closing of the Business Combinations.

17

On June 15, 2021, in connection with the closing of the Business Combinations, we entered into an indenture (the “2026 Indenture”) with Wilmington Trust, National Association, a national banking association, (the “Indenture Trustee”) in its capacity as trustee thereunder, in respect of the $160.0 million in aggregate principal amount of unsecured convertible notes due in 2026 (the “2026 Notes”) that were issued to certain institutional investors. The 2026 Notes bear interest at a rate of 6.25% per annum, payable semi-annually, and were convertible following the reverse split of our shares into approximately 1,502,347 shares of common stock at a conversion price of $106.50 in accordance with the terms of the 2026 Indenture, and will mature on June 15, 2026. The total proceeds received from the 2026 Notes were $151.9 million, net of debt issuance costs of $8.1 million. In accounting for the 2026 Notes, we bifurcated and accounted for the conversion option as a derivative measured at fair value on the issuance date in accordance with ASC 815, Derivatives and Hedging. The difference between the proceeds allocated to the 2026 Notes at issuance and the fair value of the conversion option was allocated to the host debt contract. As of June 30, 2023 and December 31, 2022, the fair value of the derivative was $59 thousand and $0.1 million, respectively, all of which was included in other liabilities, noncurrent, in our unaudited condensed consolidated balance sheets.

Interest expense in the three months ended June 30, 2023 was $4.3 million, of which $1.8 million related to contractual interest expense, $2.2 million related to derivative accretion, and $0.3 million related to debt issuance costs amortization. Interest expense in the three months ended June 30, 2022 was $6.0 million, of which $2.5 million related to contractual interest expense, $3.1 million related to derivative accretion, and $0.4 million related to debt issuance costs amortization. Interest expense in the six months ended June 30, 2023 was $8.6 million, of which $3.6 million related to contractual interest expense, $4.4 million related to derivative accretion, and $0.6 million related to debt issuance costs amortization. Interest expense in the six months ended June 30, 2022 was $12.0 million, of which $5.0 million related to contractual interest expense, $6.2 million related to derivative accretion, and $0.8 million related to debt issuance costs amortization.

Other income, net in the three months ended June 30, 2023 and 2022 included a $29 thousand loss and a $1.8 million gain on the fair value of the derivative liability, respectively. Other income, net in the six months ended June 30, 2023 and 2022 included a $3 thousand loss and a $6.7 million gain on the fair value of the derivative liability, respectively

On August 12, 2022, concurrently and in connection with the issuance of our 2025 senior secured convertible notes and indenture (see below), Oppenheimer & Co. Inc. (“OpCo”) commenced a private offer to repurchase approximately $45.0 million in aggregate principal amount of our 2026 Notes (the “2026 Notes Repurchase”). In connection with the 2026 Notes Repurchase, OpCo entered into a note purchase agreement with each institutional investor pursuant to which OpCo agreed to purchase 2026 Notes from each investor, concurrently with each investor’s purchase of 2025 Notes in the 2025 Notes Offering (see below). At the closing, each investor had the ability to sell $2.0 million in principal amount of 2026 Notes at 100% of par value for each $3.0 million in principal amount of 2025 Notes purchased in the 2025 Notes Offering. Concurrently and in connection with the closing on August 18, 2022, OpCo purchased from each investor the principal amount of the 2026 Notes set forth in each investor’s note purchase agreement, pursuant to and in accordance with the terms thereof. Following the reverse split of shares, the remaining 2026 Notes are convertible into approximately 1,079,812 shares of common stock at a conversion price of $106.50 in accordance with the terms of the Indenture.

2025 Senior Secured Convertible Notes and Indenture

On August 12, 2022, we entered into an indenture (the “2025 Indenture”) with the Indenture Trustee in its capacity as trustee thereunder, in respect of the $67.5 million in aggregate principal amount of a new series of variable rate convertible senior secured notes due December 15, 2025 (the “2025 Notes”) issued to holders of our 2026 Notes in a private placement transaction (“2025 Notes Offering”), raising approximately $22.5 million in gross cash proceeds, net of debt issuance costs of $2.2 million, after paying for a repurchase of $45.0 million of the 2026 Notes, which net proceeds were used in part to fully repay the Seller Notes (see below). The debt issuance costs consisted of cash paid in the amount of $1.5 million and the issuance of 115,000 shares of common stock, following the reverse stock split, with a value of $0.7 million. The 2025 Notes are convertible following the reverse split of our shares into 3,857,142 shares of our common stock at a conversion price, subject to the occurrence of certain corporate events, of $17.50 per share. The 2025 Notes are senior secured obligations of UpHealth, secured by substantially all of our assets and those of our domestic subsidiaries, and accrue interest at a rate equal to the daily secured overnight financing rate (“SOFR”) plus 9.0% per annum, with a minimum rate of 10.5% per annum, payable quarterly in arrears, for a quarterly rate of 12.21% for our December 15, 2022 interest payment date. The 2025 Notes will mature on December 15, 2025, unless earlier repurchased, redeemed or converted. Holders will have the right to convert their 2025 Notes at any time. Upon the occurrence of certain corporate events, holders of the 2025 Notes can require us to repurchase for cash all or part of their 2025 Notes in principal amounts of $1,000 or an integral multiple thereof at a repurchase price that will be equal to 105% of the principal amount of the 2025 Notes to be repurchased, plus accrued and unpaid interest thereon, if any. In the event that we sell assets with net proceeds in excess of $15.0 million, then it will make an offer to all holders of the 2025 Notes to repurchase the 2025 Notes for an aggregate amount of cash equal to 20.0% of the net proceeds of such asset sale, at a repurchase price per 2025 Note equal to 100.0% of the principal amount thereof, plus accrued and unpaid interest, if any. We may not otherwise seek to redeem the 2025 Notes prior to June 16, 2024. We will settle conversions solely in shares of its common stock, except for payments of cash in lieu of fractional shares.

As discussed in Note 3, Significant Transactions, on May 11, 2023 we completed the sale of 100% of the outstanding capital stock of Innovations Group. In accordance with the terms and conditions set forth in the 2025 Indenture, on June 9, 2023, we

18

commenced an offer to purchase up to $10.3 million (representing 20% of the net proceeds from the sale subject to adjustment to maintain the authorized denominations of the 2025 Notes) in aggregate principal amount of our 2025 Notes for cash, at a repurchase price per Note equal to 100% of the principal amount thereof, plus accrued and unpaid interest (if any), from the holders of the 2025 Notes (the “Offer”). On June 15, 2023, we completed the repurchase of $10.3 million in aggregate principal amount of 2025 Notes, which were validly tendered and accepted for repurchase by us in accordance with the terms and conditions of the Offer (the “Note Repurchase”), representing 15.22% of the outstanding principal amount of the 2025 Notes before the Note Repurchase. Following the completion of the Note Repurchase, there is $57.2 million in aggregate principal amount of 2025 Notes outstanding.

Total interest expense in the three months ended June 30, 2023 was $2.7 million, of which $2.3 million related to contractual interest expense and $0.4 million related to debt issuance costs amortization. Total interest expense in the six months ended June 30, 2023 was $5.2 million, of which $4.6 million related to contractual interest expense and $0.6 million related to debt issuance costs amortization. Included in the debt issuance costs amortization in the three and six months ended June 30, 2023 was a write-off of $0.3 million, which was the proportionate share of the remaining debt issuance costs related to the repurchased 2025 Notes.

In March 2023, the Indenture Trustee, in its capacity as calculation agent, notified us of the quarterly rate reset of 14.03% for our June 15, 2023 interest payment date. In June 2023, the Indenture Trustee, in its capacity as calculation agent, notified us of the quarterly rate reset of 14.25% for our September 15, 2023 interest payment date.

Related Party Debt

One of our subsidiaries has notes payable to related parties totaling $0.2 million and $0.3 million as of June 30, 2023 and December 31, 2022. The notes bear interest at rates of 3.50% per annum. The notes are payable in eight quarterly installments starting from October 1, 2022, or upon a liquidity event, as defined in the note agreement. The accrued interest payable was zero as of both June 30, 2023 and December 31, 2022. Interest expense was $3 thousand and $11 thousand in the three months ended June 30, 2023 and 2022, respectively. Interest expense was $6 thousand and $21 thousand in the six months ended June 30, 2023 and 2022, respectively.

Seller Notes

As part of the purchase price consideration for several of UpHealth Holdings’ merger entities, we entered into seller notes payable to their former shareholders, which accrue interest at specific rates, per the respective merger agreements. On June 9, 2021, in connection with the closing of the Business Combination, we paid $88.1 million of the seller notes. In August 2021, we paid an additional $11.1 million of the seller notes and deferred the maturity date to September 2022. In August 2022, we paid the remaining $18.7 million of seller notes plus accrued interest of $1.9 million. As of both June 30, 2023 and December 31, 2022, the seller notes totaled zero.

Accrued interest payable was zero as of both June 30, 2023 and December 31, 2022. Interest expense was zero and $0.5 million in the three months ended June 30, 2023 and 2022, respectively. Interest expense was zero and $0.9 million in the six months ended June 30, 2023 and 2022, respectively.

9. Fair Value of Financial Instruments

We estimate the fair value of our financial instruments using available market information and valuation methodologies we believe to be appropriate. As of June 30, 2023 and December 31, 2022, the fair values of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued expenses approximate their carrying values due to the short-term nature of these instruments. Additionally, the fair values of short-term and long-term debt instruments approximate their carrying values.

The fair value hierarchy is as follows:

Level 1 - Quoted (unadjusted) prices in active markets for identical assets or liabilities.

Level 2 - Other observable inputs, either directly or indirectly, other than quoted prices included in Level 1, including:

•Quoted prices for similar assets/liabilities in active markets;

•Quoted prices for identical or similar assets/liabilities in non-active markets (e.g., few transactions, limited information, non-current prices, high variability over time);

•Inputs other than quoted prices that are observable for the asset/liability (e.g., interest rates, yield curves, volatilities, default rates); and

•Inputs that are derived principally from or corroborated by other observable market data.

Level 3 - Unobservable inputs that cannot be corroborated by observable market data.

The following tables present information about our financial assets and liabilities measured at fair value on are recurring basis:

19

	June 30, 2023
(In thousands)	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents - money market funds	$	37,918	$	—	$	—	$	37,918
	$	37,918	$	—	$	—	$	37,918
Liabilities:
Derivative liability	$	—	$	—	$	59	$	59
Warrant liability	—		17		—		17
	$	—	$	17	$	59	$	76

	December 31, 2022
(In thousands)	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents - money market funds	$	1,681	$	—	$	—	$	1,681
	$	1,681	$	—	$	—	$	1,681
Liabilities:
Derivative liability	$	—	$	—	$	56	$	56
Warrant liability	—		9		—		9
	$	—	$	9	$	56	$	65

Money Market Funds

As of June 30, 2023 and December 31, 2022, our cash equivalents consisted of money market funds which were classified as Level 1. We used observable prices in active markets in determining the classification of our money market funds as Level 1. There were no transfers between the hierarchy levels in the three and six months ended June 30, 2023 and the year ended December 31, 2022.

Cash equivalents as of June 30, 2023 and December 31, 2022 were as follows:

	June 30, 2023
(In thousands)	Amortized Cost		Unrealized Gain		Unrealized Loss		Fair Value
Cash equivalents:
Money market funds	$	37,918	$	—	$	—	$	37,918
Total cash equivalents	$	37,918	$	—	$	—	$	37,918

	December 31, 2022
(In thousands)	Amortized Cost		Unrealized Gain		Unrealized Loss		Fair Value
Cash equivalents:
Money market funds	$	1,681	$	—	$	—	$	1,681
Total cash equivalents	$	1,681	$	—	$	—	$	1,681

Derivative Liability

As of June 30, 2023 and December 31, 2022, the fair value of the derivative was $59 thousand and $56 thousand, respectively, which was included in other liabilities, noncurrent in our unaudited condensed consolidated balance sheets. Other income, net in the three months ended June 30, 2023 and 2022 included a loss of $29 thousand and a gain of $1.8 million, respectively, on the fair value of the derivative liability. Other income, net in the six months ended June 30, 2023 and 2022 included a loss of $3 thousand and a gain of $6.7 million, respectively, on the fair value of the derivative liability.

The fair value of the derivative liability is considered a Level 3 valuation and is determined using a Binomial Lattice Option Pricing Model. The significant assumptions used in the model were:

20

	June 30, 2023	December 31, 2022
Stock price	$1.90	$1.63
Volatility	100.0%	95.0%
Risk free rate	4.51%	4.17%
Exercise price	$106.50	$106.50
Expected life (in years)	2.95	3.44
Conversion periods	5 months-3 years	2-4 years
Future share price	$5.90-$594.30	$0.10-$405.60

2021 Private Placement Warrants and 2021 PIPE Warrants

As of June 30, 2023, the fair value of the 2021 Private Placement Warrants (the “2021 Private Placement Warrants”) and the 2021 PIPE Warrants (the “2021 PIPE Warrants”) was determined to be $0.02 per warrant, totaling $11 thousand and $6 thousand respectively, and are included in other liabilities, noncurrent in our unaudited condensed consolidated balance sheets. As of December 31, 2022, the fair value of the 2021 Private Placement Warrants and the 2021 PIPE Warrants was determined to be $0.01 per warrant, totaling $6 thousand and $3 thousand respectively, and are included in other liabilities, noncurrent in our unaudited condensed consolidated balance sheets. In the three months ended June 30, 2023, we recorded no gain or loss due to the fair value changes in the 2021 Private Placement Warrants and no gain or loss due to the fair value changes in the 2021 PIPE Warrants. In the three months ended June 30, 2022, we recorded a $0.1 million gain due to the fair value changes in the 2021 Private Placement Warrants and a $33 thousand gain due to the fair value changes in the 2021 PIPE Warrants, both of which are included in other income, net in our unaudited condensed consolidated statements of operations. In the six months ended June 30, 2023, we recorded a $5 thousand loss due to the fair value changes in the 2021 Private Placement Warrants and a $3 thousand loss due to the fair value changes in the 2021 PIPE Warrants, both of which are included in other income, net in our unaudited condensed consolidated statements of operations. In the six months ended June 30, 2022, we recorded a $0.1 million gain due to the fair value changes in the 2021 Private Placement Warrants and a $0.1 million gain due to the fair value changes in the 2021 PIPE Warrants, both of which are included in other income, net in our unaudited condensed consolidated statements of operations.

There were no transfers between fair value levels in the three and six months ended June 30, 2023 and year ended December 31, 2022.

10. Capital Structure

2023 Private Placement

On March 9, 2023, we entered into a Securities Purchase Agreement, with a single institutional investor, pursuant to which, in a private placement (the “2023 Private Placement”), we agreed to issue and sell (i) 1,650,000 shares of our common stock, par value $0.0001 per share; (ii) warrants that are exercisable six months from the date of issuance and will have a term of five years from the initial exercise date to purchase up to an additional 3,000,000 shares of our common stock (the “Series A Warrants”); (iii) warrants that are exercisable six months from the date of issuance and will have a term of two years from the initial exercise date to purchase up to an additional 3,000,000 shares of our common stock (the “Series B Warrants” and, collectively with Series A Warrants, the “Common Stock Purchase Warrants”); and (iv) pre-funded warrants (the “Pre-Funded Warrants,” and together with the Common Stock Purchase Warrants, the “Private Placement Warrants”) to purchase an additional 1,350,000 shares of our common stock (all of such shares issuable upon exercise of the Warrants, the “Warrant Shares”). On March 13, 2023, we announced that we completed the closing of the 2023 Private Placement. The purchase price of each share of common stock sold in the 2023 Private Placement was $1.50, the exercise price of each Common Stock Purchase Warrants (as defined above) is $2.04, and the exercise price of each Pre-Funded Warrant is $0.0001 and the purchase price of each Pre-Funded Warrant was $1.4999. The aggregate gross proceeds to us from the 2023 Private Placement were approximately $4.5 million, before deducting $0.3 million of placement agent fees and other offering expenses. We intend to use the net proceeds from the offering for general corporate purposes, including working capital.

On June 6, 2023, 100,000 Pre-Funded Warrants were exercised, bringing the total outstanding to 1,250,000 as of June 30, 2023.

Common Stock Reserved for Future Issuance

The following table summarizes shares of common stock reserved for future issuance as of June 30, 2023 (recorded on a post-reverse split basis):

21

(In thousands)	Number of Shares
Restricted stock units outstanding	2,222
Stock options outstanding	54
Shares issuable upon conversion of 2025 Notes	3,857
Shares issuable upon conversion of 2026 Notes	1,080
Shares issuable upon conversion of 2021 Public Warrants	1,725
Shares issuable upon conversion of 2021 Private Warrants	57
Shares issuable upon conversion of 2021 PIPE Warrants	29
Shares issuable upon conversion of the 2023 Private Placement Series A Warrants	3,000
Shares issuable upon conversion of the 2023 Private Placement Series B Warrants	3,000
Shares issuable upon conversion of the 2023 Private Placement Pre-Funded Warrants	1,250
Shares available for future grant under 2021 EIP	575
	16,849

2015 Cloudbreak Incentive Plan

The following table summarizes stock option activity under the Cloudbreak Plan (recorded on a post-reverse split basis):

	Number of Shares	Weighted Average Exercise Price Per Share
Outstanding as of December 31, 2022	138	$	50.76
Options exercised	—	$	—
Outstanding as of March 31, 2023	138	$	50.76
Options forfeited or expired	(84)	$	53.00
Outstanding as of June 30, 2023	54	$	47.35

2021 Equity Incentive Plan

The following table summarizes our RSU activity under the 2021 EIP (recorded on a post-reverse split basis):

	Number of Shares	Weighted Average Grant Date Fair Value Per Share
Outstanding as of December 31, 2022	878	$	6.61
RSUs granted	663	$	2.03
RSUs vested and released	(82)	$	16.09
RSUs forfeited	(118)	$	7.10
Outstanding as of March 31, 2023	1,341	$	3.91
RSUs granted	1,000	$	1.56
RSUs vested and released	(277)	$	5.67
RSUs forfeited	(42)	$	1.95
Outstanding as of June 30, 2023	2,022	$	2.55

2023 Inducement Equity Incentive Plan

On May 1, 2023, our Board of Directors approved up to 700,000 shares to be issued under a 2023 Inducement Equity Incentive Plan, the “2023 IEIP”. The following table summarizes our RSU activity under the 2023 IEIP:

22

	Number of Shares	Weighted Average Grant Date Fair Value Per Share
Outstanding as of December 31, 2022	—	$	—
RSUs granted	200	$	1.24
RSUs vested and released	—	$	—
RSUs forfeited	—	$	—
Outstanding as of June 30, 2023	200	$	1.24

11. Income Taxes

As discussed in Note 1, Organization and Business, we deconsolidated Glocal in the three months ended September 30, 2022; accordingly, the financial results of Glocal in the three and six months ended June 30, 2022 are included in our unaudited condensed consolidated financial statements, and the financial position of Glocal as of June 30, 2023 and December 31, 2022 and the financial results of Glocal in the three and six months ended June 30, 2023 are not included in our unaudited condensed consolidated financial statements.

The income tax benefit (expense) was $(0.9) million and $2.2 million in the three months ended June 30, 2023 and 2022, respectively. The income tax benefit (expense) was $(0.9) million and $4.5 million in the six months ended June 30, 2023 and 2022, respectively.

Consistent with our conclusion as of December 31, 2022, we continue to believe that it is not more likely than not that the deferred tax assets will be realized and we therefore maintained a full valuation allowance against the deferred tax assets as of June 30, 2023. However, we expect to suffer minimal income tax expense due to U.S. tax rules related to the utilization of net operating loss carryforwards. As a result, in the three and six months ended June 30, 2023, we recorded discrete tax items totaling $0.6 million related to the sale of Innovations Group and state minimum income taxes totaling $0.3 million.

The Internal Revenue Service (“IRS”) audited the 2008 and 2009 tax returns for a business in our Integrated Care Management segment for the proper year of inclusion of approximately $15.0 million long-term capital gain on the sale of certain intellectual property rights. The business originally reported the gain on its 2010 S Corporation tax return, matching the year of inclusion for financial accounting purposes. The corporate level tax was paid to California and the business passed the gain through to its shareholders. The IRS has asserted that the business owes C Corporation tax of approximately $5.0 million for 2008, or in the alternative, the business owes C Corporation tax of approximately $5.0 million for 2009 as a built-in gain. In addition, the business could be assessed additional California franchise tax of approximately $1.3 million; and if additional income taxes are imposed, interest will be charged at approximately 4% per year, compounded annually, resulting in potential interest of approximately $3.0 million. The IRS has not asked that penalties be imposed.

The matter is currently pending before the U.S. Tax Court, Docket 11565-15. There are related tax cases for some of the former shareholders of the business for additional income taxes due if the gain is shifted to 2009. On December 4, 2018, the IRS filed a motion for summary judgment; however, the business prevailed, and the motion was denied. In January 2020, the business filed a motion for summary judgment arguing that either the gain was properly reported in 2010 and all taxes have been paid or in the alternative it should have been taxable in 2009 with no built-in gains tax. In both cases, there would be no additional income tax due for 2008 or 2009. The IRS filed an objection to the business’ motion. On March 3, 2021, the U.S. Tax Court, without consideration of the merits of the case, issued a very brief court order dismissing the business’ motion. Had the motion been granted, the need for a trial would have been obviated. The business intends to vigorously defend its position in the case and believes it will prevail if the case is taken to trial. In addition, when we acquired the business in November 2020, all of the former shareholders of the business agreed to indemnify us for any losses as a result of this dispute with the IRS. We have accrued $0.2 million representing probable additional taxes and interest imposed, in other liabilities, current in the unaudited condensed consolidated balance sheets.

12. Earnings (Loss) Per Share

Basic earnings (loss) per share applicable to common stockholders is computed by dividing earnings applicable to common stockholders by the weighted average number of common shares outstanding. Diluted earnings (loss) per share assumes the conversion of any convertible securities using the treasury stock method or the if-converted method.

23

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands, except per share data)	2023		2022		2023		2022
Numerator:
Net income (loss) attributable to UpHealth, Inc.	$	(19,127)	$	(12,438)	$	(27,210)	$	(29,883)
Denominator:
Weighted average shares outstanding(1)	18,220		14,462		16,975		14,458
Diluted effect of stock options	—		—		—		—
Diluted effect of RSUs	—		—		—		—
Weighted average shares outstanding assuming dilution	18,220		14,462		16,975		14,458
Net income (loss) per share attributable to UpHealth, Inc.:
Basic	$	(1.05)	$	(0.86)	$	(1.60)	$	(2.07)
Diluted	$	(1.05)	$	(0.86)	$	(1.60)	$	(2.07)

(1) The shares and earnings per share as of June 30, 2022 differ from those published in our prior unaudited condensed consolidated financial statements as they were retrospectively adjusted as a result of the Reverse Stock Split (as described in Note 1, Organization and Business).

In the three months ended June 30, 2023, the calculation of basic and dilutive earnings per share included the 1.25 million pre-funded warrants with an exercise price of $0.0001, as the shares are issuable for little consideration, and excluded outstanding warrants to purchase 1.8 million shares of common stock at $115.00 per share; 6.0 million Common Stock Purchase Warrants at $2.04 per share; 0.1 million of stock options; 2.2 million of RSUs; 2025 Notes convertible into 3.9 million shares of common stock at a conversion price, subject to the occurrence of certain corporate events, of $17.50 per share; and 2026 Notes, convertible into 1.1 million shares of common stock at $106.50 per share, because the effect would be anti-dilutive. In the three months ended June 30, 2022, the calculation of dilutive earnings per share excluded outstanding warrants to purchase 1.8 million shares of common stock at $115.00 per share; 0.2 million of stock options; 0.4 million of RSUs; and 2026 Notes convertible into 1.5 million shares of common stock at $106.50 per share, because the effect would be anti-dilutive.

In the six months ended June 30, 2023, the calculation of basic and dilutive earnings per share included the 1.25 million pre-funded warrants with an exercise price of $0.0001, as the shares are issuable for little consideration, and excluded outstanding warrants to purchase 1.8 million shares of common stock at $115.00 per share; 6.0 million Common Stock Purchase Warrants at $2.04 per share; 0.1 million of stock options; 2.2 million of RSUs; 2025 Notes convertible into 3.9 million shares of common stock at a conversion price, subject to the occurrence of certain corporate events, of $17.50 per share; and 2026 Notes, convertible into 1.1 million shares of common stock at $106.50 per share, because the effect would be anti-dilutive. In the six months ended June 30, 2022, the calculation of dilutive earnings per share excluded outstanding warrants to purchase 1.8 million shares of common stock at $115.00 per share; 0.2 million of stock options; 0.4 million of RSUs; 2026 Notes convertible into 1.5 million shares of common stock at $106.50 per share; and 0.2 million shares of common stock under the terms of the forward share purchase agreement, because the effect would be anti-dilutive.

13. Related Party Transactions

See Note 8, Debt, for related party debt.

See Note 16, Commitments and Contingencies, for leases with related parties.

We make guaranteed payments to related parties. Guaranteed payments aggregated $0.2 million and $1.4 million in the three months ended June 30, 2023 and 2022, respectively, and $0.6 million and $2.8 million in the six months ended June 30, 2023 and 2022, respectively. These amounts are presented in cost of revenues in our unaudited condensed consolidated statements of operations. We had unpaid guaranteed payments of $6 thousand and $0.5 million as of June 30, 2023 and December 31, 2022, respectively, which is included in accrued expenses in our unaudited condensed consolidated balance sheets. 

Due to related parties consisted of $0.3 million and $0.2 million as of June 30, 2023 and December 31, 2022, respectively, which is included in accrued expenses in our unaudited condensed consolidated balance sheets. Due from related parties consisted $14 thousand as of December 31, 2022, which is included in prepaid expenses and other current assets in our unaudited condensed consolidated balance sheets.

14. Segment Reporting

Our business is organized into three operating business segments and one non-operating business segment:

24

•Virtual Care Infrastructure—consisting of U.S. Telehealth and International Telehealth businesses(1);

•Services—consisting of Behavioral and Pharmacy businesses(2);

•Integrated Care Management—consisting of SaaS business; and

•Corporate—consisting of holding company.

(1) As discussed in Note 1, Organization and Business, we deconsolidated Glocal in the three months ended September 30, 2022; accordingly, the financial results of Glocal in the three and six months ended June 30, 2022 are included in our unaudited condensed consolidated financial statements, and the financial results of Glocal as of June 30, 2023 and December 31, 2022 and in the three and six months ended June 30, 2023 are not included in our unaudited condensed consolidated financial statements.

(2) As discussed in Note 3, Significant Transactions, we completed the sale of Innovations Group, which comprised our Pharmacy business, on May 11, 2023. In addition, we substantially completed the wind down of a company within our Behavioral business in our Services segment in the three months ended June 30, 2023.

We evaluate performance based on several factors, of which Revenues, Gross Profit, and Total Assets are the primary financial measures:

Revenues by segment consisted of the following:

	Three Months Ended June 30,				Six Months Ended June 30,
In thousands	2023		2022		2023		2022
Virtual Care Infrastructure	$	16,838	$	16,815	$	34,296	$	32,445
Services	15,503		19,030		36,317		36,760
Integrated Care Management	5,482		7,823		9,355		10,435
Total revenues	$	37,823	$	43,668	$	79,968	$	79,640

Gross profit by segment consisted of the following:

	Three Months Ended June 30,				Six Months Ended June 30,
In thousands	2023		2022		2023		2022
Virtual Care Infrastructure	$	8,470	$	7,255	$	18,655	$	13,756
Services	7,728		6,774		17,639		12,626
Integrated Care Management	3,778		6,894		6,358		8,532
Total gross profit	$	19,976	$	20,923	$	42,652	$	34,914

Total assets by segment consisted of the following:

In thousands	June 30, 2023		December 31, 2022
Virtual Care Infrastructure	$	133,078	$	140,776
Services	48,981		124,980
Integrated Care Management	47,635		44,776
Corporate	65,384		29,272
Total assets	$	295,078	$	339,804

All long-lived assets were located in the U.S. as of June 30, 2023 and December 31, 2022.

15. Leases

The components of lease expense consisted of the following in the three and six months ended June 30, 2023:

25

	Three Months Ended June 30, 2023						Six Months Ended June 30, 2023
In thousands	Third Party		Related Party		Total		Third Party		Related Party		Total
Finance lease costs:
Amortization of right-of-use assets	$	847	$	—	$	847	$	1,732	$	—	$	1,732
Interest on lease liabilities	81		—		81		169		—		169
Operating lease costs	593		98		691		1,309		196		1,505
Short-term lease costs	39		—		39		66		67		133
Variable lease costs	309		—		309		453		—		453
Sublease income	(113)		—		(113)		(242)		—		(242)
Total lease costs	$	1,756	$	98	$	1,854	$	3,487	$	263	$	3,750

Lease-related assets and liabilities recorded on the unaudited condensed consolidated balance sheet are as follows:

	June 30, 2023						December 31, 2022
In thousands	Third Party		Related Party		Total		Third Party		Related Party		Total
Assets
Finance lease right-of-use assets (included in property and equipment, net)	$	4,804	$	—	$	4,804	$	5,916	$	—	$	5,916
Operating lease right-of-use assets	4,496		1,232		5,728		5,819		1,394		7,213
Total leased assets	$	9,300	$	1,232	$	10,532	$	11,735	$	1,394	$	13,129
Liabilities
Lease liabilities, current:
Finance lease liabilities	$	2,946	$	—	$	2,946	$	3,023	$	—	$	3,023
Operating lease liabilities	1,845		350		2,195		2,130		322		2,452
Lease liabilities, current	4,791		350		5,141		5,153		322		5,475
Lease liabilities, noncurrent:
Finance lease liabilities	2,018		—		2,018		2,976		—		2,976
Operating lease liabilities	4,020		909		4,929		4,672		1,093		5,765
Lease liabilities, noncurrent	6,038		909		6,947		7,648		1,093		8,741
Total leased liabilities	$	10,829	$	1,259	$	12,088	$	12,801	$	1,415	$	14,216

Accumulated amortization related to the finance lease assets was $5.7 million and $3.9 million as of June 30, 2023 and December 31, 2022, respectively.

The following table summarizes our lease term and discount rate assumptions as of June 30, 2023:

	June 30, 2023
	Third Party	Related Party	Total
Weighted-average remaining lease term (years):
Finance leases	1.79	—	1.79
Operating leases	3.53	3.42	3.51
Weighted-average discount rate:
Finance leases	6.5%	—	6.5%
Operating leases	7.3%	5.3%	7.0%

Undiscounted future minimum lease payments (displayed by year and in the aggregate) under noncancelable operating leases with terms of more than one year, as of June 30, 2023, have been reconciled to the total operating and finance lease liabilities recognized on the unaudited condensed consolidated balance sheets as of June 30, 2023 as follows:

26

	June 30, 2023
	Finance Leases						Operating Leases
In thousands	Third Party		Related Party		Total		Third Party		Related Party		Total
Remaining 2023	$	1,668	$	—	$	1,668	$	1,108	$	195	$	1,303
2024	2,625		—		2,625		2,068		421		2,489
2025	932		—		932		1,651		427		2,078
2026	25		—		25		1,029		324		1,353
2027	—		—		—		457		—		457
Thereafter	—		—		—		379		—		379
Total lease payments	5,250		—		5,250		6,692		1,367		8,059
Less: Interest	286		—		286		827		108		935
Present value of lease liabilities	$	4,964	$	—	$	4,964	$	5,865	$	1,259	$	7,124

In the three months ended June 30, 2023, we recorded an impairment charge of $0.4 million in our Integrated Care Management segment in connection with the write-down of an office lease which is included in impairment of goodwill, intangible assets, and other long-lived assets in our unaudited condensed consolidated statements of operations.

Prior to the adoption of ASC 2016-02, Leases, the following was disclosed in our Quarterly Report on Form 10-Q in the three and six months ended June 30, 2022:

Total rent expense under related party and third-party agreements consisted of the following:

In thousands	Three Months Ended June 30, 2022		Six Months Ended June 30, 2022
Related party	$	218	$	400
Third-party	1,106		1,976
Sublease income	(149)		(246)
Total rent expense, net of sublease income	$	1,175	$	2,130

In the six months ended June 30, 2022, we recorded additional lease abandonment expense totaling $0.1 million related to a termination fee we paid to exit an office which is included in impairment of goodwill, intangible assets, and other long-lived assets in our unaudited condensed consolidated statements of operations.

16. Commitments and Contingencies

Commitments

Operating leases

See Note 15, Leases, for commitments related to our operating leases.

Contingencies

From time to time, we may be subjected to claims or lawsuits which arise in the ordinary course of business, including the previously disclosed tax matter (see Note 11, Income Taxes, for further information) and matters described below. Estimates for resolution of legal and other contingencies are accrued when losses are probable and reasonably estimable in accordance with ASC 450, Contingencies. Except as set forth below, in the opinion of management, after consulting with legal counsel, none of these other claims are currently expected to have a material adverse effect on our condensed consolidated results of operations, financial position or cash flows.

Advisory Services Agreement Dispute

We are in a services agreement dispute with a third-party advisory firm for fees due under the services agreement. The advisory firm claims $31.0 million, plus interest, is owed in fees. Based on consultation with legal counsel, we previously proposed a settlement in the amount of $8.0 million, which has been accrued for as of June 30, 2023 and December 31, 2022, and is included in accrued

27

expenses in our unaudited condensed consolidated balance sheets. The amount of the ultimate loss may range from $8.0 million to $26.3 million.

Indemnification

Certain of our agreements require us to indemnify our customers from any claim or finding of intellectual property infringements, as well as from any losses incurred relating to breach of representations, failure to perform, or specific events as outlined within the particular contract. We have not received any claims or estimated the maximum potential amount of indemnification liability under these agreements and have recorded no liabilities for these agreements.

17. Subsequent Events

Management has determined that no material events or transactions have occurred subsequent to the balance sheet date, other than those events noted below, that require disclosure in our unaudited condensed consolidated financial statements.

On August 8, 2023, the Board approved an Amended and Restated Employment Agreement between the Chief Financial Officer and the Company that amends and restates in its entirety, and replaces, the Employment Agreement between the Chief Financial Officer and the Company dated October 24, 2021. The Company and the Chief Financial Officer entered into the Amended and Restated Employment Agreement on August 8, 2023.

28

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Unless otherwise indicated or the context otherwise requires, references in this report (this “Quarterly Report”) to “we,” “our,” “us,” “UpHealth” or the “Company” and other similar terms refer to UpHealth, Inc. and its consolidated subsidiaries. The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and the notes thereto contained elsewhere in this Quarterly Report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.

Special Note Regarding Forward-Looking Statements

This Quarterly Report includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act that are not historical facts, and involve risks and uncertainties that could cause actual results to differ materially from those expected and projected. All statements, other than statements of historical fact included in this Quarterly Report including, without limitation, statements in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” regarding the company’s financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements. Words such as “expect,” “believe,” “anticipate,” “intend,” “estimate,” “seek,” “may,” “might,” “plan,” “possible,” “potential,” “should, “would” and similar words and expressions are intended to identify such forward-looking statements. Such forward-looking statements relate to future events or future performance, but reflect management’s current beliefs, based on information currently available. A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussed in the forward-looking statements. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the “Risk Factors” section in Part II, Item 1A. of this Quarterly Report, the “Risk Factors” section in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the SEC on March 31, 2023 (our “Annual Report”) and in any more recent filings with the SEC. The Company’s securities filings can be accessed on the EDGAR section of the SEC’s website at www.sec.gov. Except as expressly required by applicable securities law, the company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

UpHealth, Inc. Business Overview

In 2022, after undergoing a process launched in the second half of 2021 designed to help us determine how to tie the various components of the businesses brought together between November 2020 and June 2021, we turned to transforming our business strategy to create a company that can profitably fulfill our mission as an integrated whole. By considering our previous financial performance, we determined that it was necessary for us to pivot and to focus on fewer investments for growth. As a result, we sought to establish a company that will deliver high-quality, predictable revenue streams, conserve cash and readjust our operating expenses, and improve operational excellence. This led us to make the following decisions with regard to our reporting segments:

•As a result of the previously disclosed ongoing control issues and legal proceedings with Glocal, we deconsolidated Glocal in July 2022. These issues and disputes are described in our Current Reports on Form 8-K filed with the SEC on October 3, 2022 and November 14, 2022, and in our Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2022 filed with the SEC on December 29, 2022, as well as in Part II, Item 1, Legal Proceedings, of this Quarterly Report. Accordingly, the financial results of Glocal in the three and six months ended June 30, 2022 are included in the discussion of our financial results for the Virtual Care Infrastructure segment, but are excluded in the discussion in the three and six months ended June 30, 2023. As of June 30, 2023, the operations of Glocal remain deconsolidated from the rest of UpHealth as we continue to pursue all legal recourse against the founders of that business.

•On February 26, 2023, UpHealth Holdings agreed to sell 100% of the outstanding capital stock of Innovations Group to Belmar MidCo, Inc., a Delaware corporation (“Belmar”) and a wholly owned subsidiary of Belmar Holdings, Inc., a Delaware corporation, a portfolio company of Webster Capital IV, L.P., a Delaware limited partnership, pursuant to a stock purchase agreement, dated February 26, 2023, by and among UpHealth, UpHealth Holdings, Innovations Group, and Belmar. The sale closed on May 11, 2023 for gross proceeds of $56.0 million, subject to working capital, closing debt, and other adjustments. Accordingly, the financial results of Innovations Group for the period from April 1, 2023 through May 10, 2023, the period from January 1, 2023 through May 10, 2023, and the three and six months ended June 30, 2022 are included in the discussion of our financial results for the Services segment.

•At the start of 2023, we made the decision to integrate BHS into our legacy TTC operations and wind-down our provider practice in Missouri, which was substantially completed in the three months ended June 30, 2023. The financial results of BHS in the three and six months ended June 30, 2023 and 2022 are included in the discussion of our financial results for the Services segment.

Following all of these changes, our reporting structure remains the same. We have three business segments: (a) Integrated Care Management, which uses the SyntraNetTM technology platform; (b) Virtual Care Infrastructure, which consists of our U.S. Telehealth business; and (c) Services, which consists of our Behavioral business.

29

Going forward, we will offer patient-centric digital health technologies and technology-enabled services to manage health and behavioral health across our strategic businesses. We are focused on integrating the value streams represented across these three product and service lines, and focusing on building more data and analytics capabilities to complement our technology. Additionally, we are working on a partnership to incorporate artificial intelligence (“AI”) into our core product offerings.

Virtual Care Infrastructure Segment

Overview

The Virtual Care Infrastructure segment consists of the U.S. Telehealth business, a technology and technology-enabled services business that connects healthcare systems with platforms, analytics, and services that make clinical and administrative processes simpler and more efficient. Hospital systems, physicians, and patients depend on us to help them improve performance, reduce costs and advance care quality through technology-enabled services built directly into clinical workflows.

The U.S. Telehealth business is a provider of unified telehealth solutions and digital health tools aimed at increasing access to healthcare and resolving health disparities across the care continuum. Through our MarttiTM platform, which serves as the digital front door to in-hospital care, the U.S. Telehealth business provides digital health infrastructure enabling its partners to implement unique, private-label telehealth strategies customized to their specific needs and markets, with language access built-in. The MarttiTM platform has one of the largest installed user bases in the nation, performing more than 300,000 encounters per month on over 40,000 video endpoints at over 2,800 healthcare venues in over 250 languages across the United States.

In 2022, the U.S. Telehealth business expanded its operations by leveraging its existing platform to include other telemedicine use cases such as telestroke, teleneurology, and telepsychiatry. We also launched a home health virtual visit platform enabling healthcare system partners to see their patients remotely on any device, at any time, anywhere the patient may be, and in any language they may speak.

The U.S. Telehealth’s products and services are sold primarily through a direct sales force. The U.S. Telehealth’s products are also supported and distributed through an array of alliances and business partnerships with other technology vendors, who integrate and interface our products with their applications. The U.S. Telehealth's business offers an expanding suite of telehealth use cases, which are delivered under multi-year contracts that include fixed minimums with upside attributable to usage-based fees. Our client base includes hospitals and health systems, federally qualified healthcare clinics (“FQHCs”), urgent care centers, stand-alone clinics, and medical practices.

As discussed in Note 1, Organization and Business, in the Notes to Condensed Consolidated Financial Statements of this Quarterly Report, we deconsolidated Glocal, which comprised the International Telehealth business, in the three months ended September 30, 2022. Accordingly, the financial results of Glocal in the three and six months ended June 30, 2022 are included in our unaudited condensed consolidated financial statements, and the financial position of Glocal as of June 30, 2023 and the financial results of Glocal in the three and six months then ended are not included in our unaudited condensed consolidated financial statements.

Components of Results of Operations

Revenues

Services. Services revenues from the U.S. Telehealth business are generated primarily from the sale of subscription-based fixed monthly minute and variable rate per unit of service medical language interpretation services. Ancillary revenues are also generated from the rental of Martti™ devices and from the provision of information technology services that include connectivity and ongoing support of the Martti™ software platform. Generally, medical language interpretation and information technology services are invoiced monthly. Fixed monthly minute medical language interpretation subscription and information technology services fees are invoiced in advance in the period preceding the service. Variable rate per unit medical language interpretation and information technology services fees (including overage fees related to minutes used by the customer in excess of the fixed monthly minute subscription) are invoiced monthly in arrears. Martti™ device leases are invoiced monthly in advance in the period preceding the usage. Invoiced amounts are typically due within 30 days of the invoice date.

In the three and six months ended June 30, 2022, services revenues also included revenues from the International Telehealth business, which were generated primarily from operating hospitals and clinics, including pharmacy and medicine sales, and transaction fees per telemedicine consultation.

Products. Products revenues consist of the sale of Martti™ devices to its customers. Sale of Martti™ devices are generally invoiced at contract execution (50%) and upon the delivery of the devices to the customer (50%). Invoiced amounts are typically due within 30 days of the invoice date.

In the three and six months ended June 30, 2022, products revenues also included revenues from the International Telehealth business, which were generated primarily from the sale of HelloLyf CX digital dispensaries and the construction of HelloLyf HX digital hospitals.

30

Cost of Revenues

Cost of revenues primarily consist of costs related to supporting and hosting the product offerings and delivering services, and include the cost of maintaining data centers, customer support team, and professional services staff, in addition to third-party service provider costs such as data center and networking expenses, amortization of capitalized software development costs, the cost of purchased equipment inventory sold to customers, and an allocation of facilities, information technology, and depreciation costs.

In the three and six months ended June 30, 2022, cost of revenues also included cost of revenues from the International Telehealth business, which primarily consisted of costs of building and operating hospitals, including costs for the purchase of medicines, professional/doctor fees, the cost to build HelloLyf CX digital dispensaries and HelloLyf HX digital hospitals, and an allocation of information technology and depreciation costs.

Operating Expenses

Sales and Marketing (S&M) Expenses. S&M expenses consist of compensation and benefits, costs related to advertising, marketing programs, and events, and an allocation of facilities, information technology, and depreciation costs.

General and Administrative (G&A) Expenses. G&A expenses consist of compensation and benefits expense, and other administrative costs, related to its executive, finance, human resources, legal, facilities, and information technology teams, net of allocations to cost of revenues and S&M.

Depreciation and Amortization Expenses. Depreciation expense relates to the depreciation of computer equipment, purchased software, furniture and fixtures, and office equipment, net of amounts allocated to cost of revenues. Amortization expense relates to the amortization of intangible assets from the acquisitions of the Virtual Care Infrastructure businesses.

Services Segment

Overview

The Services segment consists of the Behavioral business, which provides behavioral health services in the United States and is critically important to managing whole person care and its associated costs. The Services segment also included the Pharmacy business until we sold Innovations Group, a compounding pharmacy business, on May 11, 2023.

Our Behavioral business is powered by our UpHealth BehavioralTM platform, which provides evidence-based and tech-enabled behavioral health and substance abuse services via onsite care delivery and telehealth. Our UpHealth BehavioralTM platform is working to deliver an increasing volume of services, including telehealth services, to existing customers, as well as clients belonging to the Integrated Care Management and Virtual Care Infrastructure platforms. In the three months ended June 30, 2023, we substantially completed the wind-down of a company within our Behavioral business in our Services segment.

UpHealth BehavioralTM provides comprehensive patient-centered care, addressing the physical, mental, and social well-being of our clients. We engage people in the most appropriate care settings, including clinical sites, out-patient and virtual. UpHealth BehavioralTM delivers behavioral health services; helps patients and providers navigate and address complex, chronic behavioral health needs; offers post-acute care planning services; and serves consumers and care providers through advanced, on-demand digital health technologies, such as telehealth. UpHealth BehavioralTM works directly with consumers, care delivery systems, providers, payors, and public-sector entities to provide high quality, accessible and equitable care with improved health outcomes and reduced total cost of care.

UpHealth BehavioralTM sells its products primarily through its direct sales force, and strategic collaborations in two key areas: payors including health plans, third-party administrators; and public entities including the U.S. Departments of Veterans Affairs and other federal, state, and local health care agencies.

The Pharmacy business consisted of Innovations Group and was powered by MedQuest Pharmacy, a full-service retail and compounding pharmacy licensed in all 50 U.S. states and the District of Columbia that dispensed prescribed medications shipped directly to patients. It was capable of serving as a retail or national fulfillment center. Other services and products were also available, such as lab and testing services, nutritional supplements, and education and training for medical practitioners. On February 26, 2023, UpHealth Holdings agreed to sell 100% of the outstanding capital stock of Innovations Group. The sale closed on May 11, 2023. Accordingly, the financial results of Innovations Group for the period from April 1, 2023 through May 10, 2023, the period from January 1, 2023 through May 10, 2023, and the three and six months ended June 30, 2022 are included in the discussion of our financial results for the Services segment.

Components of Results of Operations

31

Revenues

Services. Services revenues from the Behavioral business are generated primarily through services provided to clients in both inpatient and outpatient treatment settings. Third-party payors are billed weekly for the services provided in the prior week. Client-related revenues, such as inpatient and outpatient programs, are generally recognized over time as the performance obligation is satisfied at the estimated net realizable value amount from clients, third-party payors, and others for services provided. The majority of payments are received from commercial payors at out-of-network rates. Client service revenues are recorded at established billing rates, less adjustments to estimate net realizable value. Provisions for estimated third party payor reimbursements are provided in the period related services are rendered and adjusted in future periods when actual reimbursements are received. A significant or sustained decrease in reimbursement rates could have a material adverse effect on operating results.

Diagnostic laboratory testing service revenues are recognized over time as the performance obligation is satisfied at the estimated net realizable value amount from clients, third-party payors, and others for services provided. Diagnostic laboratory service revenues are recorded at established billing rates, less adjustments to estimate net realizable value. Provisions for estimated third party payor reimbursements are provided in the period related services are rendered and adjusted in future periods when actual reimbursements are received.

Services revenues are also generated by providing psychiatric and mental health services and billing services. Although the underlying tasks will vary by service and by patient, medical professionals perform inquiries, obtain vital statistics, perform certain lab tests, administer therapy, and provide any additional goods and services as necessary depending on the information obtained. In addition, services revenues are generated from CME educational courses.

Products. For the period from April 1, 2023 through May 10, 2023, the period from January 1, 2023 through May 10, 2023, and the three and six months ended June 30, 2022, products revenues through our Pharmacy business were generated primarily from the sale of prescription medications directly to patients, as well as through the sale of supplemental products to providers. The majority of the customer revenues were billed and collected before the medications and products are shipped from the facility. The Pharmacy business generated approximately 60% of its revenue from sales of compounded medications and approximately 40% of its revenue from sales of manufactured medications and supplements. Products revenues are also generated by providing retail pharmacy services in the Behavioral business.

Cost of Revenues

Services. Cost of revenues consist primarily of provider compensation expenses, the cost of pharmaceutical medications sold to patients, the cost of operating the facilities, professional/medical fees, and an allocation of facilities, information technology, and depreciation costs. Provider compensation expenses include consulting payments to healthcare providers, including medical doctors in psychiatry, psychologists, nurse practitioners, and clinical social workers, based on an incentive-based compensation plan with provider agreements that compensate the providers based upon a percentage of revenue generated and ultimately collected for services provided. Pharmaceutical medications are primarily purchased through a large industry distributor with many suppliers, but also purchases some directly from other suppliers.

Products. For the period from April 1, 2023 through May 10, 2023, the period from January 1, 2023 through May 10, 2023, and the three and six months ended June 30, 2022, cost of revenues at the Pharmacy business primarily consisted of costs of raw ingredients and materials to compound various drugs and supplements, the cost of manufactured product purchased directly from the distributors for resale, the cost of fulfillment and shipping services and an allocation of facilities, information technology, and depreciation costs. The Pharmacy business purchased these items through a large industry distributor with many suppliers and also sources products and supplies directly with manufacturers. The Pharmacy business was also able to leverage the size of its operations to purchase larger quantities of certain ingredients and materials at lower prices.

Operating Expenses

Sales and Marketing Expenses. S&M expenses consist of cost related to compensation and benefits, advertising and marketing programs, events, fees paid to third party marketing firms, and an allocation of facilities, information technology, and depreciation cost.

General and Administrative Expenses. G&A expenses include compensation and benefits expense, and other administrative costs, related to its executive, finance, human resources, legal, facilities, and information technology teams, net of allocations to cost of revenues and S&M expenses.

Depreciation and Amortization Expenses. Depreciation expense relates to the depreciation of computer equipment, purchased software, furniture and fixtures, office equipment, and leasehold improvements, net of amounts allocated to cost of revenues. Amortization expense relates to the amortization of intangible assets from the acquisitions of the Services businesses.

32

Integrated Care Management Segment

Overview

Integrated Care Management is a healthcare technology business that serves organizations that pay for healthcare, including health plans and state, federal and municipal agencies that ensure the people they sponsor receive high-quality care, administered and delivered efficiently and effectively, all while driving health equity so that every individual, family, and community has access to the care they need.

The Integrated Care Management business is powered by the SyntraNetTM technology platform and applications. SyntraNetTM is a configurable integrated health management platform that enables clinical and community-based care teams to share information, coordinate care, manage utilization, and improve health outcomes and costs for individuals and populations – especially individuals with complex medical, behavioral health, and social needs.

SyntraNetTM creates virtual “care communities” – logical networks of organizations, care managers and service providers – that function as an integrated care team to deploy programs to improve health, quality, performance, efficiency, and costs.

Core features of the platform include the ability to:

• Create virtual, cross-sector care communities;

• Integrate and organize information from a wide range of health and social health data sources;

• Gain insight into health, risks, and opportunities with advanced analytics;

• Qualify and enroll groups into programs;

• Coordinate care teams across the continuum of care; and

• Analyze and report on various measures of success.

SyntraNetTM provides health plans and provider groups the ability to manage health with new value-based models of care. Our clients include the largest public health plan in the United States, entities that are part of the nation’s most comprehensive “whole person care” initiatives, and one of the fastest growing value-based pharmacy benefit managers.

Products are sold primarily through a direct sales force, strategic collaborations and external producers in two key areas: payors including health plans and third-party administrators and public entities including state and local health care agencies. Revenues are derived from license fees, recurring subscription fees, and professional services for implementation.

Components of Results of Operations

Revenues

Integrated Care Management derives revenues broadly from the sales of (a) products—with associated license, subscription, and hosting fees and (b) services—largely to implement, configure, and extend the technology, and train and on-board users on the use of the platform and applications.

Licenses and Subscriptions Revenues. License revenues are typically associated with rights granted to customers to deploy the platform to a certain number of care communities of a certain size, usually measured as the total population of patients that can be included within a care community. License revenues are recognized based on the nature of the license provided, either fully on the date license rights are granted to the customer if there are no further performance obligations or ratably over the license term beginning on the effective date of each contract, the date the customer takes possession of the license rights.

Subscription fees are recurring fees charged for access to the platform and applications. Subscription fees are typically pegged to a measure of use, such as population size, number of providers, members enrolled in programs, or number of members managed by applications. Subscription fees can grow as customers subscribe to additional application features or launch additional programs. Revenues from subscription fees are recognized ratably over the subscription term.

Services. The majority of contracts to provide professional services are priced on a time and materials basis, whereby revenues are recognized as the services are rendered. In some cases, professional services contracts are entered into where professional services fees are defined for specific milestones, whereby revenues are recognized upon achievement of the milestones.

Cost of Revenues

Cost of revenues include: costs related to hosting SyntraNetTM in a HIPAA-compliant cloud environment; costs of third-party product licenses embedded with SyntraNetTM; costs of a core professional services team; and an allocation of facilities, information technology, and

33

depreciation costs. Added compliance requirements for security infrastructure is likely to add some additional costs for hosting services. In addition, costs will increase for third-party licenses that will be added as the scope and footprint of the technology platform expands.

Hosting Infrastructure. Technology and solutions are designed to be agnostic to any particular cloud services provider. Currently, customer environments are hosted through contracts with two cloud service providers.

As the capabilities of cloud service providers continues to grow, and costs become increasingly competitive, we will continue to evaluate offerings in the marketplace to determine the optimum mix of security, reliability, scalability, and performance to meet customer needs. Hosting infrastructure costs are related to the number and size of environments deployed for customers and also on the service level agreements (“SLAs”) negotiated with customers. As the average size of customers continues to grow, hosting infrastructure costs are expected to grow as a percentage of revenue.

Third-Party Product Licenses. SyntraNetTM embeds certain third-party technology components to support some of its technology capabilities. There are multiple vendors for these components, and we are not dependent on any specific vendor.

Professional Services Team. A professional services team works closely with the product team and is best understood as an “A-team” created to lead showcase implementations. The goal is to keep the professional services team small in order to focus it on deploying reference customers and facilitating the on-boarding and coaching of systems integration partners.

Operating Expenses

Sales and Marketing Expenses. S&M expenses include an internal sales and marketing team and contracts with business development consultants to generate and qualify leads, and an allocation of facilities, information technology, and depreciation costs.

Research and Development (“R&D”) Expenses. The core R&D team consists of a small team of very experienced software developers. R&D expenses also includes an allocation of facilities, information technology, and depreciation costs.

General and Administrative Expenses. G&A expenses include compensation and benefits expense, and other administrative costs, related to its executive, finance, human resources, legal, facilities, and information technology teams, net of allocations to cost of revenues, S&M expenses, and R&D expenses.

Depreciation and Amortization Expenses. Depreciation expense relates to the depreciation of computer equipment, purchased software, furniture and fixtures, and office equipment, net of amounts allocated to cost of revenues. Amortization expense relates to the amortization of intangible assets from the acquisition of the Integrated Care Management business.

UpHealth, Inc. Consolidated Results of Operations

Operating Results

As discussed in Note 1, Organization and Business, in the Notes to Condensed Consolidated Financial Statements of this Quarterly Report, we deconsolidated Glocal in the three months ended September 30, 2022. Accordingly, the financial results of Glocal in the three and six months ended June 30, 2022 are included in the discussion of our financial results for the Virtual Care Infrastructure segment in the three and six months ended June 30, 2022, but are excluded in the discussion in the three and six months ended June 30, 2023.

As discussed in Note 3, Significant Transactions, we completed the sale of Innovations Group, which comprised our Pharmacy operations, on May 11, 2023. Accordingly, the financial results of Innovations Group for the period from April 1, 2023 through May 10, 2023, the period from January 1, 2023 through May 10, 2023, and the three and six months ended June 30, 2022 are included in the discussion of our financial results for the Services segment.

In addition, we substantially completed the wind-down of a company within our Behavioral business in our Services segment in the three months ended June 30, 2023.

34

The following table sets forth our consolidated results of operations:

(Unaudited, in thousands)	Three Months Ended June 30,								Six Months Ended June 30,
	2023		2022		$ Change		% Change		2023		2022		$ Change		% Change
Revenues:
Services	$	31,087	$	28,096	$	2,991	11	%	$	62,028	$	53,782	$	8,246	15	%
Licenses and subscriptions	2,852		6,812		(3,960)		(58)	%	4,788		8,593		(3,805)		(44)	%
Products	3,884		8,760		(4,876)		(56)	%	13,152		17,265		(4,113)		(24)	%
Total revenues	37,823		43,668		(5,845)		(13)	%	79,968		79,640		328		—	%
Costs of revenues:
Services	14,954		16,232		(1,278)		(8)	%	28,698		31,990		(3,292)		(10)	%
License and subscriptions	403		217		186		86	%	722		450		272		60	%
Products	2,490		6,296		(3,806)		(60)	%	7,896		12,286		(4,390)		(36)	%
Total costs of revenues	17,847		22,745		(4,898)		(22)	%	37,316		44,726		(7,410)		(17)	%
Gross profit	19,976		20,923		(947)		(5)	%	42,652		34,914		7,738		22	%
Operating expenses:
Sales and marketing	2,421		3,539		(1,118)		(32)	%	7,040		6,973		67		1	%
Research and development	848		2,011		(1,163)		(58)	%	2,133		3,769		(1,636)		(43)	%
General and administrative	12,765		12,880		(115)		(1)	%	23,774		24,347		(573)		(2)	%
Depreciation and amortization	1,736		4,700		(2,964)		(63)	%	3,347		9,936		(6,589)		(66)	%
Stock-based compensation	1,058		1,088		(30)		(3)	%	2,047		2,462		(415)		(17)	%
Impairment of goodwill, intangible assets, and other long-lived assets	8,246		—		8,246		—	%	8,741		6,249		2,492		40	%
Acquisition, integration, and transformation costs	3,644		6,749		(3,105)		(46)	%	7,090		9,133		(2,043)		(22)	%
Total operating expenses	30,718		30,967		(249)		(1)	%	54,172		62,869		(8,697)		(14)	%
Loss from operations	(10,742)		(10,044)		(698)		7	%	(11,520)		(27,955)		16,435		(59)	%
Other expense:
Interest expense	(7,136)		(6,603)		(533)		8	%	(13,994)		(13,598)		(396)		3	%
Other income, net, including interest income	126		1,950		(1,824)		(94)	%	127		6,858		(6,731)		(98)	%
Total other expense	(7,010)		(4,653)		(2,357)		51	%	(13,867)		(6,740)		(7,127)		106	%
Loss before income tax benefit (expense)	(17,752)		(14,697)		(3,055)		21	%	(25,387)		(34,695)		9,308		(27)	%
Income tax benefit (expense)	(867)		2,232		(3,099)		(139)	%	(867)		4,525		(5,392)		(119)	%
Net loss	(18,619)		(12,465)		(6,154)		49	%	(26,254)		(30,170)		3,916		(13)	%
Less: net income (loss) attributable to noncontrolling interests	508		(27)		535		(1,981)	%	956		(287)		1,243		(433)	%
Net loss attributable to UpHealth, Inc.	$	(19,127)	$	(12,438)	$	(6,689)	54	%	$	(27,210)	$	(29,883)	$	2,673	(9)	%

35

The following table sets forth our consolidated results of operations as a percentage of total revenue:

	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
Revenues:
Services	82	%	64	%	78	%	68	%
Licenses and subscriptions	8	%	16	%	6	%	11	%
Products	10	%	20	%	16	%	22	%
Total revenues	100	%	100	%	100	%	100	%
Costs of revenues:
Services	40	%	37	%	36	%	40	%
License and subscriptions	1	%	—	%	1	%	1	%
Products	7	%	14	%	10	%	15	%
Total costs of revenues	47	%	52	%	47	%	56	%
Gross profit	53	%	48	%	53	%	44	%
Operating expenses:
Sales and marketing	6	%	8	%	9	%	9	%
Research and development	2	%	5	%	3	%	5	%
General and administrative	34	%	29	%	30	%	31	%
Depreciation and amortization	5	%	11	%	4	%	12	%
Stock-based compensation	3	%	2	%	3	%	3	%
Impairment of goodwill, intangible assets, and other long-lived assets	22	%	—	%	11	%	8	%
Acquisition, integration, and transformation costs	10	%	15	%	9	%	11	%
Total operating expenses	81	%	71	%	68	%	79	%
Loss from operations	(28)	%	(23)	%	(14)	%	(35)	%
Other expense:
Interest expense	(19)	%	(15)	%	(17)	%	(17)	%
Other income, net, including interest income	—	%	4	%	—	%	9	%
Total other expense	(19)	%	(11)	%	(17)	%	(8)	%
Loss before income tax benefit (expense)	(47)	%	(34)	%	(32)	%	(44)	%
Income tax benefit (expense)	(2)	%	5	%	(1)	%	6	%
Net loss	(49)	%	(29)	%	(33)	%	(38)	%
Less: net income (loss) attributable to noncontrolling interests	1	%	—	%	1	%	—	%
Net loss attributable to UpHealth, Inc.	(51)	%	(28)	%	(34)	%	(38)	%

Due to the deconsolidation of Glocal in the third quarter of 2022, as well as the sale of Innovations Group on May 11, 2023, the numbers presented above are not directly comparable between periods.

Three months ended June 30, 2023 and 2022

Revenues

In the three months ended June 30, 2023, revenues were $37.8 million, representing a decrease of $5.8 million, or 13%, compared to $43.7 million in the three months ended June 30, 2022.

Services revenues increased $3.0 million due to an increase in the Integrated Care Management segment of $1.6 million, the Services segment of $1.2 million and the Virtual Care Infrastructure segment of $0.2 million. The increase in the Integrated Care Management segment was primarily due to an increase in professional services revenue for existing customers. The increase in the Services segment was primarily due to a $3.2 million increase in revenues in our Behavioral business, attributed to higher census and improved payor mix, partially offset by a $1.8 million decrease in revenues resulting from the decision to wind-down a company within our Behavioral business in the second quarter of 2023. The increase in the Virtual Care Infrastructure segment was primarily due to a $3.7 million increase in revenues resulting from an increase in minutes from both new and existing U.S. Telehealth customers, partially offset by no revenues being recognized for Glocal in the three months ended June 30, 2023 as a result of its deconsolidation in the third quarter of 2022.

Licenses and subscriptions revenues decreased $4.0 million in the Integrated Care Management segment in the three months ended June 30, 2023. The decrease was primarily due to a one-time license fee that occurred in the second quarter of 2022.

36

Products revenues decreased $4.9 million, due to a decrease in the Services segment of $4.7 million and a decrease in the Virtual Care Infrastructure segment of $0.2 million. The decrease in the Services segment was primarily due to a $3.8 million decrease in the sales of prescriptions in the Pharmacy business due to the strategic sale of Innovations Group on May 11, 2023.

Cost of Revenues

In the three months ended June 30, 2023, cost of revenues was $17.8 million, a decrease of $4.9 million, or 22%, compared to $22.7 million in the three months ended June 30, 2022.

Services cost of revenues decreased $1.3 million, primarily due to decreases in the Virtual Care Infrastructure segment of $1.0 million and the Services segment of $0.9 million, partially offset by increases in the Integrated Care Management segment of $0.6 million. The decrease in the Virtual Care Infrastructure segment was primarily due to no revenues being recognized for Glocal in the three months ended June 30, 2023 as a result of its deconsolidation in the third quarter of 2022, partially offset by a $1.8 million increase in cost of revenues associated with higher revenues and a shift in mix from audio to video minutes in the U.S. Telehealth business. The decrease in the Services segment was primarily due to a $1.5 million decrease in cost of revenues resulting from the decision to wind-down a company within our Behavioral business in the second quarter of 2023, partially offset by a $0.7 million increase in costs of revenues at the remaining Behavioral business due to higher census and improved mix of services.

License and subscriptions cost of revenues increased $0.2 million in the Integrated Care Management segment in the three months ended June 30, 2023.

Products cost of revenues decreased $3.8 million due to a decrease in the Services segment of $3.6 million and the Virtual Care Infrastructure segment of $0.2 million. The decrease in the Services segment was primarily due to a $3.0 million decrease in cost of revenues from the sale of prescriptions in the Pharmacy business primarily due to the strategic sale of Innovations Group on May 11, 2023 and a $0.6 million decrease in cost of revenues resulting from the decision to wind-down a company within our Behavioral business in the second quarter of 2023.

Operating Expenses

Sales and Marketing. In the three months ended June 30, 2023, S&M expenses were $2.4 million, representing a decrease of $1.1 million, or 32%, compared to $3.5 million in the three months ended June 30, 2022, primarily due to a net decrease in compensation, benefits, and contractor expenses as a result of the strategic sale of Innovations Group on May 11, 2023, and reversal of a $0.7 million accrual as a result of a settlement.

Research and Development. In the three months ended June 30, 2023, R&D expenses were $0.8 million, representing a decrease of $1.2 million, or 58%, compared to $2.0 million in the three months ended June 30, 2022, primarily due to an increase in capitalized software development costs and reduced headcount.

General and Administrative. In the three months ended June 30, 2023, G&A expense were $12.8 million, representing a decrease of $0.1 million, or 1%, compared to $12.9 million in the three months ended June 30, 2022.

Depreciation and Amortization. In the three months ended June 30, 2023, depreciation and amortization expenses were $1.7 million, primarily consisting of $1.1 million of amortization of intangible assets and $0.6 million of depreciation related to property and equipment, net of allocations to cost of revenues. In the three months ended June 30, 2022 depreciation and amortization expenses were $4.7 million, primarily consisting of $4.2 million of amortization of intangible assets and $0.5 million of depreciation related to property and equipment, net of allocations to cost of revenues. The decrease in depreciation and amortization expenses was due to the deconsolidation of Glocal in the third quarter of 2022, the impairment of intangible assets in the Integrated Care Management segment in the third quarter of 2022, and no depreciation and amortization expense being recorded at Innovations Group in the three months ended June 30, 2023 due to its sale, partially offset by increased amortization related to an increase in capitalized software development costs and increased depreciation related to additions to property and equipment.

Stock-Based Compensation. In the three months ended June 30, 2023, stock-based compensation was $1.1 million, remaining consistent with $1.1 million recognized in the three months ended June 30, 2022.

Impairment of Goodwill, Intangible Assets and Other Long-Lived Assets. An impairment charge of $8.2 million was recognized in the three months ended June 30, 2023, consisting of a $6.4 million goodwill impairment resulting from the decision to wind-down a company within our Behavioral business, $1.4 million from the remeasurement of the Innovations Group disposal group to the expected proceeds, less cost to sell, and a $0.4 million right-of-use asset impairment in our Integrated Care Management segment. No impairment charges were recognized in the three months ended June 30, 2022.

37

Acquisition, Integration and Transformation Costs. In the three months ended June 30, 2023 and 2022, acquisition, integration and transformation costs were $3.6 million and $6.7 million, respectively, primarily related to legal and litigation expenses associated with the prior acquisitions, as well as costs related to our integration and transformation of the businesses.

Other Expense

In the three months ended June 30, 2023, other expense was $7.0 million, primarily consisting of $7.1 million of interest expense. In the three months ended June 30, 2022, other expense was $4.7 million, primarily consisting of $6.6 million of interest expense, partially offset by a $1.8 million gain on fair value of derivative liability and a $0.1 million gain on fair value of warrants.

Income Tax Benefit (Expense)

In the three months ended June 30, 2023, income tax expense was $0.9 million. In the three months ended June 30, 2022, income tax benefit was $2.2 million.

Income tax benefit (expense) reflects management’s best assessment of estimated current and future taxes to be paid. The objectives for accounting for income taxes, as prescribed by the relevant accounting guidance, are to recognize the amount of taxes payable or refundable for the current year and deferred tax assets and liabilities for future tax consequences of events that have been recognized in our financial statements. Consistent with our conclusion as of December 31, 2022, we continue to believe that it is not more likely than not that the deferred tax assets will be realized and we therefore maintained a full valuation allowance against the deferred tax assets as of June 30, 2023. However, we expect to suffer minimal income tax expense due to U.S. tax rules related to the utilization of net operating loss carryforwards. Additionally, in the three months ended June 30, 2023, we recorded discrete tax items totaling $0.6 million related to the sale of Innovations Group.

Six months ended June 30, 2023 and 2022

Revenues

In the six months ended June 30, 2023, revenues were $80.0 million, representing an increase of $0.3 million, or 0.4%, compared to $79.6 million in the six months ended June 30, 2022.

Services revenues increased $8.2 million due to an increase in the Services segment of $3.4 million, the Integrated Care Management segment of $2.7 million and the Virtual Care Infrastructure segment of $2.1 million. The increase in the Services segment was primarily due to a $6.2 million increase in revenues in the Behavioral business attributed to higher census and improved payor mix, partially offset by a $2.8 million decrease in revenues resulting from the decision to wind-down a company within our Behavioral business in the second quarter of 2023. The increase in the Integrated Care Management segment was primarily due to an increase in professional services revenue for existing customers. The increase in the Virtual Care Infrastructure segment was primarily due to a $8.9 million increase in revenues resulting from an increase in minutes from both new and existing U.S. Telehealth customers, partially offset by no revenues being recognized for Glocal in the three months ended June 30, 2023 as a result of its deconsolidation in the third quarter of 2022.

Licenses and subscriptions revenues decreased $3.8 million in the Integrated Care Management segment in the six months ended June 30, 2023. The decrease was primarily due to a one-time license fee recognized in the second quarter of 2022.

Products revenues decreased $4.1 million, due to a decrease in the Services segment of $3.8 million and the Virtual Care Infrastructure segment of $0.3 million. The decrease in the Services segment was primarily due to a $2.8 million decrease in the sale of prescriptions in the Pharmacy business due to the strategic sale of Innovations Group on May 11, 2023. The decrease in the Virtual Care Infrastructure segment was primarily due to the shift away from equipment sales to incorporating into service rates in the U.S. Telehealth business, as well as no revenues being recognized for Glocal in the six months ended June 30, 2023 as a result of its deconsolidation in the third quarter of 2022.

We expect revenues to decrease in the year ending December 31, 2023 compared to the year ended December 31, 2022, primarily as a result of a decrease in revenues in our Services segment due to a partial year of revenues to be recognized at Innovations Group as a result of its sale on May 11, 2023 and the wind-down of a company within our Behavioral business, partially offset by increased revenues at the remaining Behavioral business. We also expect a decline in revenues in our Integrated Care Management segment in the year ending December 31, 2023 compared to the year ended December 31, 2022. We expect these decreases will be partially offset by increased revenues in the Virtual Care Infrastructure segment as we continue to add new customers and integrate and develop our technology platforms across each of our segments, partially offset by no revenues being recognized for Glocal in the year ending December 31, 2023 as a result of its deconsolidation in July 2022.

Cost of Revenues

In the six months ended June 30, 2023, cost of revenues was $37.3 million, a decrease of $7.4 million, or 17%, compared to $44.7 million in the six months ended June 30, 2022.

38

Services cost of revenues decreased $3.3 million, primarily due to decreases in the Virtual Care Infrastructure segment of $2.8 million and the Services segment of $1.3 million, partially offset by increases in the Integrated Care Management segment of $0.8 million. The decrease in the Virtual Care Infrastructure segment was primarily due to no cost of revenues being recognized for Glocal in the six months ended June 30, 2023 as a result of its deconsolidation in July 2022, partially offset by a $2.6 million increase in cost of revenues associated with higher revenues and a shift in mix from audio to video minutes in the U.S. Telehealth business. The decrease in the Services segment was primarily due to a $2.4 million decrease in cost of revenues resulting from the decision to wind-down a company within our Behavioral business in the second quarter of 2023, partially offset by a $1.1 million increase in cost of revenues at the remaining Behavioral business due to higher census and improved mix of services.

License and subscriptions cost of revenues increased $0.3 million in the Integrated Care Management segment in the six months ended June 30, 2023.

Products cost of revenues decreased $4.4 million due to a decrease in the Services segment of $4.1 million and the Virtual Care Infrastructure segment of $0.3 million. The decrease in the Services segment was primarily due to a $3.1 million decrease in cost of revenues from the sale of prescriptions in the Pharmacy business primarily due to the strategic sale of Innovations Group on May 11, 2023 and a $1.0 million decrease in cost of revenues resulting from the decision to wind-down a company within our Behavioral business in the second quarter of 2023.

We expect cost of revenues to decrease in the year ending December 31, 2023 compared to the year ended December 31, 2022, commensurate with the decrease in revenues. Cost of revenues from our Services segment is expected to decrease due to a partial year of cost of revenues to be recognized at Innovations Group as a result of its sale on May 11, 2023, and the wind-down of a Behavioral business, partially offset by increased cost of revenues at the remaining Behavioral business, commensurate with the expected growth in revenues. We also expect a decline in costs of revenues in our Integrated Care Management segment, commensurate with the expected decline in revenues. We expect these decreases will be partially offset by increased cost of revenues in the Virtual Care Infrastructure segment commensurate with the expected increase in revenues in the U.S. Telehealth business, partially offset by no cost of revenues being recognized for Glocal in the year ending December 31, 2023 as a result of its deconsolidation in July 2022. Our cost of revenues may fluctuate as a percentage of our total revenue (gross margin %) from period to period due to the changes in the percentage of revenue contributed by each of our segments.

Operating Expenses

Sales and Marketing. In the six months ended June 30, 2023, S&M expenses were $7.0 million, remaining flat compared to $7.0 million in the six months ended June 30, 2022, primarily due to an increase in compensation, benefits, and contractor expenses, partially reduced as a result of the strategic sale of Innovations Group on May 11, 2023, and reversal of a $0.7 million on accrual as a result of a settlement.

We expect S&M expenses to decrease in the year ending December 31, 2023 compared to the year ended December 31, 2022 as we continue to consolidate our sales and marketing teams. Our S&M expenses may fluctuate as a percentage of our total revenues from period to period due to the timing and extent we promote our brands through a variety of marketing and public relations activities.

Research and Development. In the six months ended June 30, 2023, R&D expenses were $2.1 million, representing a decrease of $1.6 million, or 43%, compared to $3.8 million in the six months ended June 30, 2022, primarily due to a increase in capitalized software development costs and reduced headcount.

We expect our R&D expenses to decrease in the year ending December 31, 2023 compared to the year ended December 31, 2022, as we decrease R&D efforts in certain segments, while also increasing our capitalization of software development costs. Our R&D expenses may fluctuate as a percentage of our total revenues from period to period due to the timing and extent of our technology and development expenses, including the ability to capitalize software development costs.

General and Administrative. In the six months ended June 30, 2023, G&A expense were $23.8 million, representing a decrease of $0.6 million, or 2%, compared to $24.3 million in the six months ended June 30, 2022, primarily due to a decrease in compensation, benefits, and contractor expenses.

We expect G&A expenses to decrease in the year ending December 31, 2023 compared to the year ended December 31, 2022, primarily as a result of a decrease in legal and other professional fees. Our G&A expenses may fluctuate as a percentage of our total revenues from period to period due to the timing and extent of our G&A expenses.

Depreciation and Amortization. In the six months ended June 30, 2023, depreciation and amortization expenses were $3.3 million, primarily consisting of $2.3 million of amortization of intangible assets and $1.0 million of depreciation related to property and equipment, net of allocations to cost of revenues. In the six months ended June 30, 2022 depreciation and amortization expenses were $9.9 million, primarily consisting of $9.3 million of amortization of intangible assets and $0.6 million of depreciation related to property and equipment, net of allocations to cost of revenues. The decrease in depreciation and amortization expenses was due to the deconsolidation of Glocal in the third

39

quarter of 2022, the impairment of intangible assets in the Integrated Care Management segment in the third quarter of 2022, and no depreciation and amortization expense being recorded at Innovations Group in the six months ended June 30, 2023 due to its classification as held-for-sale in Q1 2023 and subsequent sale on May 11, 2023, partially offset by increased amortization related to an increase in capitalized software development costs and increased depreciation related to additions to property and equipment.

We expect depreciation and amortization expenses to decrease in the year ended December 31, 2023 compared to the year ending December 31, 2022 due to decreased amortization expense related to the decrease in intangible assets, partially offset by an increase in amortization related to capitalized software development costs and an increase in depreciation from purchases of property and equipment.

Stock-Based Compensation. In the six months ended June 30, 2023, stock-based compensation expenses were $2.0 million, representing a decrease of $0.4 million, or 17%, compared to $2.5 million in the six months ended June 30, 2022. We expect stock-based compensation expenses to decrease in the year ending December 31, 2023, primarily due to lower equity grants outstanding and fewer new grants expected to be made in the second half of 2023.

Impairment of Goodwill, Intangible Assets, and Other Long-Lived Assets. An impairment charge of $8.7 million was recognized in the six months ended June 30, 2023, consisting of a $6.4 million goodwill impairment resulting from the decision to wind-down a company within our Behavioral business, $1.9 million from the remeasurement of the Innovations Group disposal group to the expected proceeds, less cost to sell, and a $0.4 million right-of-use asset impairment in our Integrated Care Management segment. An impairment charge of $6.2 million was recognized in the six months ended June 30, 2022, primarily consisting of a $5.5 million measurement period adjustment at Glocal that was immediately impaired, and a $0.7 million trade name intangible asset impairment at a company within our Behavioral business.

Acquisition, Integration and Transformation Costs. In the six months ended June 30, 2023, acquisition, integration and transformation costs were $7.1 million, primarily related to legal and litigation expenses associated with the prior acquisitions, as well as costs related to our integration and transformation of the businesses. In the six months ended June 30, 2022, acquisition, integration and transformation costs were $9.1 million, primarily related to legal and litigation expenses associated with the prior acquisitions, costs related to our integration and transformation of the businesses, and a lease abandonment accrual in the amount of $0.1 million related to office spaces we vacated in the period.

Other Expense

In the six months ended June 30, 2023, other expense was $13.9 million, primarily consisting of $14.0 million of interest expense. In the six months ended June 30, 2022, other expense was $6.7 million, primarily consisting of $13.6 million of interest expense, partially offset by a $6.7 million gain on fair value of derivative liability and a $0.2 million gain on fair value of warrants.

Income Tax Benefit (Expense)

In the six months ended June 30, 2023, income tax expense was $0.9 million. In the six months ended June 30, 2022, income tax benefit was $4.5 million.

Income tax benefit (expense) reflects management’s best assessment of estimated current and future taxes to be paid. The objectives for accounting for income taxes, as prescribed by the relevant accounting guidance, are to recognize the amount of taxes payable or refundable for the current year and deferred tax assets and liabilities for future tax consequences of events that have been recognized in our financial statements. Consistent with our conclusion as of December 31, 2022, we continue to believe that it is not more likely than not that the deferred tax assets will be realized and we therefore maintained a full valuation allowance against the deferred tax assets as of June 30, 2023. However, we expect to suffer minimal income tax expense due to U.S. tax rules related to the utilization of net operating loss carryforwards. Additionally, in the six months ended June 30, 2023, we recorded discrete tax items totaling $0.6 million related to the sale of Innovations Group.

Segment Information

We evaluate performance based on several factors, of which revenues and gross profit by operating segment are the primary financial measures.

Revenues

Revenues by segment consisted of the following:

40

	Three Months Ended June 30,				Six Months Ended June 30,
In thousands	2023		2022		2023		2022
Virtual Care Infrastructure	$	16,838	$	16,815	$	34,296	$	32,445
Services	15,503		19,030		36,317		36,760
Integrated Care Management	5,482		7,823		9,355		10,435
Total revenues	$	37,823	$	43,668	$	79,968	$	79,640

Three Months Ended June 30, 2023 and 2022. Revenues from the Virtual Care Infrastructure segment remained flat, consisting of a $0.2 million increase in services revenues, offset by a $0.2 million decrease in products revenues. There were no revenues from Glocal, which was deconsolidated in the third quarter of 2022, compared to $3.6 million of revenue in the second quarter of 2022, partially offset by services and products revenues in the U.S. Telehealth business, which increased $3.6 million resulting from an increase in minutes from both new and existing U.S. Telehealth customers.

Revenues from the Services segment decreased $3.5 million, consisting of a $4.7 million decrease in products revenues, partially offset by a $1.2 million increase in services revenues. The decrease was primarily due to the strategic sale of Innovations Group on May 11, 2023. The increase in services revenues, which was in our Behavioral business, was attributed to higher census and improved payor mix, partially offset by a $1.8 million decrease in revenues resulting from the decision to wind-down a company within our Behavioral business in the second quarter of 2023.

Revenues from the Integrated Care Management segment decreased $2.3 million, consisting of a $4.0 million decrease in licenses and subscriptions revenues due to a one-time license fee recognized in the second quarter of 2022, partially offset by a $1.6 million increase in services revenues primarily due to an increase in professional services for existing customers.

Six Months Ended June 30, 2023 and 2022. Revenues from the Virtual Care Infrastructure segment increased $1.9 million, consisting of a $2.1 million increase in services revenues, partially offset by a $0.3 million decrease in products revenues. The overall segment increase was due to an increase in minutes from both new and existing U.S. Telehealth customers, partially offset by no revenues from Glocal, which was deconsolidated in the third quarter of 2022, compared to $6.9 million of revenue in the six months ended June 30, 2022.

Revenues from the Services segment decreased $0.4 million, consisting of a $3.8 million decrease in products revenues, partially offset by a $3.4 million increase in services revenues. The decrease in products revenue was primarily due to the strategic sale of Innovations Group on May 11, 2023 and the decision to wind-down a company within our Behavioral business in the second quarter of 2023. The increase in services revenues, which was in our Behavioral business, was attributed to higher census and improved payor mix, partially offset by a $2.8 million decrease in revenues resulting from the decision to wind-down a company within our Behavioral business in the second quarter of 2023.

Revenues from the Integrated Care Management segment decreased $1.1 million, consisting of a $3.8 decrease in licenses and subscriptions revenue due to a one-time license fee in the second quarter of 2022, partially offset by a $2.7 million increase in services revenue primarily due to an increase in professional services revenue for existing customers.

Gross profit

Gross profit by segment consisted of the following:

	Three Months Ended June 30,				Six Months Ended June 30,
In thousands	2023		2022		2023		2022
Virtual Care Infrastructure	$	8,470	$	7,255	$	18,655	$	13,756
Services	7,728		6,774		17,639		12,626
Integrated Care Management	3,778		6,894		6,358		8,532
Total gross profit	$	19,976	$	20,923	$	42,652	$	34,914

Three Months Ended June 30, 2023 and 2022. Gross profit from the Virtual Care Infrastructure segment increased $1.2 million, primarily due to a $1.2 million increase in services gross profit as a result in the shift in mix from audio to video minutes in the U.S. Telehealth business, partially offset by no revenues being recognized for Glocal, which was deconsolidated in the third quarter of 2022.

Gross profit from the Services segment increased $1.0 million, consisting of a $2.0 million increase in services gross profit, partially offset by a $1.1 million decrease in products gross profit. The increase in services gross profit, which was in our Behavioral business, was attributed to higher census and improved payor mix, partially offset by a decrease in gross profit resulting from the decision to wind-down a company within our Behavioral business in the second quarter of 2023. The decrease in products gross profit was primarily due to the strategic sale of Innovations Group on May 11, 2023.

41

Gross profit from the Integrated Care Management segment decreased $3.1 million, as a result of a $4.1 million decrease in licenses and subscriptions gross profit resulting from a one-time license fee recognized in the second quarter of 2022, partially offset by a $1.0 million increase in services gross profit from increased professional services performed at higher margins.

Six Months Ended June 30, 2023 and 2022. Gross profit from the Virtual Care Infrastructure segment increased $4.9 million, primarily due to a $4.9 million increase in services gross profit as a result in the shift in mix from audio to video minutes in the U.S. Telehealth business, partially offset by no revenue being recognized for Glocal, which was deconsolidated in the third quarter of 2022.

Gross profit from the Services segment increased $5.0 million, consisting of a $4.7 million increase in services gross profit and a $0.3 million increase in products gross profit. The increase in services gross profit, which was in our Behavioral business, was attributed to higher census and improved payor mix, partially offset by a decrease in gross profit resulting from the decision to wind-down a company within our Behavioral business in the second quarter of 2023. The increase in products gross profit was primarily due increased gross profit at Innovations Group, until its strategic sale on May 11, 2023.

Gross profit from the Integrated Care Management segment decreased $2.2 million, as a result of a $4.1 million decrease in licenses and subscriptions gross profit resulting from a one-time license fee recognized in the second quarter of 2022, partially offset by a $1.9 million increase in services gross profit from increased professional services performed at higher margins.

Liquidity and Capital Resources

As of June 30, 2023 and December 31, 2022, we had free cash on hand of $46.8 million and $15.6 million, respectively. Excluded from cash and cash equivalents as of June 30, 2023 and December 31, 2022, was $7.0 million in funds held in a designated “Share Account” maintained with a leading bank in India in the name of Glocal for which our Chief Financial Officer is the sole authorized signatory. As of June 30, 2023 and December 31, 2022, we had no restricted cash included in our unaudited condensed consolidated balance sheets.

We believe our current cash and expected cash collections will be sufficient to fund our operations for at least twelve months after the filing date of this Quarterly Report.

Cash Flows

The following tables summarize cash flows in the six months ended June 30, 2023 and 2022 (unaudited):

	Six Months Ended June 30,
(In thousands)	2023		2022
Net cash used in operating activities	$	(12,053)	$	(7,841)
Net cash provided by (used in) investing activities	51,943		(3,783)
Net cash used in financing activities	(8,644)		(23,580)
Effect of exchange rate changes on cash and cash equivalents	—		(460)
Net increase (decrease) in cash and cash equivalents	$	31,246	(35,664)

Due to the deconsolidation of Glocal in the third quarter of 2022, as well as the sale of Innovations Group on May 11, 2023, the numbers presented above are not directly comparable between periods.

In the six months ended June 30, 2023, cash used in operating activities was $12.1 million, primarily attributed to the net loss of $26.3 million and the changes in operating assets and liabilities, net of effects of acquisitions, of $8.8 million, partially offset by $23.0 million of net non-cash items (debt issuance cost amortization, depreciation, intangible amortization, stock-based compensation, impairments, provision for credit losses, loss (gain) on fair value of warrant liabilities, loss (gain) on fair value of derivative liability and operating lease right-of-use asset amortization). The changes in operating assets and liabilities, net of effects of acquisitions, were primarily due to a decrease in accounts payable and accrued expenses of $5.7 million, an increase in accounts receivable of $0.4 million resulting from increased revenues in our Virtual Care Infrastructure segment, a decrease in operating lease liabilities of $1.2 million and an increase in prepaid expenses and other current assets of $1.0 million.

In the six months ended June 30, 2022, cash used in operating activities was $7.8 million, primarily attributed to the net loss of $30.2 million, partially offset by $16.1 million of non-cash items (impairments, depreciation, intangible amortization, debt issuance cost amortization and stock-based compensation) and the changes in operating assets and liabilities, net of effects of acquisitions, of $6.2 million. The changes in operating assets and liabilities, net of effects of acquisitions, was primarily due to an increase in accounts payable and accrued expenses of $8.3 million due to delayed payments to vendors and an increase in deferred revenue of $3.8 million, partially offset by a decrease in accounts receivable of $6.2 million due to net collections of receivables.

42

In the six months ended June 30, 2023, cash provided investing activities was $51.9 million, primarily consisting of proceeds from sale of business, net of expenses, of $54.9 million, partially offset by purchases of property and equipment and capitalized software development costs of $2.9 million. In the six months ended June 30, 2022, cash used in investing activities was $3.8 million, primarily consisting of purchases of property and equipment.

In the six months ended June 30, 2023, cash used in financing activities was $8.6 million, primarily consisting of repayments of debt of $10.3 million, payments of finance lease obligations of $1.8 million and distribution to noncontrolling interest of $0.7 million, partially offset by proceeds from equity issuance of $4.2 million.

In the six months ended June 30, 2022, cash used in financing activities was $23.6 million, primarily consisting of the repayment of the forward share purchase of $18.5 million, repayments of debt obligations of $3.2 million and payments of capital lease obligations of $1.6 million.

Debt

See Note 8, Debt, in the Notes to Condensed Consolidated Financial Statements of this Quarterly Report for our debt.

Contractual Obligations and Commitments

See Note 15, Leases, and Note 16, Commitments and Contingencies, in the Notes to Condensed Consolidated Financial Statements of this Quarterly Report for information about our operating lease obligations and our non-cancellable contractual service and licensing obligations. 

Off-Balance Sheet Arrangements

As of June 30, 2023, we have not entered into any off-balance sheet financing arrangements, established any additional special purpose entities, guaranteed any debt or commitments of other entities, or purchased any non-financial assets.

Recent Accounting Pronouncements

See Note 2, Summary of Significant Accounting Policies, in the Notes to Condensed Consolidated Financial Statements of this Quarterly Report for the recently issued accounting standards that could have an effect on us.

Critical Accounting Policies

The preparation of financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and income and expenses in the periods reported. These estimates and assumptions are based on current facts, historical experience, and various other factors that we believe are reasonable under the circumstances to determine reported amounts of assets, liabilities, revenues and expenses that are not readily apparent from other sources. To the extent there are material differences between our estimates and the actual results, our future consolidated results of comprehensive income (loss) may be affected.

Among our significant accounting policies, which are described in Note 2, Summary of Significant Accounting Policies, in the Notes to Condensed Consolidated Financial Statements of this Quarterly Report, as well as Note 2, Summary of Significant Accounting Policies, in the Notes to Consolidated Financial Statements for the year ended December 31, 2022 included in our Annual Report, the following accounting policies and specific estimates involve a greater degree of judgment and complexity:

•Business combinations;

•Identification and reporting of variable interest entities (“VIEs”);

•Accounting for equity investments;

•Goodwill and intangible assets;

•Revenue recognition; and

•Income taxes.

43

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not required.

Item 4. Controls and Procedures

Evaluation of Our Disclosure Controls and Procedures

We maintain a system of disclosure controls and procedures, as defined in Rule 13a-15(e) under the Exchange Act, that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information is accumulated and communicated to management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), as appropriate, to allow timely decisions regarding required disclosure. Our management, under the supervision and with the participation of our CEO and CFO, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report. Based on that evaluation, our CEO and CFO concluded that our entity-level controls and business process controls were effective as of June 30, 2023; however, our CEO and CFO also concluded that the previously identified material weakness in our information technology general controls (“ITGCs”) in the areas of user access, segregation of duties, and change management related to certain information technology systems that support our financial reporting process were remediated, but not tested, as of June 30, 2023, and that the material weakness remains for these ITGCs. Testing will be performed in the third quarter of 2023 to confirm the material weaknesses in our ITGCs have been remediated.

Changes in Internal Control Over Financial Reporting

Other than the remediation efforts related to our ITGCs described above, there was no change in our internal control over financial reporting that occurred in the three months ended June 30, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations on Effectiveness of Controls

The effectiveness of any system of internal control over financial reporting, including ours, is subject to inherent limitations, including the exercise of judgment in designing, implementing, operating, and evaluating the controls and procedures, and the inability to eliminate misconduct completely. Accordingly, in designing and evaluating the disclosure controls and procedures, management recognizes that any system of internal control over financial reporting, including ours, no matter how well designed and operated, can only provide reasonable, not absolute assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs. Moreover, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. We intend to continue to monitor and upgrade our internal controls as necessary or appropriate for our business, but cannot assure you that such improvements will be sufficient to provide us with effective internal control over financial reporting.

44

Part II - Other Information

Item 1. Legal Proceedings

From time to time, we may be subjected to claims or lawsuits which arise in the ordinary course of business. Estimates for resolution of legal and other contingencies are accrued when losses are probable and reasonably estimable. In the opinion of management, after consulting with legal counsel, none of these other claims are currently expected to have a material adverse effect on our condensed consolidated results of operations, financial position or cash flows. Except as set forth below, our material legal proceedings are described in Note 16, Commitments and Contingencies, in the Notes to Condensed Consolidated Financial Statements in Part I of this Quarterly Report.

Dispute and Litigation Regarding Control of Glocal Board of Directors

Please refer to Part I, Item 3 of our Annual Report for information regarding the dispute and litigation regarding control of the Glocal board of directors, which we update with the following information. The dispute is the subject of an arbitration brought by UpHealth Holdings against its counterparties to the October 30, 2020 Share Purchase Agreement pursuant to which UpHealth Holdings acquired Glocal (the “SPA”). The arbitration is being administered by the International Court of Arbitration (the “ICA”) of the International Chamber of Commerce (the “ICC”).

As disclosed in part I, Item 3 of our Annual Report, on November 4, 2022, UpHealth Holdings filed a Request for Arbitration before the ICA against Glocal, the three individuals who have constituted the board of directors of Glocal since UpHealth Holdings entered into the SPA, Dr. Syed Sabahat Azim (“Sabahat Azim”), Richa Azim (“Richa Azim,” and together with Sabahat Azim, the “Azims”) and Gautam Chowdhury (“Chowdhury,” and together with the Azims, the “Glocal Board”), a former shareholder of Glocal, Meleveetil Damodaran (“Damodaran,”) and another former shareholder of Glocal, Kimberlite Social Infra Private Limited, an Indian entity of which the Azims are equity owners and the sole directors (“Kimberlite”, and together with Glocal, the Azims, Chowdhury and Damodaran, collectively the “Arbitration Respondents”), for breach of the SPA, obstruction of UpHealth Holdings’ exercise of its statutory rights under the Indian Company Act as a super-majority shareholder of Glocal, and misrepresentation. UpHealth Holdings seeks an order for the following relief in the arbitration:

(i) Declaring that UpHealth Holdings holds (i) 7,503,016 equity shares in Glocal (95.29% of the total equity shares), (ii) 24,867 preference shares in Glocal (37.52% of the total preference shares), and (iii) 94.81% of the total (equity plus preference) shares in Glocal;

(ii) Declaring that UpHealth Holdings has good and marketable title over its shareholding in Glocal as detailed above, free and clear of all encumbrances and together with all rights, title, interest and benefits appertaining thereto;

(iii) Issuing a permanent mandatory injunction:

(a) pursuant to Clauses 5.2.1(b)(iii) and 12 of the SPA (as amended), directing the Arbitration Respondents to take all necessary steps to (i) convene a meeting of the Glocal Board to appoint UpHealth Holdings’ designee(s) as director(s) of the Glocal Board, and (ii) and, at that meeting, authorizes the appointment of UpHealth Holdings’ designee(s) as director(s) of the Glocal Board;

(b) pursuant to Clauses 5.2.1(c) and 12 of the SPA (as amended), directing the Arbitration Respondents, both individually and jointly, to file Form DIR-12 with the jurisdictional registrar of companies in relation to the appointment of UpHealth Holdings’ designee(s) to the Glocal Board;

(c) pursuant to Clauses 5.2.1(d) and 12 of the SPA (as amended), directing the Arbitration Respondents, both individually and jointly, to provide UpHealth Holdings with true extracts, duly certified by the Glocal Board, of board resolutions appointing UpHealth Holdings’ designee(s) to the Glocal Board, following such appointment;

(d) directing the Arbitration Respondents, both individually and jointly, to (in the following order): (i) convene a general meeting to approve and authorize the amendment of the Articles of Association of Glocal, (ii) approve and authorize the amendment of the Articles of Association of Glocal, (iii) take all necessary steps under Indian law to ensure UpHealth Holdings is provided a right for its designee on the Glocal Board to act as the Chairman of the general meeting, having the right to exercise a casting vote in case of a deadlock, and (iv) at the general meeting, if a poll is demanded in accordance with the provisions of the Companies Act, approve and implement such demand and conduct the voting by poll;

45

(e) pursuant to Clauses 10.2 and 12 of the SPA (as amended), directing the Arbitration Respondents to take all necessary steps to ensure that UpHealth Holdings owns 100% of the share capital of Glocal, when and as required by UpHealth Holdings; and

(f) directing the Arbitration Respondents, both individually and jointly, to take all necessary steps to provide UpHealth Holdings with full access to all financial statement(s), information, data, documents, books and records in the form and manner requested by UpHealth Holdings.

(iv) Ordering the Azim, Chowdhury, Damodaran and Kimberlite to, jointly and severally, pay damages to UpHealth Holdings in the amount of $1.7 million (or such other amount as the arbitral tribunal may determine to be appropriate), arising from these Respondents’ breaches of contract.

(v) Ordering Azim and Kimberlite to, jointly and severally, pay damages to UpHealth Holdings in the amount of $121.1 million (or such other amount as the arbitral tribunal may determine to be appropriate), arising from these Respondents’ misrepresentations.

(vi) Ordering the Azims and Chowdhury (“Respondents Group A”) to, jointly and severally, reimburse to UpHealth Holdings all costs and expenses, including legal fees, incurred as a result of (i) the prior Emergency Arbitration conducted in the Fall of 2022 (including UpHealth Holdings’ legal costs, fees and expenses, as well as the fees and expenses of the Emergency Arbitrator and the ICC); and (ii) the litigations to enforce the Emergency Arbitrator’s Order in India (including UpHealth Holdings’ legal costs, fees and expenses), all of which were only necessary as a result of Respondents Group A’s misconduct.

(v) Ordering the Azims, Chowdhury, Damodaran, and Kimberlite to, jointly and severally, reimburse to UpHealth Holdings all costs and expenses, including legal and expert fees, incurred as a result of this arbitration (including UpHealth Holdings’ legal costs, fees and expenses, and all the fees and expenses of the arbitrators and the ICC), which was only necessary as a result of these Respondents’ misconduct.

(vi) Ordering that pre- and post-award interest is payable, jointly and severally, by the Azims, Chowdhury, Damodaran and Kimberlite, according to the principal amounts of damages they are respectively ordered to pay in the award.

(vii) Ordering the Azims, Chowdhury, Damodaran and Kimberlite, jointly and severally, to gross up any amounts to be paid by them to UpHealth Holdings that may be subject to taxes in India, or any other jurisdiction where the Arbitration Respondents may be located, to ensure that UpHealth Holdings receives the full amount of damages due to it.

(viii) Giving continuing effect to subparts (c), (e), and (f) of Section VV (the dispositif) of the Emergency Arbitrator’s Order, as amended below, pursuant to the arbitral tribunal’s authority under Article 29(3) of the ICC Rules and Article 6(6)(c) of Appendix V to the ICC Rules.

(c) Respondents Group A are directed, both individually and jointly, to cooperate with UpHealth Holdings, and with any PCAOB-registered accounting firm identified by UpHealth Holdings, in providing access to all unaudited financial statement(s), data, documents, books and records of Glocal, as and when required and in the form and manner requested by UpHealth Holdings;

(e) Respondents Group A are directed, both individually and jointly, to cooperate with any PCAOB-registered accounting firm identified by UpHealth Holdings in their review of the information provided pursuant to paragraph (c) above, including responding to any questions, making any company employees or officers available to respond to questions, and complying with any requests for further information or clarifications; and

(f) Respondents Group A are, jointly and individually, ordered to refrain from (i) taking any steps to access the funds in Glocal’s bank account at ICICI Bank whether on the basis of the August 15, 2022 board resolution or otherwise, (ii) making, or causing to be made, any changes to the authorized signatory that can access such bank account, and (iii) making, or causing to be made, any other changes to such bank account.

(ix) Holding and declaring that Martin Beck (our Chief Financial Officer) and/or Jeremy Livianu (our Chief Legal Officer) and/or such other person as may be designated by the board of directors of UpHealth Holdings, by board resolution, from time to time

46

(and notified in writing to ICICI Bank by the Chief Executive Officer of UpHealth Holdings, attaching a certified copy of the resolution of the board of directors of UpHealth Holdings designating such person) may, jointly or severally, be permitted to access and operate Glocal’s bank account at ICICI bank.

In December 2022, before the arbitral tribunal was constituted, each of the Arbitration Respondents wrote to the ICC seeking to not have the arbitration proceed, including Glocal and the Glocal Board, claiming that there is no jurisdiction for an arbitration, in part due to the existence of a proceeding brought by the Glocal Board and an employee and shareholder of Glocal in India before the National Company Law Tribunal, Kolkata Bench (the “NCLT”), and Damodaran claiming that he should not have to bear the expense of an arbitration notwithstanding having been a party to the SPA and receiving significant consideration from UpHealth Holdings for the sale of shares of Glocal. The ICC declined to consider these arguments and determined that they should be addressed by the arbitral tribunal, once constituted.

In the arbitration, UpHealth Holdings filed an Amended Request for Arbitration on January 8, 2023. The three-member arbitral tribunal was constituted on March 6, 2023. The arbitral tribunal invited the parties’ views on the timetable for the arbitration and other procedural issues. None of the Arbitration Respondents responded to that invitation, and none of them has communicated with the arbitral tribunal or with UpHealth Holdings (in the context of the arbitration) since the arbitral tribunal was constituted. The Arbitration Respondents have received all arbitration-related correspondence from UpHealth Holdings and the Tribunal electronically and in hard copy.

The arbitral tribunal held a case management conference via Zoom on April 12, 2023. The Arbitration Respondents were invited to the conference, but none of them attended. At the conference, the arbitral tribunal decided that UpHealth Holdings would be given until June 22, 2023, to file its Statement of Claim, and that the Arbitration Respondents would then have until July 6, 2023 to indicate whether they planned to respond to the Statement of Claim or otherwise participate in the arbitration. Absent such indication, the hearing would be held in Chicago, Illinois, during the week starting July 31, 2023.

UpHealth Holdings filed its Statement of Claim on June 22, 2023. The Arbitration Respondents received electronic and hard copies of this submission. None of the Arbitration Respondents confirmed their intention to participate in the arbitration, either before their deadline to do so (July 6, 2023) or thereafter.

The merits hearing in the arbitration was held in person in Chicago, Illinois, from July 31, 2023 through August 2, 2023. None of the Arbitration Respondents attended the hearing. During the hearing, the arbitral tribunal requested additional information from the damages expert retained by UpHealth Holdings. That additional information is due to be provided by August 25, 2023. UpHealth Holdings expects the tribunal to issue additional directions after receiving the supplemental information from the expert.

Item 1A. Risk Factors

As of the date of this Quarterly Report on Form 10-Q, we supplement the risk factors disclosed in our Annual Report with the following risk factors. Any of these risk factors disclosed in our Annual Report or herein could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. We may disclose changes to such risk factors or disclose additional risk factors from time to time in our future filings with the SEC.

Risks Relating to UpHealth’s Business and Industry

In order to support the growth of our business, we may need to seek capital through new equity or debt financings, and such sources of additional capital may not be available to us on acceptable terms or at all.

We intend to continue to make significant investments to support our business growth, respond to business challenges or opportunities, develop new applications and services, enhance our existing solutions and services, enhance our operating infrastructure and potentially acquire complementary businesses and technologies. In the six months ended June 30, 2023 and 2022, aggregate net cash used in operating activities was $12.1 million and $7.8 million, respectively.

Our future capital requirements may be significantly different from our current estimates and will depend on many factors, including our growth rate, both organically and through acquisitions, the timing and extent of spending to support development efforts, the expansion of sales and marketing activities, the introduction of new or enhanced services and the continuing market acceptance of digital health. Accordingly, we may need to engage in additional equity or debt financings or collaborative arrangements to secure additional funds. If we raise additional funds through further issuances of equity or convertible debt securities, our existing

47

stockholders could suffer significant dilution, and any new equity securities we issue could have rights, preferences and privileges superior to those of holders of our common stock. Any debt financing secured by us in the future could involve additional restrictive covenants relating to our capital-raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and to pursue business opportunities, including potential acquisitions. In addition, during times of economic instability, it has been difficult for many companies to obtain financing in the public markets or to obtain debt financing, and we may not be able to obtain additional financing on commercially reasonable terms, if at all. If we are unable to obtain adequate financing on terms satisfactory to us, it could have a material adverse effect on our business, financial condition and results of operations.

Our debt agreements contain restrictions that may limit our flexibility in operating and financing our business, and any default on our secured credit facility could result in foreclosure by our secured noteholders on our assets.

Our Indenture governing our 2025 Notes, Security Agreement and related documents contain, and instruments governing any future indebtedness of ours would likely contain, a number of covenants that will impose significant operating and financial restrictions on us, including restrictions on our ability to, among other things:

•create liens on certain assets;

•incur additional debt or issue new equity;

•consolidate, merge, sell or otherwise dispose of all or substantially all of our assets; and

•sell certain assets.

Any of these restrictions could limit our ability to plan for or react to market conditions and could otherwise restrict corporate activities. Any failure to comply with these covenants could result in a default under our secured credit facility or instruments governing any future indebtedness of ours. Additionally, our credit facility for the 2025 Notes is secured by substantially all of our assets and those of our domestic subsidiaries. Upon a default, unless waived, the lenders under our secured credit facility could elect to terminate their commitments, cease making further loans, foreclose on our assets pledged to such lenders to secure our obligations under our Security Agreement and force us into bankruptcy or liquidation. In addition, a default under our secured credit facility could trigger a cross default under agreements governing any future indebtedness as well as the Indenture governing our 2026 Notes. Our results of operations may not be sufficient to service our indebtedness and to fund our other expenditures, and we may not be able to obtain financing to meet these requirements. If we experience a default under our secured credit facility, our unsecured credit facility or instruments governing our future indebtedness, our business, financial condition, and results of operations may be adversely impacted.

In addition, the 2025 Notes mature on December 15, 2025. There are no assurances that that we will have sufficient funds available to satisfy the 2025 Notes at maturity, or that the holders will elect to convert the 2025 Notes into shares of our common stock prior to or at the time of maturity.

As of June 30, 2023, we were in compliance with all covenants and restrictions associated with our debt agreements.

We qualify as an emerging growth company as defined under the JOBS Act as well as a smaller reporting company within the meaning of the Securities Act, and if we take advantage of certain exemptions from disclosure requirements available to emerging growth companies or smaller reporting companies, this could make our securities less attractive to investors and may make it more difficult to compare our performance with other public companies.

We qualify as an “emerging growth company” within the meaning of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies for as long as we continue to be an emerging growth company, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”), reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. As a result, our stockholders may not have access to certain information they may deem important. We will remain an emerging growth company until the earliest of (i) the last day of the fiscal year in which the market value of our common stock that is held by non-affiliates exceeds $700.0 million as of the end of that year’s second fiscal quarter, (ii) the last day of the fiscal year in which we have total annual gross revenues of $1.235 billion or more during such fiscal year (as indexed for inflation), (iii) the date on which we have issued more than $1.0 billion in non-convertible debt in the prior three-year period or (iv) the last day of the fiscal year following the fifth anniversary of our IPO. We cannot predict whether investors will find our securities less attractive because we will rely on these exemptions. If some investors find our securities less attractive as a result of our reliance on these exemptions, the trading prices of our securities may be lower than they otherwise would be, there may be a less active trading market for our securities and the trading prices of our securities may be more volatile.

48

In addition, Section 107 of the JOBS Act also provides that an emerging growth company can take advantage of the exemption from complying with new or revised accounting standards provided in Section 7(a)(2)(B) of the Securities Act as long as we are an emerging growth company. An emerging growth company can therefore delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have not elected to opt out of such extended transition period and, therefore, we may not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. This may make comparison of our financial statements with another public company which is not an emerging growth company or is an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accountant standards used.

Additionally, we qualify as a “smaller reporting company” as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (i) the market value of our common stock held by non-affiliates exceeds $250.0 million as of the end of that year’s second fiscal quarter, or (ii) our annual revenues exceeded $100.0 million during such completed fiscal year and the market value of our common stock held by non-affiliates exceeds $700.0 million as of the end of that year’s second fiscal quarter. To the extent we take advantage of such reduced disclosure obligations, it may also make comparison of our financial statements with other public companies difficult or impossible.

If we fail to maintain an effective system of disclosure controls and internal control over financial reporting, our ability to produce timely and accurate financial statements or comply with applicable regulations could be impaired, and the price of our common stock may be adversely affected.

As a publicly traded company following the consummation of the Business Combinations, we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and the rules and regulations of the applicable listing standards of the New York Stock Exchange (“NYSE”). We expect that the requirements of these rules and regulations will continue to increase our legal, accounting and financial compliance costs, make some activities more difficult, time-consuming and costly and place significant strain on our personnel, systems and resources. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. We are continuing to develop and refine our disclosure controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we will file with the SEC is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and that information required to be disclosed in reports under the Exchange Act is accumulated and communicated to our principal executive and financial officers.

As previously disclosed in our Annual Report on Form 10‑K for year ended December 31, 2021, our disclosure controls and procedures and internal controls over financial reporting were not effective as of December 31, 2021 due to certain material weaknesses described in Part I, Item 4, Controls and Procedures, of this Quarterly Report, as well as in Part II, Item 9A, Controls and Procedures, of our Annual Report. To address these material weaknesses that we identified as of December 31, 2021, we implemented measures designed to improve our internal controls over financial reporting in the year ended December 31, 2022. These measures included enhancing our internal and external technical accounting resources and engaging third party consultants for the formalization of our internal procedures, and implementing a new enterprise resource planning (“ERP”) system. As of December 31, 2022, all of the U.S. entities were live on the ERP system. We completed documentation and tests of design and tests of operational effectiveness of our entity-level controls, certain areas of our ITGCs, and controls over our business processes, and we remediated control gaps identified and performed tests of operating effectiveness on remediated items.

As a result of our remediation efforts, our management, under the supervision and with the participation of our CEO and our CFO and oversight of the Board of Directors, conducted an evaluation of the effectiveness of our internal controls over financial reporting as of December 31, 2022, based on the criteria set forth in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Based on this evaluation, our management concluded that as of December 31, 2022, we no longer have the material weaknesses in internal controls over financial reporting described above for entity-level controls and business process controls, which we previously identified existed as of December 31, 2021 and our assessment has not changed as of June 30, 2023; however, our management also concluded that the previously identified material weakness in our ITGCs in the areas of user access, segregation of duties, and change management related to certain information technology systems that support our financial reporting process were remediated, but not tested, as of June 30, 2023, and that the material weakness remains for these ITGCs. Testing will be performed in the third quarter of 2023 to confirm the material weaknesses in our ITGCs have been remediated.

In order to maintain and improve the effectiveness of our disclosure controls and procedures and internal control over financial reporting, we have expended, and anticipate that we will continue to expend, significant resources, including accounting-related costs and significant management oversight. If any of these new or improved controls and systems do not perform as expected, we may experience additional material weaknesses in our controls. Our current controls and any new controls that we develop may become

49

inadequate because of changes in conditions in our business. Further, additional weaknesses in our disclosure controls and internal control over financial reporting may be discovered in the future.

Any failure to develop or maintain effective controls or any difficulties encountered in their implementation or improvement could harm our results of operations or cause us to fail to meet our reporting obligations and may result in a restatement of our financial statements for prior periods. Any failure to implement and maintain effective internal control over financial reporting also could adversely affect the results of periodic management evaluations and annual independent registered public accounting firm attestation reports regarding the effectiveness of internal control over financial reporting that we will eventually be required to include in our periodic reports that will be filed with the SEC. Ineffective disclosure controls and procedures and internal control over financial reporting could also cause investors to lose confidence in our reported financial and other information, which would likely have a negative effect on the trading price of our common stock. In addition, if we are unable to continue to meet these requirements, we may not be able to remain listed on the NYSE.

General Risks Related to the Company

The Company may be required to take write-downs or write-offs, restructuring and impairment or other charges that could have a significant negative effect on its financial condition, results of operations and stock price, which could cause you to lose some or all of your investment.

As a result of events which occurred in the three months ended September 30, 2022, as discussed under the heading “Dispute and Litigation Regarding Control of Glocal Board of Directors” in Item 3, Legal Proceedings, of Part I of our Annual Report, we determined that a reconsideration event occurred in July 2022, which required us to reassess whether Glocal was a VIE and whether we continued to have a controlling financial interest in Glocal. Based on this assessment, we concluded that Glocal was a VIE, and furthermore, that we no longer have the ability to direct any activities of Glocal and no longer have a controlling financial interest. As a result, effective July 2022, we deconsolidated Glocal and recorded a $37.7 million loss on deconsolidation of equity investment in our consolidated statements of operations, measured as the difference between the probability-weighted fair value of Glocal of $21.2 million and the carrying amount of Glocal’s assets and liabilities as of June 30, 2022. The probability-weighted fair value of Glocal is included in equity investment in our consolidated balance sheets. Further, we assessed the prospective accounting for our equity investment in Glocal. Since we no longer had the ability to exercise significant influence over operating and financial policies of Glocal, we concluded the investment should be accounted for utilizing the ASC 621 measurement alternative, whereby the investment was measured at cost and will continue to be evaluated for any indicators of impairment. In addition, we derecognized $14.3 million of noncontrolling interests related to Glocal. If through the legal processes discussed under the heading “Dispute and Litigation Regarding Control of Glocal Board of Directors” in Item 3, Legal Proceedings, of Part I of our Annual Report, we are able to obtain the ability to direct the activities of Glocal, and it is our intent to exercise all legal rights and remedies to achieve such a result, then we will further reassess the appropriate accounting treatment of our investment in Glocal.

The Company may be forced to write-down or write-off assets in the future, restructure its operations, or incur impairment or other charges that could result in losses. Even though these charges may be non-cash items and may not have an immediate impact on the Company’s liquidity, the fact that the Company reports charges of this nature could contribute to negative market perceptions about it or its securities. Furthermore, as a result of indicators of impairment identified in the three months ended September 30, 2022, we performed a goodwill impairment assessment as of September 30, 2022, which included both qualitative and quantitative assessments. Our assessment included a comparison of carrying value to an estimated fair value using a market approach based on our market capitalization. Based on this assessment, we concluded the fair value of two segments was below the carrying value primarily due to the recent change in our market valuation and financial performance and recorded a goodwill impairment in the amount of $89.1 million and an intangible asset impairment in the amount of $16.9 million. Additionally, in the three months ended June 30, 2023, we impaired goodwill in the amount of $6.4 million at a company within our Behavioral business we wound down in the period. We also recorded a $1.4 million, $0.5 million, and a $1.8 million charge on the remeasurement of the disposal group held for sale in the three months ended June 30, 2023, March 31, 2023 and December 31, 2022, respectively, in connection with the pending and ultimate sale of Innovations Group on May 11, 2023. In addition, we recorded a $5.5 million measurement period adjustment at Glocal that was immediately impaired, and a $0.7 million trade name intangible asset impairment at TTC in the three months ended March 31, 2022. Future charges of this nature may cause the Company to be unable to obtain future financing on favorable terms or at all.

Resales of our shares of common stock could depress the market price of our common stock.

We have approximately 17,161,024 shares of common stock outstanding as of August 9, 2023. The shares held by the Company’s public stockholders are freely tradable. In addition, the Company registered shares of common stock issued as merger consideration (none of which remain subject to a contractual lockup period), registered for resale shares of common stock issued in the 2023 Private Placement, and will be registering shares for resales by its officers, directors and other affiliates, as well as shares underlying the warrants and Convertible Notes issued by the Company, which shares will become available for resale following the exercise or conversion of the warrants or Convertible Notes, respectively. Rule 144 also became available for the resale of shares of our common

50

stock on June 14, 2022. Such sales of shares of common stock or the perception of such sales may depress the market price of our common stock.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

Employment Agreement with Martin Beck

As previously disclosed in the Company’s Current Report on Form 8-K filed with the SEC on October 25, 2021, on October 24, 2021, the Company entered into an employment agreement with its Chief Financial Officer, Martin Beck (the “CFO Employment Agreement”). On August 8, 2023, the Board approved an Amended and Restated Employment Agreement between Mr. Beck and the Company that amends and restates in its entirety, and replaces, the CFO Employment Agreement (the “Amended and Restated Employment Agreement”). The Company and Mr. Beck entered into the Amended and Restated Employment Agreement on August 8, 2023.

The Amended and Restated Employment Agreement provides that Mr. Beck will receive a base salary at an annual rate of $400,000, subject to increase from time to time as determined by the Board or the Compensation Committee, as well as that he shall continue to be eligible to receive an annual bonus of 75% of his base salary based on the Board’s determination, in good faith, as to whether applicable performance milestones have been achieved. The Amended and Restated Employment Agreement further provides that Mr. Beck may be awarded an additional bonus for performance determined solely by the Board in its discretion, and any such determination will be final and binding on Mr. Beck.

In addition, the Amended and Restated Employment Agreement provides that, during and after Mr. Beck’s employment with the Company, Mr. Beck shall cooperate fully with the Company in (i) the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company or any of its subsidiaries or affiliates which relate to events or occurrences that transpired while Mr. Beck was employed by the Company; (ii) the investigation, whether internal or external, of any matters about which the Company believes Mr. Beck may have knowledge or information; and (iii) any investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while Mr. Beck was employed by the Company. Mr. Beck’s full cooperation in connection with such claims, actions or investigations shall include, but not be limited to, being available to meet with counsel to answer questions or to prepare for discovery or trial and to provide truthful testimony on behalf of the Company at mutually convenient times (the “Litigation Cooperation Requirement”). The Company shall reimburse Mr. Beck for any reasonable out of pocket expenses incurred in connection with Mr. Beck’s performance of obligations pursuant to the Litigation Cooperation Requirement. In the event that Mr. Beck is requested to provide such cooperation services following Mr. Beck’s last day of employment by the Company, the Company shall (i) pay Mr. Beck for his time (other than time in which Mr. Beck is testifying under oath and for which no payment will be due) at the rate of $200.00 per hour, and (ii) be reasonably accommodating with respect to Mr. Beck’s work schedule and responsibilities for any subsequent employer.

The Amended and Restated Employment Agreement also provides that Mr. Beck will be eligible to earn a one-time bonus payment of $400,000 less all applicable withholdings (the “Retention Bonus”). The Retention Bonus will be paid to Mr. Beck as an unearned advance on the first regular payroll date after the effective date of the Amended and Restated Employment Agreement. Mr. Beck is eligible to earn the Retention Bonus subject to satisfaction of each of the following conditions: (i) Mr. Beck’s continued employment with the Company through the earlier of: (A) March 31, 2024, or (B) the applicable date of filing of the Company’s Annual Report on Form 10-K for the 2023 fiscal year (such applicable date, the “Retention Date”), (ii) the Company’s timely submission of all required filings with the SEC prior to the Retention Date, (iii) Mr. Beck’s cooperation and assistance prior to the Retention Date with searching for and identifying a candidate to succeed to Mr. Beck’ position and duties with the Company (“New CFO”) and (iv) if a New CFO is identified by the Company prior to the Retention Date, Mr. Beck cooperates with and reasonably assists the Company in the transition of Mr. Beck’s duties to the New CFO. If Mr. Beck provides written notice to the Company that he will resign from employment on March 31, 2024, the provision of such notification to the Company, by itself, shall not be deemed to constitute a termination of Mr. Beck’s continued employment for purposes of eligibility to earn the Retention Bonus. The period commencing on the effective date of the Amended and Restated Employment Agreement and ending on the Retention Date is the “Retention Period.” Mr. Beck is eligible to earn a pro-rata portion of the Retention Bonus if Mr. Beck resigns for Good Reason (as defined below) during the Retention Period, with such pro-rata portion calculated by reference to the number of days that Mr. Beck was employed during the Retention Period

51

divided by the total number of days in the Retention Period. Additionally, the Retention Bonus will be earned in full upon a Change in Control (as such term is defined in the Amended and Restated Employment Agreement), subject to Mr. Beck’s continued employment with the Company through the closing of the Change in Control. The Retention Bonus will also be earned in full if the Company terminates Mr. Beck’s employment without Cause (as such term is defined in the Amended and Restated Employment Agreement) before the Retention Date. If for any reason the Retention Bonus is not earned, in whole or in part, Mr. Beck must repay the entire gross value amount of the unearned portion of the Retention Bonus (the “Repayment Amount”) in cash to the Company no later than 30 days after Mr. Beck is notified in writing that Mr. Beck is required to repay the Company the Repayment Amount. The Company may elect to offset such owed Repayment Amount against Mr. Beck’s final paycheck, any vacation cash out, and any expense reimbursements not previously paid, if applicable and to the extent permitted by applicable law. Additionally, if Mr. Beck fails to timely repay the Repayment Amount to the Company, Mr. Beck is required to reimburse the Company all costs incurred by the Company in connection with collection of the Repayment Amount, including reasonable attorneys’ fees.

The Amended and Restated Employment Agreement provides that “Good Reason” for Mr. Beck to terminate his employment shall mean the occurrence of any of the following events without his consent: (i) the relocation of Mr. Beck’s primary work location to a point more than 50 miles from Delray Beach, Florida; (ii) a material reduction by the Company of Mr. Beck’s base salary or annual target bonus opportunity, without the written consent of Mr. Beck, as initially set forth in the Amended and Restated Employment Agreement or as the same may be increased from time to time pursuant to the Amended and Restated Employment Agreement, except for across-the-board salary reductions implemented prior to a Change in Control which are implemented based on the Company’s financial performance and similarly affecting all or substantially all senior management employees of the Company; and (iii) a material breach by the Company of the terms of the Amended and Restated Employment Agreement. Provided, however, that such termination by Mr. Beck shall only be deemed for Good Reason pursuant to the foregoing definition if (i) the Company is given written notice from Mr. Beck within 60 days following the first occurrence of the condition that he considers to constitute Good Reason describing the condition and the Company fails to satisfactorily remedy such condition within 30 days following such written notice, and (ii) Mr. Beck terminates employment within 30 days following the end of the period within which the Company was entitled to remedy the condition constituting Good Reason but failed to do so.

The Amended and Restated Employment Agreement also provides that Mr. Beck will be eligible to earn performance bonuses in the aggregate target amount of $1,000,000 based on the Company’s performance during the 2023, 2024 and 2025 fiscal years (together, such fiscal years are the “Performance Period”). Mr. Beck is eligible to earn a performance bonus with respect to each fiscal year in the Performance Period (each a “Revenue Bonus”). His target Revenue Bonus amount applicable to each fiscal year within the Performance Period is $333,333.33. The amount of Revenue Bonus eligible to be earned by Mr. Beck for each fiscal year during the Performance Period will be determined based on the applicable level of revenue received by the Company during such fiscal year. The applicable percentage of his Revenue Bonus that is eligible to be earned for each fiscal year within the Performance Period will be determined by reference to the Company’s level of revenue received for the applicable fiscal year as measured against the target revenue performance levels for such fiscal year as determined by the Board, with 100% of the target Revenue Bonus for a fiscal year being paid in the event that the targeted level of revenue is achieved by the Company, 85% of the target Revenue Bonus for a fiscal year being paid in the event that 85% of the targeted level of revenue is achieved by the Company, 125% of the target Revenue Bonus for a fiscal year being paid in the event that 125% of the targeted level of revenue is achieved by the Company, and linear interpolation between these designated performance levels.

The threshold and stretch targeted levels of revenue for each fiscal year within the Performance Period are independent for each fiscal year (i.e., if 85% of the targeted levels of revenue for a fiscal year is attained for such fiscal year and 110% of the targeted levels of revenue for a fiscal year is attained for such fiscal year, with respect to those fiscal years the Revenue Bonus amounts eligible to be earned are $283,333.33 and $366,666.66, respectively). If the Company does not meet the threshold goal of 85% of the targeted levels of revenue for the applicable fiscal year, Mr. Beck is not eligible to earn or receive any Revenue Bonus with respect to such fiscal year. If the Company exceeds 125% of the targeted levels of revenue for the applicable fiscal year, the Revenue Bonus that Mr. Beck is eligible to earn and receive for such fiscal year is 125% of the targeted levels of revenue amount for such fiscal year (i.e., $416,666.66). Whether and to what extent the applicable targeted levels of revenue for a fiscal year was attained for such fiscal year will be determined by the Board in a manner consistent with the amounts reported on the Company’s annual audited financial statements, and its determination will be final and binding on Mr. Beck.

In all cases, Mr. Beck’s eligibility to earn a Revenue Bonus for a fiscal year is subject to Mr. Beck’s continued employment with the Company through the applicable date of payment of such Revenue Bonus. If a Revenue Bonus is eligible to be earned by Mr. Beck for a fiscal year based on performance for such fiscal year, the applicable Revenue Bonus for such fiscal year will be paid to Mr. Beck in the calendar year immediately following the fiscal year with respect to which the targeted levels of revenue were attained. For the Revenue Bonus eligible to be earned based on performance for the 2023 fiscal year, Mr. Beck must also remain employed through the applicable date of filing of the Company’s Annual Report on Form 10-K for the 2023 fiscal year in order for him to be eligible to earn a Revenue Bonus in respect of the 2023 fiscal year; provided, however, that if the Company terminates Mr. Beck’s employment without Cause (as such term is defined in the Amended and Restated Employment Agreement) prior to the date of filing of the Company’s Annual Report on Form 10-K for the 2023 fiscal year, Mr. Beck shall be deemed to have earned the applicable amount of Revenue Bonus solely for the 2023 fiscal year, based on Company performance for the 2023 fiscal year, and Mr. Beck shall not be eligible to earn any Revenue Bonus in respect of the 2024 or 2025 fiscal years. If earned, such Revenue Bonus for 2023 will be paid in the first payroll period following the date of filing of the Company’s Annual Report on Form 10-K for the 2023 fiscal year. Any

52

Revenue Bonus earned with respect to Company performance for the 2024 and 2025 fiscal years will be paid no later than March 15 of the calendar year immediately following the fiscal year with respect to which the applicable level of revenue was attained.

In the event there is a Change in Control of the Company which occurs prior to the end of the Performance Period, and subject to Mr. Beck’s continued employment with the Company through the date of such Change in Control, the applicable level of revenue for the remainder of the Performance Period (commencing with the fiscal year in which the Change in Control occurs) will be deemed to have been attained at the target level upon such Change in Control so that Mr. Beck will instead be entitled to receive the target amount of Revenue Bonus for the remainder of the Performance Period, which will be paid in cash to Mr. Beck no later than fifteen days following such Change in Control. For example, if a Change in Control transaction occurs on June 1, 2024 and Mr. Beck remains employed by the Company on such date, then Mr. Beck will receive a total Revenue Bonus equal to $666,666.66 for the 2024 and 2025 fiscal years ($333,333.33 for 2024 and $333,333.33 for 2025) and regardless of the Company’s actual level of revenue for the 2024 and 2025 fiscal years.

Except for payment of the Revenue Bonus that is triggered in connection with a Change in Control transaction in which case the form of payment shall always be in cash, the Company may, in its sole discretion, settle its obligation to pay the Revenue Bonus in cash or in vested shares of the Company’s common stock, to be issued pursuant to the terms of the Company’s 2021 Equity Incentive Plan, with a then current fair market value equal to the amount of the cash payment, with such Company share value determined in the same manner that the Company calculates such fair market value for tax administration and withholding purposes.

The Amended and Restated Employment Agreement also provides that the terms of the Indemnity Agreement previously entered into by the Company and Mr. Beck, an executed copy of which is attached as an exhibit to the Amended and Restated Employment Agreement (the “Indemnity Agreement”), shall continue to be applicable. To the extent the Indemnity Agreement is not applicable, the following provisions shall apply. The Company covenants and agrees to indemnify Mr. Beck, his heirs and representatives, and hold them harmless, to the fullest extent allowed by governing law, from and in connection with any loss, cost, damage, award, judgment, claim and/or expense, including without limiting the generality of the foregoing, attorneys’ fees and related expenses, in the event Mr. Beck is made or threatened to be made a party or is otherwise involved in any threatened, pending or completed action, suit or proceeding, whether civil, administrative, investigative or otherwise or the provision of any cooperation or assistance hereunder including but not limited to the Litigation Cooperation Requirement (a “Proceeding”), by reason of his acceptance and/or performance of the employment contemplated herein, or that otherwise arises out of or relates to Mr. Beck’s service as an officer or employee of the Company or any affiliate of the Company. Mr. Beck shall have the right to engage, at the Company’s expense, independent counsel in connection with such a Proceeding. The Company agrees to pay all expenses incurred in connection with any such Proceeding (including but not limited to the fees and expenses associated with the engagement of Mr. Beck’s independent counsel) directly to the billing party, when and as incurred, and in advance of the final disposition of such Proceeding, so as to avoid Mr. Beck having to pay or advance such costs. The Company also agrees to pay all other costs associated with such a Proceeding, including any bond costs, liability award or judgment, together with any costs or accrued interest, directly so as to avoid Mr. Beck having to pay or advance such sums. Mr. Beck shall retain full control of his representation and the decisions affecting his interests in connection with such a Proceeding. In addition, during Mr. Beck’s employment and thereafter, the Company shall provide Mr. Beck with coverage under a policy of directors’ and officers’ liability insurance that provides him with coverage on the same basis as is provided for the officers and directors of the Company.

The Amended and Restated Employment Agreement also provides that Mr. Beck may receive certain severance benefits if he terminates his employment with the Company pursuant to a Qualifying Resignation (as defined below) or a Scheduled Resignation (as defined below). A Qualified Resignation shall occur if (i) Mr. Beck’s resignation is due to a material adverse change in Mr. Beck’s title or a material reduction in Mr. Beck’s duties, authority, or responsibilities relative to the duties, authority, or responsibilities in effect immediately prior to such reduction (each a “Resignation Condition”), and (ii) Mr. Beck’s resignation of employment occurs after the Retention Date; provided, however, that such resignation by Mr. Beck shall only be deemed a Qualifying Resignation pursuant to the foregoing definition if (x) the Company is given written notice from Mr. Beck within 60 days following the later of (A) the Retention Date, or (B) the date of occurrence of the condition that he considers to constitute a Resignation Condition describing the Resignation Condition and the Company fails to satisfactorily remedy such Resignation Condition within 30 days following such written notice, and (y) Mr. Beck terminates his employment with the Company within 30 days following the end of the period within which the Company was entitled to remedy the Resignation Condition but failed to do so. A Scheduled Resignation means Mr. Beck’s resignation of employment for any or no reason which meets each of the following criteria; (i) Mr. Beck provides written notice to the Company no later than December 31, 2023 that Mr. Beck will resign from employment on March 31, 2024 (the “Resignation Date”), (ii) Mr. Beck remains employed with the Company through the Resignation Date, and (iii) Mr. Beck resigns from employment with the Company on the Resignation Date. In no event is Mr. Beck’s termination of employment a Scheduled Resignation if Mr. Beck: (i) terminates employment for any reason prior to the Resignation Date, (ii) fails to provide the Company with written notice by December 31, 2023 of Mr. Beck’s intent to resign on the Resignation Date, or (iii) does not resign on the Resignation Date.

The Amended and Restated Employment Agreement also provides that Mr. Beck may receive certain severance benefits if he terminates his employment for any or no reason with written notice to the Company at any time within 30 days following a Change in Control of the Company. For all purposes of the Amended and Restated Employment Agreement, Mr. Beck’s termination of employment for any or no reason within 30 days following a Change in Control of the Company does not mean or include any termination of Mr. Beck by the Company for Cause which occurs during such 30-day period.

53

The Amended and Restated Employment Agreement also provides that upon any termination of Mr. Beck’s employment the Company shall pay Mr. Beck’s base salary, accrued but unpaid business expenses and accrued and unused vacation benefits earned through the date of termination at the rate in effect at the time of termination (the “Accrued Amounts”), less standard deductions and withholdings.

If the Company terminates Mr. Beck’s employment without Cause or Mr. Beck terminates his employment for Good Reason or due to a Qualifying Resignation or Scheduled Resignation, and a Change in Control Trigger (as defined below) has not occurred, the Company shall pay the Accrued Amounts subject to standard deductions and withholdings, to be paid as a lump sum no later than 30 days after the date of termination. In addition, subject to the limitations stated in the Amended and Restated Employment Agreement and upon Mr. Beck’s furnishing to the Company an executed Release (as defined in the Amended and Restated Employment Agreement) and Mr. Beck continuing to comply with his obligations pursuant to the Proprietary Information and Inventions Agreement attached as an exhibit to the Amended and Restated Employment Agreement and entered into by him concurrently with the entry into the CFO Employment Agreement (the “Proprietary Information and Inventions Agreement”), and subject to Mr. Beck continuing to satisfy the Litigation Cooperation Requirement, the Company shall provide Mr. Beck with the following severance benefits (a) the equivalent of one times Mr. Beck’s annual base salary in effect at the time of termination, less standard deductions and withholdings, will be paid in a lump sum on the first regular payroll date following the effectiveness of the Release, subject to any delay in payment required for purposes of compliance with Section 409A of the Internal Revenue Code; (b) any Accrued and Unpaid Bonus (as defined in the Amended and Restated Employment Agreement) for the prior year, if applicable, will be paid in a lump sum on the first regular payroll date following the effectiveness of the Release, subject to any delay in payment required for purposes of compliance with Section 409A of the Internal Revenue Code; (c) a pro-rated portion of his target bonus amount for the year of termination, as applicable, if any such bonus has been determined by the Board or the Compensation Committee to have been achieved, based on the actually achieved level of performance, in the ordinary course when determinations are made for all officers and employees of the Company based upon the metrics associated with such bonus (the “Bonus Determination Date”) (pro-rated based upon the portion of the calendar year that Mr. Beck was employed by the Company), less standard deductions and withholdings, which pro-rata bonus, if earned, will be paid to Mr. Beck during the calendar year immediately following the year of termination in a single lump sum and within 10 days after the Bonus Determination Date, subject to any delay in payment required for purposes of compliance with Section 409A of the Internal Revenue Code; and (d) payment of the premiums for continued coverage under the Company’s medical, dental, life and disability insurance until the earlier of either (i) the end of 12 months following the termination date, or, (ii) the date on which Mr. Beck begins full-time employment with another company or business entity which offers comparable health insurance coverage to Mr. Beck.

If the Company (or its successor) terminates Mr. Beck’s employment without Cause or Mr. Beck terminates his employment for Good Reason or due to a Qualifying Resignation within the period commencing 3 months immediately prior to a Change in Control of the Company and ending 12 months immediately following a Change in Control of the Company (a “Change in Control Trigger”), or within 30 days following a Change in Control of the Company Mr. Beck terminates his employment for any or no reason, Mr. Beck shall receive the Accrued Amounts subject to standard deductions and withholdings, to be paid as a lump sum no later than 30 days after the date of termination. In addition, subject to the limitations stated in the Amended and Restated Employment Agreement and upon Mr. Beck’s furnishing to the Company (or its successor) an executed Release, and subject to Mr. Beck continuing to comply with his obligations pursuant to the Proprietary Information and Inventions Agreement, and subject to Mr. Beck continuing to satisfy the Litigation Cooperation Requirement, the Company shall provide Mr. Beck with the following severance benefits (a) the equivalent of one times Mr. Beck’s annual base salary in effect at the time of termination, less standard deductions and withholdings, will be paid in a lump sum on the first regular payroll date following the effectiveness of the Release, subject to any delay in payment required for purposes of compliance with Section 409A of the Internal Revenue Code; (b) an amount equal to one times the target bonus for the year of termination, or if none, one times the last target bonus in effect for Mr. Beck, less standard deductions and withholdings, will be paid to Mr. Beck in a lump sum on the first regular payroll date following the effectiveness of the Release, subject to any delay in payment required for purposes of compliance with Section 409A of the Internal Revenue Code; (c) any Accrued and Unpaid Bonus for the prior year, if applicable, will be paid in a lump sum on the first regular payroll date following the effectiveness of the Release, subject to any delay in payment required for purposes of compliance with Section 409A of the Internal Revenue Code; (d) a pro-rated portion of his target bonus amount for the year of termination, as applicable, if any such bonus has been determined by the Board or the Compensation Committee to have been achieved, based on the actually achieved level of performance, in the ordinary course on the Bonus Determination Date (pro-rated based upon the portion of the calendar year that Mr. Beck was employed by the Company), less standard deductions and withholdings, which pro-rata bonus, if earned, will be paid to Mr. Beck during the calendar year immediately following the year of termination in a single lump sum and within 10 days after the Bonus Determination Date, subject to any delay in payment required for purposes of compliance with Section 409A of the Internal Revenue Code; and (e) payment of the premiums for continued coverage under the Company’s medical, dental, life and disability insurance for a period of 12 months following the date of termination.

The Amended and Restated Employment Agreement also provides that, in the event that Mr. Beck’s employment is terminated due to Mr. Beck’s death or Complete Disability (as defined in the Amended and Restated Employment Agreement), the Company will pay Mr. Beck or his estate the Accrued Amounts and any Accrued and Unpaid Bonus for the prior year, if applicable, subject to standard deductions and withholdings, to be paid in a lump sum no later than 30 days after the date of termination.

In addition, in the event that Mr. Beck’s employment is terminated without Cause or for Good Reason or due to a Qualifying Resignation or Scheduled Resignation and a Change in Control Trigger has not occurred, or in the event of Mr. Beck’s death or

54

Complete Disability, the vesting of any Time-Based Vesting Equity Awards (as defined in the Amended and Restated Employment Agreement) shall be fully accelerated such that on the effective date of such termination 100% of any Time-Based Vesting Equity Awards granted to Mr. Beck prior to such termination shall be fully vested and immediately exercisable, if applicable, by Mr. Beck. Furthermore, in the event that Mr. Beck’s employment is terminated without Cause or for Good Reason or due to a Qualifying Resignation and a Change in Control Trigger has occurred, or within 30 days following a Change in Control of the Company Mr. Beck terminates his employment for any or no reason, then (i) the vesting of any Time-Based Vesting Equity Awards shall be fully accelerated such that on the effective date of such termination (or if later, the date of the Change in Control) 100% of any Time-Based Vesting Equity Awards granted to Mr. Beck prior to such termination shall be fully vested and immediately exercisable, if applicable, by Mr. Beck, and (ii) the vesting of any Performance Equity Awards (as defined in the Amended and Restated Employment Agreement) that were granted to Mr. Beck prior to the effective date of the Amended and Restated Employment Agreement will be accelerated at the target performance level. Any such equity vesting acceleration provided under the Amended and Restated Employment Agreement shall be conditioned upon and subject to Mr. Beck’s satisfaction of each of the following conditions: (i) the delivery by Mr. Beck (or in the event of Mr. Beck’s death, the executor of Mr. Beck’s estate, or in the event of Mr. Beck’s Complete Disability wherein Mr. Beck lacks the capacity to act on his own behalf, Mr. Beck’s legal representative) of an executed Release; (ii) Mr. Beck continuing to comply with his obligations pursuant to the Proprietary Information and Inventions Agreement; and (iii) Mr. Beck continuing to satisfy the Litigation Cooperation Requirement.

The Amended and Restated Employment Agreement does not make any other substantive changes to the terms and conditions of the CFO Employment Agreement, and to the extent such terms and conditions have been previously stated in the Current Report on Form 8‑K filed with the SEC on October 25, 2021, such descriptions are incorporated by reference herein. The foregoing summary of the amended terms and conditions of the Amended and Restated Employment Agreement is not complete and is qualified in its entirety by reference to the full text of the Amended and Restated Employment Agreement, which is included as an exhibit to this Quarterly Report on Form 10-Q, and the terms of which are incorporated herein by reference.

Item 6. Exhibits

Exhibit No.	Description
3.1**	Second Amended and Restated Certificate of Incorporation of UpHealth, Inc., as amended by the Certificate of Amendment effective December 8, 2022 (incorporated by reference to Exhibit 3.1 to UpHealth, Inc.’s Annual Report on Form 10-K filed with the SEC on March 31, 2023).
3.2**	Second Amended and Restated Bylaws of UpHealth, Inc., effective August 22, 2022 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on August 24, 2022).
4.1**	Form of Series A Warrant (incorporated by reference to Exhibit 4.1 to UpHealth, Inc.’s Current Report on Form 8-K filed with the SEC on March 9, 2023).
4.2**	Form of Series B Warrant (incorporated by reference to Exhibit 4.2 to UpHealth, Inc.’s Current Report on Form 8-K filed with the SEC on March 9, 2023).
4.3**	Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.3 to UpHealth, Inc.’s Current Report on Form 8-K filed with the SEC on March 9, 2023).
10.1#**	Inducement Equity Incentive Plan (incorporated by reference to Exhibit 4.4 to UpHealth, Inc.’s Registration Statement on Form S-8 filed with the SEC on May 8, 2023).
10.2#*	Form of Restricted Stock Units Agreement (incorporated by reference to Exhibit 10.2 to UpHealth, Inc’s Quarterly Report on Form 10-Q filed with the SEC on May 11, 2023).
10.3#*	Form of Notice of Grant of Restricted Stock Units (incorporated by reference to Exhibit 10.3 to UpHealth, Inc’s Quarterly Report on Form 10-Q filed with the SEC on May 11, 2023).
10.4††#**	Amended and Restated Employment Agreement, dated May 11, 2023, by and between UpHealth, Inc. and Samuel J. Meckey (incorporated by reference to Exhibit 10.1 to UpHealth, Inc.’s Current Report on Form 8-K filed with the SEC on May 17, 2023).
10.5††*	Amended and Restated Employment Agreement, dated August 8, 2023, by and between UpHealth, Inc. and Martin Beck.
10.6†**	Stock Purchase Agreement, dated February 26, 2023, by and among UpHealth, Inc., UpHealth Holdings, Inc., Innovations Group, Inc. and Belmar MidCo, Inc. (incorporated by reference to Exhibit 2.1 to UpHealth, Inc.’s Current Report on Form 8-K filed with the SEC on February 27, 2023).
10.7**	Release Agreement, dated February 26, 2023, by and among UpHealth, Inc., UpHealth Holdings, Inc. and Innovations Group, Inc. (incorporated by reference to Exhibit 10.1 to UpHealth, Inc.’s Current Report on Form 8-K filed with the SEC on February 27, 2023).

55

10.8**	Form of Securities Purchase Agreement, dated as of March 9, 2023, by and between UpHealth, Inc. and the Purchaser (incorporated by reference to Exhibit 10.1 to UpHealth, Inc.’s Current Report on Form 8-K filed with the SEC on March 13, 2023).
10.9**	Form of Registration Rights Agreement, dated as of March 9, 2023, by and between UpHealth, Inc. and the Purchaser (incorporated by reference to Exhibit 10.2 to UpHealth, Inc.’s Current Report on Form 8-K filed with the SEC on March 9, 2023).
31.1*	Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*	Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*	Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS	Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.
101.SCH	Inline XBRL Taxonomy Extension Schema Document.
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

*	Filed herewith.
**	Previously filed.
†	Certain exhibits and schedules to this exhibit have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant agrees to furnish a copy of the omitted exhibits and schedules to the SEC on a supplemental basis upon its request.
††	Certain identified information in these exhibits have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is not material and is the type of information that the registrant treats as private or confidential.
#	Indicates a management contract or compensatory plan or arrangement.

56

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized on August 10, 2023.

UPHEALTH, INC.
By:	/s/ Samuel J. Meckey
Name:	Samuel J. Meckey
Title:	Chief Executive Officer (Principal Executive Officer)
By:	/s/ Martin S. A. Beck
Name:	Martin S. A. Beck
Title:	Chief Financial Officer (Principal Financial and Accounting Officer)

57

EX-10.5

Certain identified information in this Exhibit 10.5 [(indicated by “[***]”) has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is not material and is the type of information that the Company treats as private or confidential. AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the “Agreement”) is entered into as of the _8th day of August 2023 by and between Martin Beck (the “Executive”) and UpHealth, Inc. (the “Company”; the Executive and the Company are collectively referred to as the “Parties”). This Agreement shall be effective as of August _8th , 2023 (the “Effective Date”). As of the Effective Date, this Agreement amends and supersedes in its entirety the Employment Agreement entered into by and between the Company and Executive on October 24, 2021 (the “Prior Agreement”). RECITALS WHEREAS, the Company desires to continue to employ the Executive and the Executive desires to continue to be employed by the Company on the terms contained herein. NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows: 1. Employment 1.1 Title. The Executive will continue to have the title of Chief Financial Officer (CFO) and the Executive shall serve in such other capacity or capacities commensurate with his position as the Chief Executive Officer (CEO) of the Company may from time to time prescribe. 1.2 Duties. The Executive shall do and perform all services, acts or things necessary or advisable to manage and conduct the business of the Company and shall have the authority and responsibilities which are generally associated with the position of CFO. The Executive shall report to the CEO. 1.3 Policies and Practices. The employment relationship between the Parties shall be governed by this Agreement and the policies and practices established by the Company and its Board of Directors (hereinafter referred to as the “Board”). 1.4 Location. The Executive shall perform the services the Executive is required to perform pursuant to this Agreement at the Company’s offices in, or near, Delray Beach, Florida or in accordance with the Company’s policies for remote work. Notwithstanding anything to the contrary in this Section 1.4, the Executive agrees to abide by any policies with respect to remote working or in-office requirements that the Company may put in place in connection with or as a result of the COVID- 19 pandemic.

Page 2 of 24 1.5 Travel. The Company may from time to time require the Executive to travel temporarily to other locations outside of Delray Beach, Florida in connection with the Company’s business. 2. Loyalty of Executive. 2.1 Loyalty. During the Executive’s employment with the Company, the Executive shall devote the Executive’s business energies, interest, abilities and productive time to the proper and efficient performance of Executive’s duties under this Agreement. 2.2 No Conflicting Employment. The Executive shall devote his full working time and efforts to the business and affairs of the Company. Notwithstanding the foregoing, Executive may engage in any civic and not-for-profit activities so long as such activities are disclosed to the Board and do not materially interfere with the performance of his duties hereunder or present a conflict of interest with the Company. The Executive also may serve on one or more for-profit boards of directors so long as such activities do not require more than 30 hours in aggregate per quarter of Executive’s time, are disclosed to the Board and do not, in the Board’s good faith reasonable judgment, materially interfere with the performance of Executive’s duties hereunder or present a conflict of interest with the Company. The Executive has disclosed his current service on boards of directors (attached hereto as Exhibit A) and the Company has agreed to permit his continued service on such boards. 2.3 Agreement not to Participate in Company’s Competitors. During the term of this Agreement, the Executive agrees not to acquire, assume or participate in, directly or indirectly, any position, investment or interest known by Executive to be adverse or antagonistic to the Company, its business or prospects, financial or otherwise or in any company, person or entity that is, directly or indirectly, in competition with the business of the Company or any of its affiliates. Notwithstanding the foregoing, the Executive may invest and/or maintain investments in any public or private entity up to an amount of 2% of an entity’s fully diluted shares and on a passive basis. 2.4 Litigation Cooperation Requirement. During and after Executive’s employment, Executive shall cooperate fully with the Company in (i) the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company or any of its subsidiaries or affiliates which relate to events or occurrences that transpired while Executive was employed by the Company; (ii) the investigation, whether internal or external, of any matters about which the Company believes Executive may have knowledge or information; and (iii) any investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while Executive was employed by the

Page 3 of 24 Company. Executive’s full cooperation in connection with such claims, actions or investigations shall include, but not be limited to, being available to meet with counsel to answer questions or to prepare for discovery or trial and to provide truthful testimony on behalf of the Company at mutually convenient times (the “Litigation Cooperation Requirement”). The Company shall reimburse the Executive for any reasonable out-of-pocket expenses incurred in connection with the Executive’s performance of obligations pursuant to the Litigation Cooperation Requirement. In the event that Executive is requested to provide such cooperation services following the Executive’s last day of employment by the Company, the Company shall (i) pay the Executive for Executive’s time (other than time in which Executive is testifying under oath and for which no payment will be due) at the rate of $200.00 per hour, and (ii) be reasonably accommodating with respect to Executive’s work schedule and responsibilities for any subsequent employer. 3. Compensation to Executive. 3.1 Base Salary. The Company shall continue to pay the Executive a base salary at the annualized rate of $400,000 per year, subject to standard deductions and withholdings, or such other rate as may be determined from time to time by the Board or the Compensation Committee (hereinafter referred to as the “Base Salary”). Such Base Salary shall be paid in accordance with the Company’s standard payroll practice. Executive’s Base Salary will be reviewed annually, and the Executive shall be eligible to receive a salary increase annually, during the compensation cycle, in an amount to be determined by the Board or the Compensation Committee in its sole and exclusive discretion. Once adjusted, the new salary shall become the Base Salary for purposes of this Agreement. Any material reduction in the Base Salary of the Executive, without his written consent, may be deemed grounds for resignation for Good Reason as set forth in and subject to Section 4.5.3 of this Agreement. The Company shall pay or reimburse the Executive for reasonable expenses incurred or paid by the Executive in the performance of his duties hereunder in accordance with the generally applicable policies and procedures of the Company, as in effect from time to time. 3.2 Discretionary Bonus. Provided the Executive meets the conditions stated in this Section 3.2, the Executive shall continue to be eligible for an annual discretionary bonus (hereinafter referred to as the “Bonus”) with a target amount of seventy- five percent (75%) of the Executive’s Base Salary, subject to standard deductions and withholdings, based on the Board’s determination, in good faith, as to whether such performance milestones as are established by the Board or the Compensation Committee (hereinafter referred to as the “Performance Milestones”) have been achieved. The Performance Milestones will be based on certain factors including, but not limited to, the Executive’s performance and the Company’s performance and shall be consistent with the methodology for other C-suite executives. The Executive’s Bonus target will be reviewed annually and

Page 4 of 24 may be adjusted by the Board or the Compensation Committee in its discretion. The Executive must be employed on the date the Bonus is paid to be eligible for the Bonus, subject to the termination provisions herein. The Bonus shall be paid during the calendar year following the performance calendar year. Furthermore, the Executive may be awarded an additional bonus for performance determined solely by the Board in its discretion and any such determination will be final and binding. 3.3 Equity Awards. 3.3.1 Prior Equity Awards. Executive acknowledges and agrees that prior to the Effective Date and in accordance with the terms of the Prior Agreement, on October 20, 2021 Executive was granted awards of restricted stock units under the Company’s 2021 Equity Incentive Plan. 3.3.2 Additional Equity Grants. Executive will be eligible to receive any additional grants of equity awards under the 2021 Equity Plan or any successor plan, as determined at the sole discretion of the Compensation Committee. 3.4 Retention Bonus. 3.4.1 Executive will be eligible to earn a one-time bonus payment of $400,000 less all applicable withholdings (the “Retention Bonus”). The Retention Bonus will be paid to Executive as an unearned advance on the first payroll after the Effective Date. 3.4.2 The Executive is eligible to earn the Retention Bonus subject to satisfaction of each of the following conditions: (i) Executive’s continued employment with the Company through the earlier of: (A) March 31, 2024, or (B) the applicable date of filing of the Company’s Form 10-K for the 2023 fiscal year (such applicable date, the “Retention Date”), (ii) the Company’s timely submission of all required filings with the Securities and Exchange Commission prior to the Retention Date, (iii) Executive’s cooperation and assistance prior to the Retention Date with searching for and identifying a candidate to succeed to Executive’ position and duties with the Company (“New CFO”) and (iv) if a New CFO is identified by the Company prior to the Retention Date, Executive cooperates with and reasonably assists the Company in the transition of Executive’s duties to the New CFO. If Executive provides written notice to the Company that Executive will resign from employment on March 31, 2024 the provision of such notification to the Company, by itself, shall not be deemed to constitute a termination of Executive’s continued employment for purposes of eligibility to earn the Retention Bonus.

Page 5 of 24 3.4.3 The period commencing on the Effective Date and ending on the Retention Date is the “Retention Period.” Executive is eligible to earn a pro-rata portion of the Retention Bonus if Executive resigns for Good Reason during the Retention Period, with such pro-rata portion calculated by reference to the number of days that Executive was employed during the Retention Period divided by the total number of days in the Retention Period. 3.4.4 Additionally, the Retention Bonus will be earned in full upon a Change in Control, subject to Executive’s continued employment with the Company through the closing of the Change in Control. The Retention Bonus will also be earned in full if the Company terminates Executive’s employment without Cause before the Retention Date. 3.4.5 If for any reason the Retention Bonus is not earned, in whole or in part, Executive must repay the entire gross value amount of the unearned portion of the Retention Bonus (the “Repayment Amount”) in cash to the Company no later than 30 days after the Executive is notified in writing that Executive is required to repay the Company the Repayment Amount. The Company may elect to offset such owed Repayment Amount against Executive’s final paycheck, any vacation cash out, and any expense reimbursements not previously paid, if applicable and to the extent permitted by applicable law. Additionally, if Executive fails to timely repay the Repayment Amount to the Company, Executive is required to reimburse the Company all costs incurred by the Company in connection with collection of the Repayment Amount, including reasonable attorneys’ fees. 3.5 Revenue Performance Bonuses. The Executive will be eligible to earn performance bonuses in the aggregate target amount of $1,000,000 based on the Company’s performance during the 2023, 2024 and 2025 fiscal years (together, such fiscal years are the “Performance Period”). Executive is eligible to earn a performance bonus with respect to each fiscal year in the Performance Period (each a “Revenue Bonus”). Executive’s target Revenue Bonus amount applicable to each fiscal year within the Performance Period is $333,333.33. The amount of Revenue Bonus eligible to be earned by Executive for each fiscal year during the Performance Period will be determined based on the applicable level of revenue received by the Company during such fiscal year. The applicable percentage of the Executive’s Revenue Bonus that is eligible to be earned for each fiscal year within the Performance Period will be determined by reference to the Company’s level of revenue received for the applicable fiscal year as measured against the target revenue performance levels for such fiscal year as indicated in the chart below (the “Revenue Goals”), with linear interpolation between the designated performance levels:

Page 6 of 24 [***] The threshold and stretch Revenue Goals for each fiscal year within the Performance Period are independent for each fiscal year (i.e., if 85% of the target Revenue Goal for a fiscal year is attained for such fiscal year and 110% of the target Revenue Goal for a fiscal year is attained for such fiscal year, with respect to those fiscal years the Revenue Bonus amounts eligible to be earned are $283,333.33 and $366,666.66, respectively. If the Company does not meet the threshold goal of 85% of target Revenue Goal for the applicable fiscal year, the Executive is not eligible to earn or receive any Revenue Bonus with respect to such fiscal year. If the Company exceeds 125% of the target Revenue Goal for the applicable fiscal year, the Revenue Bonus the Executive is eligible to earn and receive for such fiscal year is 125% of the target Revenue Bonus amount for such fiscal year ($416,666.66). Whether and to what extent the applicable Revenue Goal for a fiscal year was attained for such fiscal year will be determined by the Board in a manner consistent with the amounts reported the Company’s annual audited financial statements, and its determination will be final and binding on Executive. In all cases, Executive’s eligibility to earn a Revenue Bonus for a fiscal year is subject to the Executive’s continued employment with the Company through the applicable date of payment of such Revenue Bonus. If a Revenue Bonus is eligible to be earned by Executive for a fiscal year based on performance for such fiscal year, the applicable Revenue Bonus for such fiscal year will be paid to Executive in the calendar year immediately following the fiscal year with respect to which the Revenue Goals was attained. For the Revenue Bonus eligible to be earned based on performance for the 2023 fiscal year, Executive must also remain employed through the applicable date of filing of the Company’s 10-K for the 2023 fiscal year in order for Executive to be eligible to earn a Revenue Bonus in respect of the 2023 fiscal year; provided however, if the Company terminates Executive’s employment without Cause prior to the date of filing of the Company’s 10-K for the 2023 fiscal year, Executive shall be deemed to have

Page 7 of 24 earned the applicable amount of Revenue Bonus solely for the 2023 fiscal year, based on Company performance for the 2023 fiscal year, and Executive shall not be eligible to earn any Revenue Bonus in respect of the 2024 or 2025 fiscal years. If earned such Revenue Bonus for 2023 will be paid in the first payroll period following the actual 10-K filing date. Any Revenue Bonus earned with respect to Company performance for the 2024 and 2025 fiscal years will be paid no later than March 15 of the calendar year immediately following the fiscal year with respect to which the Revenue Goal was attained. In the event there is a Change in Control which occurs prior to the end of the Performance Period, and subject to Executive’s continued employment with the Company through the date of such Change in Control, the Revenue Goals for the remainder of the Performance Period (commencing with the fiscal year in which the Change in Control occurs) will be deemed to have been attained at the target level upon such Change in Control so that Executive will instead be entitled to receive the target amount of Revenue Bonus for the remainder of the Performance Period, which will be paid in cash to Executive no later than fifteen (15) days following such Change in Control. For example, if a Change in Control transaction occurs on June 1, 2024 and Executive remains employed by the Company on such date, then Executive will receive a total Revenue Bonus equal to $666,666.66 for the 2024 and 2025 fiscal years ($333,333.33 for 2024 and $333,333.33 for 2025) and regardless of the Company’s actual level of attainment of the Revenue Goals for the 2024 and 2025 fiscal years. Except for payment of the Revenue Bonus that is triggered in connection with a Change in Control transaction in which case the form of payment shall always be in cash, the Company may, in its sole discretion, settle its obligation to pay the Revenue Bonus in cash or in vested shares of the Company’s common stock with a Fair Market Value (as herein defined) equal to the amount of the cash payment. For the purposes of this Section 3.5, the Fair Market Value of the Company’s shares will be determined in the same manner that the Company calculates such fair market value for tax administration and withholding purposes. 3.6 Taxes. All amounts paid under this Agreement to the Executive by the Company will be paid less applicable tax withholdings and any other withholdings required by law or authorized by the Executive. 3.7 Benefits. The Executive shall, in accordance with Company policy and the terms of the applicable plan documents, be eligible to participate in benefits under any executive benefit plan or arrangement which may be in effect from time to time and made available to the Company’s executives or key management employees, including unlimited Paid Time Off subject to the terms and conditions of the Company’s PTO Policy. Executive acknowledges that the benefits offered by the Company may change from time to time.

Page 8 of 24 3.8 Legal Fees. The Company shall reimburse Executive in accordance with the Company’s expense reimbursement policies for Executive’s legal fees incurred in connection with the negotiation and execution of this Agreement, plus an additional payment amount necessary to cover applicable tax withholding in connection with such reimbursement payment, so that Executive is eligible to retain a maximum net reimbursement payment of $7,500 (as calculated on a net after-tax withholding basis). To be eligible for reimbursement, within sixty (60) days following the Effective Date the Executive must provide the Company with a copy of the invoice for legal fees for which Executive is requesting reimbursement. 3.9 Indemnification Agreement. 3.9.1 The Company and Executive have previously entered into the Indemnity Agreement, the terms of which shall continue to be applicable, and an executed copy of which is attached hereto as Exhibit B (the “Indemnity Agreement”). 3.9.2 To the extent the Indemnity Agreement is not applicable, the following provisions shall apply. The Company covenants and agrees to indemnify Executive, his heirs and representatives, and hold them harmless, to the fullest extent allowed by governing law, from and in connection with any loss, cost, damage, award, judgment, claim and/or expense, including without limiting the generality of the foregoing, attorneys’ fees and related expenses, in the event Executive is made or threatened to be made a party or is otherwise involved in any threatened, pending or completed action, suit or proceeding, whether civil, administrative, investigative or otherwise or the provision of any cooperation or assistance hereunder including but not limited to the Litigation Cooperation Requirement (a “Proceeding”), by reason of his acceptance and/or performance of the employment contemplated herein, or that otherwise arises out of or relates to Executive’s service as an officer or employee of the Company or any affiliate of the Company. Executive shall have the right to engage, at the Company’s expense, independent counsel in connection with such a Proceeding. The Company agrees to pay all expenses incurred in connection with any such Proceeding (including but not limited to the fees and expenses associated with the engagement of Executive’s independent counsel) directly to the billing party, when and as incurred, and in advance of the final disposition of such Proceeding, so as to avoid Executive having to pay or advance such costs. The Company also agrees to pay all other costs associated with such a Proceeding, including any bond costs, liability award or judgment, together with any costs or accrued interest, directly so as to avoid Executive having to pay or advance such sums. Executive shall retain full control of his representation and the decisions affecting his interests in connection with such a Proceeding.

Page 9 of 24 3.9.3 During Executive’s employment and thereafter, the Company shall provide Executive with coverage under a policy of directors’ and officers’ liability insurance that provides him with coverage on the same basis as is provided for the officers and directors of the Company. 4. Termination. 4.1 Employment is At-Will. The Executive’s employment with the Company is “at will” and is terminable by the Company at any time and for any reason or no reason, including but not limited to the following conditions: 4.1.1 Termination for Death or Disability. The Executive’s employment with the Company shall terminate effective upon the date of the Executive’s death or “Complete Disability” (as defined in Section 4.5.2), provided, however, that this Section 4.1.1 shall in no way limit the Company’s obligations to provide such reasonable accommodations to the Executive as may be required by law. 4.1.2 Termination by the Company For Cause. The Company may terminate the Executive’s employment under this Agreement for “Cause” (as defined in Section 4.5.4) by delivery of written notice to the Executive specifying the Cause or Causes relied upon for such termination. Any notice of termination given pursuant to this Section 4.1.2 shall effect termination as of the date of the notice or such date as specified in the notice. The Executive shall have the right to appear before the CEO before any termination for Cause becomes effective and binding upon the Executive. 4.1.3 Termination by the Company Without Cause. The Company may terminate the Executive’s employment under this Agreement at any time and for any reason or no reason subject to the requirements set out in Section 4.4 of this Agreement. Such termination shall be effective on the date the Executive is so informed or as otherwise specified by the Company, pursuant to notice requirements set forth in Section 6 of this Agreement. 4.2 Termination By The Executive. The Executive may terminate his employment with the Company at any time and for any reason or no reason, including, but not limited, to the following conditions: 4.2.1 Good Reason. The Executive may terminate his employment under this Agreement for “Good Reason” (as defined below in Section 4.5.3) by delivery of written notice to the Company specifying the Good Reason relied upon by the Executive for such termination in accordance with the requirements of such section.

Page 10 of 24 4.2.2 Without Good Reason. The Executive may terminate the Executive’s employment hereunder for other than Good Reason upon sixty (60) days’ written notice to the Company. Notwithstanding the foregoing, in the event that the Executive gives written notice of termination to the Company, the Company may unilaterally accelerate the date of termination and such acceleration shall not result in a termination by the Company for purposes of this Agreement. 4.2.3 Due to a Qualifying Resignation or Scheduled Resignation. The Executive may terminate his employment under this Agreement for a “Qualifying Resignation” as defined in and pursuant to the terms of Section 4.5.6 or for a “Scheduled Resignation” (as defined in and pursuant to the terms of Section 4.5.7). 4.2.4 Within thirty (30) days following a Change in Control. The Executive may terminate his employment hereunder for any or no reason with written notice to the Company at any time within thirty (30) days following a Change in Control of the Company (as defined in Section 4.5.5). 4.3 Termination by Mutual Agreement of the Parties. The Executive’s employment pursuant to this Agreement may be terminated at any time upon a mutual agreement in writing of the Parties. Any such termination of employment shall have the consequences specified in such mutual agreement. 4.4 Compensation to Executive Upon Termination. In connection with any termination of the Executive’s employment for any reason, the Executive or the Executive’s estate, as applicable, shall be entitled to any amounts payable to the Executive or the Executive’s beneficiaries subject to and accordance with the terms of the Company’s employee welfare benefit plans or policies (excluding any severance pay). 4.4.1 With Cause or Without Good Reason. If the Executive’s employment shall be terminated by the Company for Cause, or if the Executive terminates employment hereunder without Good Reason, or for any other reason other than those specifically outlined herein, the Company shall pay the Executive’s Base Salary, accrued but unpaid business expenses and accrued and unused vacation benefits earned through the date of termination at the rate in effect at the time of termination (the “Accrued Amounts”), less standard deductions and withholdings.

Page 11 of 24 4.4.2 Without Cause or For Good Reason or due to a Qualifying Resignation or Scheduled Resignation. 4.4.2.1 Not in Connection with a Change in Control. If the Company terminates the Executive’s employment without Cause or the Executive terminates his employment for Good Reason or due to a Qualifying Resignation or Scheduled Resignation, and Section 4.4.2.2 below does not apply, the Company shall pay the Accrued Amounts subject to standard deductions and withholdings, to be paid as a lump sum no later than thirty (30) days after the date of termination. In addition, subject to the limitations stated in this Agreement and upon the Executive’s furnishing to the Company an executed waiver and release of claims (in substantially the form of release attached as Exhibit B to the Chief Executive Officer’s Amended and Restated Employment Agreement with the Company dated May 11, 2023) (the “Release”) within the applicable time period set forth therein, but in no event later than forty-five days following termination of employment and permitting such Release to become effective in accordance with its terms (the “Release Effective Date”), and subject to Executive continuing to comply with his obligations pursuant to the Proprietary Information and Inventions Agreement (a copy of which is attached as Exhibit A), and subject to the Executive continuing to satisfy the Litigation Cooperation Requirement, the Executive shall be paid or entitled to receive, as applicable, the following: (a) the equivalent of one (1) times the Executive’s annual Base Salary in effect at the time of termination less standard deductions and withholdings, to be paid in a lump sum on the first regular payroll date following the Release Effective Date subject to any delay in payment required by Section 4.6; (b) any Accrued and Unpaid Bonus for the prior year, if applicable, to be paid in a lump sum on the first regular payroll date following the Release Effective Date subject to any delay in payment required by Section 4.6; (c) the Executive shall also receive a pro-rated portion of his target Bonus amount for the year of termination, as applicable, if any such Initial Bonus or Bonus has been determined by the Board or the Compensation Committee to have been achieved, based on the actually achieved level of performance, in the ordinary course when determinations are made for all officers and employees of the Company based upon the metrics associated with such Bonus (the

Page 12 of 24 “Bonus Determination Date”) (pro-rated based upon the portion of the calendar year that the Executive was employed by the Company), less standard deductions and withholdings. If earned, the Pro-Rata Bonus which will be paid to Executive during the calendar year immediately following the year of termination less standard deductions and withholdings in a single a lump sum and within ten (10) days after the Bonus Determination Date, subject to any delay in payment required by Section 4.6; and (d) in the event the Executive timely elects continued coverage under COBRA, the Company will pay the Executive’s COBRA health insurance premium, including any amounts that Company paid for benefits to the qualifying family members of the Executive, following the date of termination up until the earlier of either (i) the end of twelve (12) months following his termination date or, (ii) the date on which the Executive begins full-time employment with another company or business entity which offers comparable health insurance coverage to the Executive (such period, the “Non Change in Control COBRA Payment Period”). Notwithstanding the foregoing, if the Company determines, in its sole discretion, that the Company cannot provide the COBRA premium benefits without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company shall in lieu thereof pay Executive a taxable cash amount, which payment shall be made regardless of whether the Executive or his qualifying family members elect COBRA continuation coverage (the “Health Care Benefit Payment”). The Health Care Benefit Payment shall be paid in monthly or bi-weekly installments on the same schedule that the COBRA premiums would otherwise have been paid to the insurer. The Health Care Benefit Payment shall be equal to the amount that the Company otherwise would have paid for COBRA insurance premiums (which amount shall be calculated based on the premium for the first month of coverage), and shall be paid until the expiration of the Non Change in Control COBRA Payment Period. 4.4.2.2 In Connection With a Change in Control. If the Company (or its successor) terminates the Executive’s employment without Cause or the Executive terminates his employment for Good Reason or due to a Qualifying Resignation within the period commencing three (3) months immediately prior to a Change in Control of the Company and ending twelve (12) months immediately following a Change in Control of the Company (as defined in Section 4.5.5 of this Agreement), or within thirty (30)

Page 13 of 24 days following a Change in Control of the Company (as defined in Section 4.5.5) the Executive terminates his employment for any or no reason, the Executive shall receive the Accrued Amounts subject to standard deductions and withholdings, to be paid as a lump sum no later than thirty (30) days after the date of termination. In addition, subject to the limitations stated in this Agreement and upon the Executive’s furnishing to the Company (or its successor) an executed Release within the applicable time period set forth therein, but in no event later than forty-five days following termination of employment and permitting such Release to become effective in accordance with its terms, and subject to Executive continuing to comply with his obligations pursuant to the Proprietary Information and Inventions Agreement (a copy of which is attached as Exhibit A), and subject to the Executive continuing to satisfy the Litigation Cooperation Requirement, the Executive shall be entitled to: (a) the equivalent of one (1) times the Executive’s annual Base Salary in effect at the time of termination less standard deductions and withholdings, to be paid in a lump sum on the first regular payroll date following the Release Effective Date subject to any delay in payment required by Section 4.6; (b) an amount equal to one (1) times the target Bonus for the year of termination, or if none, one (1) times the last target Bonus in effect for Executive, less standard deductions and withholdings, to be paid in a lump sum on the first regular payroll date following the Release Effective Date subject to any delay in payment required by Section 4.6; (c) any Accrued and Unpaid Bonus for the prior year, if applicable, to be paid in a lump sum on the first regular payroll date following the Release Effective Date subject to any delay in payment required by Section 4.6; (d) the Executive shall also receive a pro-rated portion of his target Bonus amount for the year of termination, as applicable, if any such Bonus has been determined by the Board or the Compensation Committee to have been achieved, based on the actually achieved level of performance, in the ordinary course on the Bonus Determination Date (pro-rated based upon the portion of the calendar year that the Executive was employed by the Company), less standard deductions and withholdings. If earned, the Pro-Rata Bonus which will be paid to Executive during the calendar year immediately following the year of termination less

Page 14 of 24 standard deductions and withholdings in a single a lump sum and within ten (10) days after the Bonus Determination Date, subject to any delay in payment required by Section 4.6; and (e) in the event the Executive timely elects continued coverage under COBRA, the Company will pay the Executive’s COBRA health insurance premium, including any amounts that Company paid for benefits to the qualifying family members of the Executive, for the Change in Control Severance Period. Notwithstanding the foregoing, if the Company determines, in its sole discretion, that the Company cannot provide the COBRA premium benefits without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company shall in lieu thereof pay Executive the Health Care Benefit Payment, which payment shall be made regardless of whether the Executive or his qualifying family members elect COBRA continuation coverage. The Health Care Benefit Payment shall be paid in monthly or bi-weekly installments on the same schedule that the COBRA premiums would otherwise have been paid to the insurer. The Health Care Benefit Payment shall be equal to the amount that the Company otherwise would have paid for COBRA insurance premiums (which amount shall be calculated based on the premium for the first month of coverage), and shall be paid until the expiration of the Change in Control Severance Period. 4.4.2.3 No Duplication of Benefits; Interpretation. For the avoidance of doubt, in no event will Executive be entitled to benefits under Section 4.4.2.1 and Section 4.4.2.2. If Executive commences to receive benefits under Section 4.4.2.1 due to a qualifying termination prior to a Change in Control and thereafter becomes entitled to benefits under Section 4.4.2.2, any benefits provided to Executive under Section 4.4.2.1 shall offset the benefits to be provided to Executive under Section 4.4.2.2 and shall be deemed to have been provided to Executive pursuant to Section 4.4.2.2. In all cases, any severance benefits provided for herein shall be calculated without giving effect to any reductions in compensation that would give rise to Executive’s right to resign for Good Reason. For all purposes of this Agreement, including Section 4.4.2.2 and Section 4.4.4.2, Executive’s termination of employment for any or no reason within thirty (30) days following a Change in Control of the Company does not mean or include any termination of Executive by the Company for Cause which occurs during such thirty (30) day period.

Page 15 of 24 4.4.3 Due to Death or Disability. If the Executive’s employment is terminated due to Executive’s death or Complete Disability, the Company shall pay Executive or his estate the Accrued Amounts and any Accrued and Unpaid Bonus for the prior year, if applicable, subject to standard deductions and withholdings, to be paid as a lump sum no later than thirty (30) days after the date of termination. 4.4.4 Equity Award Acceleration. 4.4.4.1 Not in Connection With a Change in Control. In the event that the Executive’s employment is terminated without Cause or for Good Reason or due to a Qualifying Resignation or Scheduled Resignation and Section 4.4.4.2 below does not apply, or in the event of the Executive’s Complete Disability or death, the vesting of any equity awards granted to Executive that vest solely subject to Executive’s continued services to the Company (the “Time- Based Vesting Equity Awards”) shall be fully accelerated such that on the effective date of such termination one hundred percent (100%) of any Time-Based Vesting Equity Awards granted to Executive prior to such termination shall be fully vested and immediately exercisable, if applicable, by the Executive. Treatment of any performance based vesting equity awards (“Performance Equity Awards”) will be governed solely by the terms of the agreements under which such awards were granted and will not be eligible to accelerate vesting pursuant to the foregoing provision. 4.4.4.2 In Connection With a Change in Control. In the event that the Executive’s employment is terminated without Cause or for Good Reason or due to a Qualifying Resignation within the three (3) months immediately preceding or during the twelve (12) months immediately following a Change in Control of the Company (as defined in Section 4.5.5 of this Agreement), or within thirty (30) days following a Change in Control of the Company, the Executive terminates his employment for any or no reason, then (i) the vesting of any Time-Based Vesting Equity Awards shall be fully accelerated such that on the effective date of such termination (or if later, the date of the Change in Control) one hundred percent (100%) of any Time-Based Vesting Equity Awards granted to Executive prior to such termination shall be fully vested and immediately exercisable, if applicable, by the Executive, and (ii) the vesting of any Performance Equity Awards that were granted to Executive prior to the Effective Date will be accelerated at the target performance level.

Page 16 of 24 4.4.4.3 Release and Waiver. Any equity vesting acceleration pursuant to this Section 4.4.4 shall be conditioned upon and subject to Executive’s satisfaction of each of following conditions: (i) delivery by the Executive (or in the case of Executive’s death, the executor of Executive’s estate, or in the case of Executive’s Complete Disability wherein Executive lacks the capacity to act on his own behalf, Executive’s legal representative) to the Company of a fully effective Release in accordance with the terms specified by Section 4.4.2.1 hereof, (ii) Executive continuing to comply with his obligations pursuant to the Proprietary Information and Inventions Agreement (a copy of which is attached as Exhibit A), and (iii) Executive continuing to satisfy the Litigation Cooperation Requirement, and such vesting acceleration benefit shall be in addition to the benefits provided by Section 4.4.2 hereof. 4.5 Definitions. For purposes of this Agreement, the following terms shall have the following meanings: 4.5.1 "Accrued and Unpaid Bonus” shall mean the amount of bonus otherwise eligible to be earned pursuant to Section 3.2 of this Agreement as a discretionary bonus when the following conditions are met: (i) Executive provided services through the last day of the prior calendar year; (ii) the Company has determined the amount of discretionary bonuses to be paid for the prior calendar year based on the year end financials; and (iii) Executive’s employment is terminated for any reason other than for Cause after the amount has been determined but before the Company has paid the bonus. Notwithstanding anything contained herein to the contrary, Executive shall not be entitled to receive a Section 3.2 discretionary bonus amount as an Accrued and Unpaid Bonus in the event his employment is terminated for Cause. 4.5.2 “Complete Disability” shall mean the inability of the Executive to perform the Executive’s duties under this Agreement, whether with or without reasonable accommodation, because the Executive has become permanently disabled within the meaning of any policy of disability income insurance covering employees of the Company then in force. In the event the Company has no policy of disability income insurance covering employees of the Company in force when the Executive becomes disabled, the term “Complete Disability” shall mean the inability of the Executive to perform the Executive’s duties under this Agreement, whether with or without reasonable accommodation, by reason of any incapacity, physical or mental, which the Board, based upon medical advice or an opinion provided by a licensed physician, determines to have incapacitated the Executive from satisfactorily performing all of the Executive’s usual services for the Company, with or without reasonable

Page 17 of 24 accommodation, for a period of at least one hundred eighty (180) days during any twelve (12) month period that need not be consecutive. 4.5.3 “Good Reason” for the Executive to terminate the Executive’s employment hereunder shall mean the occurrence of any of the following events without the Executive’s consent: (i) the relocation of the Executive’s primary work location to a point more than fifty (50) miles from the Executive’s current work location set forth in Section 1.4; (ii) a reduction by the Company of the Executive’s base salary or annual target Bonus opportunity, without the written consent of the Executive, as initially set forth herein or as the same may be increased from time to time pursuant to this Agreement, except for across-the-board salary reductions implemented prior to a Change in Control which are implemented based on the Company’s financial performance and similarly affecting all or substantially all senior management employees of the Company; and (iii) a material breach by the Company of the terms of this Agreement. Provided, however that, such termination by the Executive shall only be deemed for Good Reason pursuant to the foregoing definition if (i) the Company is given written notice from the Executive within sixty (60) days following the occurrence of the condition that he considers to constitute Good Reason describing the condition and the Company fails to satisfactorily remedy such condition within thirty (30) days following such written notice, and (ii) the Executive terminates employment within thirty (30) days following the end of the period within which the Company was entitled to remedy the condition constituting Good Reason but failed to do so. 4.5.4 “Cause” for the Company to terminate Executive’s employment hereunder shall mean the occurrence of any of the following events, as determined reasonably and in good faith by the Board or a committee designated by the Board: (i) the Executive’s gross negligence or willful failure to substantially perform his duties and responsibilities to the Company or willful and deliberate violation of a Company policy; (ii) the Executive’s conviction of a felony or the Executive’s commission of any act of fraud, embezzlement or dishonesty against the Company or involving moral turpitude that is likely to inflict or has inflicted material injury on the business of the Company; (iii) the Executive’s unauthorized use or disclosure of any proprietary information or trade secrets of the Company or any other party that the Executive owes an obligation of nondisclosure as a result of the Executive’s relationship with the Company; and (iv) the Executive’s willful and deliberate breach of this Agreement that causes or could reasonably be expected to cause material injury to the business of the Company.

Page 18 of 24 4.5.5 For purposes of this Agreement, “Change in Control” means: (i) a sale of all or substantially all of the assets of the Company; (ii) a merger or consolidation in which the Company is not the surviving entity and in which the holders of the Company’s outstanding voting stock immediately prior to such transaction own, immediately after such transaction, securities representing less than fifty percent (50%) of the voting power of the entity surviving such transaction or, where the surviving entity is a wholly-owned subsidiary of another entity, the surviving entity’s parent; (iii) a reverse merger in which the Company is the surviving entity but the shares of Common Stock outstanding immediately preceding the merger are converted by virtue of the merger into other property, whether in the form of securities of the surviving entity’s parent, cash or otherwise, and in which the holders of the Company’s outstanding voting stock immediately prior to such transaction own, immediately after such transaction, securities representing less than fifty percent (50%) of the voting power of the Company or, where the Company is a wholly-owned subsidiary of another entity, the Company’s parent; or (iv) an acquisition by any person, entity or group (excluding any employee benefit plan, or related trust, sponsored or maintained by the Company or subsidiary of the Company or other entity controlled by the Company) of the beneficial ownership of securities of the Company representing at least seventy-five percent (75%) of the combined voting power entitled to vote in the election of Directors; provided, however, that nothing in this paragraph shall apply to a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company. 4.5.6 "Qualifying Resignation” means Executive’s resignation of employment which meets each of the following criteria: (i) Executive’s resignation is due to a material adverse change in the Executive’s title or a material reduction in the Executive’s duties, authority, or responsibilities relative to the duties, authority, or responsibilities in effect immediately prior to such reduction (each a “Resignation Condition”), and (ii) Executive’s resignation of employment occurs after the Retention Date. Provided, however that, such resignation by the Executive shall only be deemed a Qualifying Resignation pursuant to the foregoing definition if (i) the Company is given written notice from the Executive within sixty (60) days following the later of (A) the Retention Date, or (B) the date of occurrence of the condition that he considers to constitute a Resignation Condition describing the Resignation Condition and the Company fails to satisfactorily remedy such Resignation Condition within thirty (30) days following such written notice, and (ii) the Executive terminates employment within thirty (30) days following the end of the period within which the Company was entitled to remedy the Resignation Condition but failed to do so.

Page 19 of 24 4.5.7 “Scheduled Resignation” means Executive’s resignation of employment for any or no reason which meets each of the following criteria: (i) Executive provides written notice to the Company no later than December 31, 2023 that Executive will resign from employment on March 31, 2024 (the “Resignation Date”), (ii) Executive remains employed with the Company through the Resignation Date, and (iii) Executive resigns from employment with the Company on the Resignation Date. In no event is Executive’s termination of employment a Scheduled Resignation if Executive: (i) terminates employment for any reason prior to the Resignation Date, (ii) fails to provide the Company with written notice by December 31, 2023 of Executive’s intent to resign on the Resignation Date, or (iii) does not resign on the Resignation Date. 4.6 Application of Internal Revenue Code Section 409A. Notwithstanding anything to the contrary set forth herein, any payments and benefits provided under this Agreement (the “Severance Benefits”) that constitute “deferred compensation” within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”) and the regulations and other guidance thereunder and any state law of similar effect (collectively “Section 409A”) shall not commence in connection with Executive’s termination of employment unless and until Executive has also incurred a “separation from service” (as such term is defined in Treasury Regulation Section 1.409A-1(h) (“Separation From Service”), unless the Company reasonably determines that such amounts may be provided to Executive without causing Executive to incur the additional 20% tax under Section 409A. It is intended that each installment of the Severance Benefits payments provided for in this Agreement is a separate “payment” for purposes of Treasury Regulation Section 1.409A-2(b)(2)(i). To the extent the Severance Benefits constitute “deferred compensation” under Section 409A and Executive is, on the termination of service, a “specified employee” of the Company or any successor entity thereto, as such term is defined in Section 409A(a)(2)(B)(i) of the Code, then, solely to the extent necessary to avoid the incurrence of the adverse personal tax consequences under Section 409A, the timing of the Severance Benefit payments shall be delayed until the earlier to occur of: (i) the date that is six months and one day after Executive’s Separation From Service, or (ii) the date of Executive’s death (such applicable date, the “Specified Employee Initial Payment Date”), the Company (or the successor entity thereto, as applicable) shall (A) pay to Executive a lump sum amount equal to the sum of the Severance Benefit payments that Executive would otherwise have received through the Specified Employee Initial Payment Date if the commencement of the payment of the Severance Benefits had not been so delayed pursuant to this Section and (B) commence paying the balance of the Severance Benefits in accordance with the applicable payment schedules set forth in this Agreement.

Page 20 of 24 Notwithstanding anything to the contrary set forth herein, Executive shall receive the Severance Benefits described above, if and only if Executive duly executes and returns to the Company within the applicable time period set forth therein, but in no event more than forty-five days following Separation From Service, a Release and permits the release of claims contained therein to become effective in accordance with its terms (such latest permitted date, the “Release Deadline”). To the extent the severance benefits are not covered by one or more exemptions from the application of Section 409A and the Release could become effective in the calendar year following the calendar year in which Executive separates from service, the Release will not be deemed effective any earlier than the Release Deadline. Notwithstanding any other payment schedule set forth in this Agreement, none of the Severance Benefits will be paid or otherwise delivered prior to the effective date (or deemed effective date) of the Release. Except to the extent that payments may be delayed until the Specified Employee Initial Payment Date pursuant to the preceding paragraph, on the first regular payroll pay day following the effective date of the Release, the Company will pay Executive the Severance Benefits Executive would otherwise have received under the Agreement on or prior to such date but for the delay in payment related to the effectiveness of the Release, with the balance of the Severance Benefits being paid as originally scheduled. The severance benefits are intended to qualify for an exemption from application of Section 409A or comply with its requirements to the extent necessary to avoid adverse personal tax consequences under Section 409A, and any ambiguities herein shall be interpreted accordingly. 4.7 Application of Internal Revenue Code Section 280G. If any payment or benefit Executive would receive pursuant to a Change in Control from the Company or otherwise (“Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then such Payment shall be equal to the Reduced Amount. The “Reduced Amount” shall be either (x) the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount, after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in Executive’s receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting “parachute payments” is necessary so that the Payment equals the Reduced Amount, reduction shall occur in the manner that results in the greatest economic benefit for Executive. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata.

Page 21 of 24 In the event it is subsequently determined by the Internal Revenue Service that some portion of the Reduced Amount as determined pursuant to clause (x) in the preceding paragraph is subject to the Excise Tax, Executive agrees to promptly return to the Company a sufficient amount of the Payment so that no portion of the Reduced Amount is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount is determined pursuant to clause (y) in the preceding paragraph, Executive will have no obligation to return any portion of the Payment pursuant to the preceding sentence. Unless Executive and the Company agree on an alternative accounting firm, the accounting firm engaged by the Company for general tax compliance purposes as of the day prior to the effective date of the Change in Control shall perform the foregoing calculations. If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change in Control, the Company shall appoint a nationally recognized accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder. The Company shall use commercially reasonable efforts to cause the accounting firm engaged to make the determinations hereunder to provide its calculations, together with detailed supporting documentation, to Executive and the Company within fifteen (15) calendar days after the date on which Executive’s right to a Payment is triggered (if requested at that time by Executive or the Company) or such other time as requested by Executive or the Company. 4.8 Proprietary Information and Inventions Agreement. The Executive shall continue to comply with the terms of the Company’s Proprietary Information and Inventions Agreement the terms of which shall continue to govern the terms of Executive’s employment, and an executed copy of which is attached as Exhibit A. 4.9 No Mitigation or Offset. The Executive shall not be required to seek or accept other employment, or otherwise to mitigate damages, as a condition to receipt of the Severance Benefits, and the Severance Benefits shall not be offset by any amounts received by the Executive from any other source, except to the extent that the Executive’s rights to the benefits described in Sections 4.4.2.1 or 4.4.2.2, as applicable, are terminated by reason of the Executive obtaining full-time employment with another company or business entity which offers comparable health insurance coverage. 5. Assignment and Binding Effect. This Agreement shall be binding upon the Executive and the Company and inure to the benefit of the Executive and the Executive’s heirs, executors, personal representatives, assigns, administrators and legal representatives. Because of the unique and personal nature of the Executive’s duties under this Agreement, neither this Agreement nor obligations under this Agreement shall be

Page 22 of 24 assignable by the Executive. This Agreement shall be binding upon and inure to the benefit of the Company and its successors, assigns and legal representatives, provided that this Agreement may only be assigned to an acquirer of all or substantially all of the Company’s assets. Any such successor of the Company will be deemed substituted for the Company under the terms of this Agreement for all purposes. For this purpose, “successor” means any person, firm, corporation or other business entity which at anytime, whether by purchase, merger or otherwise, directly or indirectly acquires all or substantially all of the assets or business of the Company. 6. Notice. For the purposes of this Agreement, notices, demands, and all other forms of communication provided for in this Agreement shall be in writing and shall be deemed to have been duly given when delivered or (unless otherwise specified) mailed by registered mail, return receipt requested, postage prepaid, or by confirmed facsimile, addressed as set forth below, or to such other address as any party may have furnished to the other in writing in accordance herewith, except that notices of address shall be effective only upon receipt, as follows: If to the Company: UpHealth, Inc. 14000 S. Military Trail, Suite 203 Delray Beach, Florida 33484 Attention: Chief Executive Officer If to the Executive: Martin Beck [***] Any such written notice shall be deemed given on the earlier of the date on which such notice is personally delivered or five (5) days after its deposit in the United States mail as specified above. Either Party may change its address for notices by giving written notice to the other Party in the manner specified in this section. 7. Choice of Law; Consent to Jurisdiction. This Agreement shall be construed under and be governed in all respects by the laws of the State of Florida, without giving effect to the conflict of laws principles of such state. The parties irrevocably consent and submit to the jurisdiction of any local, state or federal court within Palm Beach County and in the State of Florida for the enforcement of this Agreement. The parties irrevocably waive any objection she may have to venue in the defense of an inconvenient forum to the maintenance of such actions or proceedings to enforce this Agreement. 8. Integration. This Agreement, including Exhibit A, Exhibit B, the 2021 Equity Incentive Plan and the Equity Plan Documents, contains the complete, final and exclusive agreement of the Parties relating to the terms and conditions of the Executive’s

Page 23 of 24 employment and the termination of Executive’s employment, and supersedes all prior and contemporaneous oral and written employment agreements or arrangements between the Parties, including but not limited to the Prior Agreement. 9. Amendment. This Agreement cannot be amended or modified except by a written agreement signed by the Executive and the Company. 10. Waiver. No term, covenant or condition of this Agreement or any breach thereof shall be deemed waived, except with the written consent of the Party against whom the wavier is claimed, and any waiver or any such term, covenant, condition or breach shall not be deemed to be a waiver of any preceding or succeeding breach of the same or any other term, covenant, condition or breach. 11. Severability. The finding by a court of competent jurisdiction of the unenforceability, invalidity or illegality of any provision of this Agreement shall not render any other provision of this Agreement unenforceable, invalid or illegal. Such court shall have the authority to modify or replace the invalid or unenforceable term or provision with a valid and enforceable term or provision, which most accurately represents the Parties’ intention with respect to the invalid, unenforceable, or illegal term or provision. 12. Interpretation. The headings set forth in this Agreement are for convenience of reference only and shall not be used in interpreting this Agreement. 13. Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document. [Remainder of Page Left Intentionally Blank]

Page 24 of 24 IN WITNESS WHEREOF, the parties have executed this Agreement effective on the date and year first above written. UPHEALTH, INC. Dated: August 8, 2023 By: /s/ Samuel Meckey Name: Samuel Meckey Title: CEO _/s/ Martin S.A.Beck __________________ Dated: August 8, 2023 Martin Beck

Exhibit A

EMPLOYEE PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT This Agreement sets forth in writing certain understandings and procedures applicable to my employment with UpHealth, Inc. (the "Company") and these understandings and procedures apply from the date of my initial employment with Company (my "Employment Date") even if this Agreement is signed by me and Company after the Employment Date. 1. Duties. In return for the compensation and benefits now and hereafter paid or provided to me, I hereby agree to perform those duties for Company as Company may designate from time to time. During my employment with Company, I further agree that I will (i) devote my best efforts to the interests of Company, and (ii) not engage in other employment or in any conduct that could either be in direct conflict with Company's interests or that could cause a material and substantial disruption to Company and (iii) otherwise abide by all of Company's policies and procedures as they may be established and updated from time to time. Furthermore, I will not (a) reveal, disclose or otherwise make available to any unauthorized person any Company password or key, whether or not the password or key is assigned to me or (b) obtain, possess or use in any manner a Company password or key that is not assigned to me. I will use my best efforts to prevent the unauthorized use of any laptop or personal computer, peripheral device, cell phone, smartphone, personal digital assistant (PDA), software or related technical documentation that the Company issues to me. I will not input, load or otherwise attempt any unauthorized use of software in any Company computer or other device, whether or not the computer or device is assigned to me. 2. "Proprietary Information" Definition. "Proprietary Information" means (a) any information that is confidential or proprietary, technical or non-technical information of Company, including for example and without limitation, information that is a Company Innovation or is related to any Company Innovations (as defined in Section 5 below), concepts, techniques, processes, methods, systems, designs, computer programs, source documentation, trade secrets, formulas, development or experimental work, work in progress, forecasts, proposed and future products, marketing plans, business plans, customers and suppliers, employee information (such as compensation data and performance reviews) and any other nonpublic information that has commercial value and (b) any information Company has received from others that Company is obligated to treat as confidential or proprietary, which may be made known to me by Company, a third party or otherwise that I may learn during my employment with Company. 3. Ownership and Nondisclosure of Proprietary Information. All Proprietary Information and all worldwide patents (including, but not limited to, any and all patent applications, patents, continuations, continuation-in-parts, reissues, divisionals, substitutions, and extensions), copyrights, mask works, trade secrets and other worldwide intellectual property and other rights in and to the Proprietary Information are the property of Company, Company's assigns, Company's customers and Company's suppliers, as applicable. Subject to Section 12 (Defend Trade Secrets Act), I will not disclose any Proprietary Information to anyone outside Company, and I will use and disclose Proprietary Information to those inside Company only as necessary to perform my duties as an employee of Company. Nothing in this Agreement will limit my ability to provide truthful information to any government agency regarding potentially unlawful conduct. If I have any questions as to whether information is Proprietary Information, or to whom, if anyone, inside Company, any Proprietary Information may be disclosed, I will ask my manager at Company. 4. "Innovations" Definition. In this Agreement, "Innovations" means all discoveries, designs, developments, improvements, inventions (whether or not

2 protectable under patent laws), works of authorship, information fixed in any tangible medium of expression (whether or not protectable under copyright laws), trade secrets, know-how, ideas (whether or not protectable under trade secret laws), mask works, trademarks, service marks, trade names and trade dress. 5. Disclosure and License of Prior Innovations. I have listed on Exhibit A (Prior Innovations) attached hereto all Innovations relating in any way to Company's business or demonstrably anticipated research and development or business (the "Company- Related Innovations"), that were conceived, reduced to practice, created, derived, developed, or made (collectively, "Created") by me alone or jointly with others prior to my Employment Date and to which I retain any ownership rights or interest (these Company-Related Innovations collectively referred to as the "Prior Innovations"). I represent that I have no rights in any Company-Related Innovations other than those Prior Innovations listed in Exhibit A (Prior Innovations). If nothing is listed on Exhibit A (Prior Innovations), I represent that there are no Prior Innovations as of my Employment Date. I hereby grant to Company and Company's designees a royalty-free, transferable, irrevocable, worldwide, fully paid-up license (with rights to sublicense through multiple tiers of sublicensees) to fully use, practice and exploit all patent, copyright, moral right, mask work, trade secret and other intellectual property rights relating to any Innovations (including without limitation any Company-Related Innovations) owned by me or in which I have any other right or interest that I incorporate, or permit to be incorporated, in any Innovations that I, solely or jointly with others, create, derive, conceive, develop, make or reduce to practice within the scope of my employment with Company or with the use of any Company resources, facilities, equipment, or information (including without limitation Company Confidential Information) (the "Company Innovations"). Notwithstanding the foregoing, I will not incorporate, or permit to be incorporated, any Innovations that I own or in which I have any other right or interest in any Company Innovations without Company's prior written consent. 6. Disclosure and Assignment of Company Innovations. I will promptly disclose and describe to Company all Company Innovations. I hereby do and will irrevocably assign to Company or Company's designee all my right, title, and interest in and to any and all Company Innovations, which assignment operates automatically upon the earliest of the Creation of the Company Innovations. To the extent any of the rights, title and interest in and to Company Innovations cannot be assigned by me to Company, I hereby grant to Company an exclusive, royalty-free, transferable, irrevocable, worldwide, fully paid-up license (with rights to sublicense through multiple tiers of sublicensees) to fully use, practice and exploit those non-assignable rights, title and interest, including, but not limited to, the right to make, use, sell, offer for sale, import, have made, and have sold, the Company Innovations. To the extent any of the rights, title and interest in and to Company Innovations can neither be assigned nor licensed by me to Company (including non- assignable moral rights), I hereby irrevocably waive and agree never to assert the non- assignable and non-licensable rights, title and interest against Company, any of Company's successors in interest, or any of Company's customers. 7. Future Innovations. I will disclose promptly in writing to Company all Innovations conceived, reduced to practice, created, derived, developed, or made by me during my employment with Company and for three (3) months thereafter, whether or not I believe the Innovations are subject to this Agreement, to permit a determination by Company as to whether or not the Innovations are or should be considered Company Innovations. Company will receive that information in confidence. 8. Notice of Nonassignable Innovations to Employees in California and other states. This Agreement does not apply to an Innovation that qualifies fully as a non- assignable invention under the provisions of

3 Section 2870 of the California Labor Code. as well as the other states identified in Exhibit B. I have reviewed the notification in Exhibit B (Limited Exclusion Notification) and agree that my signature on this Agreement acknowledges receipt of the notification. 9. Cooperation in Perfecting Rights to Company Innovations. I agree to perform, during and after my employment, all acts that Company deems necessary or desirable to permit and assist Company, at its expense, in obtaining and enforcing the full benefits, enjoyment, rights and title throughout the world in the Company Innovations and all intellectual property rights therein as provided to Company under this Agreement. If Company is unable for any reason to secure my signature to any document required to file, prosecute, register or memorialize the assignment of any rights or application or to enforce any right under any Company Innovations as provided under this Agreement, I hereby irrevocably designate and appoint Company and Company's duly authorized officers and agents as my agents and attorneys-in-fact to act for and on my behalf and instead of me to take all lawfully permitted acts to further the filing, prosecution, registration, memorialization of assignment, issuance, and enforcement of rights under the Innovations, all with the same legal force and effect as if executed by me. The foregoing is deemed a power coupled with an interest and is irrevocable. 10. Return of Materials. At any time upon Company's request, and when my employment with Company is over, I will return all materials (including, without limitation, documents, drawings, papers, diskettes and tapes) containing or disclosing any Proprietary Information (including all copies thereof), as well as any keys, pass cards, identification cards, computers, printers, pagers, cell phones, smartphones, personal digital assistants or similar items or devices that Company has provided to me. I will provide Company with a written certification of my compliance with my obligations under this Section. 11. No Violation of Rights of Third Parties. During my employment with Company, I will not (a) breach any agreement to keep in confidence any confidential or proprietary information, knowledge or data acquired by me prior to my employment with Company or (b) disclose to Company, or use or induce Company to use, any confidential or proprietary information or material belonging to any previous employer or any other third party. I am not currently a party, and will not become a party, to any other agreement that is in conflict, or will prevent me from complying, with this Agreement. 12. Defend Trade Secrets Act. Pursuant to the Defend Trade Secrets Act of 2016, I acknowledge that I shall not have criminal or civil liability under any Federal or State trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. In addition, if I file a lawsuit for retaliation by the Company for reporting a suspected violation of law, I may disclose the trade secret to my attorney and may use the trade secret information in the court proceeding, if I (X) file any document containing the trade secret under seal and (Y) do not disclose the trade secret, except pursuant to court order. 13. Survival. This Agreement (a) shall survive my employment by Company; (b) does not in any way restrict my right to resign or the right of Company to terminate my employment at any time, for any reason or for no reason; (c) inures to the benefit of successors and assigns of Company; and (d) is binding upon my heirs and legal representatives. 14. Injunctive Relief. I agree that if I violate this Agreement, Company will suffer irreparable and continuing damage for which money damages are insufficient, and Company is entitled to injunctive relief, a decree for specific performance, and all other relief as may

4 be proper (including money damages if appropriate), to the extent permitted by law, without the need to post a bond. 15. Notices. Any notice required or permitted by this Agreement shall be in writing and shall be delivered as follows, with notice deemed given as indicated: (a) by personal delivery, when actually delivered; (b) by overnight courier, upon written verification of receipt; (c) by facsimile transmission, upon acknowledgment of receipt of electronic transmission;; (d) by email, effective (A) when the sender receives an automated message from the recipient confirming delivery or (B) one hour after the time sent (as recorded on the device from which the sender sent the email) unless the sender receives an automated message that the email has not been delivered, whichever happens first, but if the delivery or receipt is on a day which is not a business day or is after 5:00 pm (addressee's time) it is deemed to be received at 9:00 am on the following business day; or (e) by certified or registered mail, return receipt requested, upon verification of receipt. Notices to me shall be sent to any address in Company's records or other address as I may provide in writing. Notices to Company shall be sent to Company's Human Resources Department or to another address as Company may specify in writing. 16. Governing Law; Forum. The laws of the United States of America and the State of Florida govern all matters arising out of or relating to this Agreement without giving effect to any conflict of law principles. Company and I each irrevocably consent to the exclusive personal jurisdiction oft he federal and state courts located in Palm Beach County, Florida, as applicable, for any matter arising out of or relating to this Agreement, except that in actions seeking to enforce any order or any judgment of the federal or state courts located in Palm Beach County, Florida, personal jurisdiction will be nonexclusive. Additionally, notwithstanding anything in the foregoing to the contrary, a claim for equitable relief arising out of or related to this Agreement may be brought in any court of competent jurisdiction. For the avoidance of doubt, the foregoing terms will control over any conflicting terms in my offer letter. 17. Severability. If an arbitrator or court of law holds any provision of this Agreement to be illegal, invalid or unenforceable, (a) that provision shall be deemed amended to provide Company the maximum protection permitted by applicable law and (b) the legality, validity and enforceability of the remaining provisions of this Agreement shall not be affected. 18. Waiver; Modification. If Company waives any term, provision or breach by me of this Agreement, such waiver shall not be effective unless it is in writing and signed by Company. No waiver shall constitute a waiver of any other or subsequent breach by me. This Agreement may be modified only if both Company and I consent in writing. 19. Assignment. The rights and benefits of this Agreement shall extend to all successors and assigns of the Company, whether by merger, reorganization, sale of assets, operation of law or otherwise. 20. Entire Agreement. This Agreement, including any agreement to arbitrate claims or disputes relating to my employment that I may have signed in connection with my employment by Company, represents my entire understanding with Company with respect to the subject matter of this Agreement and supersedes all previous understandings, written or oral.

5 I certify and acknowledge that I have carefully read all of the provisions of this Agreement and that I understand and will fully and faithfully comply with such provisions. EMPLOYEE: UPHEALTH By: By: _/s/ Dr. Ramesh Balakrishnan /s/ Martin S.A. Beck Name: Dr. Ramesh Balakrishnan Martin S. A. Beck Title: Chief Executive Officer Dated: October 24, 2021 Dated: October 24, 2021

6 Exhibit A PRIOR INNOVATIONS

7 Exhibit B If I am employed by the Company in the State of California, the following provision applies: THIS IS TO NOTIFY you in accordance with Section 2872 of the California Labor Code that the foregoing Agreement between you and Company does not require you to assign or offer to assign to Company any invention that you developed entirely on your own time without using Company's equipment, supplies, facilities or trade secret information except for those inventions that either: (1) Relate at the time of conception or reduction to practice of the invention to Company's business, or actual or demonstrably anticipated research or development of Company; or (2) Result from any work performed by you for Company. To the extent a provision in the foregoing Agreement purports to require you to assign an invention otherwise excluded from the preceding Section, the provision is against the public policy of California and is unenforceable. This limited exclusion does not apply to any patent or invention covered by a contract between Company and the United States or any of its agencies requiring full title to a patent or invention to be in the United States. Ifl am employed by the Company in the State of Delaware, the following provision applies: Delaware Code, Title 19, § 805. Employee's right to certain inventions. Any provision in an employment agreement which provides that the employee shall assign or offer to assign any of the employee's rights in an invention to the employee's employer shall not apply to an invention that the employee developed entirely on the employee's own time without using the employer's equipment, supplies, facility or trade secret information, except for those inventions that: (i) relate to the employer's business or actual or demonstrably anticipated research or development, or (ii) result from any work performed by the employee for the employer. To the extent a provision in an employment agreement purports to apply to the type of invention described, it is against the public policy of this State and is unenforceable. An employer may not require a provision of an employment agreement made unenforceable under this section as a condition of employment or continued employment. Ifl am employed by the Company in the State of Illinois, the following provision applies: Illinois Compiled Statutes Chapter 765, Section 1060/2. Sec. 2. Employee rights to inventions - conditions. (I) A provision in an employment agreement which provides that an employee shall assign or offer to assign any of the employee's rights in an invention to the employer does not apply to an invention for which no equipment, supplies, facilities, or trade secret information of the employer was used and which was developed entirely on the employee's own time, unless (a) the invention relates (i) to the business of the employer, or (ii) to the employer's actual or demonstrably anticipated research or development, or (b) the invention results from any work performed by the employee for the employer. Any provision which purports to apply to such an invention is to that extent against the public policy of this State and is to that

8 extent void and unenforceable. The employee shall bear the burden of proof in establishing that his invention qualifies under this subsection. (2) An employer shall not require a provision made void and unenforceable by subsection (1) of this Section as a condition of employment or continuing employment. This Act shall not preempt existing common law applicable to any shop rights of employers with respect to employees who have not signed an employment agreement. (3) If an employment agreement entered into after January 1, 1984, contains a provision requiring the employee to assign any of the employee's rights in any invention to the employer, the employer must also, at the time the agreement is made, provide a written notification to the employee that the agreement does not apply to an invention for which no equipment, supplies, facility, or trade secret information of the employer was used and which was developed entirely on the employee's own time, unless (a) the invention relates (i) to the business of the employer, or (ii) to the employer's actual or demonstrably anticipated research or development, or (b) the invention results from any work performed by the employee for the employer. If I am employed by the Company in the State of Kansas, the following provision applies: Chapter 44.--LABOR AND INDUSTRIES Article 1.--PROTECTION OF EMPLOYEES 44-130. Employment agreements assigning employee rights in inventions to employer; restrictions; certain provisions void; notice and disclosure. (a) Any provision in an employment agreement which provides that an employee shall assign or offer to assign any of the employee's rights in an invention to the employer shall not apply to an invention for which no equipment, supplies, facilities or trade secret information of the employer was used and which was developed entirely on the employee's own time, unless: (1) The invention relates to the business of the employer or to the employer's actual or demonstrably anticipated research or development; or (2) the invention results from any work performed by the employee for the employer. (b) Any provision in an employment agreement which purports to apply to an invention which it is prohibited from applying to under subsection (a), is to that extent against the public policy of this state and is to that extent void and unenforceable. No employer shall require a provision made void and unenforceable by this section as a condition of employment or continuing employment. (c) If an employment agreement contains a provision requiring the employee to assign any of the employee's rights in any invention to the employer, the employer shall provide, at the time the agreement is made, a written notification to the employee that the agreement does not apply to an invention for which no equipment, supplies, facility or trade secret information of the employer was used and which was developed entirely on the employee's own time, unless: (1) The invention relates directly to the business of the employer or to the employer's actual or demonstrably anticipated research or development; or (2) the invention results from any work performed by the employee for the employer.

9 (d) Even though the employee meets the burden of proving the conditions specified in this section, the employee shall disclose, at the time of employment or thereafter, all inventions being developed by the employee, for the purpose of determining employer and employee rights in an invention. If I am employed by the Company in the State of Minnesota, the following provision applies: Minnesota Statute Section 181.78. Subdivision 1. Inventions not related to employment. Any provision in an employment agreement which provides that an employee shall assign or offer to assign any of the employee's rights in an invention to the employer shall not apply to an invention for which no equipment, supplies, facility or trade secret information of the employer was used and which was developed entirely on the employee's own time, and (I) which does not relate (a) directly to the business of the employer or (b) to the employer's actual or demonstrably anticipated research or development, or (2) which does not result from any work performed by the employee for the employer. Any provision which purports to apply to such an invention is to that extent against the public policy of this state and is to that extent void and unenforceable. If I am employed by the Company in the State of New Jersey, the following provision applies: New Jersey Statutes Section 34:lB-265. l .a.(1) Any provision in an employment contract between an employee and employer, which provides that the employee shall assign or offer to assign any of the employee's rights to an invention to that employer, shall not apply to an invention that the employee develops entirely on the employee's own time, and without using the employer's equipment, supplies, facilities or information, including any trade secret information, except for those inventions that: (a) relate to the employer's business or actual or demonstrably anticipated research or development; or (b) result from any work performed by the employee on behalf of the employer. If I am employed by the Company in the State of North Carolina, the following provision applies: North Carolina General Statutes Section 66-57.1. EMPLOYEE'S RIGHT TO CERTAIN INVENTIONS Any provision in an employment agreement which provides that the employees shall assign or offer to assign any of his rights in an invention to his employer shall not apply to an invention that the employee developed entirely on his own time without using the employer's equipment, supplies, facility or trade secret information except for those inventions that (i) relate to the employer's business or actual or demonstrably anticipated research or development, or (ii) result from any work performed by the employee for the employer. To the extent a provision in an employment agreement purports to apply to the type of invention described, it is against the public policy of this State and in unenforceable. The employee shall bear the burden of proof in establishing that his invention qualifies under this section. If I am employed by the Company in the State of Utah, the following provision applies: Utah Code, §§ 34-39-2 and 34-39-3 34-39-2. Definitions. As used in this chapter:

(1) "Employment invention" means any invention or part thereof conceived, developed, reduced to practice, or created by an employee which is: (a) conceived, developed, reduced to practice, or created by the employee: (i) within the scope of his employment; (ii) on his employer's time; or (iii) with the aid, assistance, or use of any of his employer's property, equipment, facilities, supplies, resources, or intellectual property; (b) the result of any work, services, or duties performed by an employee for his employer; (c) related to the industry or trade of the employer; or (d) related to the current or demonstrably anticipated business, research, or development of the employer. (2) "Intellectual property" means any and all patents, trade secrets, know-how, technology, confidential information, ideas, copyrights, trademarks, and service marks and any and all rights, applications, and registrations relating to them. 34-39-3. Scope of act -- When agreements between an employee and employer are enforceable or unenforceable with respect to employment inventions -- Exceptions. (1) An employment agreement between an employee and his employer is not enforceable against the employee to the extent that the agreement requires the employee to assign or license, or to offer to assign or license, to the employer any right or intellectual property in or to an invention that is: (a) created by the employee entirely on his own time; and (b) not an employment invention. (2) An agreement between an employee and his employer may require the employee to assign or license, or to offer to assign or license, to his employer any or all of his rights and intellectual property in or to an employment invention. (3) Subsection (1) does not apply to: (a) any right, intellectual property or invention that is required by law or by contract between the employer and the United States government or a state or local government to be assigned or licensed to the United States; or (b) an agreement between an employee and his employer which is not an employment agreement. (4) Notwithstanding Subsection (1), an agreement is enforceable under Subsection (1) if the employee's employment or continuation of employment is not conditioned on the employee's acceptance of such agreement and the employee receives a consideration under such agreement which is not compensation for employment.

(5) Employment of the employee or the continuation of his employment is sufficient consideration to support the enforceability of an agreement under Subsection (2) whether or not the agreement recites such consideration. (6) An employer may require his employees to agree to an agreement within the scope of Subsection (2) as a condition of employment or the continuation of employment. (7) An employer may not require his employees to agree to anything unenforceable under Subsection (1) as a condition of employment or the continuation of employment. (8) Nothing in this chapter invalidates or renders unenforceable any employment agreement or provisions of an employment agreement unrelated to employment inventions. If I am employed by the Company in the State of Washington, the following provision applies: Washington Statute 49:44.140 (1) A provision in an employment agreement which provides that an employee shall assign or offer to assign any of the employee's rights in an invention to the employer does not apply to an invention for which no equipment, supplies, facilities, or trade secret information of the employer was used and which was developed entirely on the employee's own time, unless (a) the invention relates (i) directly to the business of the employer, or (ii) to the employer's actual or demonstrably anticipated research or development, or (b) the invention results from any work performed by the employee for the employer. Any provision which purports to apply to such an invention is to that extent against the public policy of this state and is to that extent void and unenforceable. (2) An employer shall not require a provision made void and unenforceable by subsection (1) of this section as a condition of employment or continuing employment. (3) If an employment agreement entered into after September 1, 1979, contains a provision requiring the employee to assign any of the employee's rights in any invention to the employer, the employer must also, at the time the agreement is made, provide a written notification to the employee that the agreement does not apply to an invention for which no equipment, supplies, facility, or trade secret information of the employer was used and which was developed entirely on the employee's own time, unless (a) the invention relates (i) directly to the business of the employer, or (ii) to the employer's actual or demonstrably anticipated research or development, or (b) the invention results from any work performed by the employee for the employer. If I am employed by the Company in the State of Wisconsin. the following provision applies: In accordance with Wisconsin law, this Agreement does not obligate me to assign or offer to assign to the Company any of my rights in any invention I have developed entirely on my own time without using Company's equipment, supplies, facilities, trade secret information or Confidential Information. Provided, however, Company shall own inventions that either; (i) relate, at the time of the conception or reduction to practice, to Company's activities or actual or demonstrably anticipated research or development; or (ii) result from any work I performed for Company. I will advise Company promptly in writing of any inventions I believe should be an exception to this Agreement. 11

Exhibit B

INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this “Agreement”) is made as of June 15, 2021, by and between UpHealth, Inc., a Delaware corporation (the "Company"), and ("Indemnitee"). RECITALS WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations as directors, officers or in other capacities unless they are provided with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of such corporations; WHEREAS, the Board of Directors of the Company (the "Board'') has determined that, in order to attract and retain qualified individuals, the Company will attempt to maintain on an ongoing basis, at its sole expense, liability insurance to protect persons serving the Company and its subsidiaries from certain liabilities. Although the furnishing of such insurance has been a customary and widespread practice among United States-based corporations and other business enterprises, the Company believes that, given current market conditions and trends, such insurance may be available to it in the future only at higher premiums and with more exclusions. At the same time, directors, officers and other persons in service to corporations or business enterprises are being increasingly subjected to expensive and time-consuming litigation relating to, among other things, matters that traditionally would have been brought only against the Company or business enterprise itself. The Second Amended and Restated Certificate of Incorporation (the "Charter") and the Amended and Restated Bylaws (the "Bylaws") of the Company require indemnification of the officers and directors of the Company. Indemnitee may also be entitled to indemnification pursuant to applicable provisions of the Delaware General Corporation Law ("DGCL"). The Charter, Bylaws and the DGCL expressly provide that the indemnification provisions set forth therein are not exclusive, and thereby contemplate that contracts may be entered into between the Company and members of the board of directors, officers and other persons with respect to indemnification, hold harmless, exoneration, advancement and reimbursement rights; WHEREAS, the uncertainties relating to such insurance and to indemnification have increased the difficulty of attracting and retaining such persons; WHEREAS, the Board has determined that the increased difficulty in attracting and retaining such persons is detrimental to the best interests of the Company's stockholders and that the Company should act to assure such persons that there will be increased certainty of such protection in the future; WHEREAS, it is reasonable, prudent and necessary for the Company contractually to obligate itself to indemnify, hold harmless, exonerate and to advance expenses on behalf of, such persons to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company free from undue concern that they will not be so protected against liabilities; WHEREAS, this Agreement is a supplement to and in furtherance of the Charter and Bylaws of the Company and any resolutions adopted pursuant thereto, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder; WHEREAS, Indemnitee may not be willing to serve as an officer, director, advisor or in another capacity without adequate protection, and the Company desires Indemnitee to serve in such capacity. Indemnitee is willing to serve, continue to serve and to take on additional service for or on behalf of the Company on the condition that he or she be so indemnified; and NOW, THEREFORE, in consideration of the premises and the covenants contained herein, the Company and Indemnitee do hereby covenant and agree as follows:

2 TERMS AND CONDITIONS 1. SERVICES TO THE COMPANY. In consideration of the Company's covenants and obligations hereunder, Indemnitee will serve or continue to serve as an officer, director, advisor, key employee or in any other capacity of the Company, as applicable, for so long as Indemnitee is duly elected or appointed or retained or until Indemnitee tenders his or her resignation or until Indemnitee is removed. The foregoing notwithstanding, this Agreement shall continue in full force and effect after Indemnitee has ceased to serve as a director, officer, advisor, key employee or in any other capacity of the Company, as provided in Section 17. This Agreement, however, shall not impose any obligation on Indemnitee or the Company to continue Indemnitee’s service to the Company beyond any period otherwise required by law or by other agreements or commitments of the parties, if any. 2. DEFINITIONS. As used in this Agreement: (a) References to "agent" shall mean any person who is or was a director, officer or employee of the Company or a subsidiary of the Company or other person authorized by the Company to act for the Company, to include such person serving in such capacity as a director, officer, employee, advisor, fiduciary or other official of another corporation, partnership, limited liability company, joint venture, trust or other enterprise at the request of, for the convenience of, or to represent the interests of the Company or a subsidiary of the Company. (b) The terms "Beneficial Owner" and "Beneficial Ownership" shall have the meanings set forth in Rule 13d-3 promulgated under the Exchange Act (as defined below) as in effect on the date hereof. (c) A "Change in Control" shall be deemed to occur upon the earliest to occur, after the date of this Agreement, of the following events: (i) Acquisition of Stock by Third Party. The date on which any Person (as defined below) is or becomes the Beneficial Owner, directly or indirectly, of securities of the Company representing fifteen percent (15%) or more of the combined voting power of the Company's then outstanding securities entitled to vote generally in the election of directors, unless (1) the change in the relative Beneficial Ownership of the Company's securities by any Person results solely from a reduction in the aggregate number of outstanding shares of securities entitled to vote generally in the election of directors, or (2) such acquisition was approved in advance by the Continuing Directors (as defined below) and such acquisition would not constitute a Change in Control under part (iii) of this definition; (ii) Change in Board of Directors. The date on which the individuals who, as of the date hereof, constitute the Board, and any new director whose election by the Board or nomination for election by the Company's stockholders was approved by a vote of at least two-thirds of the directors then still in office who were directors on the date hereof or whose election for nomination for election was previously so approved (collectively, the "Continuing Directors"), cease for any reason to constitute at least a majority of the members of the Board; (iii) Corporate Transactions. The effective date of a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, recapitalization or other similar business combination, involving the Company and one or more businesses (a "Business Combination"), in each case, unless, following such Business Combination: (1) all or substantially all of the individuals and entities who were the Beneficial Owners of securities entitled to vote generally in the election of directors immediately prior to such Business Combination beneficially own, directly or indirectly, more than 51% of the combined voting power of the then outstanding securities of the Company entitled to vote generally in the election of directors resulting from such Business Combination (including, without limitation, a corporation which as a result of such transaction owns the Company or all or substantially all of the Company's assets either directly or through one or more Subsidiaries (as defined below)) in substantially the same proportions as their ownership immediately prior to such Business Combination, of the securities entitled to vote generally in the election of directors; (2) no Person (excluding any corporation resulting from such Business Combination) is the Beneficial Owner, directly or indirectly, of 15% or more of the combined voting power of the then outstanding securities entitled to vote generally in the election of directors of the surviving corporation except to the extent that such ownership existed prior to the Business Combination; and (3) at least a majority of the Board of Directors of the corporation resulting from such Business Combination were Continuing Directors at the time of the execution of the initial agreement, or of the action of the Board of Directors, providing for such Business Combination;

3 (iv) Liquidation. The date of the receipt by the Company of the requisite approval by its stockholders, under the Charter and the Bylaws, of (A) a complete liquidation of the Company, or (B) an agreement or series of agreements for the sale or disposition by the Company of all or substantially all of the Company's assets, other than factoring the Company's current receivables or escrows due (or, if such stockholder approval is not required, the decision by the Board to proceed with such a liquidation, sale, or disposition in one transaction or a series of related transactions); or (v) Other Events. There occurs any other event of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A of Regulation 14A (or any successor rule) (or a response to any similar item on any similar schedule or form) promulgated under the Exchange Act (as defined below), whether or not the Company is then subject to such reporting requirement. (d) "Corporate Status" describes the status of a person who is or was a director, officer, trustee, general partner, manager, managing member, fiduciary, employee or agent of the Company or of any other Enterprise (as defined below) which such person is or was serving at the request of the Company. (e) "Delaware Court" shall mean the Court of Chancery of the State of Delaware. (f) "Disinterested Director" shall mean a director of the Company who is not and was not a party to the Proceeding (as defined below) in respect of which indemnification is sought by Indemnitee. (g) "Enterprise" shall mean the Company and any other corporation, constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger to which the Company (or any of its wholly owned subsidiaries) is a party, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise of which Indemnitee is or was serving at the request of the Company as a director, officer, trustee, general partner, managing member, fiduciary, employee or agent. (h) "Exchange Act" shall mean the Securities Exchange Act of 1934, as amended. (i) "Expenses" shall include all direct and indirect costs, fees and expenses of any type or nature whatsoever, including, without limitation, all reasonable attorneys' fees and costs, retainers, court costs, transcript costs, fees of experts, witness fees, travel expenses, fees of private investigators and professional advisors, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, fax transmission charges, secretarial services and all other disbursements, obligations or expenses in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, settlement or appeal of, or otherwise participating in, a Proceeding (as defined below). Expenses also shall include Expenses incun-ed in connection with any appeal resulting from any Proceeding (as defined below), including without limitation the principal, premium, security for, and other costs relating to any cost bond, supersedeas bond, or other appeal bond or its equivalent. Expenses, however, shall not include amounts paid in settlement by Indemnitee or the amount of judgments or fines against Indemnitee. (j) References to ''fines" shall include any excise tax assessed on Indemnitee with respect to any employee benefit plan; references to "serving at the request of the Company" shall include any service as a director, officer, employee, agent or fiduciary of the Company which imposes duties on, or involves services by, such director, officer, employee, agent or fiduciary with respect to an employee benefit plan, its participants or beneficiaries; and if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in the best interests of the participants and beneficiaries of an employee benefit plan, Indemnitee shall be deemed to have acted in a manner "not opposed to the best interests of the Company" as referred to in this Agreement. (k) "Independent Counsel" shall mean a law firm or a member of a law firm with significant experience in matters of corporation law and that neither presently is, nor in the past five years has been, retained to represent: (i) the Company or Indemnitee in any matter material to either such party (other than with respect to matters concerning Indemnitee under this Agreement, or of other indemnitees under similar indemnification agreements); or (ii) any other party to the Proceeding (as defined below) giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term "Independent Counsel" shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee's rights under this Agreement. (I) The term "Person" shall have the meaning as set forth in Sections 13(d) and 14(d) of the Exchange Act as in effect on the date hereof; provided, however, that "Person" shall exclude: (i) the Company; (ii) any Subsidiaries (as defined below) of the Company; (iii) any employment benefit plan of the Company or of a

4 Subsidiary (as defined below) of the Company or of any corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company; and (iv) any trustee or other fiduciary holding securities under an employee benefit plan of the Company or of a Subsidiary (as defined below) of the Company or of a corporation owned directly or indirectly by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company. (m) The term "Proceeding" shall include any threatened, pending or completed action, suit, arbitration, mediation, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other actual, threatened or completed proceeding, whether brought in the right of the Company or otherwise and whether of a civil (including intentional or unintentional tort claims), criminal, administrative or investigative or related nature, in which Indemnitee was, is, will or might be involved as a party or otherwise by reason of the fact that Indemnitee is or was a director or officer of the Company, by reason of any action (or failure to act) taken by him or her, or of any action (or failure to act) on his or her part while acting as a director or officer of the Company, or by reason of the fact that he or she is or was serving at the request of the Company as a director, officer, trustee, general partner, managing member, fiduciary, employee or agent of any other Enterprise, in each case whether or not serving in such capacity at the time any liability or expense is incurred for which indemnification, reimbursement, or advancement of expenses can be provided under this Agreement. (n) The term "Subsidiary," with respect to any Person, shall mean any corporation, limited liability company, partnership, joint venture, trust or other entity of which a majority of the voting power of the voting equity securities or equity interest is owned, directly or indirectly, by that Person. 3. INDEMNITY IN THIRD-PARTY PROCEEDINGS. To the fullest extent permitted by applicable law, the Company shall indemnify, hold harmless and exonerate Indemnitee in accordance with the provisions of this Section 3 if Indemnitee was, is, or is threatened to be made, a party to or a participant (as a witness, deponent or otherwise) in any Proceeding, other than a Proceeding by or in the right of the Company to procure a judgment in its favor by reason of Indemnitee's Corporate Status. Pursuant to this Section 3, Indemnitee shall be indemnified, held harmless and exonerated against all Expenses, judgments, liabilities, fines, penalties and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses, judgments, fines, penalties and amounts paid in settlement) actually, and reasonably incurred by Indemnitee or on his or her behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company and, in the case of a criminal Proceeding, had no reasonable cause to believe that his or her conduct was unlawful. 4. INDEMNITY IN PROCEEDINGS BY OR IN THE RIGHT OF THE COMPANY. To the fullest extent permitted by applicable law, the Company shall indemnify, hold harmless and exonerate Indemnitee in accordance with the provisions of this Section 4 if Indemnitee was, is, or is threatened to be made, a party to or a participant (as a witness, deponent or otherwise) in any Proceeding by or in the right of the Company to procure a judgment in its favor by reason of Indemnitee's Corporate Status. Pursuant to this Section 4, Indemnitee shall be indemnified, held harmless and exonerated against all Expenses actually and reasonably incurred by him or her, or on his or her behalf, in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company. No indemnification, hold harmless or exoneration for Expenses shall be made under this Section 4 in respect of any claim, issue or matter as to which Indemnitee shall have been finally adjudged by a court to be liable to the Company, unless and only to the extent that any court in which the Proceeding was brought or the Delaware Court shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnification, to be held harmless or to exoneration. 5. INDEMNIFICATION FOR EXPENSES OF A PARTY WHO IS WHOLLY OR PARTLY SUCCESSFUL. Notwithstanding any other provisions of this Agreement except for Section 27, to the extent that Indemnitee was or is, by reason of Indemnitee's Corporate Status, a party to (or a participant in) and is successful, on the merits or otherwise, in any Proceeding or in defense of any claim, issue or matter therein, in whole or in part, the Company shall, to the fullest extent permitted by applicable law, indemnify, hold harmless and exonerate Indemnitee against all Expenses actually and reasonably incurred by him or her in connection therewith. If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall, to the fullest extent permitted by applicable law, indemnify, hold harmless and exonerate Indemnitee against all Expenses actually and reasonably

5 incurred by him or her, or on his or her behalf, in connection with each successfully resolved claim, issue or matter. If Indemnitee is not wholly successful in such Proceeding, the Company also shall, to the fullest extent permitted by applicable law, indemnify, hold harmless and exonerate Indemnitee against all Expenses reasonably incurred in connection with a claim, issue or matter related to any claim, issue, or matter on which Indemnitee was successful. For purposes of this Section and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter. 6. INDEMNIFICATION FOR EXPENSES OF A WITNESS. Notwithstanding any other provision of this Agreement except for Section 27, to the extent that Indemnitee is, by reason of his or her Corporate Status, a witness or deponent in any Proceeding to which Indemnitee was or is not a party or threatened to be made a party, he or she shall, to the fullest extent permitted by applicable law, be indemnified, held harmless and exonerated against all Expenses actually and reasonably incurred by him or her, or on his or her behalf in connection therewith. 7. ADDITIONAL INDEMNIFICATION, HOLD HARMLESS AND EXONERATION RIGHTS. Notwithstanding any limitation in Sections 3, 4 or except for Section 27, the Company shall, to the fullest extent permitted by applicable law, indemnify, hold harmless and exonerate Indemnitee if indemnitee is a party to or threatened to be made a party to any Proceeding (including a Proceeding by or in the right of the Company to procure a judgment in its favor) against all Expenses, judgments, fines, penalties and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses, judgments, fines, penalties and amounts paid in settlement) actually and reasonably incurred by Indemnitee in connection with the Proceeding. No indemnification, hold harmless or exoneration rights shall be available under this Section 7 on account of Indemnitee’s conduct which constitutes a breach of indemnitee’s duty of loyalty to the Company or its stockholders or is an act or omission not in good faith or which involves intentional misconduct or a knowing violation of the law. 8. CONTRIBUTION IN THE EVENT OF JOINT LIABILITY. (a) To the fullest extent permissible under applicable law, if the indemnification, hold harmless and/or exoneration rights provided for in this Agreement are unavailable to Indemnitee in whole or in part for any reason whatsoever, the Company, in lieu of indemnifying, holding harmless or exonerating Indemnitee, shall pay, in the first instance, the entire amount incurred by Indemnitee, whether for judgments, liabilities, fines, penalties, amounts paid or to be paid in settlement and/or for Expenses, in connection with any Proceeding without requiring Indemnitee to contribute to such payment, and the Company hereby waives and relinquishes any right of contribution it may have at any time against Indemnitee. (b) The Company shall not enter into any settlement of any Proceeding in which the Company is jointly liable with Indemnitee (or would be if joined in such Proceeding) unless such settlement provides for a full and final release of all claims asserted against Indemnitee. (c) The Company hereby agrees to fully indemnify, hold harmless and exonerate Indemnitee from any claims for contribution which may be brought by officers, directors or employees of the Company other than Indemnitee who may be jointly liable with Indemnitee. 9. EXCLUSIONS. Notwithstanding any provision in this Agreement, the Company shall not be obligated under this Agreement to make any indemnification, advance expenses, hold harmless or exoneration payment in connection with any claim made against Indemnitee: (a) for which payment has actually been received by or on behalf of Indemnitee under any insurance policy or other indemnity or advancement provision, except with respect to any excess beyond the amount actually received under any insurance policy, contract, agreement, other indemnity or advancement provision or otherwise; (b) for an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning of Section 16(b) of the Exchange Act (or any successor rule) or similar provisions of state statutory law or common law; or (c) except as otherwise provided in Sections 14{f)-(g) hereof, prior to a Change in Control, in connection with any Proceeding (or any part of any Proceeding) initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or its directors, officers, employees or other indemnitees, unless (i) the Board authorized the Proceeding (or any part of any Proceeding) prior to its

6 initiation or (ii) the Company provides the indemnification, hold harmless or exoneration payment, in its sole discretion, pursuant to the powers vested in the Company under applicable law. Indemnitee shall seek payments or advances from the Company only to the extent that such payments or advances are unavailable from any insurance policy of the Company covering Indemnitee. 10. ADVANCES OF EXPENSES; DEFENSE OF CLAIM. (a) Notwithstanding any provision of this Agreement to the contrary except for Section 27, and to the fullest extent not prohibited by applicable law, the Company shall pay the Expenses incurred by Indemnitee (or reasonably expected by Indemnitee to be incurred by Indemnitee within three months) in connection with any Proceeding within ten (10) days after the receipt by the Company of a statement or statements requesting such advances from time to time, prior to the final disposition of any Proceeding. Advances shall, to the fullest extent permitted by law, be unsecured and interest free. Advances shall, to the fullest extent permitted by law, be made without regard to Indemnitee's ability to repay the Expenses and without regard to Indemnitee's ultimate entitlement to be indemnified, held harmless or exonerated under the other provisions of this Agreement. Advances shall include any and all reasonable Expenses incurred pursuing a Proceeding to enforce this right of advancement, including Expenses incurred preparing and forwarding statements to the Company to support the advances claimed. To the fullest extent required by applicable law, such payments of Expenses in advance of the final disposition of the Proceeding shall be made only upon the Company's receipt of an undertaking, by or on behalf of Indemnitee, to repay the advanced amounts to the extent that it is ultimately determined that Indemnitee is not entitled to be indemnified by the Company under the provisions of this Agreement, the Charter, the Bylaws of the Company, applicable law or otherwise. This Section I0{a) shall not apply to any claim made by Indemnitee for which an indemnification, hold harmless or exoneration payment is excluded pursuant to Section 9. (b) The Company will be entitled to participate in the Proceeding at its own expense. (c) The Company shall not settle any action, claim or Proceeding (in whole or in part) which would impose any Expense, judgment, fine, penalty or limitation on Indemnitee without Indemnitee's prior written consent. 11. PROCEDURE FOR NOTIFICATION AND APPLICATION FOR INDEMNIFICATION. (a) Indemnitee agrees to notify promptly the Company in writing upon being served with any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding, claim, issue or matter therein which may be subject to indemnification, hold harmless or exoneration rights, or advancement of Expenses covered hereunder. The failure of Indemnitee to so notify the Company shall not relieve the Company of any obligation which it may have to Indemnitee under this Agreement, or otherwise. (b) Indemnitee may deliver to the Company a written application to indemnify, hold harmless or exonerate Indemnitee in accordance with this Agreement. Such application(s) may be delivered from time to time and at such time(s) as Indemnitee deems appropriate in his or her sole discretion. Following such a written application for indemnification by Indemnitee, Indemnitee's entitlement to indemnification shall be determined according to Section 12(a) of this Agreement. 12. PROCEDURE UPON APPLICATION FOR INDEMNIFICATION. (a) A determination, if required by applicable law, with respect to Indemnitee's entitlement to indemnification shall be made in the specific case by one of the following methods: (i) if no Change in Control has occurred, (x) by a majority vote of the Disinterested Directors, even though less than a quorum of the Board, (y) by a committee of Disinterested Directors, even though less than a quorum of the Board, or (z) if there are no Disinterested Directors, or if such Disinterested Directors so direct, by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to Indemnitee, or (ii) if a Change in Control has occurred, by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to Indemnitee. The Company promptly will advise Indemnitee in writing with respect to any determination that Indemnitee is or is not entitled to indemnification, including a description of any reason or basis for which indemnification has been denied. If it is so determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within ten (I 0) days after such determination. Indemnitee shall reasonably cooperate with the person, persons or entity making such determination with respect to Indemnitee's entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably

7 necessary to such determination. Any costs or Expenses (including reasonable attorneys' fees and disbursements) incurred by Indemnitee in so cooperating with the person, persons or entity making such determination shall be borne by the Company (irrespective of the determination as to Indemnitee's entitlement to indemnification) and the Company hereby agrees to indemnify and to hold Indemnitee harmless therefrom. (b) In the event the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 12(a) hereof, the Independent Counsel shall be selected as provided in this Section 12(b). The Independent Counsel shall be selected by Indemnitee (unless Indemnitee shall request that such selection be made by the Board), and Indemnitee shall give written notice to the Company advising it of the identity of the Independent Counsel so selected and certifying that the Independent Counsel so selected meets the requirements of "Independent Counsel" as defined in Section 2 of this Agreement. If the Independent Counsel is selected by the Board, the Company shall give written notice to Indemnitee advising him or her of the identity of the Independent Counsel so selected and certifying that the Independent Counsel so selected meets the requirements of "Independent Counsel" as defined in Section 2 of this Agreement. In either event, Indemnitee or the Company, as the case may be, may, within ten (10) days after such written notice of selection shall have been received, deliver to the Company or to Indemnitee, as the case may be, a written objection to such selection; provided, however, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of "Independent Counsel" as defined in Section 2 of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion. Absent a proper and timely objection, the person so selected shall act as Independent Counsel. If such written objection is so made and substantiated, the Independent Counsel so selected may not serve as Independent Counsel unless and until such objection is withdrawn or a court of competent jurisdiction has determined that such objection is without merit. If, within twenty (20) days after submission by Indemnitee of a written request for indemnification pursuant to Section 11(b) hereof, no Independent Counsel shall have been selected and not objected to, either the Company or Indemnitee may petition the Delaware Court for resolution of any objection which shall have been made by the Company or Indemnitee to the other's selection of Independent Counsel and/or for the appointment as Independent Counsel of a person selected by the Delaware Court, and the person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel under Section 12(a) hereof. Upon the due commencement of any judicial proceeding or arbitration pursuant to Section 14(a) of this Agreement, Independent Counsel shall be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing). (c) The Company agrees to pay the reasonable fees and expenses of Independent Counsel and to fully indemnify and hold harmless such Independent Counsel against any and all Expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto. 13. PRESUMPTIONS AND EFFECT OF CERTAIN PROCEEDINGS. (a) In making a determination with respect to entitlement to indemnification hereunder, the person, persons or entity making such determination shall presume that Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a request for indemnification in accordance with Section l l(b) of this Agreement, and the Company shall have the burden of proof to overcome that presumption in connection with the making by any person, persons or entity of any determination contrary to that presumption. Neither the failure of the Company (including by the Disinterested Directors or Independent Counsel) to have made a determination prior to the commencement of any action pursuant to this Agreement that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor an actual determination by the Company (including by the Disinterested Directors or Independent Counsel) that Indemnitee has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct. (b) If the person, persons or entity empowered or selected under Section 12 of this Agreement to determine whether Indemnitee is entitled to indemnification shall not have made a determination within thirty (30) days after receipt by the Company of the request therefor, the requisite determination of entitlement to indemnification shall, to the fullest extent permitted by law, be deemed to have been made and Indemnitee shall be entitled to such indemnification, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee's statement not materially misleading, in connection with the request for indemnification, or (ii) a final judicial determination that any or all such indemnification is expressly prohibited under applicable law; provided, however, that such 30-day period may be extended for a reasonable time, not to exceed an additional fifteen (15) days, if the person, persons or entity making the

8 determination with respect to entitlement to indemnification in good faith requires such additional time for the obtaining or evaluating of documentation and/or information relating thereto. (c) The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of nolo contendere or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that his or her conduct was unlawful. (d) For purposes of any determination of good faith, Indemnitee shall be deemed to have acted in good faith if Indemnitee's action is based on the records or books of account of the Enterprise, including financial statements, or on information supplied to Indemnitee by the directors, manager, or officers of the Enterprise in the course of their duties, or on the advice of legal counsel for the Enterprise, its Board, any committee of the Board or any director, trustee, general partner, manager or managing member, or on information or records given or reports made to the Enterprise, its Board, any committee of the Board or any director, trustee, general partner, manager or managing member, by an independent certified public accountant or by an appraiser or other expert selected by the Enterprise, its Board, any committee of the Board or any director, trustee, general partner, manager or managing member. The provisions of this Section 13(d) shall not be deemed to be exclusive or to limit in any way the other circumstances in which Indemnitee may be deemed or found to have met the applicable standard of conduct set forth in this Agreement. (e) The knowledge and/or actions, or failure to act, of any other director, officer, trustee, partner, manager, managing member, fiduciary, agent or employee of the Enterprise shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement. 14. REMEDIES OF INDEMNITEE. (a) In the event that (i) a determination is made pursuant to Section 12 of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii) advancement of Expenses, to the fullest extent permitted by applicable law, is not timely made pursuant to Section 10 of this Agreement, (iii) no determination of entitlement to indemnification shall have been made pursuant to Section 12(a) of this Agreement within thirty (30) days after receipt by the Company of the request for indemnification, (iv) payment of indemnification is not made pursuant to Section 5, Q., Z or the last sentence of Section 12(a) of this Agreement within ten (10) days after receipt by the Company of a written request therefor, (v) a contribution payment is not made in a timely manner pursuant to Section 8 of this Agreement, (vi) payment of indemnification pursuant to Section 3 or 1 of this Agreement is not made within ten (10) days after a determination has been made that Indemnitee is entitled to indemnification, or (vii) payment to Indemnitee pursuant to any hold harmless or exoneration rights under this Agreement or otherwise is not made in accordance with this Agreement, Indemnitee shall be entitled to an adjudication by the Delaware Court to such indemnification, hold harmless, exoneration, contribution or advancement rights. Alternatively, Indemnitee, at his or her option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules of the American Arbitration Association. Except as set forth herein, the provisions of Delaware law (without regard to its conflict of laws rules) shall apply to any such arbitration. The Company shall not oppose Indemnitee's right to seek any such adjudication or award in arbitration. (b) In the event that a determination shall have been made pursuant to Section 12(a) of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding or arbitration commenced pursuant to this Section 14 shall be conducted in all respects as a de novo trial, or arbitration, on the merits and Indemnitee shall not be prejudiced by reason of that adverse determination. (c) In any judicial proceeding or arbitration commenced pursuant to this Section 14, Indemnitee shall be presumed to be entitled to be indemnified, held harmless, exonerated to receive advancement of Expenses under this Agreement and the Company shall have the burden of proving Indemnitee is not entitled to be indemnified, held harmless, exonerated and to receive advancement of Expenses, as the case may be, and the Company may not refer to or introduce into evidence any determination pursuant to Section 12(a) of this Agreement adverse to Indemnitee for any purpose. If Indemnitee commences a judicial proceeding or arbitration pursuant to this Section 14, Indemnitee shall not be required to reimburse the Company for any advances pursuant to Section 10

9 until a final determination is made with respect to Indemnitee's entitlement to indemnification (as to which all rights of appeal have been exhausted or lapsed). (d) If a determination shall have been made pursuant to Section 12(a) of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this Section 14, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee's statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law. (e) The Company shall be precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this Section 14 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company is bound by all the provisions of this Agreement. (f) The Company shall indemnify and hold harmless Indemnitee to the fullest extent permitted by law against all Expenses and, if requested by Indemnitee, shall (within ten (10) days after the Company's receipt of such written request) pay to Indemnitee, to the fullest extent permitted by applicable law, such Expenses which are incurred by Indemnitee in connection with any judicial proceeding or arbitration brought by Indemnitee: (i) to enforce his or her rights under, or to recover damages for breach of, this Agreement or any other indemnification, hold harmless, exoneration, advancement or contribution agreement or provision of the Charter, or the Bylaws now or hereafter in effect; or (ii) for recovery or advances under any insurance policy maintained by any person for the benefit of Indemnitee, regardless of the outcome and whether Indemnitee ultimately is determined to be entitled to such indemnification, hold harmless or exoneration right, advancement, contribution or insurance recovery, as the case may be (unless such judicial proceeding or arbitration was not brought by Indemnitee in good faith). (g) Interest shall be paid by the Company to Indemnitee at the legal rate under Delaware law for amounts which the Company indemnifies, holds harmless or exonerates, or advances, or is obliged to indemnify, hold harmless or exonerate or advance for the period commencing with the date on which Indemnitee requests indemnification, to be held harmless, exonerated, contribution, reimbursement or advancement of any Expenses and ending with the date on which such payment is made to Indemnitee by the Company. 15. SECURITY. Notwithstanding anything herein to the contrary, except for Section 27, to the extent requested by Indemnitee and approved by the Board, the Company may at any time and from time to time provide security to Indemnitee for the Company's obligations hereunder through an irrevocable bank line of credit, funded trust or other collateral. Any such security, once provided to Indemnitee, may not be revoked or released without the prior written consent of Indemnitee. 16. NON-EXCLUSIVITY; SURVIVAL OF RIGHTS; INSURANCE; SUBROGATION. (a) The rights of Indemnitee as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Charter, the Bylaws, any agreement, a vote of stockholders or a resolution of directors, or otherwise. No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any Proceeding (regardless of when such Proceeding is first threatened, commenced or completed) or claim, issue or matter therein arising out of, or related to, any action taken or omitted by such Indemnitee in his or her Corporate Status prior to such amendment, alteration or repeal. To the extent that a change in applicable law, whether by statute or judicial decision, permits greater indemnification, hold harmless or exoneration rights or advancement of Expenses than would be afforded currently under the Charter, the Bylaws or this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy. (b) The DGCL, the Charter and the Bylaws permit the Company to purchase and maintain insurance or furnish similar protection or make other arrangements including, but not limited to, providing a trust fund, letter of credit, or surety bond ("Indemnification Arrangements") on behalf of Indemnitee against any liability asserted against him or her, or incurred by or on behalf of him or her, or in such capacity as a director,

10 officer, employee or agent of the Company, or arising out of his or her status as such, whether or not the Company would have the power to indemnify him or her against such liability under the provisions of this Agreement or under the DGCL, as it may then be in effect. The purchase, establishment, and maintenance of any such Indemnification Arrangement shall not in any way limit or affect the rights and obligations of the Company or of Indemnitee under this Agreement except as expressly provided herein, and the execution and delivery of this Agreement by the Company and Indemnitee shall not in any way limit or affect the rights and obligations of the Company or the other patty or parties thereto under any such Indemnification Arrangement. (c) To the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, officers, trustees, partners, managers, managing members, fiduciaries, employees, or agents of the Company or of any other Enterprise which such person serves at the request of the Company, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any such director, officer, trustee, partner, managers, managing member, fiduciary, employee or agent under such policy or policies. If, at the time the Company receives notice from any source of a Proceeding as to which Indemnitee is a party or a participant (as a witness, deponent or otherwise), the Company has director and officer liability insurance in effect, the Company shall give prompt notice of such Proceeding to the insurers in accordance with the procedures set forth in the respective policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms of such policies. (d) In the event of any payment under this Agreement, the Company, to the fullest extent permitted by law, shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights. (e) The Company's obligation to indemnify, hold harmless, exonerate or advance Expenses hereunder to Indemnitee who is or was serving at the request of the Company as a director, officer, trustee, partner, manager, managing member, fiduciary, employee or agent of any other Enterprise shall be reduced by any amount Indemnitee has actually received as indemnification, hold harmless or exoneration payments or advancement of expenses from such Enterprise. Notwithstanding any other provision of this Agreement to the contrary except for Section 27, (i) Indemnitee shall have no obligation to reduce, offset, allocate, pursue or apportion any indemnification, hold harmless, exoneration, advancement, contribution or insurance coverage among multiple parties possessing such duties to Indemnitee prior to the Company's satisfaction and performance of all its obligations under this Agreement, and (ii) the Company shall perform fully its obligations under this Agreement without regard to whether Indemnitee holds, may pursue or has pursued any indemnification, advancement, hold harmless, exoneration, contribution or insurance coverage rights against any person or entity other than the Company. 17. DURATION OF AGREEMENT. All agreements and obligations of the Company contained herein shall continue during the period Indemnitee serves as a director or officer of the Company or as a director, officer, trustee, partner, manager, managing member, fiduciary, employee or agent of any other corporation, partnership, joint venture, trust, employee benefit plan or other Enterprise which Indemnitee serves at the request of the Company and shall continue thereafter so long as Indemnitee shall be subject to any possible Proceeding (including any rights of appeal thereto and any Proceeding commenced by Indemnitee pursuant to Section 14 of this Agreement) by reason of his or her Corporate Status, whether or not he or she is acting in any such capacity at the time any liability or expense is incurred for which indemnification or advancement can be provided under this Agreement. 18. SEVERABILITY. If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a) the validity, legality and enforceability of the remaining provisions of this Agreement (including, without limitation, each portion of any Section, paragraph or sentence of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent permitted by law; (b) such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto; and (c) to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of any Section, paragraph or sentence of this Agreement containing any such provision held to be invalid, illegal or unenforceable,

11 that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested thereby. 19. ENFORCEMENT AND BINDING EFFECT. (a) The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in order to induce Indemnitee to serve as a director, officer or key employee of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as a director, officer or key employee of the Company. (b) Without limiting any of the rights of Indemnitee under the Charter or Bylaws of the Company as they may be amended from time to time, this Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof. (c) The indemnification, hold harmless, exoneration and advancement of expenses rights provided by or granted pursuant to this Agreement shall be binding upon and be enforceable by the parties hereto and their respective successors and assigns (including any direct or indirect successor by purchase, merger, consolidation or otherwise to all or substantially all of the business and/or assets of the Company), shall continue as to an Indemnitee who has ceased to be a director, officer, employee or agent of the Company or a director, officer, trustee, general partner, manager, managing member, fiduciary, employee or agent of any other Enterprise at the Company's request, and shall inure to the benefit of Indemnitee and his or her spouse, assigns, heirs, devisees, executors and administrators and other legal representatives. (d) The Company shall require and cause any successor (whether direct or indirect by purchase, merger, consolidation or otherwise) to all, substantially all or a substantial part, of the business and/or assets of the Company, by written agreement in form and substance satisfactory to Indemnitee, expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no such succession had taken place. (e) The Company and Indemnitee agree herein that a monetary remedy for breach of this Agreement, at some later date, may be inadequate, impracticable and difficult of proof, and further agree that such breach may cause Indemnitee irreparable harm. Accordingly, the parties hereto agree that Indemnitee may, to the fullest extent permitted by law, enforce this Agreement by seeking, among other things, injunctive relief and/or specific performance hereof, without any necessity of showing actual damage or irreparable harm and that by seeking injunctive relief and/or specific performance, Indemnitee shall not be precluded from seeking or obtaining any other relief to which he or she may be entitled. The Company and Indemnitee further agree that Indemnitee shall, to the fullest extent permitted by law, be entitled to such specific performance and injunctive relief, including temporary restraining orders, preliminary injunctions and permanent injunctions, without the necessity of posting bonds or other undertaking in connection therewith. The Company acknowledges that in the absence of a waiver, a bond or undertaking may be required of Indemnitee by a court of competent jurisdiction, the Company hereby waives any such requirement of such a bond or undertaking to the fullest extent permitted by law. 20. MODIFICATION AND WAIVER. No supplement, modification or amendment of this Agreement shall be binding unless executed in writing by the Company and Indemnitee. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions of this Agreement nor shall any waiver constitute a continuing waiver. 21. NOTICES. All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed to have been duly given (i) if delivered by hand and receipted for by the party to whom said notice or other communication shall have been directed, or (ii) mailed by certified or registered mail with postage prepaid, on the third (3rd) business day after the date on which it is so mailed: (a) If to Indemnitee, at the address indicated on the signature page of this Agreement, or such other address as Indemnitee shall provide in writing to the Company. (b) If to the Company, to: UpHealth, Inc. 17000 S. Military Trail., Suite 203 Delray Beach, FL 33484

12 Attn: Dr. Ramesh Balakrishnan With a copy, which shall not constitute notice, to DLA Piper LLP (US) 555 Mission Street Suite 2400 San Francisco, CA 94105 Attention: Jeffrey Selman; Renee Delphin-Rodriguez Email: jeffrey.selman@dlapiper.com; renee.delphin-rodriguez@us.dlapiper.com or to any other address as may have been furnished to Indemnitee in writing by the Company. 22. APPLICABLE LAW AND CONSENT TO JURISDICTION. This Agreement and the legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. Except with respect to any arbitration commenced by Indemnitee pursuant to Section 14(a) of this Agreement, to the fullest extent permitted by law, the Company and Indemnitee hereby irrevocably and unconditionally: (a) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Delaware Court and not in any other state or federal court in the United States of America or any court in any other country; (b) consent to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action or proceeding arising out of or in connection with this Agreement; (c) waive any objection to the laying of venue of any such action or proceeding in the Delaware Court; and (d) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court has been brought in an improper or inconvenient forum, or is subject (in whole or in part) to a jury trial. To the fullest extent permitted by law, the parties hereby agree that the mailing of process and other papers in connection with any such action or proceeding in the manner provided by Section 21 or in such other manner as may be permitted by law, shall be valid and sufficient service thereof. 23. IDENTICAL COUNTERPARTS. This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement. 24. MISCELLANEOUS. Use of the masculine pronoun shall be deemed to include usage of the feminine pronoun where appropriate. The headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof. 25. PERIOD OF LIMITATIONS. No legal action shall be brought and no cause of action shall be asserted by or in the right of the Company against Indemnitee, Indemnitee's spouse, heirs, executors or personal or legal representatives after the expiration of two years from the date of accrual of such cause of action, and any claim or cause of action of the Company shall be extinguished and deemed released unless asserted by the timely filing of a legal action within such two-year period; provided, however, that if any shorter period of limitations is otherwise applicable to any such cause of action such shorter period shall govern. 26. ADDITIONAL ACTS. If for the validation of any of the provisions in this Agreement any act, resolution, approval or other procedure is required to the fullest extent permitted by law, the Company undertakes to cause such act, resolution, approval or other procedure to be affected or adopted in a manner that will enable the Company to fulfill its obligations under this Agreement. 27. WAIVER OF CLAIMS TO TRUST ACCOUNT. Indemnitee hereby agrees that it does not have any right, title, interest or claim of any kind (each, a "Claim") in or to any monies in the trust account established in connection with the Company's initial public offering for the benefit of the Company and holders of shares issued in such offering, and hereby waives any Claim it may have in the future as a result of, or arising out of, any services provided to the Company and will not seek recourse against such trust account for any reason whatsoever. 28. MAINTENANCE OF INSURANCE. The Company shall use commercially reasonable efforts to obtain and maintain in effect during the entire period for which the Company is obligated to indemnify Indemnitee under this Agreement, one or more policies of insurance with reputable insurance companies to provide the officers/directors of the Company with coverage for losses from wrongful acts and omissions and to ensure the Company's performance of its indemnification obligations under this Agreement. Indemnitee shall be covered by

such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any such director or officer under such policy or policies. In all such insurance policies, Indemnitee shall be named as an insured in such a manner as to provide Indemnitee with the same rights and benefits as are accorded to the most favorably insured of the Company's directors and officers. [Signature page to follow] 13

IN WITNESS WHEREOF, the parties hereto have caused this Indemnification Agreement to be signed as of the day and year first above written. THE COMPANY: UPHEALTH, INC. /s/ Dr. Ramesh Balakrishnan___ Dr. Ramesh Balakrishnan Chief Executive Officer INDEMNITEE: /s/ Martin S.A Beck Martin S.A. Beck Address: [***] Signature page to Indemnification Agreement

EX-31.1

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

Pursuant to Rule 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934,

as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Samuel J. Meckey, certify that:

1.    I have reviewed this Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 of UpHealth, Inc.;

2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;

4.    The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

    (a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

    (b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

    (c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

    (d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.    The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

    (a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and

    (b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 10, 2023

By: /s/ Samuel J. Meckey                                  

Samuel J. Meckey

Chief Executive Officer

(Principal Executive Officer)

EX-31.2

Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

Pursuant to Rule 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934,

as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Martin S. A. Beck, certify that:

1.    I have reviewed this Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 of UpHealth, Inc.;

2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;

4.    The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

    (a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

    (b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

    (c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

    (d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.    The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

    (a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and

    (b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 10, 2023

By: /s/ Martin S. A. Beck                                              

Martin S. A. Beck

Chief Financial Officer

(Principal Financial and Accounting Officer)    

EX-32.1

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of UpHealth, Inc. (the “Company”) for the quarter ended June 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Samuel J. Meckey, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 10, 2023

                         By: /s/ Samuel J. Meckey                                           

Samuel J. Meckey

Chief Executive Officer    

(Principal Executive Officer)

EX-32.2

Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of UpHealth, Inc. (the “Company”) for the quarter ended June 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Martin S. A. Beck, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 10, 2023

                             By: /s/ Martin S. A. Beck                                       

Martin S. A. Beck

Chief Financial Officer

(Principal Financial and Accounting Officer)

XML

Cover Page - shares	6 Months Ended
	Jun. 30, 2023	Aug. 09, 2023
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2023
Document Transition Report	false
Entity File Number	001-38924
Entity Registrant Name	UpHealth, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	83-3838045
Entity Address, Address Line One	14000 S. Military Trail,
Entity Address, Address Line Two	Suite 203
Entity Address, City or Town	Delray Beach,
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33484
City Area Code	888
Local Phone Number	424-3646
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		17,161,024
Entity Central Index Key	0001770141
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Amendment Flag	false
Common Stock, par value $0.0001 per share
Document Information [Line Items]
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	UPH
Security Exchange Name	NYSE
Redeemable Warrants, exercisable for one share of Common Stock at an exercise price of $115.00 per share
Document Information [Line Items]
Title of 12(b) Security	Redeemable Warrants, exercisable for one share of Common Stock at an exercise price of $115.00 per share
Trading Symbol	UPH.WS
Security Exchange Name	NYSE

XML

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents	$ 46,803	$ 15,557
Accounts receivable, net	22,369	21,851
Inventories	18	161
Prepaid expenses and other current assets	2,121	3,005
Assets held for sale, current	0	2,748
Total current assets	71,311	43,322
Property and equipment, net	13,997	14,069
Operating lease right-of-use assets	5,728	7,213
Intangible assets, net	29,069	31,362
Goodwill	153,318	159,675
Equity investment	21,200	21,200
Other assets	455	438
Assets held for sale, noncurrent	0	62,525
Total assets	295,078	339,804
Current Liabilities:
Accounts payable	12,694	17,983
Accrued expenses	39,002	39,380
Deferred revenue	2,512	2,738
Related-party debt, current	181	0
Lease liabilities, current	5,141	5,475
Other liabilities, current	453	74
Liabilities held for sale, current	0	3,319
Total current liabilities	59,983	68,969
Related-party debt, noncurrent	0	281
Debt, noncurrent	141,255	145,962
Deferred tax liabilities	1,202	1,200
Lease liabilities, noncurrent	6,947	8,741
Other liabilities, noncurrent	276	727
Liabilities held for sale, noncurrent	0	7,787
Total liabilities	209,663	233,667
Commitments and Contingencies (Note 16)
Stockholders’ Equity:
Common stock	2	2
Additional paid-in capital	694,554	688,355
Treasury stock, at cost	(17,000)	(17,000)
Accumulated deficit	(593,419)	(566,209)
Total UpHealth, Inc., stockholders’ equity	84,137	105,148
Noncontrolling interests	1,278	989
Total stockholders’ equity	85,415	106,137
Total liabilities and stockholders’ equity	$ 295,078	$ 339,804

XML

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Total revenues		$ 37,823	$ 43,668	$ 79,968	$ 79,640
Total costs of revenues		17,847	22,745	37,316	44,726
Gross profit		19,976	20,923	42,652	34,914
Operating expenses:
Sales and marketing		2,421	3,539	7,040	6,973
Research and development		848	2,011	2,133	3,769
General and administrative		12,765	12,880	23,774	24,347
Depreciation and amortization		1,736	4,700	3,347	9,936
Stock-based compensation		1,058	1,088	2,047	2,462
Impairment of goodwill, intangible assets, and other long-lived assets		8,246	0	8,741	6,249
Acquisition, integration, and transformation costs		3,644	6,749	7,090	9,133
Total operating expenses		30,718	30,967	54,172	62,869
Loss from operations		(10,742)	(10,044)	(11,520)	(27,955)
Other expense:
Interest expense		(7,136)	(6,603)	(13,994)	(13,598)
Other income, net, including interest income		126	1,950	127	6,858
Total other expense		(7,010)	(4,653)	(13,867)	(6,740)
Loss before income tax benefit (expense)		(17,752)	(14,697)	(25,387)	(34,695)
Income tax benefit (expense)		(867)	2,232	(867)	4,525
Net loss		(18,619)	(12,465)	(26,254)	(30,170)
Less: net income (loss) attributable to noncontrolling interests		508	(27)	956	(287)
Net loss attributable to UpHealth, Inc.		$ (19,127)	$ (12,438)	$ (27,210)	$ (29,883)
Net loss per share attributable to UpHealth, Inc.:
Basic (in dollars per share)		$ (1.05)	$ (0.86)	$ (1.60)	$ (2.07)
Diluted (in dollars per share)		$ (1.05)	$ (0.86)	$ (1.60)	$ (2.07)
Weighted average shares outstanding:
Basic (in shares)	[1]	18,220	14,462	16,975	14,458
Diluted (in shares)	[1]	18,220	14,462	16,975	14,458
Services
Total revenues		$ 31,087	$ 28,096	$ 62,028	$ 53,782
Total costs of revenues		14,954	16,232	28,698	31,990
Licenses and subscriptions
Total revenues		2,852	6,812	4,788	8,593
Total costs of revenues		403	217	722	450
Products
Total revenues		3,884	8,760	13,152	17,265
Total costs of revenues		$ 2,490	$ 6,296	$ 7,896	$ 12,286

[1] Amounts as of June 30, 2022 and before that date differ from those published in our prior condensed consolidated financial statements as they were retrospectively adjusted as a result of the Reverse Stock Split (as described below in Note 1, Organization and Business). Specifically, the number of common shares outstanding during periods before the Reverse Stock Split are divided by the exchange ratio of 10:1, such that each ten shares of common stock were combined and reconstituted into one share of common stock effective December 8, 2022.

XML

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)	Dec. 08, 2022
Income Statement [Abstract]
Reverse stock split	0.1

XML

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Statement of Comprehensive Income [Abstract]
Net loss	$ (18,619)	$ (12,465)	$ (26,254)	$ (30,170)
Foreign currency translation adjustments, net of tax	0	(2,480)	0	(3,857)
Comprehensive loss	(18,619)	(14,945)	(26,254)	(34,027)
Comprehensive income (loss) attributable to noncontrolling interests	508	(27)	956	(287)
Comprehensive loss attributable to UpHealth, Inc.	$ (19,127)	$ (14,918)	$ (27,210)	$ (33,740)

XML

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) shares in Thousands, $ in Thousands		Total	Common Stock	Additional Paid-In Capital	Treasury Stock	Accumulated Deficit	Accumulated Other Comprehensive Loss	Total UpHealth, Inc. Stockholders’ Equity	Noncontrolling Interests
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period (in shares)	[1]				0
Balance at beginning of period (in shares) at Dec. 31, 2021	[1]		14,428
Balance at beginning of period at Dec. 31, 2021	[1]	$ 333,843	$ 1	$ 665,474	$ 0	$ (343,209)	$ (3,802)	$ 318,464	$ 15,379
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Equity award activity, net of shares withheld for taxes (in shares)	[1]		37
Equity award activity, net of shares withheld for taxes	[1]	(67)		(67)				(67)
Stock-based compensation		1,374		1,374				1,374
Net loss		(17,705)				(17,445)		(17,445)	(260)
Foreign currency translation adjustments		(1,377)					(1,377)	(1,377)
Balance at end of period (in shares) at Mar. 31, 2022	[1]		14,465
Balance at end of period (in shares) at Mar. 31, 2022	[1]				0
Balance at end of period at Mar. 31, 2022	[1]	316,068	$ 1	666,781	$ 0	(360,654)	(5,179)	300,949	15,119
Balance at beginning of period (in shares) at Dec. 31, 2021	[1]		14,428
Balance at beginning of period at Dec. 31, 2021	[1]	333,843	$ 1	665,474	$ 0	(343,209)	(3,802)	318,464	15,379
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(30,170)
Foreign currency translation adjustments		(3,857)
Balance at end of period (in shares) at Jun. 30, 2022	[1]		14,685
Balance at end of period (in shares) at Jun. 30, 2022	[1]				170
Balance at end of period at Jun. 30, 2022	[1]	300,884	$ 2	683,710	$ (17,000)	(373,092)	(7,659)	285,961	14,923
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period (in shares)	[1]				0
Balance at beginning of period (in shares) at Mar. 31, 2022	[1]		14,465
Balance at beginning of period at Mar. 31, 2022	[1]	316,068	$ 1	666,781	$ 0	(360,654)	(5,179)	300,949	15,119
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Equity award activity, net of shares withheld for taxes (in shares)	[1]		390
Equity award activity, net of shares withheld for taxes	[1]	(1,158)	$ 1	(1,159)				(1,158)
Stock-based compensation		1,088		1,088				1,088
Common stock repurchased in connection with forward share purchase agreement (in shares)	[1]		(170)		170
Common stock repurchased in connection with forward share purchase agreement	[1]	0		17,000	$ (17,000)
Purchase of noncontrolling interest		(30)							(30)
Distribution to noncontrolling interests		(139)							(139)
Net loss		(12,465)				(12,438)		(12,438)	(27)
Foreign currency translation adjustments		(2,480)					(2,480)	(2,480)
Balance at end of period (in shares) at Jun. 30, 2022	[1]		14,685
Balance at end of period (in shares) at Jun. 30, 2022	[1]				170
Balance at end of period at Jun. 30, 2022	[1]	300,884	$ 2	683,710	$ (17,000)	(373,092)	$ (7,659)	285,961	14,923
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period (in shares)	[1]				170
Balance at beginning of period (in shares)					170
Balance at beginning of period (in shares) at Dec. 31, 2022			15,054
Balance at beginning of period at Dec. 31, 2022		106,137	$ 2	688,355	$ (17,000)	(566,209)		105,148	989
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Equity award activity, net of shares withheld for taxes (in shares)			80
Equity award activity, net of shares withheld for taxes		(3)		(3)				(3)
Issuance of common stock in connection with 2023 private placement, net of issuance costs of $348 (in shares)			1,650
Issuance of common stock in connection with 2023 private placement, net of issuance costs of $348		4,155		4,155				4,155
Stock-based compensation		989		989				989
Distribution to noncontrolling interests		(44)							(44)
Net loss		(7,635)				(8,083)		(8,083)	448
Balance at end of period (in shares) at Mar. 31, 2023			16,784
Balance at end of period (in shares) at Mar. 31, 2023					170
Balance at end of period at Mar. 31, 2023		103,599	$ 2	693,496	$ (17,000)	(574,292)		102,206	1,393
Balance at beginning of period (in shares) at Dec. 31, 2022			15,054
Balance at beginning of period at Dec. 31, 2022		106,137	$ 2	688,355	$ (17,000)	(566,209)		105,148	989
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(26,254)
Foreign currency translation adjustments		0
Balance at end of period (in shares) at Jun. 30, 2023			17,161
Balance at end of period (in shares) at Jun. 30, 2023					170
Balance at end of period at Jun. 30, 2023		85,415	$ 2	694,554	$ (17,000)	(593,419)		84,137	1,278
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period (in shares)					170
Balance at beginning of period (in shares) at Mar. 31, 2023			16,784
Balance at beginning of period at Mar. 31, 2023		103,599	$ 2	693,496	$ (17,000)	(574,292)		102,206	1,393
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Equity award activity, net of shares withheld for taxes (in shares)			277
Equity award activity, net of shares withheld for taxes		0
Exercise of pre-funded warrants (in shares)			100
Stock-based compensation		1,058		1,058				1,058
Distribution to noncontrolling interests		(623)							(623)
Net loss		(18,619)				(19,127)		(19,127)	508
Foreign currency translation adjustments		0
Balance at end of period (in shares) at Jun. 30, 2023			17,161
Balance at end of period (in shares) at Jun. 30, 2023					170
Balance at end of period at Jun. 30, 2023		$ 85,415	$ 2	$ 694,554	$ (17,000)	$ (593,419)		$ 84,137	$ 1,278
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period (in shares)					170

[1] Amounts as of June 30, 2022 and before that date differ from those published in our prior condensed consolidated financial statements as they were retrospectively adjusted as a result of the Reverse Stock Split (as described below in Note 1, Organization and Business). Specifically, the number of common shares outstanding during periods before the Reverse Stock Split are divided by the exchange ratio of 10:1, such that each ten shares of common stock were combined and reconstituted into one share of common stock effective December 8, 2022.

XML

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (Parenthetical) $ in Thousands		3 Months Ended
	Dec. 08, 2022	Mar. 31, 2023 USD ($)
Statement of Stockholders' Equity [Abstract]
Issuance costs		$ 348
Reverse stock split	0.1

XML

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Operating activities:
Net loss	$ (26,254)	$ (30,170)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	5,461	12,725
Amortization of debt issuance costs and discount on convertible debt	5,566	6,969
Stock-based compensation	2,047	2,462
Impairment of property and equipment, goodwill, intangible assets, and other long-lived assets	8,741	5,459
Provision for credit losses	19	(37)
Loss (gain) on fair value of warrant liabilities	8	(190)
Loss (gain) on fair value of derivative liability	3	(6,670)
Deferred income taxes	0	(4,596)
Amortization of operating lease right-of-use assets	1,116	0
Changes in operating assets and liabilities, net of effects of acquisitions:
Accounts receivable	(432)	(6,151)
Inventories	142	(55)
Prepaid expenses and other current assets	(1,016)	540
Accounts payable and accrued expenses	(5,653)	8,347
Operating lease liabilities	(1,170)	0
Deferred revenue	(225)	3,838
Other liabilities	(406)	(312)
Net cash used in operating activities	(12,053)	(7,841)
Investing activities:
Purchases of property and equipment	(2,918)	(3,783)
Proceeds from sale of business, net of expenses	54,861	0
Net cash provided by (used in) investing activities	51,943	(3,783)
Financing activities:
Proceeds from equity issuance	4,155	0
Repayments of debt	(10,273)	0
Payment of debt issuance costs	0	(3,234)
Repayment of forward share purchase	0	(18,521)
Payments of finance and capital lease obligations	(1,756)	(1,619)
Net tax withholdings from share-based compensation	(3)	(67)
Payments of amounts due to members	(100)	0
Distribution to noncontrolling interest	(667)	(139)
Net cash used in financing activities	(8,644)	(23,580)
Effect of exchange rate changes on cash and cash equivalents	0	(460)
Net increase (decrease) in cash and cash equivalents	31,246	(35,664)
Cash and cash equivalents, beginning of period	15,557	76,801
Cash and cash equivalents, end of period	46,803	41,137
Supplemental cash flow information:
Cash paid for interest	8,496	5,269
Cash paid for income taxes	457	521
Non-cash investing and financing activity:
Property and equipment reclassified from other assets	0	3,751
Property and equipment acquired through capital lease and vendor financing arrangements	179	1,628
FIN 48 liability reclassified from deferred tax liabilities	0	1,750
Reconciliation of cash and cash equivalents and restricted cash:
Cash and cash equivalents	46,803	40,629
Restricted cash	0	508
Total cash and cash equivalents and restricted cash	$ 46,803	$ 41,137

XML

Organization and Business

6 Months Ended

Jun. 30, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Business

Organization and Business

UpHealth, Inc. (“UpHealth,” “we,” “us,” “our,” “UpHealth,” or the “Company”) is the parent company of both UpHealth Holdings, Inc. (“UpHealth Holdings”) and Cloudbreak Health, LLC (“Cloudbreak”).

GigCapital2, Inc. (“GigCapital2”), the Company’s predecessor, was incorporated in Delaware on March 6, 2019. GigCapital2 was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company’s business combinations (the “Business Combinations”) were consummated on June 9, 2021, and in connection with the Business Combinations, GigCapital2 changed its corporate name to UpHealth, Inc.

Deconsolidation of Glocal

As a result of events which occurred in the three months ended September 30, 2022, we determined that a reconsideration event occurred in July 2022, which required us to reassess whether Glocal Healthcare Systems Private Limited (“Glocal”), which was included in our Virtual Care Infrastructure segment, was a Variable Interest Entity (“VIE”) and whether we continued to have a controlling financial interest in Glocal. Based on this assessment, we concluded that Glocal was a VIE, and furthermore, that we no longer had the ability to direct any activities of Glocal and no longer have a controlling financial interest. As a result, effective July 2022, we deconsolidated Glocal and recorded a $37.7 million loss on deconsolidation of equity investment in our unaudited condensed consolidated statements of operations, measured as the difference between the probability-weighted fair value of Glocal of $21.2 million and the carrying amount of Glocal’s assets and liabilities as of July 1, 2022. The probability-weighted fair value of Glocal, which is included in equity investment in our unaudited condensed consolidated balance sheets, incorporated scenarios where control of Glocal was gained and Glocal would continue as a going concern, control of Glocal was gained and Glocal would need to be liquidated, and control of Glocal was not gained and the equity investment in Glocal would be worthless. Further, we assessed the prospective accounting for our equity investment in Glocal. Since we no longer had the ability to exercise significant influence over operating and financial policies of Glocal, we concluded the investment should be accounted for utilizing the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification Topic 321, Investments - Equity Securities (“ASC 321”) measurement alternative, whereby the investment was measured at cost and will continue to be evaluated for any indicators of impairment. In addition, we derecognized $14.3 million of noncontrolling interests related to Glocal. In the six months ended June 30, 2023, there has been no change in the status of Glocal, and accordingly, we continue to account for it as an equity investment. If through legal processes we are able to obtain the ability to direct the activities of Glocal, and it is our intent to exercise all legal rights and remedies to achieve such a result, then we will further reassess the appropriate accounting treatment of our investment in Glocal.

The financial results of Glocal in the three and six months ended June 30, 2022 are included in our unaudited condensed consolidated financial statements, and the financial position of Glocal as of June 30, 2023 and December 31, 2022 and the financial results of Glocal in the three and six months ended June 30, 2023 are not included in our unaudited condensed consolidated financial statements. The only transactions between us and Glocal subsequent to July 1, 2022 was the transfer by us in the three months ended September 30, 2022 of $5.1 million to a designated “Share Account” maintained with a leading bank in India in the name of Glocal for which our Chief Financial Officer is the sole authorized signatory.

Reverse Stock Split

On December 5, 2022 our stockholders approved an amendment to our Second Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) to effect a reverse split of the outstanding shares of our common stock, par value $0.0001 per share, at a specific ratio within a range of 4:1 to 10:1, with the specific ratio to be fixed within this range by our board of directors in its sole discretion without further stockholder approval (the “Reverse Stock Split”). Our board of directors fixed the Reverse Stock Split ratio at 10:1, such that each ten shares of common stock were combined and reconstituted into one share of common stock effective December 8, 2022. Except as noted, all share, stock option, restricted stock unit (“RSU”), and per share information throughout this Quarterly Report on Form 10-Q (this “Quarterly Report”) has been retroactively adjusted to reflect this Reverse Stock Split.

Sale of Innovations Group

On February 26, 2023, we agreed to sell 100% of the outstanding capital stock of our wholly owned subsidiary, Innovations Group, Inc. (“Innovations Group”), to Belmar MidCo, Inc., a Delaware corporation and a wholly owned subsidiary of Belmar Holdings, Inc., a Delaware corporation, a portfolio company of Webster Capital IV, L.P., a Delaware limited partnership, pursuant to a stock purchase agreement (the “Stock Purchase Agreement”), dated February 26, 2023. The sale closed on May 11, 2023 for gross proceeds of $56.0 million, subject to working capital, closing debt, and other adjustments. See Note 3, Significant Transactions, for further information.

XML

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2023

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

Basis of Presentation and Principles of Consolidation

Our accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information and the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Our unaudited condensed consolidated financial statements, including the condensed notes thereto, are unaudited and exclude some of the disclosures required in audited consolidated financial statements. Our unaudited condensed consolidated balance sheet as of December 31, 2022 has been derived from our audited consolidated financial statements as of that date, but do not include all of the information and footnotes required by U.S. GAAP for complete financial statements.

In the opinion of management, our accompanying unaudited condensed consolidated financial statements contain all adjustments and eliminations, consisting only of normal recurring adjustments necessary for a fair presentation in conformity with U.S. GAAP. The results of operations in the three months ended June 30, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023 or any future period. Our accompanying unaudited condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements for the year ended December 31, 2022.

Our unaudited condensed consolidated financial statements include the accounts of UpHealth and its consolidated subsidiaries. As described in Note 1, Organization and Business, our Glocal subsidiary was deconsolidated effective July 2022.

All intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts in the unaudited condensed consolidated financial statements and accompanying notes thereto.

Significant estimates and assumptions made by management include the determination of:

•The identification and reporting of variable interest entities (“VIEs”). We consolidate VIEs when we have variable interests and are the primary beneficiary. We continually evaluate our involvement with VIEs to determine when these criteria are met.

•The valuation of equity investments, including our determination of the carrying value of Glocal;

•The valuation of assets acquired and liabilities assumed for business combinations, including intangible assets and goodwill;

•The estimated economic lives and recoverability of intangible assets;

•The valuations prepared in connection with the review of goodwill, intangible assets, and other long-lived assets for impairment:

•The timing and amount of revenues to be recognized, including standalone selling price (“SSP”) of performance obligations for revenue contracts with multiple performance obligations;

•The identification of and provision for uncollectible accounts receivable;

•The capitalization and useful life of internal-use software development costs;

•The valuation of derivatives and warrants; and

•The recognition, measurement, and valuation of current and deferred income taxes and uncertain tax positions.

Actual results could differ materially from those estimates. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the result of which forms the basis for making judgments about the carrying values of assets and liabilities.

Allowance for Expected Credit Losses

We closely monitor our accounts receivable balances and estimate the allowance for expected credit losses. The estimate is primarily based on historical collection experience and other factors, including those related to current market conditions and events. Credit losses associated with accounts receivable have not been material historically.

Equity Investment

As discussed in Deconsolidation of Equity Investment in Note 1, Organization and Business, as of June 30, 2023 and December 31, 2022, we held an interest in the privately-held equity securities of Glocal in which we did not have a controlling interest and were unable to exercise significant influence. Based on the terms of these privately-held securities, we concluded the investment should be accounted for utilizing the Accounting Standards Codification (“ASC”) 321 measurement alternative, whereby the investment was measured at cost and will continue to be evaluated for any indicators of impairment.

Held for Sale

Assets and liabilities to be disposed of by sale (“disposal groups”) are reclassified into assets and liabilities held for sale on our consolidated balance sheets as of December 31, 2022. The reclassification occurs when an agreement to sell exists, or management has committed to a plan to sell the assets within one year. Disposal groups are measured at the lower of carrying value or fair value less costs to sell and are not depreciated or amortized. When the net realizable value of a disposal group increases during a period, a gain can be recognized to the extent that it does not increase the value of the disposal group beyond its original carrying value when the disposal group was reclassified as held for sale. The fair value of a disposal group, less any costs to sell, is assessed each reporting period it remains classified as held for sale and any remeasurement to the lower of carrying value or fair value less costs to sell is reported as an adjustment to the carrying value of the disposal group. and reported in impairment of goodwill, intangible assets, and other long-lived assets in our unaudited condensed consolidated statements of operations.

New Accounting Pronouncements Not Yet Adopted

In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). This ASU simplifies the accounting for convertible instruments by eliminating the conversion option separation model for convertible debt that can be settled in cash and by eliminating the measurement model for beneficial conversion features. Convertible instruments that continue to be subject to separation models are (1) those with conversion options that are required to be accounted for as bifurcated derivatives and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. This ASU also requires entities to use the if-converted method for all convertible instruments in the diluted earnings per share calculation and include the effect of share settlement for instruments that may be settled in cash or shares, except for certain liability-classified share-based payment awards. This ASU will be effective for us on January 1, 2024. Early adoption is permitted, but no earlier than the fiscal year beginning on January 1, 2021, including interim periods within that fiscal year. We are currently evaluating the effect of the adoption of this ASU will have on our unaudited condensed consolidated financial statements.

Recently Adopted Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, and subsequently issued several supplemental/clarifying ASUs (collectively, “ASC 326”). This ASU requires entities to estimate a lifetime expected credit loss for most financial assets, including trade and other receivables, other long-term financings including available for sale and held-to-maturity debt securities, and loans. Subsequently, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments-Credit Losses, which amended the scope of ASC 326 and clarified that receivables arising from operating leases are not within the scope of the standard and should continue to be accounted for in accordance with ASC 842. This ASU was effective for us on January 1, 2023, and the adoption did not have a material effect on our unaudited condensed consolidated financial statements.

Reclassifications

Certain prior period amounts have been reclassified to conform to the current year presentation as shown below:

	Three Months Ended June 30, 2022						Six Months Ended June 30, 2022
	As Reported		Reclassifications		As Adjusted		As Reported		Reclassifications		As Adjusted
Revenues:
Services	$	28,096	$	—	$	28,096	$	53,782	$	—	$	53,782
Licenses and subscriptions	6,812		—		6,812		8,593		—		8,593
Products	8,760		—		8,760		17,265		—		17,265
Total revenues	43,668		—		43,668		79,640		—		79,640
Costs of revenues:
Services	14,762		1,470		16,232		29,207		2,783		31,990
License and subscriptions	217		—		217		450		—		450
Products	6,296		—		6,296		12,286		—		12,286
Total costs of revenues	21,275		1,470		22,745		41,943		2,783		44,726
Gross profit	22,393		(1,470)		20,923		37,697		(2,783)		34,914
Operating expenses:
Sales and marketing	3,486		53		3,539		6,212		761		6,973
Research and development	1,782		229		2,011		3,369		400		3,769
General and administrative	14,632		(1,752)		12,880		28,291		(3,944)		24,347
Depreciation and amortization	4,700		—		4,700		9,936		—		9,936
Stock-based compensation	1,088		—		1,088		2,462		—		2,462
Impairment of goodwill, intangible assets, and other long-lived assets	—		—		—		6,174		75		6,249
Acquisition, integration, and transformation costs	6,749		—		6,749		9,208		(75)		9,133
Total operating expenses	32,437		(1,470)		30,967		65,652		(2,783)		62,869
Loss from operations	(10,044)		—		(10,044)		(27,955)		—		(27,955)
Other expense:
Interest expense	(6,603)		—		(6,603)		(13,598)		—		(13,598)
Other income, net, including interest income	1,950		—		1,950		6,858		—		6,858
Total other expense	(4,653)		—		(4,653)		(6,740)		—		(6,740)
Loss before income tax benefit (expense)	(14,697)		—		(14,697)		(34,695)		—		(34,695)
Income tax benefit (expense)	2,232		—		2,232		4,525		—		4,525
Net loss	(12,465)		—		(12,465)		(30,170)		—		(30,170)
Less: net loss attributable to noncontrolling interests	(27)		—		(27)		(287)		—		(287)
Net loss attributable to UpHealth, Inc.	$	(12,438)	$	—	$	(12,438)	$	(29,883)	$	—	$	(29,883)

Certain prior period amounts have been reclassified to conform with our current period presentation.

XML

Significant Transactions

6 Months Ended

Jun. 30, 2023

Discontinued Operations and Disposal Groups [Abstract]

Significant Transactions

Significant Transactions

Sale of Innovations Group

On February 26, 2023, we agreed to sell 100% of the outstanding capital stock of our wholly owned subsidiary, Innovations Group, to Belmar MidCo, Inc., a Delaware corporation and a wholly owned subsidiary of Belmar Holdings, Inc., a Delaware corporation, a portfolio company of Webster Capital IV, L.P., a Delaware limited partnership, pursuant to the Stock Purchase Agreement dated February 26, 2023. The sale closed on May 11, 2023 for gross proceeds of $56.0 million, subject to working capital, closing debt, and other adjustments. Accordingly, the financial results of Innovations Group for the period from April 1, 2023 through May 10, 2023, the period from January 1, 2023 through May 10, 2023, and the three and six months ended June 30, 2022, and the financial position of Innovations Group as of December 31, 2022 are included in our unaudited condensed consolidated financial statements.

In connection with entering into this agreement, we concluded that the disposal group met the held for sale criteria and classified the assets and liabilities as held for sale as of December 31, 2022. There were no businesses classified as held for sale as of June 30, 2023. Assets and liabilities that were classified as held for sale were $65.3 million and $11.1 million, respectively, as of December 31, 2022.

In connection with the held for sale classification, upon the remeasurement of the disposal group to its fair value, less cost to sell, we recorded a loss of $0.5 million in the three months ended March 31, 2023 and a loss of $1.8 million in the three months ended December 31, 2022, which were recorded in impairment of goodwill, intangible assets, and other long-lived assets in the unaudited condensed consolidated statements of operations. In connection with the sale closing on May 11, 2023, based on net proceeds of $54.9 million, we recorded an additional loss of $1.4 million in the three months ended June 30, 2023, which was recorded in impairment of goodwill, intangible assets, and other long-lived assets in our unaudited condensed consolidated statements of operations.

XML

Revenues

6 Months Ended

Jun. 30, 2023

Revenue from Contract with Customer [Abstract]

Revenues

Revenues

As discussed in Note 1, Organization and Business, we deconsolidated Glocal in the three months ended September 30, 2022; accordingly, the financial results of Glocal in the three and six months ended June 30, 2022 are included in our unaudited condensed consolidated financial statements, and the financial results of Glocal in the three and six months ended June 30, 2023 are not included in our unaudited condensed consolidated financial statements.

Revenues by geography consisted of the following:

	Three months ended June 30,				Six months ended June 30,
(In thousands)	2023		2022		2023		2022
Americas	$	37,823	$	40,073	$	79,968	$	72,736
Asia	—		3,595		—		6,904
Total revenues	$	37,823	$	43,668	$	79,968	$	79,640

Our revenues are entirely derived from the healthcare industry. Revenues recognized over-time were approximately 86% and 68% of the total revenues in the three months ended June 30, 2023 and 2022, respectively. Revenues recognized over-time were approximately 80% and 71% of the total revenues in the six months ended June 30, 2023 and 2022, respectively.

Contract Assets

There were no impairments of contract assets, consisting of unbilled receivables, in the three and six months ended June 30, 2023 and 2022.

The change in contract assets was as follows:

	Six Months Ended June 30,
(In thousands)	2023		2022
Unbilled receivables, beginning of period	$	694	$	784
Reclassifications to billed receivables	(694)		(232)
Revenues recognized in excess of period billings	711		417
Unbilled receivables, end of period	$	711	$	969

Contract Liabilities

The change in contract liabilities, consisting of deferred revenue, was as follows:

	Six Months Ended June 30,
(In thousands)	2023		2022
Deferred revenue, beginning of period	$	2,737	$	2,649
Revenues recognized from balances held at the beginning of the period	(2,620)		(1,998)
Revenues deferred from period collections on unfulfilled performance obligations	2,395		5,801
Deferred revenue, end of period	$	2,512	$	6,452

Revenues recognized ratably over time are generally billed in advance and includes software-as-a-service (“SaaS”) internet hosting, subscriptions, construction of digital hospitals and dispensaries, and related consulting, implementation, services support, and advisory services.

Revenues recognized as delivered over time include professional services billed on a time and materials basis, and fixed fee professional services and training classes that are primarily billed, delivered, and recognized within the same reporting period.

Approximately 3.1% and 3.3% of revenues recognized in the three and six months ended June 30, 2023, was from the deferred revenue balance existing as of December 31, 2022. Approximately 1% and 2.5% of revenues recognized in the three and six months ended June 30, 2022, was from the deferred revenue balance existing as of December 31, 2021.

Remaining Performance Obligations

Remaining performance obligations consisted of the following as of June 30, 2023:

(In thousands)	Remaining 2023		2024		Total
Subscriptions	$	2,882	$	3,739	$	6,621
Program management and professional services	1,143		963		2,106
Total	$	4,025	$	4,702	$	8,727

XML

Supplemental Financial Statement Information

6 Months Ended

Jun. 30, 2023

Payables and Accruals [Abstract]

Supplemental Financial Statement Information

Supplemental Financial Statement Information

As discussed in Note 1, Organization and Business, we deconsolidated Glocal in the three months ended September 30, 2022; accordingly, the financial results of Glocal in the three and six months ended June 30, 2022 are included in our unaudited condensed consolidated financial statements, and the financial position of Glocal as of June 30, 2023 and December 31, 2022 and the financial results of Glocal in the three and six months ended June 30, 2023 are not included in our unaudited condensed consolidated financial statements.

Property and equipment consisted of the following: 

(In thousands)	June 30, 2023		December 31, 2022
Leasehold improvements	$	908	$	868
Electrical and other equipment	21		21
Computer equipment, furniture and fixtures	16,599		16,222
Vehicles	272		302
Capitalized software development costs	7,801		4,404
Capitalized software development costs in progress	1,322		2,590
	26,923		24,407
Accumulated depreciation and amortization	(12,926)		(10,338)
Total property and equipment, net	$	13,997	$	14,069

Depreciation expense was $1.9 million and $1.8 million in the three months ended June 30, 2023 and 2022, respectively, and $3.2 million and $3.2 million in the six months ended June 30, 2023 and 2022, respectively.

Accrued expenses consisted of the following:

(In thousands)	June 30, 2023		December 31, 2022
Accrued professional fees	$	14,885	$	14,245
Accrued products and licenses	17,820		17,820
Accrued interest on debt	673		741
Accrued payroll and bonuses	4,301		5,163
Due to related party	304		229
Income tax payable	796		388
Other accruals	223		794
Total accrued expenses	$	39,002	$	39,380

Other liabilities, noncurrent consisted of the following

(In thousands)	June 30, 2023		December 31, 2022
Derivative liability, noncurrent	$	59	$	56
Warrant liabilities, noncurrent	17		9
Other liabilities, noncurrent	200		662
Total other liabilities, noncurrent	$	276	$	727

Impairment of goodwill, intangible assets, and other long-lived assets consisted of the following:

	Three months ended June 30,				Six months ended June 30,
(In thousands)	2023		2022		2023		2022
Impairment of goodwill	$	7,797	$	—	$	8,292	$	5,494
Impairment of long-lived assets	449		—		449		75
Impairment of intangible assets	—		—		—		680
Total impairment of goodwill, intangible assets, and other long-lived assets:	$	8,246	$	—	$	8,741	$	6,249

Other income, net, including interest income consisted of the following:

	Three months ended June 30,				Six months ended June 30,
(In thousands)	2023		2022		2023		2022
Gain (loss) on fair value of derivative liability	$	(29)	$	1,841	$	(3)	$	6,670
Gain (loss) on fair value of warrant liabilities	—		95		(8)		190
Other income, net, including interest income	155		14		138		(2)
Total other income, net, including interest income	$	126	$	1,950	$	127	$	6,858

XML

Intangible Assets

6 Months Ended

Jun. 30, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

Intangible Assets

As discussed in Note 1, Organization and Business, we deconsolidated Glocal in the three months ended September 30, 2022; accordingly, the financial results of Glocal in the three and six months ended June 30, 2022 are included in our unaudited condensed consolidated financial statements, and the financial position of Glocal as of June 30, 2023 and December 31, 2022 and the financial results of Glocal in the three and six months ended June 30, 2023 are not included in our unaudited condensed consolidated financial statements.

The following table summarizes the gross carrying amount and accumulated amortization for intangible assets as of June 30, 2023:

(In thousands)	Trade Names		Technology and Intellectual Property		Customer Relationships		Total
Gross carrying amount as of June 30, 2023	$	15,242	$	10,634	$	17,613	$	43,489
Accumulated amortization	(4,012)		(5,521)		(4,887)		(14,420)
Intangible assets, net as of June 30, 2023	$	11,230	$	5,113	$	12,726	$	29,069

The following table summarizes the gross carrying amount and accumulated amortization for intangible assets as of December 31, 2022:

(In thousands)	Trade Names		Technology and Intellectual Property		Customer Relationships		Total
Gross carrying amount as of December 31, 2022	$	15,242	$	10,634	$	17,613	$	43,489
Accumulated amortization	(3,295)		(4,762)		(4,070)		(12,127)
Intangible assets, net as of December 31, 2022	$	11,947	$	5,872	$	13,543	$	31,362

No impairment charges were recognized in the three and six months ended June 30, 2023. No impairment charge was recognized in the three months ended June 30, 2022; however, an impairment charge of $0.7 million was recognized in the six months ended June 30, 2022 in our Services segment.

The estimated useful lives of trade names are 3-10 years, the estimated useful lives of technology and intellectual property are 5-7 years, and the estimated useful life of customer relationships is 10 years.

Amortization expense was $1.1 million and $4.2 million in the three months ended June 30, 2023 and 2022, respectively. Amortization expense was $2.3 million and $9.3 million in the six months ended June 30, 2023 and 2022, respectively.

The estimated amortization expense related to definite-lived intangible assets for the five succeeding years is as follows:

(In thousands)	Trade Name Amortization		Technology and Intellectual Property Amortization		Customer Relationships Amortization		Total
Remaining 2023	$	709	$	770	$	808	$	2,287
2024	1,417		1,540		1,616		4,573
2025	1,417		1,540		1,616		4,573
2026	1,417		909		1,616		3,942
2027	1,417		354		1,616		3,387
Thereafter	4,853		—		5,454		10,307
	$	11,230	$	5,113	$	12,726	$	29,069

XML

Goodwill

6 Months Ended

Jun. 30, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill

Goodwill

In the three months ended June 30, 2023, we recorded an impairment charge of $6.4 million in our Services segment in connection with the wind-down of a company within our Behavioral business and an impairment charge of $1.4 million in our Services segment in connection with the strategic sale of Innovations Group, which was classified as held for sale. No impairment charge was recorded in the three months ended June 30, 2022. In the six months ended June 30, 2023 we recorded a $6.4 million impairment charge in our Services segment in connection with the wind down of a company within our Behavioral business, and a $1.9 million impairment charge in our Services segment in connection with the strategic sale of Innovations Group. See Note 3, Significant Transactions, for further information. In the six months ended June 30, 2022, as a result of measurement period adjustments in our Virtual Care Infrastructure segment, we increased goodwill in the amount of $5.5 million, which was immediately impaired.

The carrying amount of goodwill consisted of the following:

(In thousands)	Goodwill
Balance as of December 31, 2022	$	159,675
Impairments	(6,357)
Balance as of June 30, 2023	$	153,318

XML

Debt

6 Months Ended

Jun. 30, 2023

Debt Disclosure [Abstract]

Debt

Debt

As discussed in Note 1, Organization and Business, we deconsolidated Glocal in the three months ended September 30, 2022; accordingly, the financial results of Glocal in the three and six months ended June 30, 2022 are included in our unaudited condensed consolidated financial statements, and the financial position of Glocal as of June 30, 2023 and December 31, 2022 and the financial results of Glocal in the three and six months ended June 30, 2023 are not included in our unaudited condensed consolidated financial statements.

Debt consisted of the following: 

(In thousands)	June 30, 2023		December 31, 2022
2025 Notes	$	57,227	$	67,500
2026 Notes	115,000		115,000
Total debt	172,227		182,500
Less: unamortized original issue and debt discount	(30,972)		(36,538)
Total debt, net of unamortized original issue and debt discount	141,255		145,962
Less: current portion of debt	—		—
Noncurrent portion of debt	$	141,255	$	145,962

2026 Unsecured Convertible Notes and Indenture

On January 20, 2021, GigCapital2 entered into convertible note subscription agreements, each dated January 20, 2021 and amended on June 8, 2021, with certain institutional investors, pursuant to which GigCapital2 agreed to issue and sell unsecured convertible notes in a private placement to close immediately prior to the closing of the Business Combinations.

On June 15, 2021, in connection with the closing of the Business Combinations, we entered into an indenture (the “2026 Indenture”) with Wilmington Trust, National Association, a national banking association, (the “Indenture Trustee”) in its capacity as trustee thereunder, in respect of the $160.0 million in aggregate principal amount of unsecured convertible notes due in 2026 (the “2026 Notes”) that were issued to certain institutional investors. The 2026 Notes bear interest at a rate of 6.25% per annum, payable semi-annually, and were convertible following the reverse split of our shares into approximately 1,502,347 shares of common stock at a conversion price of $106.50 in accordance with the terms of the 2026 Indenture, and will mature on June 15, 2026. The total proceeds received from the 2026 Notes were $151.9 million, net of debt issuance costs of $8.1 million. In accounting for the 2026 Notes, we bifurcated and accounted for the conversion option as a derivative measured at fair value on the issuance date in accordance with ASC 815, Derivatives and Hedging. The difference between the proceeds allocated to the 2026 Notes at issuance and the fair value of the conversion option was allocated to the host debt contract. As of June 30, 2023 and December 31, 2022, the fair value of the derivative was $59 thousand and $0.1 million, respectively, all of which was included in other liabilities, noncurrent, in our unaudited condensed consolidated balance sheets.

Interest expense in the three months ended June 30, 2023 was $4.3 million, of which $1.8 million related to contractual interest expense, $2.2 million related to derivative accretion, and $0.3 million related to debt issuance costs amortization. Interest expense in the three months ended June 30, 2022 was $6.0 million, of which $2.5 million related to contractual interest expense, $3.1 million related to derivative accretion, and $0.4 million related to debt issuance costs amortization. Interest expense in the six months ended June 30, 2023 was $8.6 million, of which $3.6 million related to contractual interest expense, $4.4 million related to derivative accretion, and $0.6 million related to debt issuance costs amortization. Interest expense in the six months ended June 30, 2022 was $12.0 million, of which $5.0 million related to contractual interest expense, $6.2 million related to derivative accretion, and $0.8 million related to debt issuance costs amortization.

Other income, net in the three months ended June 30, 2023 and 2022 included a $29 thousand loss and a $1.8 million gain on the fair value of the derivative liability, respectively. Other income, net in the six months ended June 30, 2023 and 2022 included a $3 thousand loss and a $6.7 million gain on the fair value of the derivative liability, respectively

On August 12, 2022, concurrently and in connection with the issuance of our 2025 senior secured convertible notes and indenture (see below), Oppenheimer & Co. Inc. (“OpCo”) commenced a private offer to repurchase approximately $45.0 million in aggregate principal amount of our 2026 Notes (the “2026 Notes Repurchase”). In connection with the 2026 Notes Repurchase, OpCo entered into a note purchase agreement with each institutional investor pursuant to which OpCo agreed to purchase 2026 Notes from each investor, concurrently with each investor’s purchase of 2025 Notes in the 2025 Notes Offering (see below). At the closing, each investor had the ability to sell $2.0 million in principal amount of 2026 Notes at 100% of par value for each $3.0 million in principal amount of 2025 Notes purchased in the 2025 Notes Offering. Concurrently and in connection with the closing on August 18, 2022, OpCo purchased from each investor the principal amount of the 2026 Notes set forth in each investor’s note purchase agreement, pursuant to and in accordance with the terms thereof. Following the reverse split of shares, the remaining 2026 Notes are convertible into approximately 1,079,812 shares of common stock at a conversion price of $106.50 in accordance with the terms of the Indenture.

2025 Senior Secured Convertible Notes and Indenture

On August 12, 2022, we entered into an indenture (the “2025 Indenture”) with the Indenture Trustee in its capacity as trustee thereunder, in respect of the $67.5 million in aggregate principal amount of a new series of variable rate convertible senior secured notes due December 15, 2025 (the “2025 Notes”) issued to holders of our 2026 Notes in a private placement transaction (“2025 Notes Offering”), raising approximately $22.5 million in gross cash proceeds, net of debt issuance costs of $2.2 million, after paying for a repurchase of $45.0 million of the 2026 Notes, which net proceeds were used in part to fully repay the Seller Notes (see below). The debt issuance costs consisted of cash paid in the amount of $1.5 million and the issuance of 115,000 shares of common stock, following the reverse stock split, with a value of $0.7 million. The 2025 Notes are convertible following the reverse split of our shares into 3,857,142 shares of our common stock at a conversion price, subject to the occurrence of certain corporate events, of $17.50 per share. The 2025 Notes are senior secured obligations of UpHealth, secured by substantially all of our assets and those of our domestic subsidiaries, and accrue interest at a rate equal to the daily secured overnight financing rate (“SOFR”) plus 9.0% per annum, with a minimum rate of 10.5% per annum, payable quarterly in arrears, for a quarterly rate of 12.21% for our December 15, 2022 interest payment date. The 2025 Notes will mature on December 15, 2025, unless earlier repurchased, redeemed or converted. Holders will have the right to convert their 2025 Notes at any time. Upon the occurrence of certain corporate events, holders of the 2025 Notes can require us to repurchase for cash all or part of their 2025 Notes in principal amounts of $1,000 or an integral multiple thereof at a repurchase price that will be equal to 105% of the principal amount of the 2025 Notes to be repurchased, plus accrued and unpaid interest thereon, if any. In the event that we sell assets with net proceeds in excess of $15.0 million, then it will make an offer to all holders of the 2025 Notes to repurchase the 2025 Notes for an aggregate amount of cash equal to 20.0% of the net proceeds of such asset sale, at a repurchase price per 2025 Note equal to 100.0% of the principal amount thereof, plus accrued and unpaid interest, if any. We may not otherwise seek to redeem the 2025 Notes prior to June 16, 2024. We will settle conversions solely in shares of its common stock, except for payments of cash in lieu of fractional shares.

As discussed in Note 3, Significant Transactions, on May 11, 2023 we completed the sale of 100% of the outstanding capital stock of Innovations Group. In accordance with the terms and conditions set forth in the 2025 Indenture, on June 9, 2023, we

commenced an offer to purchase up to $10.3 million (representing 20% of the net proceeds from the sale subject to adjustment to maintain the authorized denominations of the 2025 Notes) in aggregate principal amount of our 2025 Notes for cash, at a repurchase price per Note equal to 100% of the principal amount thereof, plus accrued and unpaid interest (if any), from the holders of the 2025 Notes (the “Offer”). On June 15, 2023, we completed the repurchase of $10.3 million in aggregate principal amount of 2025 Notes, which were validly tendered and accepted for repurchase by us in accordance with the terms and conditions of the Offer (the “Note Repurchase”), representing 15.22% of the outstanding principal amount of the 2025 Notes before the Note Repurchase. Following the completion of the Note Repurchase, there is $57.2 million in aggregate principal amount of 2025 Notes outstanding.

Total interest expense in the three months ended June 30, 2023 was $2.7 million, of which $2.3 million related to contractual interest expense and $0.4 million related to debt issuance costs amortization. Total interest expense in the six months ended June 30, 2023 was $5.2 million, of which $4.6 million related to contractual interest expense and $0.6 million related to debt issuance costs amortization. Included in the debt issuance costs amortization in the three and six months ended June 30, 2023 was a write-off of $0.3 million, which was the proportionate share of the remaining debt issuance costs related to the repurchased 2025 Notes.

In March 2023, the Indenture Trustee, in its capacity as calculation agent, notified us of the quarterly rate reset of 14.03% for our June 15, 2023 interest payment date. In June 2023, the Indenture Trustee, in its capacity as calculation agent, notified us of the quarterly rate reset of 14.25% for our September 15, 2023 interest payment date.

Related Party Debt

One of our subsidiaries has notes payable to related parties totaling $0.2 million and $0.3 million as of June 30, 2023 and December 31, 2022. The notes bear interest at rates of 3.50% per annum. The notes are payable in eight quarterly installments starting from October 1, 2022, or upon a liquidity event, as defined in the note agreement. The accrued interest payable was zero as of both June 30, 2023 and December 31, 2022. Interest expense was $3 thousand and $11 thousand in the three months ended June 30, 2023 and 2022, respectively. Interest expense was $6 thousand and $21 thousand in the six months ended June 30, 2023 and 2022, respectively.

Seller Notes

As part of the purchase price consideration for several of UpHealth Holdings’ merger entities, we entered into seller notes payable to their former shareholders, which accrue interest at specific rates, per the respective merger agreements. On June 9, 2021, in connection with the closing of the Business Combination, we paid $88.1 million of the seller notes. In August 2021, we paid an additional $11.1 million of the seller notes and deferred the maturity date to September 2022. In August 2022, we paid the remaining $18.7 million of seller notes plus accrued interest of $1.9 million. As of both June 30, 2023 and December 31, 2022, the seller notes totaled zero.

Accrued interest payable was zero as of both June 30, 2023 and December 31, 2022. Interest expense was zero and $0.5 million in the three months ended June 30, 2023 and 2022, respectively. Interest expense was zero and $0.9 million in the six months ended June 30, 2023 and 2022, respectively.

XML

Fair Value of Financial Instruments

6 Months Ended

Jun. 30, 2023

Fair Value Disclosures [Abstract]

Fair Value of Financial Instruments

Fair Value of Financial Instruments

We estimate the fair value of our financial instruments using available market information and valuation methodologies we believe to be appropriate. As of June 30, 2023 and December 31, 2022, the fair values of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued expenses approximate their carrying values due to the short-term nature of these instruments. Additionally, the fair values of short-term and long-term debt instruments approximate their carrying values.

The fair value hierarchy is as follows:

Level 1 - Quoted (unadjusted) prices in active markets for identical assets or liabilities.

Level 2 - Other observable inputs, either directly or indirectly, other than quoted prices included in Level 1, including:

•Quoted prices for similar assets/liabilities in active markets;

•Quoted prices for identical or similar assets/liabilities in non-active markets (e.g., few transactions, limited information, non-current prices, high variability over time);

•Inputs other than quoted prices that are observable for the asset/liability (e.g., interest rates, yield curves, volatilities, default rates); and

•Inputs that are derived principally from or corroborated by other observable market data.

Level 3 - Unobservable inputs that cannot be corroborated by observable market data.

The following tables present information about our financial assets and liabilities measured at fair value on are recurring basis:

	June 30, 2023
(In thousands)	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents - money market funds	$	37,918	$	—	$	—	$	37,918
	$	37,918	$	—	$	—	$	37,918
Liabilities:
Derivative liability	$	—	$	—	$	59	$	59
Warrant liability	—		17		—		17
	$	—	$	17	$	59	$	76

	December 31, 2022
(In thousands)	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents - money market funds	$	1,681	$	—	$	—	$	1,681
	$	1,681	$	—	$	—	$	1,681
Liabilities:
Derivative liability	$	—	$	—	$	56	$	56
Warrant liability	—		9		—		9
	$	—	$	9	$	56	$	65

Money Market Funds

As of June 30, 2023 and December 31, 2022, our cash equivalents consisted of money market funds which were classified as Level 1. We used observable prices in active markets in determining the classification of our money market funds as Level 1. There were no transfers between the hierarchy levels in the three and six months ended June 30, 2023 and the year ended December 31, 2022.

Cash equivalents as of June 30, 2023 and December 31, 2022 were as follows:

	June 30, 2023
(In thousands)	Amortized Cost		Unrealized Gain		Unrealized Loss		Fair Value
Cash equivalents:
Money market funds	$	37,918	$	—	$	—	$	37,918
Total cash equivalents	$	37,918	$	—	$	—	$	37,918

	December 31, 2022
(In thousands)	Amortized Cost		Unrealized Gain		Unrealized Loss		Fair Value
Cash equivalents:
Money market funds	$	1,681	$	—	$	—	$	1,681
Total cash equivalents	$	1,681	$	—	$	—	$	1,681

Derivative Liability

As of June 30, 2023 and December 31, 2022, the fair value of the derivative was $59 thousand and $56 thousand, respectively, which was included in other liabilities, noncurrent in our unaudited condensed consolidated balance sheets. Other income, net in the three months ended June 30, 2023 and 2022 included a loss of $29 thousand and a gain of $1.8 million, respectively, on the fair value of the derivative liability. Other income, net in the six months ended June 30, 2023 and 2022 included a loss of $3 thousand and a gain of $6.7 million, respectively, on the fair value of the derivative liability.

The fair value of the derivative liability is considered a Level 3 valuation and is determined using a Binomial Lattice Option Pricing Model. The significant assumptions used in the model were:

	June 30, 2023	December 31, 2022
Stock price	$1.90	$1.63
Volatility	100.0%	95.0%
Risk free rate	4.51%	4.17%
Exercise price	$106.50	$106.50
Expected life (in years)	2.95	3.44
Conversion periods	5 months-3 years	2-4 years
Future share price	$5.90-$594.30	$0.10-$405.60

2021 Private Placement Warrants and 2021 PIPE Warrants

As of June 30, 2023, the fair value of the 2021 Private Placement Warrants (the “2021 Private Placement Warrants”) and the 2021 PIPE Warrants (the “2021 PIPE Warrants”) was determined to be $0.02 per warrant, totaling $11 thousand and $6 thousand respectively, and are included in other liabilities, noncurrent in our unaudited condensed consolidated balance sheets. As of December 31, 2022, the fair value of the 2021 Private Placement Warrants and the 2021 PIPE Warrants was determined to be $0.01 per warrant, totaling $6 thousand and $3 thousand respectively, and are included in other liabilities, noncurrent in our unaudited condensed consolidated balance sheets. In the three months ended June 30, 2023, we recorded no gain or loss due to the fair value changes in the 2021 Private Placement Warrants and no gain or loss due to the fair value changes in the 2021 PIPE Warrants. In the three months ended June 30, 2022, we recorded a $0.1 million gain due to the fair value changes in the 2021 Private Placement Warrants and a $33 thousand gain due to the fair value changes in the 2021 PIPE Warrants, both of which are included in other income, net in our unaudited condensed consolidated statements of operations. In the six months ended June 30, 2023, we recorded a $5 thousand loss due to the fair value changes in the 2021 Private Placement Warrants and a $3 thousand loss due to the fair value changes in the 2021 PIPE Warrants, both of which are included in other income, net in our unaudited condensed consolidated statements of operations. In the six months ended June 30, 2022, we recorded a $0.1 million gain due to the fair value changes in the 2021 Private Placement Warrants and a $0.1 million gain due to the fair value changes in the 2021 PIPE Warrants, both of which are included in other income, net in our unaudited condensed consolidated statements of operations.

There were no transfers between fair value levels in the three and six months ended June 30, 2023 and year ended December 31, 2022.

XML

Capital Structure

6 Months Ended

Jun. 30, 2023

Equity [Abstract]

Capital Structure

Capital Structure

2023 Private Placement

On March 9, 2023, we entered into a Securities Purchase Agreement, with a single institutional investor, pursuant to which, in a private placement (the “2023 Private Placement”), we agreed to issue and sell (i) 1,650,000 shares of our common stock, par value $0.0001 per share; (ii) warrants that are exercisable six months from the date of issuance and will have a term of five years from the initial exercise date to purchase up to an additional 3,000,000 shares of our common stock (the “Series A Warrants”); (iii) warrants that are exercisable six months from the date of issuance and will have a term of two years from the initial exercise date to purchase up to an additional 3,000,000 shares of our common stock (the “Series B Warrants” and, collectively with Series A Warrants, the “Common Stock Purchase Warrants”); and (iv) pre-funded warrants (the “Pre-Funded Warrants,” and together with the Common Stock Purchase Warrants, the “Private Placement Warrants”) to purchase an additional 1,350,000 shares of our common stock (all of such shares issuable upon exercise of the Warrants, the “Warrant Shares”). On March 13, 2023, we announced that we completed the closing of the 2023 Private Placement. The purchase price of each share of common stock sold in the 2023 Private Placement was $1.50, the exercise price of each Common Stock Purchase Warrants (as defined above) is $2.04, and the exercise price of each Pre-Funded Warrant is $0.0001 and the purchase price of each Pre-Funded Warrant was $1.4999. The aggregate gross proceeds to us from the 2023 Private Placement were approximately $4.5 million, before deducting $0.3 million of placement agent fees and other offering expenses. We intend to use the net proceeds from the offering for general corporate purposes, including working capital.

On June 6, 2023, 100,000 Pre-Funded Warrants were exercised, bringing the total outstanding to 1,250,000 as of June 30, 2023.

Common Stock Reserved for Future Issuance

The following table summarizes shares of common stock reserved for future issuance as of June 30, 2023 (recorded on a post-reverse split basis):

(In thousands)	Number of Shares
Restricted stock units outstanding	2,222
Stock options outstanding	54
Shares issuable upon conversion of 2025 Notes	3,857
Shares issuable upon conversion of 2026 Notes	1,080
Shares issuable upon conversion of 2021 Public Warrants	1,725
Shares issuable upon conversion of 2021 Private Warrants	57
Shares issuable upon conversion of 2021 PIPE Warrants	29
Shares issuable upon conversion of the 2023 Private Placement Series A Warrants	3,000
Shares issuable upon conversion of the 2023 Private Placement Series B Warrants	3,000
Shares issuable upon conversion of the 2023 Private Placement Pre-Funded Warrants	1,250
Shares available for future grant under 2021 EIP	575
	16,849

2015 Cloudbreak Incentive Plan

The following table summarizes stock option activity under the Cloudbreak Plan (recorded on a post-reverse split basis):

	Number of Shares	Weighted Average Exercise Price Per Share
Outstanding as of December 31, 2022	138	$	50.76
Options exercised	—	$	—
Outstanding as of March 31, 2023	138	$	50.76
Options forfeited or expired	(84)	$	53.00
Outstanding as of June 30, 2023	54	$	47.35

2021 Equity Incentive Plan

The following table summarizes our RSU activity under the 2021 EIP (recorded on a post-reverse split basis):

	Number of Shares	Weighted Average Grant Date Fair Value Per Share
Outstanding as of December 31, 2022	878	$	6.61
RSUs granted	663	$	2.03
RSUs vested and released	(82)	$	16.09
RSUs forfeited	(118)	$	7.10
Outstanding as of March 31, 2023	1,341	$	3.91
RSUs granted	1,000	$	1.56
RSUs vested and released	(277)	$	5.67
RSUs forfeited	(42)	$	1.95
Outstanding as of June 30, 2023	2,022	$	2.55

2023 Inducement Equity Incentive Plan

On May 1, 2023, our Board of Directors approved up to 700,000 shares to be issued under a 2023 Inducement Equity Incentive Plan, the “2023 IEIP”. The following table summarizes our RSU activity under the 2023 IEIP:

	Number of Shares	Weighted Average Grant Date Fair Value Per Share
Outstanding as of December 31, 2022	—	$	—
RSUs granted	200	$	1.24
RSUs vested and released	—	$	—
RSUs forfeited	—	$	—
Outstanding as of June 30, 2023	200	$	1.24

XML

Income Taxes

6 Months Ended

Jun. 30, 2023

Income Tax Disclosure [Abstract]

Income Taxes

Income Taxes

As discussed in Note 1, Organization and Business, we deconsolidated Glocal in the three months ended September 30, 2022; accordingly, the financial results of Glocal in the three and six months ended June 30, 2022 are included in our unaudited condensed consolidated financial statements, and the financial position of Glocal as of June 30, 2023 and December 31, 2022 and the financial results of Glocal in the three and six months ended June 30, 2023 are not included in our unaudited condensed consolidated financial statements.

The income tax benefit (expense) was $(0.9) million and $2.2 million in the three months ended June 30, 2023 and 2022, respectively. The income tax benefit (expense) was $(0.9) million and $4.5 million in the six months ended June 30, 2023 and 2022, respectively.

Consistent with our conclusion as of December 31, 2022, we continue to believe that it is not more likely than not that the deferred tax assets will be realized and we therefore maintained a full valuation allowance against the deferred tax assets as of June 30, 2023. However, we expect to suffer minimal income tax expense due to U.S. tax rules related to the utilization of net operating loss carryforwards. As a result, in the three and six months ended June 30, 2023, we recorded discrete tax items totaling $0.6 million related to the sale of Innovations Group and state minimum income taxes totaling $0.3 million.

The Internal Revenue Service (“IRS”) audited the 2008 and 2009 tax returns for a business in our Integrated Care Management segment for the proper year of inclusion of approximately $15.0 million long-term capital gain on the sale of certain intellectual property rights. The business originally reported the gain on its 2010 S Corporation tax return, matching the year of inclusion for financial accounting purposes. The corporate level tax was paid to California and the business passed the gain through to its shareholders. The IRS has asserted that the business owes C Corporation tax of approximately $5.0 million for 2008, or in the alternative, the business owes C Corporation tax of approximately $5.0 million for 2009 as a built-in gain. In addition, the business could be assessed additional California franchise tax of approximately $1.3 million; and if additional income taxes are imposed, interest will be charged at approximately 4% per year, compounded annually, resulting in potential interest of approximately $3.0 million. The IRS has not asked that penalties be imposed.

The matter is currently pending before the U.S. Tax Court, Docket 11565-15. There are related tax cases for some of the former shareholders of the business for additional income taxes due if the gain is shifted to 2009. On December 4, 2018, the IRS filed a motion for summary judgment; however, the business prevailed, and the motion was denied. In January 2020, the business filed a motion for summary judgment arguing that either the gain was properly reported in 2010 and all taxes have been paid or in the alternative it should have been taxable in 2009 with no built-in gains tax. In both cases, there would be no additional income tax due for 2008 or 2009. The IRS filed an objection to the business’ motion. On March 3, 2021, the U.S. Tax Court, without consideration of the merits of the case, issued a very brief court order dismissing the business’ motion. Had the motion been granted, the need for a trial would have been obviated. The business intends to vigorously defend its position in the case and believes it will prevail if the case is taken to trial. In addition, when we acquired the business in November 2020, all of the former shareholders of the business agreed to indemnify us for any losses as a result of this dispute with the IRS. We have accrued $0.2 million representing probable additional taxes and interest imposed, in other liabilities, current in the unaudited condensed consolidated balance sheets.

XML

Earnings (Loss) Per Share

6 Months Ended

Jun. 30, 2023

Earnings Per Share [Abstract]

Earnings (Loss) Per Share

Earnings (Loss) Per Share

Basic earnings (loss) per share applicable to common stockholders is computed by dividing earnings applicable to common stockholders by the weighted average number of common shares outstanding. Diluted earnings (loss) per share assumes the conversion of any convertible securities using the treasury stock method or the if-converted method.

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands, except per share data)	2023		2022		2023		2022
Numerator:
Net income (loss) attributable to UpHealth, Inc.	$	(19,127)	$	(12,438)	$	(27,210)	$	(29,883)
Denominator:
Weighted average shares outstanding(1)	18,220		14,462		16,975		14,458
Diluted effect of stock options	—		—		—		—
Diluted effect of RSUs	—		—		—		—
Weighted average shares outstanding assuming dilution	18,220		14,462		16,975		14,458
Net income (loss) per share attributable to UpHealth, Inc.:
Basic	$	(1.05)	$	(0.86)	$	(1.60)	$	(2.07)
Diluted	$	(1.05)	$	(0.86)	$	(1.60)	$	(2.07)

(1) The shares and earnings per share as of June 30, 2022 differ from those published in our prior unaudited condensed consolidated financial statements as they were retrospectively adjusted as a result of the Reverse Stock Split (as described in Note 1, Organization and Business).

In the three months ended June 30, 2023, the calculation of basic and dilutive earnings per share included the 1.25 million pre-funded warrants with an exercise price of $0.0001, as the shares are issuable for little consideration, and excluded outstanding warrants to purchase 1.8 million shares of common stock at $115.00 per share; 6.0 million Common Stock Purchase Warrants at $2.04 per share; 0.1 million of stock options; 2.2 million of RSUs; 2025 Notes convertible into 3.9 million shares of common stock at a conversion price, subject to the occurrence of certain corporate events, of $17.50 per share; and 2026 Notes, convertible into 1.1 million shares of common stock at $106.50 per share, because the effect would be anti-dilutive. In the three months ended June 30, 2022, the calculation of dilutive earnings per share excluded outstanding warrants to purchase 1.8 million shares of common stock at $115.00 per share; 0.2 million of stock options; 0.4 million of RSUs; and 2026 Notes convertible into 1.5 million shares of common stock at $106.50 per share, because the effect would be anti-dilutive.

In the six months ended June 30, 2023, the calculation of basic and dilutive earnings per share included the 1.25 million pre-funded warrants with an exercise price of $0.0001, as the shares are issuable for little consideration, and excluded outstanding warrants to purchase 1.8 million shares of common stock at $115.00 per share; 6.0 million Common Stock Purchase Warrants at $2.04 per share; 0.1 million of stock options; 2.2 million of RSUs; 2025 Notes convertible into 3.9 million shares of common stock at a conversion price, subject to the occurrence of certain corporate events, of $17.50 per share; and 2026 Notes, convertible into 1.1 million shares of common stock at $106.50 per share, because the effect would be anti-dilutive. In the six months ended June 30, 2022, the calculation of dilutive earnings per share excluded outstanding warrants to purchase 1.8 million shares of common stock at $115.00 per share; 0.2 million of stock options; 0.4 million of RSUs; 2026 Notes convertible into 1.5 million shares of common stock at $106.50 per share; and 0.2 million shares of common stock under the terms of the forward share purchase agreement, because the effect would be anti-dilutive.

XML

Related Party Transactions

6 Months Ended

Jun. 30, 2023

Related Party Transactions [Abstract]

Related Party Transactions

Related Party Transactions

See Note 8, Debt, for related party debt.

See Note 16, Commitments and Contingencies, for leases with related parties.

We make guaranteed payments to related parties. Guaranteed payments aggregated $0.2 million and $1.4 million in the three months ended June 30, 2023 and 2022, respectively, and $0.6 million and $2.8 million in the six months ended June 30, 2023 and 2022, respectively. These amounts are presented in cost of revenues in our unaudited condensed consolidated statements of operations. We had unpaid guaranteed payments of $6 thousand and $0.5 million as of June 30, 2023 and December 31, 2022, respectively, which is included in accrued expenses in our unaudited condensed consolidated balance sheets. 

Due to related parties consisted of $0.3 million and $0.2 million as of June 30, 2023 and December 31, 2022, respectively, which is included in accrued expenses in our unaudited condensed consolidated balance sheets. Due from related parties consisted $14 thousand as of December 31, 2022, which is included in prepaid expenses and other current assets in our unaudited condensed consolidated balance sheets.

XML

Segment Reporting

6 Months Ended

Jun. 30, 2023

Segment Reporting [Abstract]

Segment Reporting

Segment Reporting Our business is organized into three operating business segments and one non-operating business segment:

•Virtual Care Infrastructure—consisting of U.S. Telehealth and International Telehealth businesses(1);

•Services—consisting of Behavioral and Pharmacy businesses(2);

•Integrated Care Management—consisting of SaaS business; and

•Corporate—consisting of holding company.

(1) As discussed in Note 1, Organization and Business, we deconsolidated Glocal in the three months ended September 30, 2022; accordingly, the financial results of Glocal in the three and six months ended June 30, 2022 are included in our unaudited condensed consolidated financial statements, and the financial results of Glocal as of June 30, 2023 and December 31, 2022 and in the three and six months ended June 30, 2023 are not included in our unaudited condensed consolidated financial statements.

(2) As discussed in Note 3, Significant Transactions, we completed the sale of Innovations Group, which comprised our Pharmacy business, on May 11, 2023. In addition, we substantially completed the wind down of a company within our Behavioral business in our Services segment in the three months ended June 30, 2023.

We evaluate performance based on several factors, of which Revenues, Gross Profit, and Total Assets are the primary financial measures:

Revenues by segment consisted of the following:

	Three Months Ended June 30,				Six Months Ended June 30,
In thousands	2023		2022		2023		2022
Virtual Care Infrastructure	$	16,838	$	16,815	$	34,296	$	32,445
Services	15,503		19,030		36,317		36,760
Integrated Care Management	5,482		7,823		9,355		10,435
Total revenues	$	37,823	$	43,668	$	79,968	$	79,640

Gross profit by segment consisted of the following:

	Three Months Ended June 30,				Six Months Ended June 30,
In thousands	2023		2022		2023		2022
Virtual Care Infrastructure	$	8,470	$	7,255	$	18,655	$	13,756
Services	7,728		6,774		17,639		12,626
Integrated Care Management	3,778		6,894		6,358		8,532
Total gross profit	$	19,976	$	20,923	$	42,652	$	34,914

Total assets by segment consisted of the following:

In thousands	June 30, 2023		December 31, 2022
Virtual Care Infrastructure	$	133,078	$	140,776
Services	48,981		124,980
Integrated Care Management	47,635		44,776
Corporate	65,384		29,272
Total assets	$	295,078	$	339,804

All long-lived assets were located in the U.S. as of June 30, 2023 and December 31, 2022.

XML

Leases

6 Months Ended

Jun. 30, 2023

Leases [Abstract]

Leases

LeasesThe components of lease expense consisted of the following in the three and six months ended June 30, 2023:

	Three Months Ended June 30, 2023						Six Months Ended June 30, 2023
In thousands	Third Party		Related Party		Total		Third Party		Related Party		Total
Finance lease costs:
Amortization of right-of-use assets	$	847	$	—	$	847	$	1,732	$	—	$	1,732
Interest on lease liabilities	81		—		81		169		—		169
Operating lease costs	593		98		691		1,309		196		1,505
Short-term lease costs	39		—		39		66		67		133
Variable lease costs	309		—		309		453		—		453
Sublease income	(113)		—		(113)		(242)		—		(242)
Total lease costs	$	1,756	$	98	$	1,854	$	3,487	$	263	$	3,750

Lease-related assets and liabilities recorded on the unaudited condensed consolidated balance sheet are as follows:

	June 30, 2023						December 31, 2022
In thousands	Third Party		Related Party		Total		Third Party		Related Party		Total
Assets
Finance lease right-of-use assets (included in property and equipment, net)	$	4,804	$	—	$	4,804	$	5,916	$	—	$	5,916
Operating lease right-of-use assets	4,496		1,232		5,728		5,819		1,394		7,213
Total leased assets	$	9,300	$	1,232	$	10,532	$	11,735	$	1,394	$	13,129
Liabilities
Lease liabilities, current:
Finance lease liabilities	$	2,946	$	—	$	2,946	$	3,023	$	—	$	3,023
Operating lease liabilities	1,845		350		2,195		2,130		322		2,452
Lease liabilities, current	4,791		350		5,141		5,153		322		5,475
Lease liabilities, noncurrent:
Finance lease liabilities	2,018		—		2,018		2,976		—		2,976
Operating lease liabilities	4,020		909		4,929		4,672		1,093		5,765
Lease liabilities, noncurrent	6,038		909		6,947		7,648		1,093		8,741
Total leased liabilities	$	10,829	$	1,259	$	12,088	$	12,801	$	1,415	$	14,216

Accumulated amortization related to the finance lease assets was $5.7 million and $3.9 million as of June 30, 2023 and December 31, 2022, respectively.

The following table summarizes our lease term and discount rate assumptions as of June 30, 2023:

	June 30, 2023
	Third Party	Related Party	Total
Weighted-average remaining lease term (years):
Finance leases	1.79	—	1.79
Operating leases	3.53	3.42	3.51
Weighted-average discount rate:
Finance leases	6.5%	—	6.5%
Operating leases	7.3%	5.3%	7.0%

Undiscounted future minimum lease payments (displayed by year and in the aggregate) under noncancelable operating leases with terms of more than one year, as of June 30, 2023, have been reconciled to the total operating and finance lease liabilities recognized on the unaudited condensed consolidated balance sheets as of June 30, 2023 as follows:

	June 30, 2023
	Finance Leases						Operating Leases
In thousands	Third Party		Related Party		Total		Third Party		Related Party		Total
Remaining 2023	$	1,668	$	—	$	1,668	$	1,108	$	195	$	1,303
2024	2,625		—		2,625		2,068		421		2,489
2025	932		—		932		1,651		427		2,078
2026	25		—		25		1,029		324		1,353
2027	—		—		—		457		—		457
Thereafter	—		—		—		379		—		379
Total lease payments	5,250		—		5,250		6,692		1,367		8,059
Less: Interest	286		—		286		827		108		935
Present value of lease liabilities	$	4,964	$	—	$	4,964	$	5,865	$	1,259	$	7,124

In the three months ended June 30, 2023, we recorded an impairment charge of $0.4 million in our Integrated Care Management segment in connection with the write-down of an office lease which is included in impairment of goodwill, intangible assets, and other long-lived assets in our unaudited condensed consolidated statements of operations.

Prior to the adoption of ASC 2016-02, Leases, the following was disclosed in our Quarterly Report on Form 10-Q in the three and six months ended June 30, 2022:

Total rent expense under related party and third-party agreements consisted of the following:

In thousands	Three Months Ended June 30, 2022		Six Months Ended June 30, 2022
Related party	$	218	$	400
Third-party	1,106		1,976
Sublease income	(149)		(246)
Total rent expense, net of sublease income	$	1,175	$	2,130

In the six months ended June 30, 2022, we recorded additional lease abandonment expense totaling $0.1 million related to a termination fee we paid to exit an office which is included in impairment of goodwill, intangible assets, and other long-lived assets in our unaudited condensed consolidated statements of operations.

Leases

LeasesThe components of lease expense consisted of the following in the three and six months ended June 30, 2023:

	Three Months Ended June 30, 2023						Six Months Ended June 30, 2023
In thousands	Third Party		Related Party		Total		Third Party		Related Party		Total
Finance lease costs:
Amortization of right-of-use assets	$	847	$	—	$	847	$	1,732	$	—	$	1,732
Interest on lease liabilities	81		—		81		169		—		169
Operating lease costs	593		98		691		1,309		196		1,505
Short-term lease costs	39		—		39		66		67		133
Variable lease costs	309		—		309		453		—		453
Sublease income	(113)		—		(113)		(242)		—		(242)
Total lease costs	$	1,756	$	98	$	1,854	$	3,487	$	263	$	3,750

Lease-related assets and liabilities recorded on the unaudited condensed consolidated balance sheet are as follows:

	June 30, 2023						December 31, 2022
In thousands	Third Party		Related Party		Total		Third Party		Related Party		Total
Assets
Finance lease right-of-use assets (included in property and equipment, net)	$	4,804	$	—	$	4,804	$	5,916	$	—	$	5,916
Operating lease right-of-use assets	4,496		1,232		5,728		5,819		1,394		7,213
Total leased assets	$	9,300	$	1,232	$	10,532	$	11,735	$	1,394	$	13,129
Liabilities
Lease liabilities, current:
Finance lease liabilities	$	2,946	$	—	$	2,946	$	3,023	$	—	$	3,023
Operating lease liabilities	1,845		350		2,195		2,130		322		2,452
Lease liabilities, current	4,791		350		5,141		5,153		322		5,475
Lease liabilities, noncurrent:
Finance lease liabilities	2,018		—		2,018		2,976		—		2,976
Operating lease liabilities	4,020		909		4,929		4,672		1,093		5,765
Lease liabilities, noncurrent	6,038		909		6,947		7,648		1,093		8,741
Total leased liabilities	$	10,829	$	1,259	$	12,088	$	12,801	$	1,415	$	14,216

Accumulated amortization related to the finance lease assets was $5.7 million and $3.9 million as of June 30, 2023 and December 31, 2022, respectively.

The following table summarizes our lease term and discount rate assumptions as of June 30, 2023:

	June 30, 2023
	Third Party	Related Party	Total
Weighted-average remaining lease term (years):
Finance leases	1.79	—	1.79
Operating leases	3.53	3.42	3.51
Weighted-average discount rate:
Finance leases	6.5%	—	6.5%
Operating leases	7.3%	5.3%	7.0%

Undiscounted future minimum lease payments (displayed by year and in the aggregate) under noncancelable operating leases with terms of more than one year, as of June 30, 2023, have been reconciled to the total operating and finance lease liabilities recognized on the unaudited condensed consolidated balance sheets as of June 30, 2023 as follows:

	June 30, 2023
	Finance Leases						Operating Leases
In thousands	Third Party		Related Party		Total		Third Party		Related Party		Total
Remaining 2023	$	1,668	$	—	$	1,668	$	1,108	$	195	$	1,303
2024	2,625		—		2,625		2,068		421		2,489
2025	932		—		932		1,651		427		2,078
2026	25		—		25		1,029		324		1,353
2027	—		—		—		457		—		457
Thereafter	—		—		—		379		—		379
Total lease payments	5,250		—		5,250		6,692		1,367		8,059
Less: Interest	286		—		286		827		108		935
Present value of lease liabilities	$	4,964	$	—	$	4,964	$	5,865	$	1,259	$	7,124

In the three months ended June 30, 2023, we recorded an impairment charge of $0.4 million in our Integrated Care Management segment in connection with the write-down of an office lease which is included in impairment of goodwill, intangible assets, and other long-lived assets in our unaudited condensed consolidated statements of operations.

Prior to the adoption of ASC 2016-02, Leases, the following was disclosed in our Quarterly Report on Form 10-Q in the three and six months ended June 30, 2022:

Total rent expense under related party and third-party agreements consisted of the following:

In thousands	Three Months Ended June 30, 2022		Six Months Ended June 30, 2022
Related party	$	218	$	400
Third-party	1,106		1,976
Sublease income	(149)		(246)
Total rent expense, net of sublease income	$	1,175	$	2,130

In the six months ended June 30, 2022, we recorded additional lease abandonment expense totaling $0.1 million related to a termination fee we paid to exit an office which is included in impairment of goodwill, intangible assets, and other long-lived assets in our unaudited condensed consolidated statements of operations.

XML

Commitments and Contingencies

6 Months Ended

Jun. 30, 2023

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Commitments and Contingencies

Commitments

Operating leases

See Note 15, Leases, for commitments related to our operating leases.

Contingencies

From time to time, we may be subjected to claims or lawsuits which arise in the ordinary course of business, including the previously disclosed tax matter (see Note 11, Income Taxes, for further information) and matters described below. Estimates for resolution of legal and other contingencies are accrued when losses are probable and reasonably estimable in accordance with ASC 450, Contingencies. Except as set forth below, in the opinion of management, after consulting with legal counsel, none of these other claims are currently expected to have a material adverse effect on our condensed consolidated results of operations, financial position or cash flows.

Advisory Services Agreement Dispute

We are in a services agreement dispute with a third-party advisory firm for fees due under the services agreement. The advisory firm claims $31.0 million, plus interest, is owed in fees. Based on consultation with legal counsel, we previously proposed a settlement in the amount of $8.0 million, which has been accrued for as of June 30, 2023 and December 31, 2022, and is included in accrued

expenses in our unaudited condensed consolidated balance sheets. The amount of the ultimate loss may range from $8.0 million to $26.3 million.

Indemnification

Certain of our agreements require us to indemnify our customers from any claim or finding of intellectual property infringements, as well as from any losses incurred relating to breach of representations, failure to perform, or specific events as outlined within the particular contract. We have not received any claims or estimated the maximum potential amount of indemnification liability under these agreements and have recorded no liabilities for these agreements.

XML

Subsequent Events

6 Months Ended

Jun. 30, 2023

Subsequent Events [Abstract]

Subsequent Events

Subsequent Events

Management has determined that no material events or transactions have occurred subsequent to the balance sheet date, other than those events noted below, that require disclosure in our unaudited condensed consolidated financial statements.

On August 8, 2023, the Board approved an Amended and Restated Employment Agreement between the Chief Financial Officer and the Company that amends and restates in its entirety, and replaces, the Employment Agreement between the Chief Financial Officer and the Company dated October 24, 2021. The Company and the Chief Financial Officer entered into the Amended and Restated Employment Agreement on August 8, 2023.

XML

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2023

Accounting Policies [Abstract]

Basis of Presentation and Consolidation

Basis of Presentation and Principles of Consolidation

Our accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information and the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Our unaudited condensed consolidated financial statements, including the condensed notes thereto, are unaudited and exclude some of the disclosures required in audited consolidated financial statements. Our unaudited condensed consolidated balance sheet as of December 31, 2022 has been derived from our audited consolidated financial statements as of that date, but do not include all of the information and footnotes required by U.S. GAAP for complete financial statements.

In the opinion of management, our accompanying unaudited condensed consolidated financial statements contain all adjustments and eliminations, consisting only of normal recurring adjustments necessary for a fair presentation in conformity with U.S. GAAP. The results of operations in the three months ended June 30, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023 or any future period. Our accompanying unaudited condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements for the year ended December 31, 2022.

Principles of Consolidation

Our unaudited condensed consolidated financial statements include the accounts of UpHealth and its consolidated subsidiaries. As described in Note 1, Organization and Business, our Glocal subsidiary was deconsolidated effective July 2022. All intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

Use of Estimates

The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts in the unaudited condensed consolidated financial statements and accompanying notes thereto.

Significant estimates and assumptions made by management include the determination of:

•The identification and reporting of variable interest entities (“VIEs”). We consolidate VIEs when we have variable interests and are the primary beneficiary. We continually evaluate our involvement with VIEs to determine when these criteria are met.

•The valuation of equity investments, including our determination of the carrying value of Glocal;

•The valuation of assets acquired and liabilities assumed for business combinations, including intangible assets and goodwill;

•The estimated economic lives and recoverability of intangible assets;

•The valuations prepared in connection with the review of goodwill, intangible assets, and other long-lived assets for impairment:

•The timing and amount of revenues to be recognized, including standalone selling price (“SSP”) of performance obligations for revenue contracts with multiple performance obligations;

•The identification of and provision for uncollectible accounts receivable;

•The capitalization and useful life of internal-use software development costs;

•The valuation of derivatives and warrants; and

•The recognition, measurement, and valuation of current and deferred income taxes and uncertain tax positions.

Actual results could differ materially from those estimates. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the result of which forms the basis for making judgments about the carrying values of assets and liabilities.

Allowance for Expected Credit Losses

Allowance for Expected Credit Losses

We closely monitor our accounts receivable balances and estimate the allowance for expected credit losses. The estimate is primarily based on historical collection experience and other factors, including those related to current market conditions and events. Credit losses associated with accounts receivable have not been material historically.

Equity Investment

Equity InvestmentAs discussed in Deconsolidation of Equity Investment in Note 1, Organization and Business, as of June 30, 2023 and December 31, 2022, we held an interest in the privately-held equity securities of Glocal in which we did not have a controlling interest and were unable to exercise significant influence. Based on the terms of these privately-held securities, we concluded the investment should be accounted for utilizing the Accounting Standards Codification (“ASC”) 321 measurement alternative, whereby the investment was measured at cost and will continue to be evaluated for any indicators of impairment.

Held for Sale

Held for Sale

Assets and liabilities to be disposed of by sale (“disposal groups”) are reclassified into assets and liabilities held for sale on our consolidated balance sheets as of December 31, 2022. The reclassification occurs when an agreement to sell exists, or management has committed to a plan to sell the assets within one year. Disposal groups are measured at the lower of carrying value or fair value less costs to sell and are not depreciated or amortized. When the net realizable value of a disposal group increases during a period, a gain can be recognized to the extent that it does not increase the value of the disposal group beyond its original carrying value when the disposal group was reclassified as held for sale. The fair value of a disposal group, less any costs to sell, is assessed each reporting period it remains classified as held for sale and any remeasurement to the lower of carrying value or fair value less costs to sell is reported as an adjustment to the carrying value of the disposal group. and reported in impairment of goodwill, intangible assets, and other long-lived assets in our unaudited condensed consolidated statements of operations.

New Accounting Pronouncements Not Yet Adopted/Recently Adopted Accounting Pronouncements

New Accounting Pronouncements Not Yet Adopted

In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). This ASU simplifies the accounting for convertible instruments by eliminating the conversion option separation model for convertible debt that can be settled in cash and by eliminating the measurement model for beneficial conversion features. Convertible instruments that continue to be subject to separation models are (1) those with conversion options that are required to be accounted for as bifurcated derivatives and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. This ASU also requires entities to use the if-converted method for all convertible instruments in the diluted earnings per share calculation and include the effect of share settlement for instruments that may be settled in cash or shares, except for certain liability-classified share-based payment awards. This ASU will be effective for us on January 1, 2024. Early adoption is permitted, but no earlier than the fiscal year beginning on January 1, 2021, including interim periods within that fiscal year. We are currently evaluating the effect of the adoption of this ASU will have on our unaudited condensed consolidated financial statements.

Recently Adopted Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, and subsequently issued several supplemental/clarifying ASUs (collectively, “ASC 326”). This ASU requires entities to estimate a lifetime expected credit loss for most financial assets, including trade and other receivables, other long-term financings including available for sale and held-to-maturity debt securities, and loans. Subsequently, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments-Credit Losses, which amended the scope of ASC 326 and clarified that receivables arising from operating leases are not within the scope of the standard and should continue to be accounted for in accordance with ASC 842. This ASU was effective for us on January 1, 2023, and the adoption did not have a material effect on our unaudited condensed consolidated financial statements.

Fair Value of Financial Instruments

The fair value hierarchy is as follows:

Level 1 - Quoted (unadjusted) prices in active markets for identical assets or liabilities.

Level 2 - Other observable inputs, either directly or indirectly, other than quoted prices included in Level 1, including:

•Quoted prices for similar assets/liabilities in active markets;

•Quoted prices for identical or similar assets/liabilities in non-active markets (e.g., few transactions, limited information, non-current prices, high variability over time);

•Inputs other than quoted prices that are observable for the asset/liability (e.g., interest rates, yield curves, volatilities, default rates); and

•Inputs that are derived principally from or corroborated by other observable market data.

Level 3 - Unobservable inputs that cannot be corroborated by observable market data.

XML

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2023

Accounting Policies [Abstract]

Schedule of Error Corrections and Prior Period Adjustments

Certain prior period amounts have been reclassified to conform to the current year presentation as shown below:

	Three Months Ended June 30, 2022						Six Months Ended June 30, 2022
	As Reported		Reclassifications		As Adjusted		As Reported		Reclassifications		As Adjusted
Revenues:
Services	$	28,096	$	—	$	28,096	$	53,782	$	—	$	53,782
Licenses and subscriptions	6,812		—		6,812		8,593		—		8,593
Products	8,760		—		8,760		17,265		—		17,265
Total revenues	43,668		—		43,668		79,640		—		79,640
Costs of revenues:
Services	14,762		1,470		16,232		29,207		2,783		31,990
License and subscriptions	217		—		217		450		—		450
Products	6,296		—		6,296		12,286		—		12,286
Total costs of revenues	21,275		1,470		22,745		41,943		2,783		44,726
Gross profit	22,393		(1,470)		20,923		37,697		(2,783)		34,914
Operating expenses:
Sales and marketing	3,486		53		3,539		6,212		761		6,973
Research and development	1,782		229		2,011		3,369		400		3,769
General and administrative	14,632		(1,752)		12,880		28,291		(3,944)		24,347
Depreciation and amortization	4,700		—		4,700		9,936		—		9,936
Stock-based compensation	1,088		—		1,088		2,462		—		2,462
Impairment of goodwill, intangible assets, and other long-lived assets	—		—		—		6,174		75		6,249
Acquisition, integration, and transformation costs	6,749		—		6,749		9,208		(75)		9,133
Total operating expenses	32,437		(1,470)		30,967		65,652		(2,783)		62,869
Loss from operations	(10,044)		—		(10,044)		(27,955)		—		(27,955)
Other expense:
Interest expense	(6,603)		—		(6,603)		(13,598)		—		(13,598)
Other income, net, including interest income	1,950		—		1,950		6,858		—		6,858
Total other expense	(4,653)		—		(4,653)		(6,740)		—		(6,740)
Loss before income tax benefit (expense)	(14,697)		—		(14,697)		(34,695)		—		(34,695)
Income tax benefit (expense)	2,232		—		2,232		4,525		—		4,525
Net loss	(12,465)		—		(12,465)		(30,170)		—		(30,170)
Less: net loss attributable to noncontrolling interests	(27)		—		(27)		(287)		—		(287)
Net loss attributable to UpHealth, Inc.	$	(12,438)	$	—	$	(12,438)	$	(29,883)	$	—	$	(29,883)

XML

Revenues (Tables)

6 Months Ended

Jun. 30, 2023

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregation of Revenues

Revenues by geography consisted of the following:

	Three months ended June 30,				Six months ended June 30,
(In thousands)	2023		2022		2023		2022
Americas	$	37,823	$	40,073	$	79,968	$	72,736
Asia	—		3,595		—		6,904
Total revenues	$	37,823	$	43,668	$	79,968	$	79,640

Schedule of Change in Contract Assets and Contract Liabilities

The change in contract assets was as follows:

	Six Months Ended June 30,
(In thousands)	2023		2022
Unbilled receivables, beginning of period	$	694	$	784
Reclassifications to billed receivables	(694)		(232)
Revenues recognized in excess of period billings	711		417
Unbilled receivables, end of period	$	711	$	969

The change in contract liabilities, consisting of deferred revenue, was as follows:

	Six Months Ended June 30,
(In thousands)	2023		2022
Deferred revenue, beginning of period	$	2,737	$	2,649
Revenues recognized from balances held at the beginning of the period	(2,620)		(1,998)
Revenues deferred from period collections on unfulfilled performance obligations	2,395		5,801
Deferred revenue, end of period	$	2,512	$	6,452

Schedule of Remaining Performance Obligations

Remaining performance obligations consisted of the following as of June 30, 2023:

(In thousands)	Remaining 2023		2024		Total
Subscriptions	$	2,882	$	3,739	$	6,621
Program management and professional services	1,143		963		2,106
Total	$	4,025	$	4,702	$	8,727

XML

Supplemental Financial Statement Information (Tables)

6 Months Ended

Jun. 30, 2023

Payables and Accruals [Abstract]

Schedule of Property and Equipment

Property and equipment consisted of the following: 

(In thousands)	June 30, 2023		December 31, 2022
Leasehold improvements	$	908	$	868
Electrical and other equipment	21		21
Computer equipment, furniture and fixtures	16,599		16,222
Vehicles	272		302
Capitalized software development costs	7,801		4,404
Capitalized software development costs in progress	1,322		2,590
	26,923		24,407
Accumulated depreciation and amortization	(12,926)		(10,338)
Total property and equipment, net	$	13,997	$	14,069

Schedule of Accrued Liabilities

Accrued expenses consisted of the following:

(In thousands)	June 30, 2023		December 31, 2022
Accrued professional fees	$	14,885	$	14,245
Accrued products and licenses	17,820		17,820
Accrued interest on debt	673		741
Accrued payroll and bonuses	4,301		5,163
Due to related party	304		229
Income tax payable	796		388
Other accruals	223		794
Total accrued expenses	$	39,002	$	39,380

Summary of Other Noncurrent Liabilities

Other liabilities, noncurrent consisted of the following

(In thousands)	June 30, 2023		December 31, 2022
Derivative liability, noncurrent	$	59	$	56
Warrant liabilities, noncurrent	17		9
Other liabilities, noncurrent	200		662
Total other liabilities, noncurrent	$	276	$	727

Summary of Impairment of Goodwill, Intangible Assets and Other Long lived Assets

Impairment of goodwill, intangible assets, and other long-lived assets consisted of the following:

	Three months ended June 30,				Six months ended June 30,
(In thousands)	2023		2022		2023		2022
Impairment of goodwill	$	7,797	$	—	$	8,292	$	5,494
Impairment of long-lived assets	449		—		449		75
Impairment of intangible assets	—		—		—		680
Total impairment of goodwill, intangible assets, and other long-lived assets:	$	8,246	$	—	$	8,741	$	6,249

Summary of Other Income, Net, Including Interest Income

Other income, net, including interest income consisted of the following:

	Three months ended June 30,				Six months ended June 30,
(In thousands)	2023		2022		2023		2022
Gain (loss) on fair value of derivative liability	$	(29)	$	1,841	$	(3)	$	6,670
Gain (loss) on fair value of warrant liabilities	—		95		(8)		190
Other income, net, including interest income	155		14		138		(2)
Total other income, net, including interest income	$	126	$	1,950	$	127	$	6,858

XML

Intangible Assets (Tables)

6 Months Ended

Jun. 30, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Changes in Carrying Amounts of Intangible Assets

The following table summarizes the gross carrying amount and accumulated amortization for intangible assets as of June 30, 2023:

(In thousands)	Trade Names		Technology and Intellectual Property		Customer Relationships		Total
Gross carrying amount as of June 30, 2023	$	15,242	$	10,634	$	17,613	$	43,489
Accumulated amortization	(4,012)		(5,521)		(4,887)		(14,420)
Intangible assets, net as of June 30, 2023	$	11,230	$	5,113	$	12,726	$	29,069

The following table summarizes the gross carrying amount and accumulated amortization for intangible assets as of December 31, 2022:

(In thousands)	Trade Names		Technology and Intellectual Property		Customer Relationships		Total
Gross carrying amount as of December 31, 2022	$	15,242	$	10,634	$	17,613	$	43,489
Accumulated amortization	(3,295)		(4,762)		(4,070)		(12,127)
Intangible assets, net as of December 31, 2022	$	11,947	$	5,872	$	13,543	$	31,362

Schedule of Estimated Amortization Expense Related to Definite-Lived Intangible Assets

The estimated amortization expense related to definite-lived intangible assets for the five succeeding years is as follows:

(In thousands)	Trade Name Amortization		Technology and Intellectual Property Amortization		Customer Relationships Amortization		Total
Remaining 2023	$	709	$	770	$	808	$	2,287
2024	1,417		1,540		1,616		4,573
2025	1,417		1,540		1,616		4,573
2026	1,417		909		1,616		3,942
2027	1,417		354		1,616		3,387
Thereafter	4,853		—		5,454		10,307
	$	11,230	$	5,113	$	12,726	$	29,069

XML

Goodwill (Tables)

6 Months Ended

Jun. 30, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Changes in the Carrying Amount of Goodwill

The carrying amount of goodwill consisted of the following:

(In thousands)	Goodwill
Balance as of December 31, 2022	$	159,675
Impairments	(6,357)
Balance as of June 30, 2023	$	153,318

XML

Debt (Tables)

6 Months Ended

Jun. 30, 2023

Debt Disclosure [Abstract]

Schedule of Long-Term Debt

Debt consisted of the following: 

(In thousands)	June 30, 2023		December 31, 2022
2025 Notes	$	57,227	$	67,500
2026 Notes	115,000		115,000
Total debt	172,227		182,500
Less: unamortized original issue and debt discount	(30,972)		(36,538)
Total debt, net of unamortized original issue and debt discount	141,255		145,962
Less: current portion of debt	—		—
Noncurrent portion of debt	$	141,255	$	145,962

XML

Fair Value of Financial Measurements (Tables)

6 Months Ended

Jun. 30, 2023

Fair Value Disclosures [Abstract]

Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following tables present information about our financial assets and liabilities measured at fair value on are recurring basis:

	June 30, 2023
(In thousands)	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents - money market funds	$	37,918	$	—	$	—	$	37,918
	$	37,918	$	—	$	—	$	37,918
Liabilities:
Derivative liability	$	—	$	—	$	59	$	59
Warrant liability	—		17		—		17
	$	—	$	17	$	59	$	76

	December 31, 2022
(In thousands)	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents - money market funds	$	1,681	$	—	$	—	$	1,681
	$	1,681	$	—	$	—	$	1,681
Liabilities:
Derivative liability	$	—	$	—	$	56	$	56
Warrant liability	—		9		—		9
	$	—	$	9	$	56	$	65

Schedule of Cash and Cash Equivalents

Cash equivalents as of June 30, 2023 and December 31, 2022 were as follows:

	June 30, 2023
(In thousands)	Amortized Cost		Unrealized Gain		Unrealized Loss		Fair Value
Cash equivalents:
Money market funds	$	37,918	$	—	$	—	$	37,918
Total cash equivalents	$	37,918	$	—	$	—	$	37,918

	December 31, 2022
(In thousands)	Amortized Cost		Unrealized Gain		Unrealized Loss		Fair Value
Cash equivalents:
Money market funds	$	1,681	$	—	$	—	$	1,681
Total cash equivalents	$	1,681	$	—	$	—	$	1,681

Schedule of Fair Value Significant Assumptions

The fair value of the derivative liability is considered a Level 3 valuation and is determined using a Binomial Lattice Option Pricing Model. The significant assumptions used in the model were:

	June 30, 2023	December 31, 2022
Stock price	$1.90	$1.63
Volatility	100.0%	95.0%
Risk free rate	4.51%	4.17%
Exercise price	$106.50	$106.50
Expected life (in years)	2.95	3.44
Conversion periods	5 months-3 years	2-4 years
Future share price	$5.90-$594.30	$0.10-$405.60

XML

Capital Structure (Tables)

6 Months Ended

Jun. 30, 2023

Equity [Abstract]

Schedule of Common Stock Reserved for Future Issuance

The following table summarizes shares of common stock reserved for future issuance as of June 30, 2023 (recorded on a post-reverse split basis):

(In thousands)	Number of Shares
Restricted stock units outstanding	2,222
Stock options outstanding	54
Shares issuable upon conversion of 2025 Notes	3,857
Shares issuable upon conversion of 2026 Notes	1,080
Shares issuable upon conversion of 2021 Public Warrants	1,725
Shares issuable upon conversion of 2021 Private Warrants	57
Shares issuable upon conversion of 2021 PIPE Warrants	29
Shares issuable upon conversion of the 2023 Private Placement Series A Warrants	3,000
Shares issuable upon conversion of the 2023 Private Placement Series B Warrants	3,000
Shares issuable upon conversion of the 2023 Private Placement Pre-Funded Warrants	1,250
Shares available for future grant under 2021 EIP	575
	16,849

Summary of Stock Option Activity

The following table summarizes stock option activity under the Cloudbreak Plan (recorded on a post-reverse split basis):

	Number of Shares	Weighted Average Exercise Price Per Share
Outstanding as of December 31, 2022	138	$	50.76
Options exercised	—	$	—
Outstanding as of March 31, 2023	138	$	50.76
Options forfeited or expired	(84)	$	53.00
Outstanding as of June 30, 2023	54	$	47.35

Summary of RSU Activity

The following table summarizes our RSU activity under the 2021 EIP (recorded on a post-reverse split basis):

	Number of Shares	Weighted Average Grant Date Fair Value Per Share
Outstanding as of December 31, 2022	878	$	6.61
RSUs granted	663	$	2.03
RSUs vested and released	(82)	$	16.09
RSUs forfeited	(118)	$	7.10
Outstanding as of March 31, 2023	1,341	$	3.91
RSUs granted	1,000	$	1.56
RSUs vested and released	(277)	$	5.67
RSUs forfeited	(42)	$	1.95
Outstanding as of June 30, 2023	2,022	$	2.55

2023 Inducement Equity Incentive Plan

On May 1, 2023, our Board of Directors approved up to 700,000 shares to be issued under a 2023 Inducement Equity Incentive Plan, the “2023 IEIP”. The following table summarizes our RSU activity under the 2023 IEIP:

	Number of Shares	Weighted Average Grant Date Fair Value Per Share
Outstanding as of December 31, 2022	—	$	—
RSUs granted	200	$	1.24
RSUs vested and released	—	$	—
RSUs forfeited	—	$	—
Outstanding as of June 30, 2023	200	$	1.24

XML

Earnings (Loss) Per Share (Tables)

6 Months Ended

Jun. 30, 2023

Earnings Per Share [Abstract]

Schedule of Earnings (Loss) Per Share

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands, except per share data)	2023		2022		2023		2022
Numerator:
Net income (loss) attributable to UpHealth, Inc.	$	(19,127)	$	(12,438)	$	(27,210)	$	(29,883)
Denominator:
Weighted average shares outstanding(1)	18,220		14,462		16,975		14,458
Diluted effect of stock options	—		—		—		—
Diluted effect of RSUs	—		—		—		—
Weighted average shares outstanding assuming dilution	18,220		14,462		16,975		14,458
Net income (loss) per share attributable to UpHealth, Inc.:
Basic	$	(1.05)	$	(0.86)	$	(1.60)	$	(2.07)
Diluted	$	(1.05)	$	(0.86)	$	(1.60)	$	(2.07)

(1) The shares and earnings per share as of June 30, 2022 differ from those published in our prior unaudited condensed consolidated financial statements as they were retrospectively adjusted as a result of the Reverse Stock Split (as described in Note 1, Organization and Business).

XML

Segment Reporting (Tables)

6 Months Ended

Jun. 30, 2023

Segment Reporting [Abstract]

Schedule of Segment Reporting

Revenues by segment consisted of the following:

	Three Months Ended June 30,				Six Months Ended June 30,
In thousands	2023		2022		2023		2022
Virtual Care Infrastructure	$	16,838	$	16,815	$	34,296	$	32,445
Services	15,503		19,030		36,317		36,760
Integrated Care Management	5,482		7,823		9,355		10,435
Total revenues	$	37,823	$	43,668	$	79,968	$	79,640

Gross profit by segment consisted of the following:

	Three Months Ended June 30,				Six Months Ended June 30,
In thousands	2023		2022		2023		2022
Virtual Care Infrastructure	$	8,470	$	7,255	$	18,655	$	13,756
Services	7,728		6,774		17,639		12,626
Integrated Care Management	3,778		6,894		6,358		8,532
Total gross profit	$	19,976	$	20,923	$	42,652	$	34,914

Total assets by segment consisted of the following:

In thousands	June 30, 2023		December 31, 2022
Virtual Care Infrastructure	$	133,078	$	140,776
Services	48,981		124,980
Integrated Care Management	47,635		44,776
Corporate	65,384		29,272
Total assets	$	295,078	$	339,804

XML

Leases (Tables)

6 Months Ended

Jun. 30, 2023

Leases [Abstract]

Schedule of Components of Lease Expense

The components of lease expense consisted of the following in the three and six months ended June 30, 2023:

	Three Months Ended June 30, 2023						Six Months Ended June 30, 2023
In thousands	Third Party		Related Party		Total		Third Party		Related Party		Total
Finance lease costs:
Amortization of right-of-use assets	$	847	$	—	$	847	$	1,732	$	—	$	1,732
Interest on lease liabilities	81		—		81		169		—		169
Operating lease costs	593		98		691		1,309		196		1,505
Short-term lease costs	39		—		39		66		67		133
Variable lease costs	309		—		309		453		—		453
Sublease income	(113)		—		(113)		(242)		—		(242)
Total lease costs	$	1,756	$	98	$	1,854	$	3,487	$	263	$	3,750

Schedule of Company's Lease Assets and Liabilities, Lease Term and Discount Rate Assumptions

Lease-related assets and liabilities recorded on the unaudited condensed consolidated balance sheet are as follows:

	June 30, 2023						December 31, 2022
In thousands	Third Party		Related Party		Total		Third Party		Related Party		Total
Assets
Finance lease right-of-use assets (included in property and equipment, net)	$	4,804	$	—	$	4,804	$	5,916	$	—	$	5,916
Operating lease right-of-use assets	4,496		1,232		5,728		5,819		1,394		7,213
Total leased assets	$	9,300	$	1,232	$	10,532	$	11,735	$	1,394	$	13,129
Liabilities
Lease liabilities, current:
Finance lease liabilities	$	2,946	$	—	$	2,946	$	3,023	$	—	$	3,023
Operating lease liabilities	1,845		350		2,195		2,130		322		2,452
Lease liabilities, current	4,791		350		5,141		5,153		322		5,475
Lease liabilities, noncurrent:
Finance lease liabilities	2,018		—		2,018		2,976		—		2,976
Operating lease liabilities	4,020		909		4,929		4,672		1,093		5,765
Lease liabilities, noncurrent	6,038		909		6,947		7,648		1,093		8,741
Total leased liabilities	$	10,829	$	1,259	$	12,088	$	12,801	$	1,415	$	14,216

The following table summarizes our lease term and discount rate assumptions as of June 30, 2023:

	June 30, 2023
	Third Party	Related Party	Total
Weighted-average remaining lease term (years):
Finance leases	1.79	—	1.79
Operating leases	3.53	3.42	3.51
Weighted-average discount rate:
Finance leases	6.5%	—	6.5%
Operating leases	7.3%	5.3%	7.0%

Summary of Operating Lease Maturity

Undiscounted future minimum lease payments (displayed by year and in the aggregate) under noncancelable operating leases with terms of more than one year, as of June 30, 2023, have been reconciled to the total operating and finance lease liabilities recognized on the unaudited condensed consolidated balance sheets as of June 30, 2023 as follows:

	June 30, 2023
	Finance Leases						Operating Leases
In thousands	Third Party		Related Party		Total		Third Party		Related Party		Total
Remaining 2023	$	1,668	$	—	$	1,668	$	1,108	$	195	$	1,303
2024	2,625		—		2,625		2,068		421		2,489
2025	932		—		932		1,651		427		2,078
2026	25		—		25		1,029		324		1,353
2027	—		—		—		457		—		457
Thereafter	—		—		—		379		—		379
Total lease payments	5,250		—		5,250		6,692		1,367		8,059
Less: Interest	286		—		286		827		108		935
Present value of lease liabilities	$	4,964	$	—	$	4,964	$	5,865	$	1,259	$	7,124

Summary of Finance Leases Maturity

Undiscounted future minimum lease payments (displayed by year and in the aggregate) under noncancelable operating leases with terms of more than one year, as of June 30, 2023, have been reconciled to the total operating and finance lease liabilities recognized on the unaudited condensed consolidated balance sheets as of June 30, 2023 as follows:

	June 30, 2023
	Finance Leases						Operating Leases
In thousands	Third Party		Related Party		Total		Third Party		Related Party		Total
Remaining 2023	$	1,668	$	—	$	1,668	$	1,108	$	195	$	1,303
2024	2,625		—		2,625		2,068		421		2,489
2025	932		—		932		1,651		427		2,078
2026	25		—		25		1,029		324		1,353
2027	—		—		—		457		—		457
Thereafter	—		—		—		379		—		379
Total lease payments	5,250		—		5,250		6,692		1,367		8,059
Less: Interest	286		—		286		827		108		935
Present value of lease liabilities	$	4,964	$	—	$	4,964	$	5,865	$	1,259	$	7,124

Schedule of Rent Expense

Total rent expense under related party and third-party agreements consisted of the following:

In thousands	Three Months Ended June 30, 2022		Six Months Ended June 30, 2022
Related party	$	218	$	400
Third-party	1,106		1,976
Sublease income	(149)		(246)
Total rent expense, net of sublease income	$	1,175	$	2,130

XML

Organization and Business - Narrative (Details) $ / shares in Units, $ in Millions			1 Months Ended	3 Months Ended	6 Months Ended
	Dec. 08, 2022	Dec. 05, 2022 $ / shares	Jul. 31, 2022 USD ($)	Sep. 30, 2022 USD ($)	Jun. 30, 2023 USD ($)	May 11, 2023 USD ($)	Feb. 26, 2023	Jun. 30, 2022 USD ($)
Class of Stock [Line Items]
Loss on deconsolidation of equity investment			$ 37.7
Fair value of Glocal								$ 21.2
Amount derecognized					$ 14.3
Company transferred amount to a designated “Share Account”				$ 5.1
Common stock, par value (in dollars per share) | $ / shares		$ 0.0001
Reverse stock split	0.1
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Innovation Group
Class of Stock [Line Items]
Consideration						$ 56.0
Innovations Group
Class of Stock [Line Items]
Noncontrolling interest, ownership percentage by parent						100.00%	100.00%
Minimum
Class of Stock [Line Items]
Reverse stock split		0.4
Maximum
Class of Stock [Line Items]
Reverse stock split		0.1

XML

Summary of Significant Accounting Policies - Reclassifications (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total revenues	$ 37,823		$ 43,668		$ 79,968	$ 79,640
Total costs of revenues	17,847		22,745		37,316	44,726
Gross profit	19,976		20,923		42,652	34,914
Operating expenses:
Sales and marketing	2,421		3,539		7,040	6,973
Research and development	848		2,011		2,133	3,769
General and administrative	12,765		12,880		23,774	24,347
Depreciation and amortization	1,736		4,700		3,347	9,936
Stock-based compensation	1,058		1,088		2,047	2,462
Impairment of goodwill, intangible assets, and other long-lived assets	8,246		0		8,741	6,249
Acquisition, integration, and transformation costs	3,644		6,749		7,090	9,133
Total operating expenses	30,718		30,967		54,172	62,869
Loss from operations	(10,742)		(10,044)		(11,520)	(27,955)
Other expense:
Interest expense	(7,136)		(6,603)		(13,994)	(13,598)
Other income, net, including interest income	126		1,950		127	6,858
Total other expense	(7,010)		(4,653)		(13,867)	(6,740)
Loss before income tax benefit (expense)	(17,752)		(14,697)		(25,387)	(34,695)
Income tax benefit (expense)	(867)		2,232		(867)	4,525
Net loss	(18,619)	$ (7,635)	(12,465)	$ (17,705)	(26,254)	(30,170)
Less: net income (loss) attributable to noncontrolling interests	508		(27)		956	(287)
Net loss attributable to UpHealth, Inc.	(19,127)		(12,438)		(27,210)	(29,883)
As reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total revenues			43,668			79,640
Total costs of revenues			21,275			41,943
Gross profit			22,393			37,697
Operating expenses:
Sales and marketing			3,486			6,212
Research and development			1,782			3,369
General and administrative			14,632			28,291
Depreciation and amortization			4,700			9,936
Stock-based compensation			1,088			2,462
Impairment of goodwill, intangible assets, and other long-lived assets			0			6,174
Acquisition, integration, and transformation costs			6,749			9,208
Total operating expenses			32,437			65,652
Loss from operations			(10,044)			(27,955)
Other expense:
Interest expense			(6,603)			(13,598)
Other income, net, including interest income			1,950			6,858
Total other expense			(4,653)			(6,740)
Loss before income tax benefit (expense)			(14,697)			(34,695)
Income tax benefit (expense)			2,232			4,525
Net loss			(12,465)			(30,170)
Less: net income (loss) attributable to noncontrolling interests			(27)			(287)
Net loss attributable to UpHealth, Inc.			(12,438)			(29,883)
Reclassifications
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total costs of revenues			1,470			2,783
Gross profit			(1,470)			(2,783)
Operating expenses:
Sales and marketing			53			761
Research and development			229			400
General and administrative			(1,752)			(3,944)
Impairment of goodwill, intangible assets, and other long-lived assets						75
Acquisition, integration, and transformation costs						(75)
Total operating expenses			(1,470)			(2,783)
Loss from operations			0			0
Other expense:
Loss before income tax benefit (expense)			0			0
Net loss			0			0
Net loss attributable to UpHealth, Inc.			0			0
Services
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total revenues			28,096			53,782
Total costs of revenues			16,232			31,990
Services | As reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total revenues			28,096			53,782
Total costs of revenues			14,762			29,207
Services | Reclassifications
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total costs of revenues			1,470			2,783
Licenses and subscriptions
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total revenues	2,852		6,812		4,788	8,593
Total costs of revenues	403		217		722	450
Licenses and subscriptions | As reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total revenues			6,812			8,593
Total costs of revenues			217			450
Products
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total revenues	3,884		8,760		13,152	17,265
Total costs of revenues	$ 2,490		6,296		$ 7,896	12,286
Products | As reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total revenues			8,760			17,265
Total costs of revenues			$ 6,296			$ 12,286

XML

Significant Transactions - Narrative (Details) $ in Thousands		3 Months Ended			6 Months Ended
	May 11, 2023 USD ($)	Jun. 30, 2023 USD ($) business	Mar. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Jun. 30, 2023 USD ($) business	Jun. 30, 2022 USD ($)	Feb. 26, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Businesses classified as held for sale | business		0			0
Proceeds from sale of business, net of expenses					$ 54,861	$ 0
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Innovations Group
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration	$ 56,000
Total loss on disposal group held for sale		$ 1,400
Proceeds from sale of business, net of expenses	$ 54,900
Disposal Group, Held-for-sale, Not Discontinued Operations | Innovations Group
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Assets				$ 65,300
Liabilities				11,100
Total loss on disposal group held for sale		$ 1,400	$ 500	$ 1,800	$ 1,900
Innovations Group
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Noncontrolling interest, ownership percentage by parent	100.00%						100.00%

XML

Revenues - Disaggregation of Revenues (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Disaggregation of Revenue [Line Items]
Total revenues	$ 37,823	$ 43,668	$ 79,968	$ 79,640
Americas
Disaggregation of Revenue [Line Items]
Total revenues	37,823	40,073	79,968	72,736
Asia
Disaggregation of Revenue [Line Items]
Total revenues	$ 0	$ 3,595	$ 0	$ 6,904

XML

Revenues - Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Concentration Risk [Line Items]
Impairment of contract assets	$ 0	$ 0	$ 0	$ 0
Revenue recognized, percentage	3.10%	1.00%	3.30%	2.50%
Revenue Recognition Timing | Total revenue | Transferred over-time
Concentration Risk [Line Items]
Concentration risk, percentage	86.00%	68.00%	80.00%	71.00%

XML

Revenues - Contract Assets (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Change In Contract With Customer, Asset [Roll Forward]
Unbilled receivables, beginning of period	$ 694	$ 784
Reclassifications to billed receivables	(694)	(232)
Revenues recognized in excess of period billings	711	417
Unbilled receivables, end of period	$ 711	$ 969

XML

Revenues - Contract Liabilities (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Change In Contract With Customer, Liability [Roll Forward]
Deferred revenue, beginning of period	$ 2,737	$ 2,649
Revenues recognized from balances held at the beginning of the period	(2,620)	(1,998)
Revenues deferred from period collections on unfulfilled performance obligations	2,395	5,801
Deferred revenue, end of period	$ 2,512	$ 6,452

XML

Revenues - Remaining Performance Obligations (Details) $ in Thousands	Jun. 30, 2023 USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	$ 8,727
Subscriptions
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	6,621
Program management and professional services
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	2,106
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-07-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	$ 4,025
Remaining performance obligations, period	6 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-07-01 | Subscriptions
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	$ 2,882
Remaining performance obligations, period	6 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-07-01 | Program management and professional services
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	$ 1,143
Remaining performance obligations, period	6 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	$ 4,702
Remaining performance obligations, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 | Subscriptions
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	$ 3,739
Remaining performance obligations, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 | Program management and professional services
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	$ 963
Remaining performance obligations, period	1 year

XML

Supplemental Financial Statement Information (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 26,923	$ 24,407
Accumulated depreciation and amortization	(12,926)	(10,338)
Total property and equipment, net	13,997	14,069
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	908	868
Electrical and other equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	21	21
Computer equipment, furniture and fixtures
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	16,599	16,222
Vehicles
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	272	302
Capitalized software development costs
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	7,801	4,404
Capitalized software development costs in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 1,322	$ 2,590

XML

Supplemental Financial Statement Information - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Payables and Accruals [Abstract]
Depreciation expense	$ 1.9	$ 1.8	$ 3.2	$ 3.2

XML

Supplemental Financial Statement Information - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Accrued professional fees	$ 14,885	$ 14,245
Accrued products and licenses	17,820	17,820
Accrued interest on debt	673	741
Accrued payroll and bonuses	4,301	5,163
Due to related party	304	229
Income tax payable	796	388
Other accruals	223	794
Total accrued expenses	$ 39,002	$ 39,380

XML

Supplemental Financial Statement Information - Schedule of Other Liabilities, Noncurrent (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Derivative liability, noncurrent	$ 59	$ 56
Warrant liabilities, noncurrent	17	9
Other liabilities, noncurrent	200	662
Total other liabilities, noncurrent	$ 276	$ 727

XML

Supplemental Financial Statement Information - Summary of Goodwill, Intangible Assets and Other Long-Lived Assets (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Payables and Accruals [Abstract]
Impairment of goodwill	$ 7,797,000	$ 0	$ 8,292,000	$ 5,494,000
Impairment of long-lived assets	449,000	0	449,000	75,000
Impairment of intangible assets	0	0	0	680,000
Total impairment of goodwill, intangible assets, and other long-lived assets:	$ 8,246,000	$ 0	$ 8,741,000	$ 6,249,000

XML

Supplemental Financial Statement Information - Schedule of Other Income, Net (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Payables and Accruals [Abstract]
Gain (loss) on fair value of derivative liability	$ (29)	$ 1,841	$ (3)	$ 6,670
Gain (loss) on fair value of warrant liabilities	0	95	(8)	190
Other income, net, including interest income	155	14	138	(2)
Total other income, net, including interest income	$ 126	$ 1,950	$ 127	$ 6,858

XML

Intangible Assets - Schedule of Changes in Carrying Amounts of Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Finite-lived Intangible Assets [Roll Forward]
Gross carrying amount	$ 43,489	$ 43,489
Accumulated amortization	(14,420)	(12,127)
Total	29,069	31,362
Trade Names
Finite-lived Intangible Assets [Roll Forward]
Gross carrying amount	15,242	15,242
Accumulated amortization	(4,012)	(3,295)
Total	11,230	11,947
Technology and Intellectual Property
Finite-lived Intangible Assets [Roll Forward]
Gross carrying amount	10,634	10,634
Accumulated amortization	(5,521)	(4,762)
Total	5,113	5,872
Customer Relationships
Finite-lived Intangible Assets [Roll Forward]
Gross carrying amount	17,613	17,613
Accumulated amortization	(4,887)	(4,070)
Total	$ 12,726	$ 13,543

XML

Intangible Assets - Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Finite-Lived Intangible Assets [Line Items]
Impairment charge	$ 0	$ 0	$ 0	$ 680,000
Amortization expense	$ 1,100,000	$ 4,200,000	$ 2,300,000	$ 9,300,000
Customer Relationships
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives (in years)	10 years		10 years
Minimum | Trade Names
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives (in years)	3 years		3 years
Minimum | Technology and Intellectual Property
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives (in years)	5 years		5 years
Maximum | Trade Names
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives (in years)	10 years		10 years
Maximum | Technology and Intellectual Property
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives (in years)	7 years		7 years

XML

Intangible Assets - Schedule of Estimated Amortization Expense Related to Definite-Lived Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Remaining 2023	$ 2,287
2024	4,573
2025	4,573
2026	3,942
2027	3,387
Thereafter	10,307
Total	29,069	$ 31,362
Trade Name Amortization
Finite-Lived Intangible Assets [Line Items]
Remaining 2023	709
2024	1,417
2025	1,417
2026	1,417
2027	1,417
Thereafter	4,853
Total	11,230	11,947
Technology and Intellectual Property Amortization
Finite-Lived Intangible Assets [Line Items]
Remaining 2023	770
2024	1,540
2025	1,540
2026	909
2027	354
Thereafter	0
Total	5,113	5,872
Customer Relationships Amortization
Finite-Lived Intangible Assets [Line Items]
Remaining 2023	808
2024	1,616
2025	1,616
2026	1,616
2027	1,616
Thereafter	5,454
Total	$ 12,726	$ 13,543

XML

Goodwill - Narrative (Details) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Goodwill [Line Items]
Impairments	$ 6,400,000			$ 0	$ 6,357,000
Measurement period adjustments						$ 5,500,000
Disposal Group, Held-for-sale, Not Discontinued Operations | Innovations Group
Goodwill [Line Items]
Loss on disposal group held for sale	$ 1,400,000	$ 500,000	$ 1,800,000		$ 1,900,000

XML

Goodwill - Schedule of Changes in the Carrying Amount of Goodwill (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023
Goodwill
Beginning balance			$ 159,675,000
Impairments	$ (6,400,000)	$ 0	(6,357,000)
Ending balance	$ 153,318,000		$ 153,318,000

XML

Debt - Schedule of Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 16, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Total debt	$ 172,227		$ 182,500
Less: unamortized original issue and debt discount	(30,972)		(36,538)
Total debt, net of unamortized original issue and debt discount	141,255		145,962
Less: current portion of debt	0		0
Noncurrent portion of debt	141,255		145,962
Convertible notes | 2025 Notes
Debt Instrument [Line Items]
Total debt	57,227	$ 57,200	67,500
Convertible notes | 2026 Notes
Debt Instrument [Line Items]
Total debt	$ 115,000		$ 115,000

XML

Debt - Narrative (Details)							1 Months Ended		3 Months Ended		6 Months Ended
	Jun. 15, 2023 USD ($)	Jun. 09, 2023 USD ($)	Dec. 15, 2022	Aug. 12, 2022 USD ($) $ / shares shares	Jun. 15, 2021 USD ($) shares	Jun. 09, 2021 USD ($)	Aug. 31, 2022 USD ($)	Aug. 31, 2021 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($) quarterly_installment	Jun. 30, 2022 USD ($)	Jun. 16, 2023 USD ($)	May 11, 2023	Mar. 31, 2023	Feb. 26, 2023	Dec. 31, 2022 USD ($)
Debt Instrument [Line Items]
Interest expense									$ 7,136,000	$ 6,603,000	$ 13,994,000	$ 13,598,000
Debt issuance costs											0	3,234,000
Stock issued during period, reverse stock splits (in shares) | shares				115,000
Stock issued during period, reverse stock splits				$ 700,000
Total debt									$ 172,227,000		$ 172,227,000						$ 182,500,000
Related Party
Debt Instrument [Line Items]
Debt instrument, interest rate									3.50%		3.50%
Interest expense									$ 3,000	11,000	$ 6,000	21,000
Notes payable to related parties									200,000		$ 200,000						300,000
Number of quarterly installments | quarterly_installment											8
Accrued interest on debt									0		$ 0						0
Innovations Group
Debt Instrument [Line Items]
Noncontrolling interest, ownership percentage by parent														100.00%		100.00%
2026 Notes | Convertible notes
Debt Instrument [Line Items]
Principal amount				$ 3,000,000	$ 160,000,000
Debt instrument, interest rate					6.25%
Convertible, shares issuable (in shares) | shares				1,079,812	1,502,347
Conversion price (in dollars per share) | $ / shares				$ 106.50
Proceeds from issuance of long-term debt					$ 151,900,000
Debt issuance costs				$ 2,200,000	$ 8,100,000
Fair value of derivative liability									59,000		59,000						56,000
Interest expense									4,300,000	6,000,000	8,600,000	12,000,000
Contractual interest expense									1,800,000	2,500,000	3,600,000	5,000,000
Derivative accretion									2,200,000	400,000	4,400,000	800,000
Debt issuance costs amortization									300,000	3,100,000	600,000	6,200,000
Loss on fair value of derivative liability									29,000
Gain on fair value of derivative liability										1,800,000		6,700,000
Loss on fair value of derivative liability											3,000
Repayments of convertible debt				45,000,000
Debt instrument, fact amount, per instrument				$ 2,000,000
Debt repurchase, percentage of principal amount				100.00%
Total debt									115,000,000		115,000,000						115,000,000
2025 Notes | Disposal Group, Not Discontinued Operations | Innovation Group
Debt Instrument [Line Items]
Net proceeds		0.20
2025 Notes | Convertible notes
Debt Instrument [Line Items]
Principal amount				$ 67,500,000
Convertible, shares issuable (in shares) | shares				3,857,142
Conversion price (in dollars per share) | $ / shares				$ 17.50
Contractual interest expense									2,300,000		4,600,000
Debt issuance costs amortization									400,000		600,000
Write off of debt issuance costs									300,000		300,000
Repayments of convertible debt	$ 10,300,000
Debt repurchase, percentage of principal amount		100.00%		105.00%
Gross cash proceeds				$ 22,500,000
Debt issuance costs				$ 1,500,000
Debt instrument, interest rate floor (percent)			12.21%	10.50%
Debt redemption, repurchase increment				$ 1,000
Sale of assets, net proceeds threshold for repurchase				$ 15,000,000
Sale of assets, cash repurchase price as a percentage of net proceeds				20.00%
Sale of assets, net proceeds threshold, redemption price percentage				100.00%
Repurchased face amount		$ 10,300,000
Percentage of principal amount redeemed	15.22%
Total debt									57,227,000		57,227,000		$ 57,200,000				67,500,000
Interest expense									$ 2,700,000		$ 5,200,000
Effective interest rate									14.25%		14.25%				14.03%
2025 Notes | Convertible notes | SOFR
Debt Instrument [Line Items]
Basis spread on variable rate (percent)				9.00%
Seller Notes | Notes payable, other payables
Debt Instrument [Line Items]
Principal amount									$ 0		$ 0						0
Interest expense									0	$ 500,000	0	$ 900,000
Accrued interest on debt									$ 0		$ 0						$ 0
Repayments of sellers notes						$ 88,100,000	$ 18,700,000	$ 11,100,000
Payment for accrued interest							$ 1,900,000

XML

Fair Value of Financial Instruments - Schedule of Financial Assets and Liabilities Measured at Fair Value On a Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Liabilities:
Warrant liability	$ 17	$ 9
Money market funds
Assets:
Cash equivalents - money market funds	37,918	1,681
Fair Value, Recurring
Assets:
Total assets	37,918	1,681
Liabilities:
Derivative liability	59	56
Warrant liability	17	9
Total liabilities	76	65
Fair Value, Recurring | Money market funds
Assets:
Cash equivalents - money market funds	37,918	1,681
Fair Value, Recurring | Level 1
Assets:
Total assets	37,918	1,681
Liabilities:
Derivative liability	0	0
Warrant liability	0	0
Total liabilities	0	0
Fair Value, Recurring | Level 1 | Money market funds
Assets:
Cash equivalents - money market funds	37,918	1,681
Fair Value, Recurring | Level 2
Assets:
Total assets	0	0
Liabilities:
Derivative liability	0	0
Warrant liability	17	9
Total liabilities	17	9
Fair Value, Recurring | Level 2 | Money market funds
Assets:
Cash equivalents - money market funds	0	0
Fair Value, Recurring | Level 3
Assets:
Total assets	0	0
Liabilities:
Derivative liability	59	56
Warrant liability	0	0
Total liabilities	59	56
Fair Value, Recurring | Level 3 | Money market funds
Assets:
Cash equivalents - money market funds	$ 0	$ 0

XML

Fair Value of Financial Instruments - Schedule of Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022
Cash and Cash Equivalents [Line Items]
Amortized Cost	$ 46,803	$ 15,557	$ 40,629
Money market funds
Cash and Cash Equivalents [Line Items]
Amortized Cost	37,918	1,681
Fair Value	$ 37,918	$ 1,681

XML

Fair Value of Financial Instruments - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of warrants	$ 17		$ 17		$ 9
Gain (loss) on fair value of warrant liabilities	$ 0	$ 95	$ (8)	$ 190
2021 Private Placement Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value price of warrants (in dollars per share)	$ 0.02		$ 0.02		$ 0.01
Fair value of warrants	$ 11		$ 11		$ 6
Gain (loss) on fair value of warrant liabilities	$ 0	100	$ (5)	100
2021 PIPE Subscription Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value price of warrants (in dollars per share)	$ 0.02		$ 0.02		$ 0.01
Fair value of warrants	$ 6		$ 6		$ 3
Gain (loss) on fair value of warrant liabilities	0	33	(3)	100
2026 Notes | Convertible notes
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of derivative liability	59		59		$ 56
Loss on fair value of derivative liability	$ 29
Gain on fair value of derivative liability		$ 1,800		$ 6,700
Loss on fair value of derivative liability			$ 3

XML

Fair Value of Financial Instruments - Schedule of Fair Value Significant Assumptions (Details) - Level 3	Jun. 30, 2023 $ / shares yr mo Year	Dec. 31, 2022 $ / shares yr Year
Stock price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	1.90	1.63
Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	1.000	0.950
Risk free rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.0451	0.0417
Exercise price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	106.50	106.50
Expected life (in years)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input | Year	2.95	3.44
Conversion periods | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	5	2
Conversion periods | Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input | yr	3	4
Future share price | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	5.90	0.10
Future share price | Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	594.30	405.60

XML

Capital Structure - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands				3 Months Ended
	Jun. 06, 2023	Mar. 13, 2023	Mar. 09, 2023	Mar. 31, 2023	Jun. 30, 2023	May 01, 2023	Dec. 05, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, par value (in dollars per share)							$ 0.0001
Issuance costs				$ 348
2023 Inducement Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized (in shares)						700,000
2023 Private Placement
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares issued or sold (in shares)			1,650,000
Common stock, par value (in dollars per share)			$ 0.0001
Number of additional shares			1,350,000
Price per share (in dollars per share)		$ 1.50
Exercise price of warrants (in dollars per share)		$ 2.04
Proceeds from issuance of stock		$ 4,500
Issuance costs		$ 300
Warrants outstanding (in shares)					1,250,000
2023 Private Placement | Series A Warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant vesting term			6 months
Warrant term			5 years
Number of securities called by warrants (in shares)			3,000,000
2023 Private Placement | Series B Warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant vesting term			6 months
Warrant term			2 years
Number of securities called by warrants (in shares)			3,000,000
2023 Private Placement | Pre-Funded Warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Price per share (in dollars per share)		$ 1.4999
Exercise price of warrants (in dollars per share)		$ 0.0001			$ 0.0001
Exercise of pre-funded warrants (in shares)	100,000

XML

Capital Structure - Schedule of Common Stock Reserved for Future Issuance (Details) shares in Thousands	Jun. 30, 2023 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)	16,849
Shares available for future grant under 2021 EIP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)	575
Shares issuable upon conversion of 2021 Public Warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)	1,725
Shares issuable upon conversion of 2021 Private Warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)	57
Shares issuable upon conversion of 2021 PIPE Warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)	29
Shares issuable upon conversion of the 2023 Private Placement Series A Warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)	3,000
Shares issuable upon conversion of the 2023 Private Placement Series B Warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)	3,000
Shares issuable upon conversion of the 2023 Private Placement Pre-Funded Warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)	1,250
Shares issuable upon conversion of 2025 Notes
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)	3,857
Shares issuable upon conversion of 2026 Notes
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)	1,080
Restricted stock units outstanding
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)	2,222
Stock options outstanding
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)	54

XML

Capital Structure - Summary of Stock Option Activity (Details) - Cloudbreak 2015 Incentive Plan - $ / shares shares in Thousands	3 Months Ended
	Jun. 30, 2023	Mar. 31, 2023
Number of Shares
Options outstanding - balance at beginning of period (in shares)	138	138
Options exercised (in shares)		0
Options forfeited or expired (in shares)	(84)
Options outstanding - balance at end of period (in shares)	54	138
Weighted Average Exercise Price Per Share
Options outstanding - balance at beginning of period (in dollars per shares)	$ 50.76	$ 50.76
Options exercised (in dollars per share)		0
Options forfeited or expired (in dollars per share)	53.00
Options outstanding - balance at end of period (in dollars per shares)	$ 47.35	$ 50.76

XML

Capital Structure - Summary of RSU Activity (Details) - RSUs - $ / shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2023
2021 Equity Incentive Plan
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Outstanding at beginning of period (in shares)	1,341	878	878
RSUs granted (in shares)	1,000	663
RSUs vested and released (in shares)	(277)	(82)
RSUs forfeited (in shares)	(42)	(118)
Outstanding at end of period (in shares)	2,022	1,341	2,022
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Outstanding at beginning of period (in dollars per share)	$ 3.91	$ 6.61	$ 6.61
RSUs granted (in dollars per share)	1.56	2.03
RSUs vested and released (in dollars per share)	5.67	16.09
RSUs forfeited (in dollars per share)	1.95	7.10
Outstanding at end of period (in dollars per share)	$ 2.55	$ 3.91	$ 2.55
2023 Inducement Equity Incentive Plan
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Outstanding at beginning of period (in shares)		0	0
RSUs granted (in shares)			200
RSUs vested and released (in shares)			0
RSUs forfeited (in shares)			0
Outstanding at end of period (in shares)	200		200
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Outstanding at beginning of period (in dollars per share)		$ 0	$ 0
RSUs granted (in dollars per share)			1.24
RSUs vested and released (in dollars per share)			0
RSUs forfeited (in dollars per share)			0
Outstanding at end of period (in dollars per share)	$ 1.24		$ 1.24

XML

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended		24 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2009	Dec. 31, 2008	Dec. 31, 2009
Income Tax Examination [Line Items]
Income tax benefit (expense)	$ (867)	$ 2,232	$ (867)	$ 4,525
Discrete tax	600		600
State and local income taxes, amount	300		300
Thrasys
Income Tax Examination [Line Items]
Long-term capital gain on sale							$ 15,000
Interest on tax, accrued	$ 200		$ 200
Thrasys | Internal Revenue Service (IRS)
Income Tax Examination [Line Items]
Assertion of tax owed					$ 5,000	$ 5,000
Interest on tax, percentage			4.00%
Potential interest expense			$ 3,000
Thrasys | California Franchise Tax Board
Income Tax Examination [Line Items]
Assertion of tax owed			$ 1,300

XML

Earnings (Loss) Per Share - Schedule of Earnings (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Numerator:
Net income (loss) attributable to UpHealth, Inc.		$ (19,127)	$ (12,438)	$ (27,210)	$ (29,883)
Denominator:
Weighted average shares outstanding (in shares)	[1]	18,220	14,462	16,975	14,458
Weighted average shares outstanding assuming dilution (in shares)	[1]	18,220	14,462	16,975	14,458
Basic (in dollars per share)		$ (1.05)	$ (0.86)	$ (1.60)	$ (2.07)
Diluted (in dollars per share)		$ (1.05)	$ (0.86)	$ (1.60)	$ (2.07)
Stock options outstanding
Denominator:
Dilutive effect of share-based payment arrangements (in shares)		0	0	0	0
RSUs
Denominator:
Dilutive effect of share-based payment arrangements (in shares)		0	0	0	0

[1] Amounts as of June 30, 2022 and before that date differ from those published in our prior condensed consolidated financial statements as they were retrospectively adjusted as a result of the Reverse Stock Split (as described below in Note 1, Organization and Business). Specifically, the number of common shares outstanding during periods before the Reverse Stock Split are divided by the exchange ratio of 10:1, such that each ten shares of common stock were combined and reconstituted into one share of common stock effective December 8, 2022.

XML

Earnings (Loss) Per Share - Narrative (Details) - $ / shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Mar. 13, 2023
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive shares (in shares)	1,800	1,800	1,800	1,800
Potentially dilutive shares, price per share (in dollars per share)	$ 115.00	$ 115.00	$ 115.00	$ 115.00
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive shares (in shares)	100	200	100	200
RSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive shares (in shares)	2,200	400	2,200	400
Senior convertible notes | 2025 Notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive shares (in shares)	3,900		3,900
Potentially dilutive shares, price per share (in dollars per share)	$ 17.50		$ 17.50
Senior convertible notes | 2026 Notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive shares (in shares)	1,100	1,500	1,100	1,500
Potentially dilutive shares, price per share (in dollars per share)	$ 106.50	$ 106.50	$ 106.50	$ 106.50
Forward share purchase agreement
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive shares (in shares)				200
Private Placement
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Exercise price of warrants (in dollars per share)					$ 2.04
Pre-Funded Warrants | Private Placement
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive shares (in shares)	1,250		1,250
Exercise price of warrants (in dollars per share)	$ 0.0001		$ 0.0001		$ 0.0001
Common Stock Warrants | Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive shares (in shares)	6,000		6,000
Potentially dilutive shares, price per share (in dollars per share)	$ 2.04		$ 2.04

XML

Related Party Transactions - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Related Party Transaction [Line Items]
Guaranteed payments	$ 17,847	$ 22,745	$ 37,316	$ 44,726
Unpaid guaranteed payments	39,002		39,002		$ 39,380
Prepaid expenses and other current assets	2,121		2,121		3,005
Related Party
Related Party Transaction [Line Items]
Guaranteed payments	200	$ 1,400	600	$ 2,800
Unpaid guaranteed payments	6		6		500
Due to related parties	$ 300		$ 300		200
Prepaid expenses and other current assets					$ 14

XML

Segment Reporting - Narrative (Details)	6 Months Ended
	Jun. 30, 2023 segment
Segment Reporting [Abstract]
Number of operating business segments	3
Number of non-operating business segments	1

XML

Segment Reporting - Schedule of Segment Reporting (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Segment Reporting Information [Line Items]
Total revenues	$ 37,823	$ 43,668	$ 79,968	$ 79,640
Total gross profit	19,976	20,923	42,652	34,914
Total assets	295,078		295,078		$ 339,804
Virtual Care Infrastructure
Segment Reporting Information [Line Items]
Total revenues	16,838	16,815	34,296	32,445
Total gross profit	8,470	7,255	18,655	13,756
Total assets	133,078		133,078		140,776
Services
Segment Reporting Information [Line Items]
Total revenues	15,503	19,030	36,317	36,760
Total gross profit	7,728	6,774	17,639	12,626
Total assets	48,981		48,981		124,980
Integrated Care Management
Segment Reporting Information [Line Items]
Total revenues	5,482	7,823	9,355	10,435
Total gross profit	3,778	$ 6,894	6,358	$ 8,532
Total assets	47,635		47,635		44,776
Corporate
Segment Reporting Information [Line Items]
Total assets	$ 65,384		$ 65,384		$ 29,272

XML

Leases - Components of Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2023
Lessee, Lease, Description [Line Items]
Amortization of right-of-use assets	$ 847	$ 1,732
Interest on lease liabilities	81	169
Operating lease costs	691	1,505
Short-term lease costs	39	133
Variable lease costs	309	453
Sublease income	(113)	(242)
Total lease costs	1,854	3,750
Third Party
Lessee, Lease, Description [Line Items]
Amortization of right-of-use assets	847	1,732
Interest on lease liabilities	81	169
Operating lease costs	593	1,309
Short-term lease costs	39	66
Variable lease costs	309	453
Sublease income	(113)	(242)
Total lease costs	1,756	3,487
Related Party
Lessee, Lease, Description [Line Items]
Amortization of right-of-use assets	0	0
Interest on lease liabilities	0	0
Operating lease costs	98	196
Short-term lease costs	0	67
Variable lease costs	0	0
Sublease income	0	0
Total lease costs	$ 98	$ 263

XML

Leases - Lease-Related Assets and Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Lessee, Lease, Description [Line Items]
Finance lease right-of-use assets (included in property and equipment, net)	$ 4,804	$ 5,916
Operating lease right-of-use assets	5,728	7,213
Total leased assets	10,532	13,129
Current finance lease liabilities	2,946	3,023
Current operating lease liabilities	2,195	2,452
Lease liabilities, current	5,141	5,475
Noncurrent finance lease liabilities	2,018	2,976
Noncurrent operating lease liabilities	4,929	5,765
Lease liabilities, noncurrent	6,947	8,741
Total leased liabilities	$ 12,088	$ 14,216
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Lease liabilities, current	Lease liabilities, current
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Lease liabilities, current	Lease liabilities, current
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Lease liabilities, noncurrent	Lease liabilities, noncurrent
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Lease liabilities, noncurrent	Lease liabilities, noncurrent
Third Party
Lessee, Lease, Description [Line Items]
Finance lease right-of-use assets (included in property and equipment, net)	$ 4,804	$ 5,916
Operating lease right-of-use assets	4,496	5,819
Total leased assets	9,300	11,735
Current finance lease liabilities	2,946	3,023
Current operating lease liabilities	1,845	2,130
Lease liabilities, current	4,791	5,153
Noncurrent finance lease liabilities	2,018	2,976
Noncurrent operating lease liabilities	4,020	4,672
Lease liabilities, noncurrent	6,038	7,648
Total leased liabilities	10,829	12,801
Related Party
Lessee, Lease, Description [Line Items]
Finance lease right-of-use assets (included in property and equipment, net)	0	0
Operating lease right-of-use assets	1,232	1,394
Total leased assets	1,232	1,394
Current finance lease liabilities	0	0
Current operating lease liabilities	350	322
Lease liabilities, current	350	322
Noncurrent finance lease liabilities	0	0
Noncurrent operating lease liabilities	909	1,093
Lease liabilities, noncurrent	909	1,093
Total leased liabilities	$ 1,259	$ 1,415

XML

Leases - Narrative (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Leases [Abstract]
Accumulated amortization related to finance lease assets	$ 5.7		$ 3.9
Impairment of office lease	$ 0.4
Additional lease abandonment expense		$ 0.1

XML

Leases - Company's Lease Term and Discount Rate Assumptions (Details)	Jun. 30, 2023
Weighted-average remaining lease term (years):
Finance leases	1 year 9 months 14 days
Operating leases	3 years 6 months 3 days
Weighted-average discount rate:
Finance leases	6.50%
Operating leases	7.00%
Third Party
Weighted-average remaining lease term (years):
Finance leases	1 year 9 months 14 days
Operating leases	3 years 6 months 10 days
Weighted-average discount rate:
Finance leases	6.50%
Operating leases	7.30%
Related Party
Weighted-average remaining lease term (years):
Operating leases	3 years 5 months 1 day
Weighted-average discount rate:
Operating leases	5.30%

XML

Leases - Undiscounted Future Minimum Lease Payments (Details) $ in Thousands	Jun. 30, 2023 USD ($)
Finance Leases
Remaining 2023	$ 1,668
2024	2,625
2025	932
2026	25
2027	0
Thereafter	0
Total lease payments	5,250
Less: Interest	286
Present value of lease liabilities	$ 4,964
Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]	Lease liabilities, current, Lease liabilities, noncurrent
Operating Leases
Remaining 2023	$ 1,303
2024	2,489
2025	2,078
2026	1,353
2027	457
Thereafter	379
Total lease payments	8,059
Less: Interest	935
Present value of lease liabilities	$ 7,124
Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]	Lease liabilities, current, Lease liabilities, noncurrent
Third Party
Finance Leases
Remaining 2023	$ 1,668
2024	2,625
2025	932
2026	25
2027	0
Thereafter	0
Total lease payments	5,250
Less: Interest	286
Present value of lease liabilities	4,964
Operating Leases
Remaining 2023	1,108
2024	2,068
2025	1,651
2026	1,029
2027	457
Thereafter	379
Total lease payments	6,692
Less: Interest	827
Present value of lease liabilities	5,865
Related Party
Finance Leases
Remaining 2023	0
2024	0
2025	0
2026	0
2027	0
Thereafter	0
Total lease payments	0
Less: Interest	0
Present value of lease liabilities	0
Operating Leases
Remaining 2023	195
2024	421
2025	427
2026	324
2027	0
Thereafter	0
Total lease payments	1,367
Less: Interest	108
Present value of lease liabilities	$ 1,259

XML

Leases - Rent Expense Under Related Party and Third Party Agreements (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2022
Lessee, Lease, Description [Line Items]
Sublease income	$ (149)	$ (246)
Total rent expense, net of sublease income	1,175	2,130
Related Party
Lessee, Lease, Description [Line Items]
Rent expense	218	400
Third Party
Lessee, Lease, Description [Line Items]
Rent expense	$ 1,106	$ 1,976

XML

Commitments and Contingencies - Contingencies Narrative (Details) - Advisory services agreement dispute - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Loss Contingencies [Line Items]
Damages sought	$ 31.0
Current accrual loss provision	8.0	$ 8.0
Minimum
Loss Contingencies [Line Items]
Estimated maximum exposure to loss	8.0
Maximum
Loss Contingencies [Line Items]
Estimated maximum exposure to loss	$ 26.3